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Evaluation of the efficacy of four intra-articular 
therapeutic protocols for the control and treatment of 





João Carlos Agostinho Alves 
 
 
Orientador(es) |    Luis Miguel Alves Carreira 
 














Universidade de Évora – Instituto de Investigação e Formação Avançada 
 
 
Programa de Doutoramento em Cîencias Veterinárias 
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Título: Avaliação da eficácia de quatro protocolos terapêuticos intra-articulares no controlo e 
tratamento da Osteoartrite em modelo Canis familiaris. 
RESUMO 
 
A osteoartrite (OA) é uma doença que afecta que afecta todos os mamíferos, com uma 
expressão clínica e económica muito importante. No cão, a sua fisiopatologia clínica, médica e 
terapêutica são muito semelhantes às do Homem, tornando esta espécie num modelo natural de 
excelência para o estudo da OA no Homem. Associando-se a doença predominantemente ao 
aparecimento de sinais e sintomas clínicos envolvendo a(s) articulação(ões) afetada(s), o uso de 
terapêuticas locais administradas por via intra-articular (IA), possibilitam reduzir a quantidade da 
substância activa a utilizar para obter o efeito médico desejado, assim como os potenciais efeitos 
sistémicos colaterais.  Desde há muito tempo que o uso de corticosteróides e ácido hialurónico têm 
assumido um papel relevante na terapia IA da OA. Actualmente, terapias inovadoras como o uso de 
concentrados de plaquetas autologas ou de anabolizantes, como o Estanozolol, têm-se revelado 
promissoras no controlo local da doença. Contudo, os seus mecanismos de ação não estão ainda 
totalmente esclarecidos, o que se traduz na dificuldade em obter consenso entre os clínicos para o 
estabelecimento de protocolos padronizados, fazendo-se assim a sua utilização com base na medicina 
de evidência resultante da  experiência individual do clínico. A monitorização da OA no que respeita 
à sua evolução e resposta à terapeutica instituída é actualmente monitorizada com o recurso a 
marcadores de inflamação, técnicas de imagem como a radiografia e termografia digita is, ao estudo 
e análise da biomecânica do doente em placas ou plataformas de força, que adicionam informação 
muito importante à colhida durante o exame clínico objectivo do doente. 
O presente estudo realizado na espécie Canis familiaris com OA na articulação coxofemora l 
apresenta como principais objetivos: 1) Determinar o efeito de quatro substâncias administradas por 
via IA no maneio da OA da anca; 2) Avaliar a variação na concentração dos marcadores inflamatór ios 
Proteína C-Reativa (PCR) e Interleucina-1 (IL-1) no líquido sinovial de doentes com OA 
coxofemoral; 3) Avaliar a relação entre a medicina laboratorial, a medicina de imagem e o exame 
médico objectivo do doente; 4) Validar o uso da termografia digital e da plataforma de pressão na 
avaliação da OA; e 5) Delinear um protocolo terapêutico para os doentes com OA coxofemora l 
utilizando o cão como modelo animal, sob o conceito geral de - Uma Única Saúde (One Health). O 
estudo foi desenvolvido numa amostra de cem articulações coxo-femorais (N = 100), de doentes com 
OA de ocorrência natural. A amostra estudada foi dividida aleatoriamente em cinco (5) grupos cada 
um com vinte (20) articulações, de acordo com o tipo de terapêutica IA administrada. Assim, 
consideraram-se: grupo de controlo (GC, n=20), grupo de hexacetonido de triancinolona (THG, 
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n=20), grupo de concentrado de plaquetas (Grupo PCG, n=20), grupo de estanozolol (SG, n=20) e o 
grupo de acido hialurónico - Hylan GF 20 (HG, n=20). Cada doente foi avaliado em nove (9) tempos 
diferentes ao longo do estudo: dia 0 (dia do tratamento) e dias 8, 15, 30, 60, 90, 120, 150 e 180 após 
tratamento. As avaliações de cada doente e articulação foram realizadas com a análise da biomecânica 
do doente em plataforma de força, goniometria da articulação (amplitude articular em flexão e 
extensão), perímetro da coxa, termografia digital, radiografia digital, análise do líquido sinovial e 
quatro instrumentos de metrologia clínica, nomeadamente: Escala Rápida de Avaliação de Dor 
Canina (Canine Brief Pain Inventory), Escala de Osteoartite Canina de Liverpool (Liverpool 
Osteoarthritis in Dogs), Índice Ortopedico Canino (Canine Orthopedic Index) e Escala Analógica 
Visual de Hudson (Hudson Visual Analogue Scale). O trabalho estatístico dos dados foi realizado 
com o programa IBM SPSS Statistics version 20. Foram realizados vários testes estatísticos, de 
acordo com a análise pretendida: teste t de amostras emparelhadas, ANOVA de medidas repetidas, 
com correcção Huynh-Feldt, ou o teste de Wilcoxon. O teste de Kaplan-Meier, comparado com o 
teste log-rank, e a regressão de Cox foram conduzidos para avaliar sobrevivência. Todos os resultados 
obtidos forma considerados como estatisticamente significativos para o valor de P<0,05. 
Os grupos PCG e HG foram aqueles que registaram melhorias mais significativas e 
duradouras, de acordo com os resultados da regressão de Cox para as diferentes avaliações realizadas. 
Considerando as avaliações objectivas, PCH e HG apresentaram uma melhora de 81% e 69%, e de 
61% e 57% para os índices de simetria e diminuição de suporte de peso em estação, respetivamente. 
De acordo com os resultados obtidos, o uso de concentrado de plaquetas autologas e de ácido 
hialurónico de alta densidade parecem ser os tratamentos preferenciais para a melhoria das alterações 
registadas nos doentes com OA, melhorando a qualidade de vida dos doentes. Os resultados obtidos 
permitiram verificar também uma redução no nível da dor nos doentes do grupo THG, o que pode ser 
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Title: Evaluation of the efficacy of four intra-articular therapeutic protocols for the control and 
treatment of osteoarthritis in a Canis familiaris model. 
ABSTRACT 
 
Osteoarthritis (OA) affects all mammals, being an important and costly disease. The 
pathologic process, clinical presentation, and response to treatment are very similar in humans and 
dogs, making the naturally occurring canine osteoarthritis model the closest to a gold standard for the 
study of human osteoarthritis. Since OA is mainly symptomatic in the affected joint while lacking 
obvious extra-articular manifestations, it is well suited to have a local therapy administered by intra-
articular (IA) injection, reducing the total amount required to produce an effect as well as systemic 
adverse effects. There are several substances used in the IA management of OA, some used for a long 
time, like corticosteroids and hyaluronan, while others have gained more recent attention, as 
autologous platelets and stanozolol. In common, regardless of how long they have been used, their 
action mechanisms and effects are not fully known, as the protocol for their use is usually based on 
the clinician’s individual experience. Disease evolution and response to treatment can be monitored 
through inflammation markers, different clinical evaluation modalities, as digital thermography, 
digital radiography, or stance analysis, which all add relevant information to the clinical examination. 
This study set four goals: 1) to determine the effect of four IA substances in the management 
of hip OA; 2) assess variations in C-reactive protein and IL-1 in the synovial fluid of patients with 
OA; 3) evaluate the relationship between laboratory medicine, with imaging results and clinica l 
assessment; 4) validate the use of digital thermography and weight bearing evaluation in OA 
assessement; and 5) to outline a treatment protocol for patients with OA, with the dog as an animal 
model, under the One Health concept. One hundred (N=100) hip joints were selected from patients 
with naturally occurring osteoarthritis and randomly assigned to five groups: control group (CG, 
n=20), triamcinolone hexacetonide group (THG, n=20), platelet concentrate group (PCG, n=20), 
stanozolol group (SG, n=20) and Hylan G-F 20 group (HG, n=20). Evaluations were conducted on 
days 0 (treatment day), 8, 15, 30, 60, 90, 120, 150, and 180 days post-treatment. They consisted of 
the evaluation of weight distribution, joint range of motion at flexion and extension, thigh girth, 
digital thermography, radiographic signs, synovial fluid analysis, and four clinical metrology 
instruments were collected: Canine Brief Pain Inventory, Liverpool Osteoarthritis in Dogs, Canine 
Orthopedic Index and the Hudson Visual Analogue Scale. All results were analyzed with IBM SPSS 
Statistics version 20. Several statiscal tests were conducted, according to the intended analysis: Paired 
Samples T-Test, Repeated Measures ANOVA, with a Huynh-Feldt correction, or Wilcoxon Signed 
Ranks Test. Kaplan-Meier estimators were conducted and compared with the log-rank test. Cox 
xi 
 
proportional hazard regression analysis was performed to determine treatment survival. A 
significance level of P<0.05 was set. 
PCG and HG registered longer lasting effects, and better improvements according to the Cox 
hazard regression with the different assessments made. Considering objective parameters, PCH 
patients showed a 69%-81% improvement in symmetry and weight-bearing reduction, respectively, 
while HG showed 61% and 57% improvements. These seem to be the preferred treatments for 
functional impairments due to OA. In addition to these evaluations, PCG and HG also registered more 
significant improvements in several scores as Hudson Visual Analogue Scale, stiffness, function, gait 
of the Canine Orthopedic Index. Better impact on pain interference was observed in THG, which 
could be attributed to the high anti-inflammatory effect of corticosteroids, and the relation between 
pain and inflammation. 
 
Keywords: Animal model; Dog; Osteoarthritis; Pain; Triamcinolone Hexacetonide; Stanozolol; 
Hylan G-F 20; Platelet concentrate; Stance Analysis; Digital Thermography; Goniometry; Digital 
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I. INTRODUCTION AND BIBLIOGRAPHIC REVISION  
 
INTRODUCTION AND MAIN GOALS 
Osteoarthritis (OA) affects all mammals, being an important and costly disease in humans, 
horses, and dogs1,2. It is a source of chronic pain, with an estimated prevalence of 20% in dogs3–5. 
This value is expected to rise due to a simultaneous increase in life expectancy and obesity across 
species. In dogs, osteoarthritis is a common process in the hip joint, and it has been registered in 98% 
of animals at the end of life6. The physiopathologic process, clinical presentation, and response to 
treatment are very similar between humans and dogs, making the dog a frequent animal model for 
the study of osteoarthritis7. Both the surgical and naturally occurring models have been widely 
studied, with anatomical resemblance, similar disease progression and result translation to human 
medicine, with the advantage of providing a faster disease progression, making it easier to study. For 
those reasons, the dog is the closest to a gold standard model8–11. While histopathology remains the 
gold standard for outcome assessment in OA animal models, there has been an increasing call for less 
invasive measures of disease onset and progression and response to treatment11. For that same reason, 
the search for biomarkers that would be a good indicator of OA's development and evolution, have 
also been under significant attention12. 
Since OA is symptomatic mainly in the affected joints and lacks obvious extra-articula r 
manifestations, it is well suited to be addressed by administering local therapy by intra-articular (IA) 
injection13–15. IA treatments present several advantages: applying the treatment directly at the 
intended place of action provides a higher concentration of the medication within the joint space, 
usually accompanied by higher efficacy, while minimizing systemic exposure, thus avoiding several 
systemic side effects. Also, systemically administered drugs have difficulty reaching the articular 
cartilage due to its avascular nature, raising the need for higher doses15–17. Many substances have 
been used in the treatment of OA for quite a long time, as corticosteroids and hyaluronic acid. 
Currently, innovative therapies as autologous platelet concentrates or anabolic steroids such as 
Stanozolol, have shown promise in the local control of the disease. However, its mechanisms of action 
are not yet fully understood, which translates into the difficulty in reaching consensus among 
clinicians for the establishment of standardized protocols, thus making their use based on evidence 
medicine resulting from the individual experience of the clinician´s18.  
 In human reports, wide discrepancies in results can be observed, maybe because prospective, 
randomized, double-blind, placebo-controlled studies, with an intetion to treat, are rare13. At the same 
time, systematic reviews of the efficacy of OA treatments in dogs highlight the poor quality of study 
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design and reporting, limiting their authors' ability to make strong therapeutic recommendations. As 
a result, it may be difficult for practitioners to choose the most appropriate treatment for their 
patients18. Disease diagnostics and monitoring can be achieved through various methodologies, with 
an increasing interest in non-invasive modalities. These include digital radiography, gait analys is, 
thermography, and others, alongside molecular techniques such as Interleukine-1 (IL-1) and C-
reactive protein (CRP) concentration level determinations19–23. 
Considering the above, the study of therapeutics and each option's effects available for OA 
management shows of crucial importance. The present study developed in dogs with hip joint OA 
naturally occurring disease aimed to: 
1. Determine the effect of four substances delivered by intra-articular route (IA), in 
patients with hip joint osteoarthritis; 
2. Evaluate the variation in the synovial fluid of patients with hip joint OA of 
inflammatory markers levels such as Protein C-Reactive (CRP) and Interleukin-1 (IL-
1) through time after the IA administration of the different substances used for the OA 
treatment; 
3. Assess the relationship between laboratory and imaging medicine data, and the 
patient's objective medical examination; 
4. Validate the use of digital thermography and weight bearing evaluation in OA 
assessement; 
5. Outline a therapeutic for IA treatment protocol for patients with hip OA using the dog 




1. THE JOINT  
 
Joints are intricate musculoskeletal structures, currently considered a complex organ, 
composed of multiple components with different characteristics1,24. They permit the movement of 
bony structures in relation to one another and, as a consequence, the movement of an individual in 
relation to the environment, translated in locomotion24. Joints must be as robust as the remaining 
musculoskeletal system, endure the forces generated during movement, reduce friction, promote a 
smooth motion, and should dampen the impact generated during contact with the ground24.  
 
1.1 Classification of joints 
There are three categories of joints: fibrous joints (in which bone is connected through dense 
connective tissue), cartilaginous joints (in which cartilage is an interface between structures), and 
synovial joints (in which there is a cavity, filled with fluid)24,25.  An example of a fibrous joint is the 
one between the vertebrae bodies, forming the nucleous pulposus of the intervertebral disc. 
Cartilaginous joints have an interface that comprises hyaline or fibrous cartilage, such as the one in 
the pubic symphysis. In synovial joints, the bony ends are covered with hyaline cartilage and glide 
over each other inside a joint capsule filled with the viscous synovial fluid (SF)24. 
Functionally, joints can also be classified accordingly to the amount of motion they allow. 
Synarthroses are joints that allow very little mobility, most of which are fibrous in nature (such as the 
ones that connect the bones of the skull). Amphiarthroses are joints that allow for more movement 
than synarthroses but still minimal (for example, the intervertebral joints). Diarthrodial joints are the 
ones that allow for maximal motion, with the range of movement being limited by intra or peri-
articular structures, such as ligaments or joint capsule24. The primary plane of motion can also be 
used to characterize joints. Hinge-type joints, such as the elbow, move in the sagittal plane, while 
ball-and-socket joints, such as the hip, can move in sagittal, frontal, and transverse planes26. Still, 
three parameters should be used to define a joint movement fully: location of the axis (includ ing 
location changes during movement), the amount of rotation that occurs, and the amount of translat ion 
(displacement along the axis) that occurs27. It is a challenging task to complete with absolute precision 
since most joints do not have a fixed axis of motion but rather a quite intricate movement28. Since 
joints exhibit three-dimensional movements, it can be useful to consider them as rotating in three 
orthogonal planes: sagittal (yaw), frontal (pitch) and horizontal (roll), and three translat ion 





1.2 The synovial joint 
The majority of tissues that compose the musculoskeletal system are classified as dense 
connective tissue. The skeletal muscle is the exception to this rule29. Synovial joints have a typical 
basic structure (represented in Figure 1) and should be considered an organ1,30. The ends of at least 
two articular bones that constitute the joint are covered with a layer of articular cartilage, and, under 
this cartilage, there is a layer of subchondral bone. Joint limits are encompassed by a joint capsule, a 
structure that restrains the SF within the joint space and holds the articular surfaces in place. 
Additional structures may be present, such as collateral or intra-articular ligaments, that aim to 
stabilize the joint and limiting movements in undesired directions, in a number that depends on the 
specific motion of that particular joint24,31.    
 
Figure 1 – A schematic representation of the basic structure of a synovial joint (adapted from van Weeren, 2015). 
 
Cartilage is an avascular connective tissue composed of chondrocytes suspended in an 
extracellular matrix (ECM). The ECM contains type II collagen (50% of dry weight), elastin, variable 
amounts of type I collagen, a variety of proteoglycans (PGs) (35% of dry weight), and water (70-
80%). There are other minor components, consisting of glycoproteins, minerals, lipids, and others24,29. 
The hyaline, fibro, and elastic types of cartilage differ in the ECM composition and organizat ion. 
Hyaline cartilage forms the contact surface of synovial joints. Fibrocartilage is a tougher form with 
dense ECM adapted to compressive stress (like the one found in the menisci). The elastic cartilage is 
found in the larynx or the pinna29.  Dense connective tissues are predominantly composed of ECM 
and have a relatively small number of cells29. These components are arranged in four layers: the 
superficial, the intermediate and deep zones (in combination, forming the hyaline cartilage), and the 
calcified cartilage. This last layer sets the demarcation between hyaline cartilage the subchondral 
bone24. The superficial layer is composed of flattened chondrocytes, dense collagen fibrils (type II), 
high water content, and relatively few PGs32. The transitional zone shows an increase in PGs content 
(compared with the superficial layer), with lower amounts of water and collagen. The deep zone has 
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the highest percentage of PGs, and the lowest of water, having chondrocytes arranged perpendicular ly 
to the subchondral bone33. 
Chondrocytes are cells with a mesenchymal origin, with the ability to differentiate into 
fibroblasts. The environment is of significant importance to maintaining the phenotype. Unlike what 
happens with cells in other tissues, chondrocytes do not seem to be connected with each other. Their 
appearance varies with its location within the cartilage, ranging from a round shape in the deep layer 
to a flattened appearance in the superficial layer. These variations in appearance seem to be related 
to shifts in metabolic profiles24. Even though they represent a small portion of the cartilaginous tissue, 
they are responsible for the synthesis, maintenance, and turnover of the ECM29. A reduced number 
of progenitor cells are also present, representing several development stages from the multipotent 
mesenchymal stem cell to the cell-specific to the tissue. These cells are essential for the processes of 
regeneration, adaptation, and remodelling29. The joint capsule comprises two layers. The outer one is 
composed of stiff fibrous tissues, frequently intimately connected with extra-articular structures, to 
provide mechanical stability.  
The joint capsule's inner layer is the synovial membrane or synovium, divided into the intima l 
and subintimal layers. It also covers the walls of bursa and tendon sheaths29. The intimal is composed 
of a layer of a couple of cells, with many blood vessels. It enables an easy passage of components 
from the blood to the synovial cavity, and vice-versa and accounts for SF's description as an 
ultrafiltrate of blood plasma, replaced several times over 24 hours14,24. There are two types of 
synoviocytes. Type A synoviocytes are similar to macrophages and have a phagocytic role, while 
type B synoviocytes are similar to fibroblasts and have the function of producing and excreting 
hyaluronan34. The synovial lining does not have a basal lamination, making it an inefficient barrier, 
providing no type of constraint to cells and mediators' movement. For this reason, periarticular tissues 
are easily and often affected by primary joint pathology while also being the source of secondary joint 
injury29. Subchondral bone supports the cartilage and connects to it through a layer of calcified 
cartilage. It also has an additional layer of compact bone and a greater distance of the cartilage, 
trabecular bone. This conformation bears mechanical characteristics, with the subchondral plate 
providing firm support, which maintains some rigidity (increasing with sclerosis), while the 
trabecular portion has some elasticity24. During athletic activity, the subchondral bone plays an 
important role in attenuation forces generated that load and impact the articular cartilage. Subchondral 
sclerosis, with its reduced elasticity, is a distinct characteristic of osteoarthritis (OA)35,36.    
Collagen molecules have an exceptionally long life when incorporated into the ECM. The 
collagen network is responsible for the tensile and shear stiffness of cartilage37,38. The largest amount 
of collagen in articular cartilage is collagen type II, with its large fibrils that give structure and 
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mechanical properties to the cartilage. Other types of collagen fibres are present in other structures 
of the musculoskeletal system, namely types I and III. Collagen type I, for example, is responsible 
for the high tensile strength of tendons and ligaments. Type II fibrils are arranged in a three-
dimensional arcade structure, with a shape that depends on the joint and main direction of loading 
while providing deformation resistance in multiple directions. These triple helices are made up of 
three polypeptides called alpha chains24,39. The remaining types of collagen fibrils have different 
characteristics, from interrupted triple helices (types IX, XII, XIV, XVI, XIX, XX, XXI and XXII) 
to short-chains (types VIII and X), which can be filamentous in nature (type VI) or a constituent of 
the basement membrane (types IV, VII, XV and XVIII). While all these types do not form fibrils and 
are called nonfibrillar collagen, they associate with fibrillary collagen and regulate its assembly, 
interaction, and diameter40,41. Elastin is another essential component of musculoskeletal tissues, being 
part of tendons, ligaments, joint capsule, and articular cartilage. It is particularly abundant on the 
ECM, in the structures that undergo repeated elongation cycles and elastic recoil, such as the joint 
capsule29.  
PG molecules (comprising a protein and a sugar component, hence glycosaminoglycan or 
GAG) in the ECM form aggregates that disperse between the fibrils of collagen type II and connect 
to them directly through hyaluronan molecules. They also exhibit some side chains of chondroit in 
sulphate24. The basic structure of a PG consists of a core protein with a  variable number of GAG side 
chains attached29. The length of the core protein and side chains decreases with age, which affects the 
structure and properties of the ECM42. They are negatively charged, therefore having a high affinity 
for water. It is this characteristic that accounts for the turgidity and resistance to compression of 
hyaline cartilage29. Hence, PG is responsible for the biomechanical properties of cartilage in 
compression38,43. Hyaluronan belongs to the same family of chondroitin sulfate but has a unique 
characteristic since it is never sulfated nor covalently linked to proteins. Besides being found in the 
ECM, it is also present in SF. Although in a smaller amount, other PGs are found in the ECM, such 
as decorin, lumican, and chondroadherin24,29. In particular, the latter is also present in bone, regulat ing 
its metabolism, decreasing the production of the cytokines interleukins IL-1 and IL-6, which, in turn, 
activate osteoclasts44. Synovial fluid (SF) comprises a high percentage of blood plasma, but with the 
distinct difference of having a high concentration of hyaluronan, which gives it its highly viscous 
character24,45. This fluid is in constant exchange with the blood plasma through the effect of the 
hydrostatic forces generated by locomotion. 
Considering the joint as an organ by itself, and not just a system of ropes, pulleys, glid ing 
surfaces, and lubrication, it is important to see it as part of the musculoskeletal system, working 
together and under the influence of other elements of the system1,6. For example, the support muscles 
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provide for joint function, and prevention of instability is critical. For this reason, during rehabilitat ion 
to correct joint pathologies, a great deal of attention is given to strengthening the muscle structures 
around the joint46. Also, a good muscle function is indispensable for processing proprioceptive 
information and thus ensuring correct joint loading. Like tendons and ligaments, the joint capsule 
provides constant information regarding the position, location in space, and state of loading, which 
allows for corrections in body position6,47. 
 
1.3 Joint physiology 
Joints depend on each of its components' relation and health to fulfill its role in the body. For 
that purpose, all its components must be in an equilibrium between anabolic and catabolic processes. 
This homeostasis among different components (cartilage, synovium, subchondral bone, and possible 
intra-articular structures) is too complicated due to a wide variety of metabolic characteristics and 
turnover rate 24.  For example, collagen type II has an extremely long turnover rate, making the 
network's restoration following injury a complicated task, and playing a crucial role in the poor 
healing capacity of cartilage24. On the other hand, the chondrocyte is the only cell found in normal 
articular cartilage and is the sole responsible for producing all of the ECM components,and  mounting 
the complex network in response to biomechanical challenges. They are arranged in close 
coordination with the orientation of the collagen fibrils with the matrix29. 
Several components regulate this metabolism, but interleukin-1 (IL-1) seems to be the key 
player on it, being regular considered as the cytokine associated with the OA development48,49. IL1 
can influence other molecules' activity, such as matrix metalloproteinases (MMPs), which are 
responsible for cleaving collagen24. MMPs play an essential role in healthy joints and maintaining 
homeostasis. Under normal conditions, chondrocytes maintain a highly balanced control over matrix 
synthesis and degradation, adjusted to meet the tissue’s functional requirements29. Tumour necrosis 
factor-α (TNF-α) acts in synergy with IL-1 and inhibits proteoglycan synthesis50.  
Other anabolic and catabolic growth factors, together with cytokines and mechanical loading, 
have a role of mutual influence to keep the balance of this metabolism.  They affect nearly every 
biological process, from embryonic development, disease pathogenesis, the progression of the 
degenerative processes, and stem cell differentiation51. A wide range of growth factors has been 
identified in joint metabolism, and several have simultaneous anabolic and catabolic effects. The 
major ones with anabolic effect are transforming growth factor-β and insulin- like growth factor-152,53. 
transforming growth factor-β stimulates PG synthesis by chondrocytes and expression of collagen 
type II, possibly counteracting the effect of IL-154. It also stimulates osteophyte formation after 
prolonged periods of exposure55. Insulin-like growth factor-1 stimulates matrix production and 
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inhibits degradation, and when in deficiency leads to OA-like lesions53,56. Cytokines are soluble or 
cell surface molecules, with a role in cellular communication through paracrine, autocrine, and 
endocrine signalling57. They can have a catabolic role, regulating cartilage remodeling by acting on 
target cells to increase products that enhance matrix degradation; anticatabolic or inhibitory action, 
inhibiting or antagonizing the catabolic activity of cytokines; and anabolic activity, acting as growth 
factors on chondrocytes to increase synthetic activity58–62. In the IA environment, cytokines and 
growth factors may diffuse from the SF towards chondrocytes and vice-versa57. The role of different 
cytokines, and their interaction with chondrocytes, are summarized in Table 1. 
 
Catabolic Modulatory Anti-catabolic Anabolic 
IL-1 IL-6 IL-4 IGF-1 
TNF-α LIF IL-10 TGF-β1,2,3 
IL-7 IL-11 IL-13 BMP-2,4,6,7,9,13 
IL-8 Basic FGF IL-1Ra  
IL-17    
IL-18    
OSM       
 
Table 1 - Cytokines and their interaction with chondrocytes  (adapted from Mary B. Goldring, 2000; Rutgers et al., 2009). 
BMP - bone morphogenetic proteins ; FGF – Fibroblast Growth Factor; IGF- Insulin-like growth factor; IL – interleukin ;  
IL-1Ra – interleukin-1 receptor antagonist; LIF – leukemia inhibitor factor; TGF – transforming growth factor; TNF – 
tumor necrosis factor. 
 Motion or movement is a foundation of life, and domestic species are no exception63. The 
effects of mechanical loading on musculoskeletal structures in general and joints, in particular, are 
more evident during an individual’s young phase, with a higher growth phase. Adult and mature 
individuals have a long turnover phase, and extensive remodeling does not seem to occur. These 
changes occur via a cellular response, derived from the nucleus and cell's stimulation, and by changes 
in hydrostatic pressure osmolality and flow of interstitial fluid24. This flow affects the supply of 
nutrients and removal of the metabolic waste and stimulates the production and activity of 
transforming growth factor-β, for example64. It is through the movement of fluid from the ECM to 
SF and vice-versa that nutrients are delivered to chondrocytes. This mechanism is one reason why 
loading is indispensable to the joint’s health, and immobilization is so detrimental.  During 
rehabilitation following joint trauma and/or surgery, correct joint loading is one of the focus of the 
therapy program29.  
Articular cartilage has a good adaptation capability to increased in response to mechanica l 
loading, and physical training has been considered to have beneficial effects on its properties65. This 
cyclic mechanical loading of joints is essential for the maintenance of cartilage tissues’ integrity6 6 . 
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The overall effect depends on the degree of loading and relies primarily on the PG matrix content 
adjustment. The femoral head's articular cartilage in young Beagle dogs has shown to undergo a 
remarkable adaptation to long-distance running, exhibiting minor biochemical changes after one year 
of training. This type of exercise increased the amount of GAG, particularly Chondroitin Sulphate, 
more extensively in the less weight bearing tissue and may have elicited a tendency opposite to 
degeneration65,67,68. There is a strong correlation between the thickness of the calcified cartilage and 
the joint's mechanical loading. Subchondral bone also becomes ticker with loading, a process that 
may not be available when subchondral sclerosis is advanced69. It is responsive to mechanica l 
loading, changing its thickness, reducing its resorption when loading increases and effects depend 
mainly on the degree of compression and, in non-contact areas, the ingrowth of connective tissue 
articular surface may take place70,71.  
Bone is known to remodel and adapt through life, but cartilage and collagen, in particular, are 
much less reactive. In the juvenile individual, however, exercise will have significant effects when 
the joint matures, but will also influence the process of joint development72. An increase in PG and 
enhanced biomechanical properties were observed with moderate exercise (4km/day) in Beagles dogs 
while maintaining an intact surface and normal histological appearance of the articular surface. A 
partial loss of these gains is observed when the exercise load increases (20km/day)65,66,73. If the joint 
is not stimulated during this period, it will still be responsive to loading later in life, but the tissue 
formed will be of inferior quality and more susceptible to lifelong wear and tear72. Exercise, on the 
other hand, predisposes to fewer gross lesions, less ECM staining, greater bone fractions and high 
bone formation rate, having a protective effect on joints, not just against OA but also others such as 
osteochondritis dissecans74,75. In horses, exercise has been shown to increase the amount of newly 
synthesized PG in cartilage. Interestingly, it has no effect on collagen content of the ECM but sites 
known to be predisposed to injury contained significantly less collagen in exercised horses76. 
Low-level activity (walking exercise for six months) does not seem to produce detectable PG 
synthesis changes by chondrocytes, while cartilage regularly submitted to high levels of stress are 
stiffer and may not be well adapted to high biomechanical demands73,77. Immobilization and disease 
place a significant toll on articular cartilage, with long-term immobilization causing alterations of its 
bio-mechanical properties in young animals, possibly permanent, with PG loss and cartilage softening 
probably as a result of a decrease in PG synthesis due to immobilization43,71,78. Changes in joint 
metabolism also occur, with a decrease in IL-1α, tissue inhibitors of matrix metalloproteinase, and 
Chondroitin Sulphate levels, although these changes are reversible in its early stages79. 
The need for continuous, adequate loading is paramount to joint health. A long- term 
deleterious effect in joint tissues was observed in a group of horses with the combination of a 
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sedentary life with bouts of high-intensity exercise72. A similar effect has also been described in 
tendons80. 
 
1.4 Joint biomechanics 
Musculoskeletal tissues are anisotropic and viscoelastic. Anisotropic tissues have mechanica l 
properties that vary depending on the direction of applied stress. Viscoelastic materials have 
mechanical properties that vary with the rate at which stress is applied. Under physiological stress, 
the primary response of these tissues is elastic29.  Between articular surfaces, smooth motion is 
paramount, creating the need for a lubricant. Cartilage provides this smooth surface with low friction, 
maintaining an efficient glide during joint motion. When healthy, cartilage provides an extremely 
low-friction bearing surface. Friction increase is expected from the beginning of a pathologica l 
disease process due to microstructural alterations driven by biochemical and environmental effects81 . 
A boundary layer of lubricants also aids in this process through hyaluronan and lubricin1,82. There are 
two mechanisms involved in this process, boundary and fluid-film lubrication. The first occurs in all 
gliding surfaces of the joint, while the second is additional lubrication between articular surfaces. 
Boundary lubrication is primarily provided by hyaluronan, adherent to gliding surfaces, providing a 
protective layer, and preventing excessive wear and tear83,84. Fluid-film lubrication occurs in various 
forms: hydrodynamic lubrication, when all surfaces retain their shape and remain completely 
separated from each other by the fluid when moving; elastohydrodynamic lubrication, if at least one 
of the surfaces has some elasticity and deforms; if no motion between surfaces occurs and the fluid 
film is squeezed out, a squeeze film lubrication takes place; finally, the fluid also can remain 
entrapped between surfaces, constituting hydrostatic lubrication. In a joint, the situation is more 
complicated since both surfaces deform when loaded, but also fluid from the ECM will be squeezed 
and added to the synovial fluid already present.  
Due to this variety of mechanisms associated with the musculoskeletal system's loading shifts 
to any given joint, synovial fluid’s viscosity changes over an activity, diminishing with increasing 
joint motion24. The ECM has an intrinsic pressure, generated by a balance of osmotic pressure 
(originated by the negative charge of chondroitin sulfation, which attracts water) and the restraint 
imposed by the collagen fibrils. These characteristics account for articular cartilage's viscoelast ic 
properties. When subjected to load, water will be squeezed out, and it will yield. When the external 
forces diminish, water will be drawn back in. If these characteristics are compromised, the described 
mechanism will not work, increasing vulnerability to damage24. This biomechanical concept requires 
an entirely homogenous tissue, which may be the reason for articular cartilage being completely 
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avascular and aneural. Nutrition and removal of waste are guaranteed by assisted diffusion from the 
SF to counteract the lack of blood vessels85.  
The articular cartilage goes through significant deformation during regular activity, but this 
deformation is completely reversible due to its strains' elasticity. The ability to be deformed enhances 
congruity and contact area of articular surfaces during loading, improving stability, and reducing 
stress per unit area29. The joint's fluid component first sustains the impact and then transferred to the 
solid component before the fluid is squeezed out of the compressed region86,87. Due to the complex 
nature of joint loading, different joint areas are subjected to different types of loading with varying 
intensity. This variability can only be addressed by cartilage with different characteristics in different 
sites and is not determined by the genetic background but instead develops in the early phase of life 
under the strong influence of biochemical loading88,89. The most relevant joint loading occurs during 
the weight-bearing phase of the stride. Forces placed by the ground on the limb during this contact 
phase are called ground reaction force (GRF)90,91. The influence of these forces on joints depends on 
their location, congruity, and existing surrounding tissues. Besides, lesions or limitations on any given 
part of a limb can affect other joints due to changes in dissipating or transfer forces26. 
Muscles transmit forces to joints through tendons, storing energy during the loading phase of 
the stride. Lesions to a tendon can affect its ability to store energy, thus increasing forces acting on 
the limb. Unlike the one in ligaments, their collagen structure has a very organized parallel 
arrangement, with a characteristic appearance. Ligaments also contribute to the force generation 
mechanism while restricting joint movement in given plains, affecting force distribution as well90,91. 
The majority of the times, tendons and ligaments are subject to forces and loads below their failure 
limit, so lesions tend to occur due to chronic stress and cumulative failure of individual collagen 
fibers. When enough fibers are damaged, tissue failure can occur, even with physiological loadings 2 6 . 
These facts stress the importance of physical activity, during which submaximal, controlled loads are 
applied to tissues, raising stiffness and strength of the fibrous joint capsule, tendons, ligaments, and 
their interface, by increasing the total amount of collagen fibers, their type, cross-links, and also 
diameter92,93.  
All structures surrounding a joint, (joint capsule, articulating bones, muscles, ligaments, and 
tendons) give it support and tend to restore it to its original position63,94. According to Wolff's law, 
these soft tissues adapt to loading with changes in their composition, in a fashion similar to bone  
(“bone in a healthy person or animal will adapt to the loads under which it is placed”)95. The synovium 
has no known biomechanical function but reacts to the mechanical stress that influences surround ing 
tissues. It increases collagen production, alters trans-synovial diffusion, and synoviocyte metabolism. 
The release of enzymes to the SF affects all tissues of the joint7,96,97. 
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When movement becomes altered or challenge imposed over joint structures exceeds the 
ability to adapt, pathology may develop26,63,72. One of the measures of this alteration is the range of 
physiological movement of the joint, referred to as a joint’s range of motion (ROM). It is 
characterized by a neutral zone (region of low stiffness, produced with minimal internal stiffness) and 
an elastic zone (measured from the end of the neutral zone up to the physiological limit) 9 8 . 
Nevertheless, stress and challenges are a requirement for the health of all tissues that compose the 
joint99. 
 
1.5 The hip joint 
The hip bone (os coxæ) is composed of four bones with different origin and development. By 
the twelfth week, the ilium, ischium, pubis, and acetabular bones fuse, forming the acetabulum. This 
cotyloid cavity receives the femur's head, forming the coxofemoral joint, also referred to as hip joint. 
It is a ball-and-socket joint with a band, with main movements of flexion and extension, although it 
permits abduction, adduction, and multidirectional movements25,100–103. The characteristic of the hip 
joint is summarized in Table 2. 
 
Participating Bones Form / 
Composition 
Classification Movements Normal ROM for dogs 
(in degrees) 
Acetabulum, formed by 
ilium, ischium, pubis 
and acetabular bone + 
head of the femur 







Abduction with a flexed hip 120 (Stifle at 90) 
Adduction with a flexed hip 65 (Stifle at 90) 
Abduction with an extended hip  85 
Adduction with an extended  hip  63 
Internal rotation 55 
External rotation 50 
Table 2 – Characterization of the hip joint (adapted from Budras et al., 2002; Levine, D., Millis, 2014; van Weeren, 2015). 
In a medium-sized dog, the acetabulum is 1cm deep by 2cm in diameter and is further 
deepened by a band of fibrocartilage on the rim, the acetabular lip (labrum acetabulare). The 
acetabulum is deficient on its smooth articular circumference on the medial portion, called the lunate 
surface. It also has a thin quadrangular, non-articular area, consisting of a depression that extends 
laterally from the acetabular notch, forming the acetabular fossa100. The acetabular fossa is an 
important landmark when performing ultrasound (US) guided intra-articular administrations. The 
joint has various mechanisms of stability. The femoral head ligament, the joint capsule itself, and the 
dorsal acetabular rim give primary stability. Secondary stabilization is achieved by the acetabular 
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labrum, hydrostatic pressure resulting from a minimal amount of synovial fluid, and the periarticular 
muscles of the gluteal complex101. 
The femur (os femoris) is the skeleton's heaviest bone and articulates with the hip bone 
proximally. Distally, it articulates with the tibia. It consists of a head, neck, prominent muscular 
processes proximally (the trochanters), and a body or shaft, which is continued distally with the 
femoral trochlea and condyles25. The bones of both pelvic limbs are in parallel sagittal planes100. 
Concerning the hip joint, the femur's relevant components are the head, neck, and two trochanters. 
The head is smooth, almost spherical (caput ossis femoris), and caps the neck's dorsocaudal and 
medial parts. It has a fovea (fovea capitis), where the ligament of the head of the femur attaches 
(ligamentum capitis ossis femoris, formerly round ligament). The neck (collum femoris) unites the 
head with the rest of the proximal femur100. Directly lateral to the femur's head and neck, there is the 
greater trochanter (trochanter major). Here is where the piriformis, gluteus medius, and profundus 
muscle insert, all of which are responsible for extending the hip joint and abducting the limb2 5 . 
Between the neck and the greater trochanter, there is the trochanteric fossa (fossa trochanterica). The 
lesser trochanter (trochanter minor) is an eminence shaped like a pyramid that projects from the 
caudomedial surface. It is connected to the greater trochanter by the intertrochanteric crest (crista 
intertrochanterica), where the deep muscles of the hip joint insert25,100. The deep hip joint muscles 
are the gemelli, internal and external obturator, and the muscles' quadratus femoris. They are the 
supinators of the limb, turning the cranial aspect of the limb laterally25. Another essential muscle 
group comprises the hamstring muscles, the biceps femoris, caudal crural abductor, semitendinous 
and semimembranous muscles, which extend the hip joint and flexion the stifle25. These muscles are 
frequently, and visible atrophied in dogs with moderate to severe OA. 
 
2. OSTEOARTHRITIS – EVOLUTION, SIGNS, AND BIOMARKERS  
 
Synovial joints are subjected to a way range of challenges as a result of its functions. They 
have an ingenious way of facing this burden, even though it comes at the cost of its flexibility and 
capacity to repair, leading to long term problems24. Articular cartilage is an aneural and avascular 
tissue in mature animals, a very distinct characteristic compared to every other tissue in the organism. 
For this reason, any damage to the cartilage, which usually starts as small damage, progresses without 
clinical signs for long periods until the disease is an advanced stage. The vital issue with joint 
homeostasis is based on the possibility of tissue integrity being maintained or not in response to insult 
and, with it, biomechanical characteristics and functionality. If the tissue cannot maintain integrity, a 
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loss in capacity to withstand subsequent loading is inevitable, and, predictably, a vicious cycle of 
overloading and deterioration will ensue. This process will end in the development of a chronic 
condition, such as OA24.   
OA represents a significant burden to societies, as it affects individual’s quality of life and 
implies an enormous cost in terms of healthcare, posing substantial welfare challenges and 
concern24,104. It is the most prevalent musculoskeletal disease in dogs and causes significant 
performance loss in working and sporting dogs29. OA seems to be as ancient as joints themselves 
since signs of OA have been found in ancient fossils, as of a saber-tooth cat 337.000-300.000 years 
old105. From this ancient nature, osteoarthritis currently displays high prevalence, duration, and 
severity, demonstrating particular welfare impact, and has emerged as a priority area for health-
related welfare improvement in the human and canine populations106. 
 
2.1 Osteoarthritis pathophysiology 
The diarthrodial joint should be considered an organ, and joint degeneration is a form of organ 
failure. OA is also referred to as a degenerative joint disease, but this terminology should be 
considered a misnomer. OA is not merely a process of wear and tear but rather a complex abnormal 
remodeling of joint tissues, driven by inflammatory mediators within the joint1. It is a relatively low-
grade inflammatory disease, but the inflammatory process affects the disease's progression, without 
systemic manifestation or presence of neutrophils in the SF107–109.  
The inflammation in OA is distinct from that in rheumatoid arthritis and other autoimmune 
diseases, as it is chronic, comparatively low-grade, and mediated primarily by the innate immune 
system110. It constitutes the endpoint of the synovial joints disease process, interrupting articular 
surface or causing instability and mechanical injury111. Growing evidence suggests that there are 
different OA phenotypes,  reflecting different mechanisms of the disease112. It is a common disease 
of diarthrodial joints, associated with the deterioration of six different structures within the joint: 
bone, articular cartilage, joint capsule, innervation, vascular supply and ligaments113.  
It is characterized by an imbalance between cartilage synthesis and degradation, leading to 
increased breakdown of matrix components, degeneration of articular cartilage, new bone formation 
at joint margins, pain, and loss of function109,114,115. It constitutes the primary cause of lameness in 
humans, dogs, and horses31. At least 80% of the cases of lameness and joint diseases in companion 
animals are classified as OA, with 20% of middle-aged and 90% of older dogs presenting OA in one 
or more joints2,116,117. It is estimated to affect around 200 000 dogs annually in the United Kingdom, 
with risk factors including breed, being neutered, of higher body weight, and older than eight years5. 
There is, however, conflicting information regarding the interactions between and relative weight of 
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risk factors, such as age and sex118. In OA, all joint tissues are affected to some extent due to their 
interaction as a functioning unit69. The osteoarthritic process usually begins long before the disease 
presents as a clinical problem since joint structure and function are typically substantially altered 
before symptoms are noticeable12.  
The initial wear and tear concept was based on the fact that OA is observed primarily in elderly 
individuals. This view is currently less favored since younger patients often display OA symptoms 
secondary to injury or genetic predisposition119,120. Changes seen in involved tissues are attributed to 
diffusible factors, various cytokines, and growth factors, including proteolytic enzymes, such as 
MMPs and members of the Disintegrin and Metalloproteinase with Thrombospondin Motifs 
(ADAMATS) family present in the joint environment during the disease121–124. These factors exert 
their effects by enhancing synthesis, secretion, or activation of proteinases123. The idea that OA is not 
one disease but a syndrome encompassing heterogeneous, stratified groups of patients with 
characteristic aetiologies has been gaining acceptance111. 
Hip OA has a large epidemiological representation in the canine population, with varying 
degrees of severity and many cases are subclinical101. The hip joint should be tight-fitting and 
congruent, capable of withstanding severe exercise throughout a dog’s life without developing OA125. 
Risk factors for OA development are typically divided into two fundamental mechanisms, related to 
the adverse effects of abnormal loading on normal cartilage or normal loading on abnormal 
cartilage126. Changes to normal movement can lead to pathological development. In several cases, 
what makes way to OA is subluxation and/or laxity, leading to partial dislocation of a bone from a 
joint63. Loading of an unstable joint causes severe changes in the structure and function of articular 
cartilage65. Clinical instability of joints, also referred to as pathological hypermobility, leads to 
damage in the structures that restrain a joint’s movement27. At the degree of functional subluxation, 
a corresponding increase in the volume of synovial fluid occurs. On the hip joint, this results in an 
increasingly more significant impact of the femoral head on the acetabular labrum upon foot strike, 
producing cartilage damage and erosion6. Hip dysplasia (HD) is a major example of this incongruity.  
Other risk factors include age, prior joint injury, obesity, genetic predispositio n, and abnormal joint 
shape1. Individual activity levels are also relevant. Sporting and working animals are more exposed 
to chronic fatigue injuries, a term used to characterize the pathological processes that start at the 
molecular and biochemical levels, leading to histological evidence of tissue damage and ultimate ly 
tissue failure, which results in clinical signs127. 
 Pathological changes that occur with OA include degradation of joint cartilage12 8 , 
subchondral bone thickening, osteophyte formation, synovial inflammation, and degeneration of 
ligaments. Besides, periarticular muscles, nerves, and bursa are also affected, contributing to OA or 
16 
 
its symptoms1. The subchondral bone remodeling has been assumed as an initiator of secondary 
changes in the articular cartilage, being more metabolically active in OA than in healthy joints69,129,130. 
Vigorous and intense exercise has also been suggested to decrease PG of the articular cartilage and 
cause erosion, pitting, and fibrillation of cartilage surface68. The failure of osteochondral defects to 
heal after injury or disease is the primary limiting factor of any rehabilitation attempt131. Cartilage 
damage can occur following traumatic injury, chronic overuse, or in consequence of physiologica l 
loads in the presence of anatomical incongruity29. With the development of modern imaging 
techniques, it is becoming evident that most joint insults and injuries, while acute in clinica l 
appearance, develop into a chronic pathological process127. Electron microscopy revealed that impact 
causes rapid structural changes in mitochondria that are related to reduced function. Mitochondria 
has a vital role in mediating cartilage's per-acute response to traumatic injury. Thus, mitochondria l 
protection may be a therapeutic strategy for injury‐induced cartilage damage132. In a traumatica lly 
injured joint, the synovium and joint capsule become inflamed, causing both physical and 
biochemical damage to the joint126. The continuous wellbeing of articular cartilage is vital for the 
joint, as it is almost totally unable to recover from trauma65.  
To evaluate clinical or functional instability, the neutral zone of a joint (a region of no or little 
resistance to motion in the middle of the joint’s ROM) may be a good indicator of clinical of 
functional instability, more than ROM, for example. In the spinal column, the neutral zone increases 
with the injury or weakness of spinal muscle98. It is reasonable to assume that the same mechanics 
may occur in the remaining joints of the body. During high-intensity activities, a greater degree of 
deformation of the ECM may occur, leading to micro-injuries. These micro-injuries induce 
inflammatory responses in vascularized tissues, and the inflammatory mediators produced may 
trigger cellular responses. Depending on the degree, this may represent a net gain in tissue strength 
through anabolic metabolism or a loss through catabolism133–135. The resulting loss of articular 
cartilage is the hallmark of late-stage clinical OA12. At the cellular level, cartilages become thinner, 
irregular, and fissures. With this, the intermediary zone's mineralization ensues, and, finally, cartilage 
loss occurs with exposure of subchondral bone29. Other tissues of the musculoskeletal system have 
different abilities to regenerate. While bone and muscle can do so, tendons, ligaments, and cartilage 
tend to produce mechanically inferior tissues29.  
At a molecular level, initially, articular cartilage becomes depleted of PG66,69,136, followed by 
progressive disruption of the collagen network, allowing water to accumulate69,137. Diseased cartilage 
experiences an increase in water content from a typical 60-85% to over 90%138. When imbalances 
between osmotic and tensile components occur, compromises to the cartilage's mechanical integrity 
take place, leading to ECM degeneration, decreased joint function, and OA139. This reaction sets OA 
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as an active response to injury rather than a degenerative process1. As a result, tissue generated during 
the healing process is usually unorganized. Cartilage overload can lead to the death of chondrocytes 
and rupture of the collagen network of the matrix29. Genes associated with OA, specifically Asporin 
and Calmodulin 1 genes, reduce chondrocytes' ability to express genes encoding Aggrecan and type 
II Collagen140. Once the cartilage's mechanical properties are compromised, there is a reduction in 
the ability to withstand the load, even at physiological levels. This stress causes further damage , 
leading cartilage to enter a vicious cycle29. The interplay between tissues is also altered, with cartilage 
and subchondral bone entering a self-perpetuating cascade of degeneration. Cartilage is highly 
sensitive to TNF-α, which works in strong synergy with IL-1. Physiological relevant concentrations 
as low as 0.25ng/mL are sufficient to increase the release of GAGs from OA cartilage in 
humans109,141,142, and may also be more responsive to IL-1 than healthy cartilage143,144 while being 
essential for its health145.  
In a healthy joint, the degradative process is usually opposed by the production of enzyme 
inhibitors and anabolic growth factors. Degeneration of joints results in forms an imbalance of this 
primary mechanism. While a moderate loss of PG can be restored, an extensive collagen network 
breakdown is irreversible and leads to progressive joint degeneration. Therefore, PG turnover is a 
significant target of the investigation since it represents a vital tissue adaption mechanism. The types 
and concentrations of PG within the ECM in response to stimulation are what allows for the tissue’s 
adaptation according to the demand29. Initially, chondrocytes react to matrix disruption by increasing 
anabolic activity and producing collagen and PG. This reparative response is limited, and, after an 
initial period, the cell ultimately shifts to a catabolic phenotype107. They become activated and 
proliferate, forming clusters that start to produce matrix proteins and matrix-degrading enzymes. This 
process then leads to matrix remodeling, hypertrophic maturation, and cartilage calcification146.  
With the critical loss of matrix components, morphologic damage occurs, going through a 
cycle of chondromalacia, with cartilage softening and swelling (due to loss of water and GAG). 
Superficial fibrillation follows, which then progresses to the middle and, finally, deeper layers of the 
cartilage, leading to loss of articular cartilage and full-thickness erosions126. The paucity of 
chondrocytes in the ECM, their inability to migrate to the zone of injury, and their relative inability 
to regenerate large ECM amounts, meaning these defects will usually progress30. It is interesting to 
note that this progressive cartilage degradation is the result of prolonged exposure to pro-
inflammatory cytokines, such as IL-1 and TNF-α. At an initial phase, these cytokines are part of a 
system for remodeling damaged ECM components in response to mechanical stress or other forms of 
injury109. OA is a common feature in overweight and obese animals. In obese people, it has been 
characterized not only as a consequence of the increased mechanical loading but of the generalized 
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low-grade inflammation that is always present147. The catabolic chondrocyte produces many pro-
inflammatory mediators and MMPs, which degrade ECM components and contribute to tissue 
remodelling148,149. 
The precursor of IL-1α is then translocated to the nucleus of the cell and activates the 
transcription of proinflammatory genes150. MMPs are produced in an inactive preform, and activity 
can be regulated to a point where they are converted into the active form. Active MMPs also form 
clusters with tissue inhibitors of MMPs (tissue inhibitors of matrix metalloproteinase), which leads 
to its inactivation. After an insult to a joint, these two mechanisms can be affected, which leads to a 
rapid increase in MMP activity 24.  The MMP family includes Aggrecanases and Collagenases, 
besides other Serine and Cysteine proteinases151. In addition to these molecules' actions, at the early 
stages of OA, there is evidence of a general increase in synthetic activity. The ECM synthesis pattern 
is also altered, for example, in terms of types of collagen produced 109. Chondrocytes from OA 
patients are deficient in glucocorticoid receptors, and this lack of response to circulat ing 
glucocorticoids may result in increased cytokine and metalloprotease synthesis levels degrading 
cartilage152,153. 
Pro-inflammatory mediators augment catabolic activity through feedback, both in a paracrine 
or autocrine manner. They can also be released in the SF and enhance gene expression of MMPs148,154. 
These mediators' synovium is rapidly activated, resulting in joint effusion and recruitment of 
leucocytes to the intra-articular space. MMPs produced by leucocytes and synovial cells begin 
furthering the cartilage through an attack on matrix components. Cytokines can stimulate the 
catabolic activity of chondrocytes, and matrix degradation results in the release of fragments of many 
of its components to the synovial space. These fragments can function as a biological mediator that 
increases the production of cytokines and MMPs29. IL-1β has been pointed as the most important pro-
inflammatory cytokine responsible for the catabolism in OA, increasing the expression of 
inflammatory genes and mediators, and in relation to lameness duration126,155,156 (figure 2), even 
though several studies have reported low or undetectable levels in OA patients157–159. Low innate 
production of IL-1β and IL-6 is associated with the absence of human OA in the old age160. A strong 
negative correlation between IL-1β and Norberg angles has been described, suggesting that SF's 
activity increases in proportion with laxity severity161. In the porcine knee, OA, the median 
concentration of IL-1α was 0.043 ng/mL in cases of mild OA and of 0.288 ng/mL in moderate OA. 
IL-1β concentrations were 0.109 ng/mL in knees with mild OA and 0.122ng/mL in moderate OA162. 
In dogs with HD, IL-6 bioactivity is correlated with the duration of clinical signs and radiographic 
signs of OA161. In vivo, likely, the presence of cytokines alone would not usually lead to joint 
pathology without any other predisposing factor, such as alterations in gait, stiffening of subchondral 
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bone, joint laxity, or some other altered joint parameter123. Comparing dogs with OA and normal 
joints, differences in pro-inflammatory and anti-inflammatory biomarkers have been detected, but no 
relationship was identified between biomarker concentrations and gait asymmetry in dogs with OA163. 
 
 
Figure 2 – The pivotal role of IL-1 in the cartilage metabolism in osteoarthritic joints (adapted from Chevalier & Kemta-
Lepka, 2010). Legend: ADAMTS – A disintegrin and metalloproteinase with thrombospondin; MMP – matrix 
metalloproteinase; NO – Nitric Oxide; RO – Free radical.  
Early phase matrix degradation might mainly be due to the actions of MMP-3, A Disintegr in, 
and Metalloproteinase with Thrombospondin Motifs 5. These degrade Aggrecan and activate 
Collagenases, particularly MMP-13, which degrades type II Collagen with excellent efficiency. 
Damage of the collagen network seems to be the state that, when reached, cannot be reversed1,115,164. 
Other MMPs are also active, such as MMP-2 and MMP-9, which play a role in tissue repair, 
angiogenesis, and inflammation, digest type-I, II, and IV collagen165–167. Elevated MMP-3 has been 
described in the hip joints of dogs with HD and stifles with Cranial Cruciate Ligament 
rupture155,161,168. MMP-9 concentration has been used to diagnose OA, differing between degrees of 
cartilage damage and described as elevated, along with MMP-2, in SF of canine OA joints169–171. The 
balance between MMPs and tissue inhibitors of matrix metalloproteinase is essential to prevent the 
progression of articular cartilage degradation126,172. MMPs can accumulate in tissues and play a 
prominent role in the degradation of tendons and ligaments as well173.  
Chondrocytes have receptors for ECM components, many of which are responsive to 
mechanical stimulation. When activated, these receptors induce the production of matrix-degrad ing 
proteinases and inflammatory cytokines and chemokines, as initiating or feedback amplificat ion 
events1. Fragments found include fibronectin, small leucine-rich PG, and collagen174–177. As 
discussed previously, disruption of the ECM is a hallmark of OA, and the products of its catabolism 
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have been linked to inflammation through activation of the complement cascade and stimulation of 
Toll-like receptors1. PGE2 produced by chondrocytes, under stimulation by IL-1 and TNF-α in joints 
induces vasodilation, enhances pain perception, proteoglycan depletion from cartilage, bone 
demineralization, and plasminogen activator secretion126. In rats, joint swelling showed to be 
proportional to TNF-α and TNF-R levels178. iNOS is induced by mechanical factors and inflammatory 
cytokines and is an inductor of chondrocyte apoptosis. Excess amounts produce both chondrocyte 
death and matrix degradation179. Chondrocytes express cytokine and chemokine receptors, IL-6, IL-
8, MMPs, PGE2, leukemia inhibitor factor (LIF), and several other genes that enhance or modulate 
inflammatory and catabolic responses, including COX-2, microsomal PGE synthase-1 (PGES-1), 
soluble phospholipase A2  and inducible nitric oxide synthase1,180. Chondrocytes can also have 
apoptosis induced by alterations in mitochondrial function, as a consequence of proinflammatory 
cytokines, prostaglandins, reactive oxygen species and NO action181. With age, they also present a 
secretory phenotype with senesce characteristics, marked by increased production of cytokines, 
chemokines and MMPs 182. Joint cartilage can then become calcified, which in turn can stimula te 
chondrocytes and synovial cells to promote the production of more inflammatory mediators183.  
The nature and characteristics of synovial inflammation may change with the evolution of the 
disease. While macrophage seems to be present in an earlier phase184, the prevalence of synovit is 
increases with the disease stage184–186. In post-traumatic synovitis cases, macrophage and lymphocyte 
infiltration are commonly observed, either diffusely or in perivascular aggregates187. More advanced 
stages are usually accompanied by villous hyperplasia, fibrosis, the debris of cartilage and bone, and 
increased vascularity188. These macrophages, along with activated monocytes, are the first to generate 
IL-1 and TNF-α in an immune response. Once those cytokines are released, they activate non-immune 
system cells such as endothelial cells, chondrocytes, and osteoblast to produce more IL-1 and TNF-
α, thus amplifying cytokine concentrations resulting in severe inflammation189. In particular, 
macrophages that express tartrate-resistant acid phosphate are considered a key factor in promoting 
progressive, irreversible articular cartilage and joint destruction associated with many other 
production degradative enzymes, which has a significant impact on the development of OA168,190–193. 
The complete regulatory mechanism of this disease process is extraordinarily complex and involves 
a wide range of agents. Just regarding pro- and anti-inflammatory cytokines, cartilage explants 
produce IL-1β, IL-4, IL-7, IL-10, and IL-13 but do not secrete IL-6, IL-8, and IL-1Ra. In contrast, 
synovial tissues explants secrete IL-6, IL-8, and IL-1Ra and do not secrete IL-1β, IL-4, IL-7, IL-10, 
and IL-13194. In OA SF, several cytokine profiles are altered: IL-1β (irregularly present), IL-1Ra 
(present), IL-6 (irregularly present), IL-7 (present), IL-8 (present), IL-10 (irregularly present), and 
IL-13 (irregularly present)195. IL-6 is strongly induced by IL-1 and TNF-α and has been described as 
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having high activity in SF samples of dogs with experimental induced OA50,189. IL-11 shares several 
actions with IL-6, including stimulation of tissue inhibitors of matrix metalloproteinase production 
without reflex on MMP production196,197. IL-17 and IL-8 are potent inducers of catabolic responses 
in chondrocytes164,198. IL-17, in particular, increases degradation of cartilage PG independently of IL-
1, and Aggrecanases are responsible for the IL-17 induced cartilage destruction199–201. IL-8 plays an 
essential role in the self-strengthening process of cytokine release and production202. Other cytokines 
play an anti-inflammatory and chondroprotective role, such as IL-10, which suppresses inflammatory 
mediators' release by macrophages (TNF-α, IL-6, and IL-1β), blocks elements of the inflammatory 
pathway, and prevents chondrocyte apoptosis203. A schematic representation of cytokine interact ions 
in the intra-articular environment is presented in Figure 3.  
 
 
Figure 3-  Schematic representation of the cytokine interactions in the intra-articular environment (adapted from Rutgers 
et al., 2009 and Sutton et al., 2009). IL – interleukin; IL-1Ra – interleukin-1 receptor antagonist; LIF: Leukocyte-
inhibitory factor; MMP: Matrix metalloproteinase; NO: Nitric oxide; OPG: Osteoprotegerin; OSM: Oncostatin M; TIMP: 
Tissue inhibitor of matrix metalloproteinase. 
Many cytokines and chemokines can promote synovitis. Many of them are increased in SF 
during OA, particularly IL-1 and TNF-α, which suppress matrix synthesis and promote cartilage 
catabolism108,146. Exposure to IL-1β stimulates chondrocytes and synovial cells to produce catabolic 
proteases with apocrine signaling, further enhancing MMP release and the resulting degradative 
cascade180,204. IL-1α also plays a role in bone pathophysiology, being known as osteoclast activating 
factor205. The level of several cytokines in SF, its sources and effects are presented in Table 3. 
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<3.0 Increase cartilage and bone resorption  
Inhibit proteoglycan synthesis  
Up-regulate MMP expression  
Production of proteolytic enzymes  
Stimulate other cells to produce proinflammatory cytokines 
Stimulate other cells to produce chemotactic cytokines 
Stimulate pro-angiogenic factor release  
Stimulate NO production 
Induce chondrocyte apoptosis 
IL-4 Synoviocytes, 
chondrocytes 
0.1 Suppress gene expression of TNF-a and IL-1b  
Reduce pro-inflammatory cytokine production, inflammation, 
vascularisation, and cartilage degradation 
Inhibit IL-1b stimulated production of PGE2  
Inhibit LIF synthesis by acting directly on OA synoviocyte IL-1b and 
TNF-a-induced LIF production 
Reduce MMP-3 transcription and activity in articular chondrocytes 
Up-regulate expression and production of IL-1Ra by human OA IL-1b-
activated synoviocytes 
Decrease osteoclast formation, thereby reducing bone resorption 




0.5 Inhibit proteoglycan synthesis  
Reduce chondrocyte proliferation  
Increase MMP-2 activity 





89.9 Recruit leucocytes  
Neutrophil chemoattractant 
Stimulate the release of pro-inflammatory cytokines  
Hypertrophic differentiation and calcification of chondrocytes 
IL-17 Activated T-
lymphocytes 
0 Induce NO synthesis  
Induce MMP synthesis  
Increase production of IL-1b, Il-6, and IL-8  
Stimulate the release of pro-angiogenic factors 
TNF-α Synoviocytes, 
chondrocytes 
<5.0 Increase cartilage and bone resorption  
Inhibit glycoprotein and collagen synthesis  
Up-regulate matrix metalloproteinase (MMP) expression 
Stimulate other cells to produce proinflammatory cytokines and growth 
factors 
Stimulate pro-angiogenic factor release 
Stimulate other cells to produce chemotactic cytokines 
Stimulate nitric oxide (NO) production  
Induce chondrocyte apoptosis 
IL-1Ra Synovial 
membrane 
614 Competitive inhibitor of the IL-1b receptor 
Inhibit MMP production 
Table 3 – Concentration of different cytokines in SF, its sources, and effects (adapted from Rutgers et al., 2009 and Sutton 
et al., 2009). IL – interleukin; IL-1Ra – interleukin-1 receptor antagonist; TNF – tumor necrosis factor. 
Synovial inflammation and damage-associated molecular patterns (DAMP) or alarmins have 
also been implicated in the activation of inflammation and catabolic events in articular cartilage and 
collagen while also acting as ligands of Toll-Like Receptors. OA cartilage lesion areas, as the 
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synovium itself, also lead to increased expression of inflammatory and catabolic genes, includ ing 
MMP-3, MMP-13, nitric oxide syntase, and C-reactive protein (CRP)206–210.  Synovial inflammatory 
infiltration is observed in OA, secondary to the release of cartilage breakdown products, and it affects 
cartilage metabolism by reducing GAG production194,211,212. Acute synovitis may be one of the first 
changes in OA, as synovial tissue from early patients has been shown to over-express inflammatory 
mediators and may even be the initiator31,213. Recent studies have demonstrated a direct association 
between joint inflammation and OA progression, and its degree is usually associated with the 
disease’s progression108,214. These changes occur from an early stage of the disease, after joint 
insult185,209. An association between this low-grade inflammation and disease manifestation has been 
made215,216. Acute synovitis and capsulitis have been described as the most common problem in high-
motion joints of athlete horses and may contribute to the degradative process in articular cartilage by 
releasing enzymes, inflammatory mediators, and cytokines, being a driver of OA126. In humans, 
synovitis was found in more than 50% of patients with normal radiographic knees and connected with 
the continuation of the structural changes seen in OA214,217. It is reasonable to assume that this is also 
true in dogs. The accumulation and activity of immunological cell populations within the inflamed 
synovium are likely to depend upon pro-inflammatory cytokines' secretion and exhibit synovial lining 
cell hypertrophy and cellular infiltration189,212. In advanced cases of OA, changes in the synovia l 
membrane can mimic those in rheumatoid arthritis217.  
CRP is an acute-phase protein, mainly synthesized in the liver during an inflammato ry 
reaction or tissue injury, and is also produced at the inflamed tissues19. It has the advantage of being 
an objective, quantitative marker of inflammation that is not biased by treatment with NSAIDs or 
glucocorticoids19,218–220. Therefore, this acute-phase protein can be used to assess the innate immune 
system’s systemic response to infection, inflammation, or trauma221–223. CRP is accepted as the most 
useful acute-phase protein in the dog, similarly to man, with the advantage of its shifts being noted 
from a very early stage19,224. At the joint level, its concentration in dogs' stifle with naturally occurring 
Cranial Cruciate Ligament rupture is higher than in normal stifles and lower in the stifles of dogs with 
OA from other sources. Its serum concentration is also higher in dogs with thoracic limb lameness 
than pelvic limb lameness, before and after treatment171,225. A study showed that dogs with OA 
correlated with SF IL-6 and serum CRP226. A small increase in CRP quantity has a potential predictive 
clinical value in rapid diagnosis progression of knee OA in humans227. Also, in humans, a reduction 
of CRP levels following therapy is predictive of clinical response within 12 to 24 weeks in over 50% 
of patients with OA228. It has also been associated with the severity of pain and the events that 
ultimately lead to radiographic progression of OA229–231. High sensitivity CRP is another biomarker 
that reflects systemic synovitis187.  
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Lymphocytes compose most perivascular infiltrates209, and many cytokines promote their 
activation, activity, and survival. For example, serum levels of IL-15 have been associated with the 
evidence and progression of radiographic OA232. Its synovial levels are also increased in early OA233. 
Lymphocytes also produce cytokines, being the predominant source of IL-17, which induces 
chemokine production by fibroblasts and chondrocytes in synergy with IL-1 or TNF-α234. A decrease 
in anti-inflammatory cytokines, such as IL-1 receptor antagonist (IL-1ra), soluble TNF receptor-I 
(sTNF-RI), and sTNF-RII, led to reduced pain and lameness scores in dogs with OA 235.  
Subchondral bone changes in volume and density reflect loading history. Bone remodeling in 
OA may also be initiated at local bone damage sites, which occur due to excessive repetitive loading. 
This damage is usually associated with the appearance of microcracks that initiate targeted 
remodelling236. Additionally, changes occur at joint margins and entheseal sites, where new bone is 
added by endochondral ossifications. Although no definitive understanding of osteophytes' role, they 
may stabilize the joint rather than contributing to OA progression237. The formation of osteophytes 
has been linked to high transforming growth factor-β concentrations238. The properties of subchondral 
bone influence the characteristics of organic bone. The properties change during the progression of 
OA, being associated with a decreased bone modulus, possibly due to a decreased and incomple te 
mineral density, resulting from an increased rate of remodeling. This remodeling may have significant 
implications in treatment strategies for targeting subchondral and periarticular bone remodeling in 
OA239. It has a substantial role as a mechanical damper and a source of inflammatory mediators in 
the OA process, pain, and the degradation of the deeper layers of cartilage119. The subchondral bone 
itself is a source of inflammatory mediators and OA pain240. The bone then enters a high and 
continued mineral deposition phase, making it more resistant to deformation and, therefore, more 
fragile, adversely affecting the overlying articular cartilage241. Also, bone plays an important role in 
cartilage health. Removal of cartilage explants from the underlying bone tissue leads to a higher 
percentage of cell death in chondrocytes than if they were left attached to the bone242. During OA, 
calcified cartilage separates articular cartilage from the subchondral bone and goes through marked 
alterations. This process involves penetration by vascular elements recapitulating the growth plate's 
vascular event that occurs during development243,244. This complex interaction between cartilage, 
synovium, and subchondral bone leads to synovial hyperplasia and villous hypertrophy, decrease the 
quality of synovial fluid, subchondral bone sclerosis, and persistent capsular inflammation and 
fibrosis29.  
SF characteristics are also affected by the osteoarthritic process during the early stages. SF 
hyaluronan concentrations are reported to increase as a result of elevated synthesis in response to 
pathological stimuli245. As the disease progresses, hyaluronan concentrations decrease to amounts 
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below normal, as synthesis is overcome by degradation and loss 246–248. All of this leads to joint 
stiffness with decreased ROM, further contributing to OA progression and continuously changing the 
patterns of cartilage loading29. 
 
2.2 In vitro and animal models 
Several models have been developed to study OA in an attempt to mimic the factors and 
conditions which initiate the disease or dissect the pathways active during its progression180. They 
are divided into spontaneous and induced, surgically, or nonsurgically249. Slowly progressive 
spontaneous models of disease have the advantage of mimicking the course of primary OA in humans 
more closely, without the need for intervention. Surgical models have the advantage of repeatability, 
rapid onset, and progression. The rapid course of the disease, however, makes them less ideal models 
of spontaneous OA11.  
Most in vitro models use supraphysiological loads of cytokine concentrations compared with 
the naturally occurring disease to impart a timely response from cells or tissues. Although this helps 
to understand the role of a single stimulus, models that comprehend different physiological and 
molecular aspects of the disease and reflect the naturally occurring disease's pathogenesis are usually 
prefered180. A limitation often pointed to in vitro approaches is that they can’t replicate the complexity 
of a multiple living tissue organ such as the joint250.   
Animal models were used to study human OA, providing valuable advantages and significant 
information in comparison with human OA research. Both the spontaneous disease  and the surgica l 
induced models have similar pathogenesis to that observed in humans121,251,252. Animal models also 
offer the opportunity to study early features of the disease's development, before the installation of a 
fulminant catabolic process, more difficult to dissect. In vivo studies suggest that different joints from 
different species are physiologically comparable180. Besides, companion animals share the same 
environment and suffer similar co-morbidities as humans, with OA usually being present for 
prolonged periods. These naturally occurring painful disease models may better reflect the complex 
genetic, environmental, temporal, and physiological influences present in humans253.  
The dog is a common and appropriate model for OA's study, and, significantly enough, 
spontaneous OA is common in dogs, in multiple joints, from various aetiologies. It is considered a 
nearly ideal species for human OA translation research and the most used research model. It has the 
advantages of being anatomically, biochemically, genomically, and molecularly similar to humans, 
with clinical progression and treatment similarities, where degenerative, trauma, and overuse 
aetiologies occur7,11,253,254. They also share many of the environmental variations that influence 
human OA. Along with their foreshortened lifespan and equivalent life stages to those in humans, the 
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dog holds the potential for a longitudinal evaluation of the disease and its treatment111,255,256. There 
are numerous studies published regarding spontaneous OA models (from HD, elbow dysplasia, to 
anterior cruciate ligament – ACL, deficiency), surgically induced models (ACL transection, abrasion, 
cartilage defect, joint distraction, and others), enzymatic/chemically induced OA (using iodoacetate, 
calcium pyrophosphate, and others) and impact models (acute patellofemoral loading)7,50,168,257. As 
referred, there are several reasons for this magnitude of interest, namely anatomical disease 
mechanism, response to treatment, and clinical similarities to humans. Other animals, such as the rat, 
are also commonly used, but they do not share the entirety of similarities with the human disease as 
the dog does, and naturally occurring disease is also very uncommon7. For example, in rodent models, 
in contrast to what happens in the canine model, the complement of MMPs and degradation products 
are not as consistent with humans, and rodent models are a poor predictor of drugs' efficacy or toxicity 
in human OA115,258,259.  
It is essential to determine to what extent induced OA represents the naturally occurring 
disease172. Most in vitro research mimic OA by adding inflammatory cytokines, such as IL-1 or TNF-
α, to cartilage explants of chondrocyte cultures. However, OA is a slowly progressing disease, and, 
in naturally affected joints, cytokine concentrations are relatively small180,194. Despite this, animal 
models still provide evidence that IL-1 has a role in inducing PG loss after intra-articular (IA) 
injection and that IL-1ra has been able to slow down the progression of OA212,260–264. IL-1ra  
expression levels increase to limit IL-1 signaling in response to several inflammatory stimuli. The 
concentration in healthy canine joint fluid and dogs with OA may play an essential role in the 
pathogenesis and treatment of OA265. Other models have also provided insight into how the initia l 
stages of the disease occur. In a chemical- induced OA model, sodium urate injection to a joint causes 
synovitis, a dramatic increase in synovial PGE2 concentration, and an initial infiltration of 
monocytes, macrophages, and mast cells. This process is followed by polymorphonuclear leukocytes 
into the synovial space and is generally accompanied by pain266,267. This infiltration by mononuc lear 
leukocytes of the synovium is a process that is initiated at a very early stage after injury and remains 
present throughout the entire development of OA268. Suitably aligned studies of spontaneous OA in 
dogs, particularly hip and knee OA, could highlight new advances regarding the disease.  
Developing cross-species collaborations will provide a wealth of research material and 
knowledge relevant to human OA, and that cannot be obtained from rodent models of experimenta lly 
induced dog models of OA. Changes in slowly progressive spontaneous dog OA closely match those 
of human OA while contrasting with those seen in rapidly advancing experimental surgical induced 
dog OA269. Dogs may, therefore, be embraced as a missing link in the translation of OA treatment 
from mice to men270. Animal studies could potentially reveal the underlying biochemical pathway(s), 
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refine treatment modalities, and provide opportunities for new treatment and prevention targets256. 
Therefore, the dog is an ideal species to study human OA and exploring spontaneous dog OA under 
the One Medicine initiative to improve the health and well-being of both humans and dogs111,252. 
The search for biomarkers measured in the SF, serum or urine, that would be a good indicator 
of OA's development and evolution, has been under significant attention, and can be measured in SF, 
serum, or urine12. A biomarker can be defined as a characteristic that can be objectively measured 
and evaluated as an indicator of normal biological or pathogenic processes or pharmacologica l 
responses to a therapeutic intervention. They can be anatomical, physiological, biochemical, or 
molecular parameters associated with the presence and severity of specific diseases, detectable by 
various methods including physical examination, laboratory essays, and imaging271,272. The best 
candidates for biomarkers are most likely to be structural molecules or fragments linked to cartilage, 
bone, or synovium and may be specific to one type of joint tissue or common to them all273. Although 
it is complex to assess the impact of different biomarkers on OA pathogenesis, it is recognized that a 
putative biomarker would offer the potential to monitor disease more easily since early structura l 
changes will likely remain asymptomatic for years172,272. Markers of other musculoskeleta l 
components have also been studied, as is the case of tenascin-C, an ECM glycoprotein of the 
myotendinous junction. SF levels have been correlated with the degree of inflammation, chondrocyte 
differentiation, cartilage degradation, and radiographic severity of OA274. Its synthesis is mainly 
regulated by IL-6, but also by IL-1 and TNF-α275–277. 
Given that, they can be categorized as direct or indirect molecular markers. Direct markers 
are measures of tissue synthesis or breakdown, reflecting anabolic or catabolic processes. Indirect 
biochemical markers, such as cytokines, inflammatory mediators, growth factors, and enzymes, are 
released with trauma and disease processes, affect tissue turnover, but are not themselves generated 
in the process of tissue synthesis or breakdown. While direct markers may more closely represent the 
status of joint degeneration, indirect markers can be used to learn more about the processes preceding 
or leading to the development of OA254,272,278. They can also be categorized using the five-point 
BIPED classification scheme developed by the Osteoarthritis Biomarkers Network, which stands for 
burden of disease, investigative, prognostic, efficacy of intervention and diagnostic273,279. Biomarkers 
can be pro-inflammatory mediators, typically produced in the early phase of inflammation or tissue 
destruction; enzymes and their inhibitors, which play a role in joint destruction; or extracellular 
cartilage products degeneration172. Several have been pointed out as sensitive and specific for early 
cartilage changes related to different joint components, such as the biomarker of intact proteoglycan 
(aggrecan 846 epitope) or cleavage (BC-3 and -14) and type II collagen degradation (Col2-3/4Clon g 
mono and Col2Ctx) and synthesis products (protocollagentype II C-protopeptide or one of its two 
28 
 
isoforms)12,172,280. These breakdown products are released into SF and cleared into the serum and 
urine, where they are measured as biomarkers for disease progression or response to therapeutic 
intervention115. High stromelysin production occurs in OA cartilage of dogs and, in cartilage explants, 
appears to correlate with OA severity164. One of the significant limitations in identifying specific 
biomarkers can be attributed to articular cartilage since most of the body’s cartilage is located in the 
respiratory system and spine12. Others provide a real-time quantification of the formative and 
resorptive activities of bone281.  
Diagnostic biomarkers ideally identify patients at an early stage of OA where treatment may 
be most effective. Although there have been many promising studies in this direction, no single 
biomarker stands out for use in OA diagnosis273. C-terminal telopeptide of collagen type II has been 
used as a biomarker for the burden of disease due to its correlation with the presence of osteophytes 
and reflection of bone turnover169,282,283. It was also studied as a prognostic biomarker since high 
urinary levels are associated with radiographic progression, independent of age, sex and body mass 
index 284, and the efficacy of intervention biomarker, since several studies have linked its urinary 
levels to interventions in OA285. Serum lysophosphatidylcholines to phosphatidylcholines ratio can 
predict clinical response to licofelone and naproxen treatments in symptomatic knee OA patients , 
with a greater than optimal ratio cutoff of 0.088 corresponding to a 2.93 fold chance to respond to 
specific NSAIDs286. Experimental models have demonstrated an increase of total and active 
collagenase in OA cartilage and an imbalance in activation and inhibition of MMPs123. Increased 
GAG levels in SF samples have been described as markers of cartilage degradation, but their levels 
may be influenced by inflammatory activity, joint effusion, and cartilage OA stage 287–289. Some 
genetic polymorphisms related to cartilage breakdown have been identified, and some provide 
interesting insight, like the fact that the risk loci are generally specific to hip or knee, indicating joint-
specific disease pathways290,291. SF CRP is a possible useful biomarker of joint inflammation and a 
tool to monitor response to anti-inflammatory treatment. Although its origin is yet not fully known, 
it is very probably located within the joint19. The level of SF CRP is elevated in dogs with naturally 
occurring OA compared to control dogs, but not with a corresponding increase in CRP serum 
levels292,293. A different study found a contrasting relation, with dogs with chronic OA showing high 
plasma CRP levels, and serum vitamin B12 and folate concentrations, compared with normal dogs294.   
Several factors, like exercise and activity, may affect biomarker levels in SF. It appears to be 
dependent on the amount of exercise performed, and most of them will not react to light-modera te 
exercise but may increase in case of strenuous exercise. These results reflect the effect of heavy 
exercise on the metabolism of the ECM components72. The evaluation of biomarkers in the serum 
and urine is usually less rewarding than in SF since other systemic conditions not related to OA may 
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affect their concentration254. An additional constraint is a fact that even mild synovitis, as seen in OA 
cases, may significantly increase the clearance of a molecule from a joint, thus affecting its 
measurement217. Additional factors, such as activity or immobilization, also affect clearance rate79. 
Overall, this field is still characterized by many contradictions, and, to date, neither a general, 
universal biomarker of OA nor a joint/aetiology specific biomarker in synovial fluid is available for 
use in small animal practice172,273. The ones with the most consistent evidence appear to be those at 
the end of the pathways of tissue destruction, which may be more specific for a particular tissue, as 
is the case of C-terminal telopeptide of collagen type II273. An alternative to this limitation is the 
possibility of analyzing clusters of biomarkers related to specific pathogenic processes, as cartilage 
synthesis, synovium, or inflammation295.  
 
2.3 Joint pain 
Pain is the most relevant clinical sign of OA and a hallmark of the disease24,249. It is a mult i-
dimensional experience, with a sensory, evaluative, and affective component. Like happiness, it is 
not directly measurable296. In dogs, OA related chronic pain is currently underdiagnosed and 
managed297. The symptomatic management of this pivotal symptom is central in both human and 
veterinary clinical practice, and the current therapeutic goal for both species is the management of 
pain and associated loss of function270,298. Pain may be classified according to its duration (acute, 
chronic, or intermittent), anatomic origin (somatic, visceral, or neuropathic), and severity (mild, 
moderate, severe, or excruciating). Chronic pain typically refers to pain with a duration greater than 
three months299. One clear difference between dogs and humans is the ability to self-report pain111. 
There is a lack of a gold standard in veterinary medicine to assess articular pain in patients with 
naturally occurring disease. Still, much progress has been made in developing methods to measure 
chronic pain via subjective and objective methods, particularly in owner assessment tools and limb 
use measurements and activity300. Others focus on clinical metrology instruments (CMI), with recent 
research areas extending to develop measures of activity, sensory function, and quality of life (QoL). 
In all of these areas, more data on validity is needed, and assessments are made by testing in field 
studies, which incur considerable time and expense301. Exploring peripheral mechanisms of arthrit ic 
pain in animals like dogs has the potential to reduce the veterinary burden of OA and to improve the 
translatability of pain research into the human clinic302. Intra-articular anesthesia is a commonly used 
tool to detect articular pain, but its limitations since the simultaneous contribution of various anatomic 
and pathological sources of pain concur in OA272. 
Serum cortisol levels may also be used to assess joint pain in dogs, with a cut-off set at 
≥1.6µg/dL to detect most dogs with pain in a trial comparing cortisol levels with force plait 
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analysis303. The perception of pain is transmitted through afferent fibers, with peripheral neurons also 
exerting efferent functions, through the mediation of neuropeptides304. Similarities in 
neurophysiology across mammals strongly suggest that humans' and animals' type of pain is 
analogous305. It involves a multiplicity of pathways, mechanisms, and transmitter systems, which 
likely explains why a single analgesics class is usually unable to provide complete analgesia30 6 . 
Neuropeptides are small molecules produced in the spinal cord's dorsal root and autonomic ganglion 
neurons capable of inducing the release of cytokines, prostaglandins, and nitric oxide (NO). They can 
also have an action similar to growth factors in a healthy joint, meaning that they play a role in joint 
homeostasis307. Canine studies of naturally occurring OA pain add valuable data supporting drug 
treatment mechanisms that may translate to humans308. 
Since the joint is a complex organ, affected by many pathological processes, the cause and 
precise origin of pain may be hard (if possible) to determine. The perception of pain and overall joint 
function will be influenced by sensory innervation of all composing tissues, from subchondral bone, 
periosteum, synovium to the capsule. When pathological processes take place, the exposure of 
subchondral bone, tissue remodeling with osteophyte formation, and marrow edema can all contribute 
to the perception of pain that is triggered when deterioration reaches the synovial membrane and/or 
the bone beneath joint cartilage by a self-perpetuating vicious cycle, which is schematica lly 
represented in Figure 4. Deep somatic pain originating in joints and tendons is a major therapeutic 
challenge 309,310. 
 




Joint swelling, a consequence of synovitis, together with fibrosis, activates the joint's 
mechanoreceptors, further increasing the perception of pain 24. Muscle masses surrounding joints also 
contribute to pain perception, both as a primary source and because of compensatory mechanisms, 
and are invariably atrophied in chronic joint pain312,313. The pain generated by OA has the potential 
to alter the normal function of the limb, a phenomenon referred to as functional allodynia314. There 
is evidence that joint pain leads to central sensitization, which facilitates nociceptive output and 
amplifies signals, resulting in greater perceived pain. This process is due to the central nervous 
system's plasticity and functional alteration in response to peripheral nociceptive input315–318. In the 
spontaneous canine OA model somatosensory sensitivity occurs, which is an indicative of central 
sensitization. This a further validation of the canine spontaneous OA model as an appropriate model 
of the human OA pain condition319. Most nociceptors are polymodal, responding to noxious 
mechanical stimuli, mechanical stimuli (painful pressure, squeezing or cutting of the tissue), thermal 
stimuli (heat or cold), and chemical stimuli320. Nociceptors of joints respond to noxious mechanica l 
stimulation of the joint or are silent321. During acute pain, the nociceptive processes and the subjective 
experience are closely related but can differ in chronic states309. With time, spinal sensitization occurs, 
increasing spinal cord neurons' excitability, making them more susceptible to peripheral inputs and, 
therefore, giving stronger signaling to stimulation318,322. With inflammation, chemical stimulation of 
nerve afferents induces pain, and polymodal nociceptors are then sensitized309. It is conducted by 
different endogenous mediators, with IL-1 and TNF-α at the head in OA, while also stimulating the 
production of other mediators, such as PGE2, cyclo-oxygenase -2 (COX2), microsomal PGE 
synthase-1, and soluble phospholipase A2. The cycle further perpetuates itself by the upregulation of 
NO production109,241. In particular, activated synoviocytes release a wide range of inflammatory 
mediators, including kinins, leukotrienes, prostaglandins, and acute-phase proteins such as serum 
amyloid A272. Many of these molecules can act on polymodal nociceptors, as free C-fiber and A-δ 
nerve endings272. These synoviocytes also have an inferior in vitro fibrochondrogenic potential 
compared to normal ones. However, given adequate conditions, they can produce ECM components 
at a comparable level of normal joints198. Inflammatory pain is linked to sensitization of sensory 
proteins at the nociceptive endings whereas pain originating from nerve damage (neuropathic pain) 
has been linked to axonal ion channels producing ectopic discharge in nociceptors as a source of pain. 
They show increased responses to normal stimuli, have a lowered threshold, and recruit silent 
nociceptors309. In humans, as in dogs, patients suffering from chronic pain conditions, such as OA, 
are deficient in controlling noxious input to the central nervous system323. This effect is associated 
with canine OA pain, and the naturally occurring canine OA model may be used to test drugs that 
normalize this function324.  
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PGE2 is also considered a central mediator of pain in OA, with the ability to sensitize neurons 
and reduce their activation threshold, enhancing response to other stimuli325,326. Its production 
requires the enzymes COX-2 and PGE synthase, both of which are induced by IL-1β 126. TNF-α is 
another crucial mediator of mechanical joint hyperalgesia, being implicated in the initiation of 
neuropathic pain pathways327–329. Several other nociceptive molecules are recruited into the 
osteoarthritic joint, including nerve growth factor, calcitonin gene-related peptide, and chemokine 
ligand 2 causes activation of peripheral nociceptors330–332. Sensory nerve fibers that express nerve 
growth factor have been observed in the vascular channels associated with osteochondral 
angiogenesis in the calcified cartilage and maybe an additional source of symptomatic pain243,244,333. 
nerve growth factor has been pointed out as a critical driver of pain in OA, and antibodies directed at 
nerve growth factor are potent analgesics in humans334. Artemin, a neurotrophic factor, and its 
receptor, glial-derived neurotrophic factor family receptor alpha-3, have been identified as involved 
in pain and may play an important role in chronic pain associated with OA in dogs. Elevated serum 
levels of artemin from osteoarthritic humans compared to healthy individuals suggest translationa l 
relevance335. 
 
2.4 Physical examination 
As a whole, orthopaedic conditions of the pelvic limb are some of the most frequently 
diagnosed causes of lameness in dogs336. Along with Cranial Cruciate Ligament disease, hip dysplasia 
and OA are the most commonly diagnosed problems337. Clinical signs of OA can vary significantly, 
both in presentation and history, ranging from mild discomfort to severe acute or chronic pain, 
restriction of activity level, limitations in the ability to perform, poorer proprioception, and loss of 
strength and flexibility6,338. Most animals with OA will probably live with the undetected disease for 
a large portion of their life, since identifying OA-associated pain signs may be very difficult, 
especially earlier in the disease process339. 
In dogs with hip dysplasia, the primary culprit is joint laxity, which causes joint subluxation 
and subsequent osteoarthritic changes. These animals will often exhibit a biphasic pattern of clinica l 
signs throughout its life. Initially, at around 5-9 months of age, a period of lameness is observed and 
is usually a consequence of capsular stretching and tearing, with degeneration of the femoral head 
ligament, synovial fluid overproduction, subchondral bone sclerosis, and synovitis. Typically, a 
period of stability then ensues, with synovial fluid reduction, joint capsule hyperplasia, and bone 
remodeling. This phase is often associated with reduced or unapparent pain. Gait alterations 
developed during this period to minimize pain may lead to subsequent compensatory problems340 .  
Particularly in large and giant breeds, most clinical signs are observed in the older population, with 
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the disease at a chronic stage. Lameness is usually due to OA's consequences, and patients exhibit a 
history of uni or bilateral pelvic limb lameness, difficulty raising, stiff gait with reluctance to run or 
jump6,101,125,341. Compared to other joints, hip OA seems to be better tolerated by animals, and dogs 
presenting with the disease often have slightly abducted pelvic limbs, easily noticeable when the 
animal is standing, increasing acetabular coverage101.  
It is necessary to conduct a neurological and orthopedic examination and rule out other 
conditions that might have a similar presentation to attribute clinical signs to the hip joint. In a 
retrospective report, 32% of cases referred to a teaching hospital for HD management had cranial 
cruciate ligament rupture342. Unlike those with musculoskeletal disease, patients with neurologic 
conditions do not have pain that worsens at different times of the day or with exercise, but rather 
signs that are always present. Some signs may be overlapping, as dogs with orthopaedic related pain 
will often have inadequate or slow paw replacement during proprioception testing343. Documenting 
the history of lameness is also essential, as the expectations for the animal’s level of activity and 
use344. While owners can identify a wide range of acute and chronic OA clinical signs, typically subtle 
and intermittent, behavioural and demeanour changes in their dogs’, few attribute these changes to 
OA. In some cases, many months can go by before these patients are presented to a veterinary 
practice345. 
During the static examination, protrusion of the greater trochanters, dorsal and laterally, may 
be observed. Dysplastic dogs may exhibit a wide-based stance (on an early phase, to reduce the hip 
joint) or a narrow-based stance (to reduce discomfort caused by reduction of the femoral head after 
subluxation).  Muscular atrophy is a consistent finding and may be evident within a few 
weeks6,101,336,346. Pelvic limbs may also be tucked under the body, the back is maintained arched, and 
shoulders muscles may be hypertrophy due to a shift of body weight towards the thoracic limbs341,346.  
On palpation, pain may sometimes be elicited by applying pressure over the hip and also when placing 
the joint through its range of motion (ROM), mainly during extension. The joint should also be 
manipulated through flexion/extension, abduction/adduction, and internal/external rotation. While 
doing this, restrictions in range (figures 5 and 6), crepitus, and pain should be assessed. Due to its 









Mild OA  Stiffness, decreased activity, 
lameness 
Moderate OA  Pain, muscle atrophy, difficulty 
rising 
Severe OA  Loss of range of motion, 
vocalization, crepitus, lethargy, 
inappetence 
Table 4 – Common clinical signs of osteoarthritis (adapted from Towell & Richardson, 2010). 
 
Goniometry is a reliable and objective method for determining the ROM of joints348 .  
Coxofemoral ROM may also be diminished, particularly during extension, and crepitus may be 
present6. This restriction is not a universal finding since animals with poor function may have a 
reasonable ROM, and those with severely restricted ROM may function reasonably well349. Normal 
ROM of the hip joint in military working German Shepherd Dogs have been described as 44°±6 at 
flexion and 155°±6 at extension350. In Labrador Retrievers, a normal ROM of 50°±2 at flexion and 
162°±3 at extension in one report, and 49°at flexion and 159° at extension in another has been 
presented348,351. Normal ROM values have some variation according to the dog size, breed and 
type352. 
 




Figure 6 - Goniometry of the hip joint at a flexion. 
  Manipulation of the joint should isolate flexion-extension from adduction-abduction and 
assess internal and external rotations. At this point, it is important to differentiate between caudal 
lumbar/lumbosacral pain and pelvic limb pain. While hip extension will inevitably produce 
lumbosacral spinal pain and hip pain, pain during abduction will not generally be presented by a dog 
with the lumbosacral disease. Yelping is not a usual finding in OA cases346. In dogs with HD, hip 
laxity may be detected under general anaesthesia or heavy sedation by inducing the Ortolani sign, by 
which the femoral head is forced into subluxation, then returning to a normal position125. Measuring 
thigh girth may also be a useful measurement in the initial assessment and as an outcome measure 
since the quadriceps muscle group is particularly prone to atrophy secondary to decreased limb 
function353. This measurement, mainly when made with a Gullick II measure, was low intra- and 
inter-observer variation, with or without clipping the hair or stifle flexion or extension353 (figure 7). 
It may also help distinguish a neurological from an orthopaedic condition since disuse atrophy is 
usually mild to moderate, taking weeks to months to ensue, while neurological atrophy sets over days 
or weeks343. The evaluation of asymmetry and muscle atrophy, measurement of static weight-
bearing, and joint ROM have been described as the most valid and sensitive physiotherapeutic 





Figure 7 – Thigh girth measurement, using a Gullick II measure. 
 
During the dynamic examination, a pelvic sway gait, which increases with exercise, is visible 
in an attempt to reduce hip flexion. Also, animals present a decreased and stiff stride with a possible 
weight shift to the thoracic limbs101,346. By placing a hand over the dog’s hips during walking, it is 
sometimes possible to palpate the clunking that occurs with subluxation and reduce an unstable hip 
at stance and swing phases346. The animal is usually evaluated at a trot since it is a symmetric gait, 
which provides a good visual presentation of movement for the clinician to diagnose lameness34 0 . 
Concerning the dynamic examination, the moment at which the physical examination is conducted 
does not change lameness scores356. The increased displacement of the hip (‘hip drop’ of the lame 
side during the swing phase) is a good indicator of hind limb lameness in dogs357.  
Lameness evaluation is an acquired ability, resulting from practice experience along with the 
integration of objective information. In working dogs, lameness often does not need to be obvious to 
limit performance. For this reason, the use of diagnostic analgesia can be an interesting tool to identify 
a lameness source correctly344. It is also interesting to note that dogs with mild lameness may be less 
prone to improve following treatment, emphasizing the need to manage OA dogs even with more 
subtle afflictions carefully358. It is well established that the hip OA radiographic signs poorly 
correlates  with clinical signs346. Also, since OA's current diagnostic methods combine radiographic 






2.5 Hip dysplasia 
In dogs, hip OA is commonly a consequence of HD. HD is the most common orthopaedic 
condition in dogs, with a prevalence of up to 71% in predisposed breeds, causing joint inflammation 
with variable degrees of clinical presentation359,360. It is defined as an inherited development disease 
of the hip joint, influenced by many genes specific for each breed (polygenetic trait)361. HD is 
developmental, and all dogs are born with normal hips, with instability emerging in the early stages 
of the disease, between 4 and 12 months of age125,341. Joint laxity leads to abnormal wearing of the 
coxofemoral joint and subsequent OA and means that, if left untreated, it will progress to OA360. It is 
comparable to human developmental dysplasia of the hip and is considered a pre-OA disease. 
Progression to OA is significantly faster in dogs than humans, occurring within 1–2 years of age, 
associated with dogs’ shorter life span, making it valuable as a pre-clinical spontaneous animal 
model256. Canine HD resembles the hip's development dysplasia but progresses over a compressed 
time frame, adding to its utility as a model111.  
 Although the etiology and pathogenesis of HD are still unclear, it has been accepted that it 
reflects the interaction of multiple genes with environmental influences, and joint laxity is central in 
the development of OA6. A study regarding the entire lifespan of a group of dogs showed that animals 
with coxofemoral subluxation developed OA, on average, 9 years earlier than those without  
subluxation. Still, 98% of all animals had developed OA by the end of their life, whether or not they 
had subluxation362. HD is known to affect any breed of dogs but is more common in large and giant 
breeds such as German Shepherd Dogs, Labrador, and Golden Retrievers, amongst others363. 
Similarly to human developmental dysplasia of the hip, it is characterized by delayed femoral capital 
ossification, underpinning instability continuum (detected by the Ortolani test), with severe forms 
characterized by complete subluxation, focal cartilage overload, and OA364–366.  
Many screening methods have been proposed and used, ranging from palpation to 
radiography. More recently, ultrasound, computed tomography, and magnetic resonance imaging are 
among the new imaging techniques that allow an HD accurate diagnosis6. The earliest signs can be 
observed at 30 days of age, consisting of a femoral head ligament with increased volume and 
increased synovial fluid (SF)140,367,368. The earliest radiographic signs can be observed around the 7th 
week of life, consisting of femoral head subluxation and underdevelopment of the acetabular rim369. 
During the development of the hip joint, the joint's functional subluxation is accompanied by an 
increase of forces that cross the joint and a decrease in the area over which the forces are exerted. 
These events promote cartilage damage, joint inflammation, and, ultimately, secondary OA6,140. Early 
subluxation of the femoral head, followed by shallowing and deformation of the acetabulum, is 
thought to be the first step in the pathogenesis, followed by varying degrees of arthrosis and 
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remodeling of the femoral head and acetabulum361. Secondary OA is also a complex trait influenced 
by several genes and environmental factors and is additively inherited, without dominance140. Several 
studies have focused on determining the genetic basis for the disease, without ever reaching a 
definitive conclusion114,370,371. Currently, none of the genetic analysis tests surpass the clinical utility 
of a phenotype-based selection program like the  Norberg-Olson Angle, the Distraction Index,or a 
subjective Hip-Extended Score 6. The Norberg-Olson angle is the angle formed by a line connecting 
the centres of both femoral heads and a second line, drawn between the centre of a femoral head and 
the acetabulum's craniodorsal rim on the same side. Lower angles have a high correlation with the 
development of OA361. A normal hip joint has been set to have an angle of 105° or more, although 
different values for different breeds have been reported, as 100.3° for German Shepherd Dogs372,373. 
 
 
Figure 8 – Measurement of the Nordberg-Olson angle. 
The Distraction Index is based on the measurement of the forces during the gait cycle, and 
this passive joint laxity is used as an estimation of functional hip laxity. This laxity leads to premature 
wear of the articular cartilage, microfractures to the subchondral bone, and, ultimately, osteophyte 





Figure 9 – Ventrodorsal extended leg X-Rays of dogs with severe hip dysplasia. 
Significantly increased passive joint laxity and, consequently, HD, have been reported in dogs 
with significantly higher volumes of SF and thickened femoral head ligament376,377. It is not clear if 
these findings are a cause or a consequence of HD. The balance between production and removal of 
synovial fluid is maintained by the intracapsular veins and lymphatic vessels, a mechanism that 
becomes impaired with the inflammatory events of joint trauma and inflammation367,378. 
The amount of pelvic muscle mass was also found to positively correlate with the development 
of HD, with non-dysplastic dogs (such as Greyhounds) showing greater muscle mass and low 
prevalence, while dysplastic dogs (like German Shepherd Dogs) have less development muscle 
masses379. Hormones, such as oestrogen and relaxin, influence skeletal development. While 
oestrogen, within physiological levels, does not seem to induce significant amounts of laxity, relaxin 
has been associated with peripheral joint laxity. This hormone is produced in high levels and secreted 
through milk in bitches, and some breeds may have even higher levels, as is the case of Labrador 
Retrievers380,381. The effect of weight and growth rate on HD development has been studied from an 
early stage. At 60 days of age, heavier dogs, of a group of German Shepherd Dogs, had the highest 
incidence of HD at maturity382. Additional reports showed that heavier Labrador Retrievers develop 
radiographic OA 6 years earlier than thinner littermates and that heavier dogs required long- term 
treatment 3 years earlier than slimmer dogs383. The rate at which growth occurs can influence final 
phenotype, and dogs with an earlier acetabular growth plate fusion seemed more prone to have 
dysplastic joints377. For these reasons, an intentionally restricted feeding regimen, leading to a slower 
growth rate, has been proposed to delay OA's onset in predisposed dogs. Additional nutritional factors 
include excessively high dietary calcium, associated with delayed endochondral ossification and 
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skeletal remodeling, and, ultimately, HD384. Dietary restriction has been shown to reduce canine OA 
while also extending longevity, and weight only correlates moderately with disease severity385. 
Despite the attempts, there has been a failure to eradicate canine HD, based on the 
radiographic selection using the Norberg-Olson angle. One of the reasons for this fact may be that it 
is only valuable if used in relation to other members of the same breed due to breed-specific laxity 
profiles. Another reason may be a lack of honesty regarding HD's control and reporting, possibly for 
financial motivations386–389.  
  
3. DIAGNOSTICS AND TREATMENT MONITORING 
 
In human and animal health, there is an increasing shift toward patient-centred healthcare39 0 . 
The assessment of pain, is pivotal to measure the response to treatment and to determine the relevance 
and utility of translation research successfully249. Dogs are the gold standard species used as study 
models for OA , and the results obtained are more accurate in predicting clinical relevance than with 
other animal species391. An outcome assessment instrument can provide information on the 
effectiveness of interventions and guide clinical practice. Methods used to assess dogs' pain include 
direct observation of the degree of lameness, gait analysis, and subjective rating scales, with no 
consensus on which is the best249,390. Histopathology has been and will likely continue to be the gold 
standard for outcome assessment in OA animal models. However, there has been an increasing call 
for less invasive measures of disease onset and progression and response to treatment11. Even though 
OA is a common canine disease, adequate outcome measures are still lacking. Visual lameness 
assessment, radiographic appearance, and an evaluation of pain seem to be the most commonly used 
outcome measures18. When making these assessments, it is important to keep in mind that a placebo 
effect has been described in humans and animals, particularly in OA treatments. In dogs, GRF is not 
affected in placebo treatment groups. In humans, it is more associated with all subjective outcomes, 
but not with objective outcomes, such as ROM and muscle girth392.  
 
3.1 Digital radiography; 
Digital radiography has exploded in the veterinary market and has significant advantages, 
such as centrally storing, searching, and sharing images with ease344. Pelvic radiographs are 
frequently performed in dogs, mainly to assess HD, OA, and fractures. They have been used for over 
four decades in several screening mechanisms worldwide and clinically and experimentally to 
determine outcome393–395. Imaging plays a vital role alongside the clinical review of patients with 
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joint disease since it can depict individual joint involvement while avoiding the need for invasive 
tissue sampling. It can also be done repeatedly and safely within recognized limits, which is important 
for following chronic conditions278,396. 
The most common radiographic view is the ventrodorsal hip extended view, for which 
sedation is required in all dogs6,397,398. For this projection, the animal is placed in dorsal recumbence, 
with the assistance of positioning aids. The limbs are internally rotated and abducted, at the point that 
the stifles are almost touching. The limbs are then extended, maintaining the internal rotation, while 
the femurs are parallel to the table. If the positioning is correct, the patella should be central over the 
femoral condyles, the femurs parallel to each other, and the obturator foramen uniform and of equal 
size. The sacrum, ilium wings, and 7th lumbar vertebra should be included in the image361,397. This 
position results in the joint's tightening, reducing the degree of visible subluxation and, 
consequentially, its score125,399. The ventrodorsal flexed view (also called frog-legged view) is also a 
valuable option, particularly in unsedated dogs with painful hips. It enhances the visibility of the 
cranial and caudal aspects of the femoral head and neck, helping in assessing circumferential femoral 
head osteophyte and caudolateral curvilinear osteophyte361.  
 
 




Figure 11 – The ventrodorsal flexed (frog-legged) view. 
It is well established that radiographic signs' development occurs later than the structura l 
changes associated with OA6. The bone must undergo a 30-40% change in density (for example, 
osteophytes must form) before OA-related changes can be detected radiographically140. Also, several 
accounts for low inter and intra-observed agreement of hip scoring have been published398,400–402. 
There is a low relationship between radiographic changes and score progression, with a progression 
or lack of progression of clinical signs, between limb function and radiographic severity signs, or 
between radiographic score and joint synovial markers155,393.  Radiographic changes also do not 
account for the level of pain experienced by the animal, as they are affected by synovit is, 
osteochondral pathology, and sensitization, which are not detected by digital radiography318,393,403. 
Therefore, plain radiography has limitations concerning the evaluation and staging of OA, not 
assessing the result of the interaction of biochemical and biomechanical factors404. Detectable 
radiographic changes include femoral periarticular osteophyte formation, subchondral sclerosis of the 
craniodorsal acetabulum, osteophytes on the cranial/caudal acetabular margin, and joint remodeling 
from chronic wear. Specifically, curvilinear opacity in the joint capsule's attachment on the femoral 
head (Morgan’s line), remodeling of the cranial and caudal acetabulum, flattening of the femoral 
head, and irregular widening of the femoral neck346. Besides bone changes, soft tissues may also 
experience transformations observable in the X-ray image405. In both cases, signs must be severe 
before being observed on the X-ray140. The features that have been deemed of major clinica l 
importance are circumferential femoral head osteophyte, caudolateral curvilinear osteophyte, and 
subchondral bone sclerosis, representing early radiographic signs that predict the development of the 
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clinical signs of hip OA361,406–408. Caudolateral curvilinear osteophyte was first described in 1961, 
and arises at the caudodorsal part of the femoral neck because due to traction on the hip joint capsule. 
It manifests as a radiopaque line (Figure 12). It correlates with hip subluxation and, therefore, 
represents a risk factor for OA later in life398. Circumferential femoral head osteophyte is a marked 
radiopaque line, encircling the junction between the femoral neck and the epiphysis, along the 
insertion of the joint capsule (Figure 12)409. Subchondral bone sclerosis of the cranial acetabular edge 
is an alteration seen as a loss or increased density of the normal trabecular bone pattern. It is 
considered to occur when excessive or abnormal joint stresses arise because of the subluxation of the 
femoral head398. 
 
Figure 12 – Ventrodorsal (left) and ventrodorsal flexed (right) views of a hip joint of a dog with osteoarthritis. The 
arrow identify the caudolateral curvilinear osteophyte. 
 
 
Figure 13 – Ventrodorsal (left) and ventrodorsal flexed (right) views of a hip joint of a dog with osteoarthritis. The 
arrow identify the circunferantional femoral head osteophyte. 
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It is beyond this work's scope to review the screening systems for canine HD, but due to their 
relevance and association between HD and OA, they will be summarily described. In 1961, the 
Orthopaedic Foundation for Animals assembled ten veterinarians to outline the standards for 
diagnosing and classifying canine HD410. They presented guidelines regarding animals' equipment 
and positioning, description of normal and dysplastic hips, radiographic and clinical signs410,411. The 
Orthopaedic Foundation for Animals score is based on three radiologists' consensus using a subjective 
seven-point grading system (excellent, good, fair, borderline, mild dysplasia, moderate dysplasia, and 
severe dysplasia). Dogs must be at least 24 months, and exam submission is voluntary by dog 
owners6. 
The Fédération Cynologique Internationale has developed a hip-grading system used 
throughout Europe, Asia, and parts of South America412. Hips are evaluated on the hip-extended 
position, with the possible addition of a frog-leg position. Animals must be 12 months old or 18 
months old in large and giant breeds. Norberg-Olson angles are measured to quantify laxity, and a 
grade, ranging from A through E, is attributed, with A being the best score. A and B grades subdivide 




Figure 14 – Grade E hip with severe secondary osteoarthritis. 
The British Veterinary Club/Kennel Club program was established in 1978 to control HD and 
applied for all breeds in 1983413. This system is used in the United Kingdom, Australia, and New 
Zealand and is based on the evaluation of hip-extended radiographs of dogs at least 12 months of age. 
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Individuals' hip features have then attributed a score that can amount to 53 points/hip (106 in total, 
with lowest scores being better)413,414. The scores estimate laxity, degree of subluxation, Norberg 
angle, and presence/severity of OA. These three methods have in common the fact that the Norberg 
angle is the only objective parameter observed386. Systems based on phenotype scoring were found 
to be only fairly reliable within and between experienced observers398. 
The University of Pennsylvania Hip Improvement Program was introduced in 1993 and is the 
most evidence-based hip screening method available368,375. This method requires the dog to be placed 
under heavy sedation or anaesthesia. Three radiographic images are obtained, a ventrodorsal hip -
extended view, a compression view, and a distraction view with legs in neutral position and hips 
distracted368. The measurement of laxity is made by a distraction device, quantifying the femoral head 
displacement from the acetabulum using a distraction index6. The significant relation between 
distraction index and the development of hip OA has been documented in several studies362,415. 
Despite the screening scheme considered, the reliability of the result is also dependent on the 
experience and integrity of the scrutineers361. 
Computed tomography and magnetic resonance imaging can also be used for diagnostics and 
monitoring joint diseases416. They are non-invasive techniques, but that requires general anaesthesia. 
Its use is often a balance between access, availability, cost, and clinical indication417. They have the 
advantage over digital radiography of detecting the articular cartilage's morphology but not early OA 
compositional changes418. On OA, magnetic resonance imaging can be useful for detecting early 
osteophyte formation, full or partial thickness cartilage loss and subchondral bone lesion419. The 
association between radiography and hip joint measures dfrom computed tomography detected 
morphology changes as early as 16 weeks of age and improved animals predisposed to hip OA373.  
 
3.2 Gait analysis; 
Gait is the result of the combined activity of the musculoskeletal and nervous systems. 
Pathological changes in these systems may lead to changes in locomotion420, which encompasses two 
primary types, gait (walk, trot, pace, gallop and swim) and nonrepetitive motions (jump, sitting, and 
others) 340. Gait analysis is the investigation of locomotion421. It can be done through visual analys is, 
a more traditional approach to lameness investigation, but still an essential part of the physical exam, 
which depends on the ability and perspicacity of the observer422. Instrument gait analysis is an 
objective method for analyzing gait, employing sophisticated equipment to measure spatial and 
temporal parameters, in addition to forces acting on the limb, allowing their quantification and 
interpretation267,421.  Limb movement and use can be assessed by analyzing GRF (kinetics), limb 
movement (kinematics), or a combination of both344.  
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The assessment of GRF is made through kinetic measurements, the gold standard, done with 
a force plait.  This evaluation requires time and expertise to ensure correct data collection and 
interpretation26,314,423,424. Forces measured are generated each time the limb hits the ground, 
comprising two opposite forces, the action, and the reaction forces, equal in magnitude and opposite 
in direction314. This analysis can be used as a window into neurodegenerative disorders to identify 
markers of subclinical pathology, inform diagnostic algorithms of disease progression, and measure 
the efficacy of interventions425. The measurement of GRF is a well-established method to describe 
gait and severity of lameness, with a 90% sensitivity and specificity22,426,427. An increasing interest in 
this field is evident in assessing response to surgical procedures, treatment outcome, orthopaedic 
conditions, and differences between breeds393,428–431. Significant breed differences have been 
reported, both at a walk and trot, which may reflect human selection based on confirmation criteria, 
which would lead to an advantage in the breed’s intended work function432. Changes observed with 
force plait analysis during the evaluation of a patient are probably the result of structural deficits and 
pain sensation, making it the most sensitive sole measure of pain in dogs391. Although measuring 
changes in limb function is not directly correlated to changes due to joint pain, one could expect 
function in the limb to have comparable changes due to it433.  
Evaluating quadrupeds may be challenging, as they can alter movement or the distribution of 
weight within the limb or paw to minimize pain, in a way that the abnormality may be 
unnoticeable340,434. Although objective gait analysis has a theoretical advantage over subjective 
measures, the ability to determine the sensitivity and specificity of any method to detect lameness is 
hampered by the lack of a criterion-referenced test for comparison435. Nonrepetitive motions are not 
usually assessed during gait analysis. These movements involve a wide ROM and segmenta l 
alignments with high force outputs and impacts and can be a source of injury of providing clinica l 
information used to reveal injuries not noted on a routine clinical exam340. 
Kinematics involves the analysis of limb movement. Each limb has a stride characterized by 
a swing and a stance phase. The stance phase is defined as when the foot is in contact with the ground, 
whereas the swing phase is the period during which the limb is propelled through the air. The stance 
phase can further be divided into braking and propulsion, with braking occurring as the limb exits the 
swing phase and transitions into propulsion before the next swing phase in the gait cycle421. For data 
collection during kinetic gait analysis, a handler leads the animal across a force plate. For a trial to be 
considered valid, the dog's velocity must be within a defined range since it influences measured 
forces. Most systems use three photoelectric switches, positioned at a predetermined distance apart, 
and an accurate method for determining trunk velocity436–438. Force plaits can be integrated on a 
treadmill, making velocity precise and controlled22,439. Critics of this evaluation method argue that 
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gait may be altered and forces values on a moving surface compared with self-propulsion on a normal 
substrate421. As the limb contacts the ground, the reaction force at the ground is measured. For each 
valid trial, three orthogonal ground reaction forces are measured from ipsilateral thoracic and pelvic 
limb440. GRF have been described as outcome measures reflecting pain-related functiona l 
impairments in the context of OA, being abnormally lower314,441,442. Similar to what is observed with 
OA's clinical signs, no correlation has been found between radiographic OA score and vertical 
GRF393. Although the use of force plaits has become a standard method for this type of evaluat ion 
and research, it presents some disadvantages. The plates must be located over a leveled surface in a 
dedicated area and do not record successive footfalls over one passage, requiring multiple passes to 
collect data for each limb21. These requirements may turn force plaits into a tool difficult to use 
outside a research centre. 
Forces vertical to the ground are represented on the Z-axis; mediolateral horizontal forces are 
depicted on the X-axis, and craniocaudal forces are plotted using the Y-axis. Vertical force is usually 
the largest of measured forces, with craniocaudal braking and mediolateral forces having smaller 
intensity421,440,443. GRF that act on the canine foot are represented in Figure 15. 
 
 
Figure 15 – Ground Reaction Forces that act on the canine foot in three orthogonal planes, X, Y, and Z. 
Data obtained during kinematic analysis is usually normalized in concern to the animal’s body 
weight so that animals of different sizes and conformations can be compared. Non-normalized Peak 
Vertical Force (PVF) of small and large dogs significantly correlate with body weight and is also 
influenced by body size, conformation, and type of gait 420,444. Collecting data from multiples footfalls 
and limbs per trial improves data accuracy concerning detecting asymmetry or evaluat ing 
compensation for lameness or neurological impairment439. For this effect, walkways are better tools, 
as they provide a large area where footfalls may occur421. Still, a good correlation between results 
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obtained in walkways and a single force platform has been found in normal dogs435. Loss of weight 
and body fat and animal in the course of treatment can influence subsequent evaluations, as with 
greater weight, greater ROM is detected during the stance phase and greater GRF445,446. Growing 
animals, which experience rapid conformation changes, may present significant variability between 
sessions447. Older animals also experience changes, mainly related to increased joint stiffness and 
consequent decrease ROM, particularly in the forelimbs448.  
PVF is an optimal measure to differentiate sound from lame animals before and after surgica l 
correction449. It is defined as the maximum force exerted perpendicular to the surface during the 
stance phase and is represented at the top of the peak vertical force curve. Along with vertical impulse, 
these are the two most commonly used parameters to compare lameness between groups or 
individuals394,421,435,438. The majority of canine biomechanical research focus on the walk and trot and 
since PVF is dependent on velocity. Further investigation is needed, particularly regarding different 
sports and activities. Velocity has an increased effect on lame dogs, as excessive trial repetition may 
exacerbate lameness during trial collection427. Trial repetition is one factor that causes more 
significant changes in results, as it is related to the variation of velocity450. Also, the influence of 
different gaits is essential. A walk may be better when dogs have marked lameness, as Cranial 
Cruciate Ligament rupture, while the trot may be more sensitive with low-grade lameness451–453. 
Additionally, the quantification of rate and location of limbs in space, comprising 
displacements, angular velocities, and ROM, are made421. Research regarding peripheral joints has 
focussed mainly on the stifle, specifically in a cranial cruciate ligament rupture and repair, both as a 
primary disease and as a model for human OA. Peak forces are the maximum forces generated in the 
described phase of the gait, and impulse is the area under the force-time curve421. Besides being used 
as a gold standard for determining the functional outcome, PVF is an indirect measure of 
pain393,394,454,455. When a limb is affected, significant adaptations occur on all limbs, both at stance 
and swing phases. Naturally, most pronounced differences occur in the affected limb, followed by 
the contralateral limb, opposing contralateral limb and, to a lesser extent, the opposing ipsilatera l 
limb456. 
Chronic pain has been associated with permanent changes in gait, even though the correlation 
between the degree of lameness and pain, while logical, is impossible to prove457. When used to 
measure lameness, it involves two- or three-dimensional evaluation of limb and body motion34 4 . 
During lameness, PVF is decreased because dogs tend to bear less weight on a painful limb. Vertical 
impulse typically decreases as well, since force and time in stance are decreased during lameness, 
reducing the area under the force-time curve421. Variations due to proximal versus distal dysfunction 
and the specific joint affected may occur, leading to an indication to which limb section is involved45 6 . 
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Although labor-intensive, gait analysis tends to be more objective than observation alone458. Kinetic 
asymmetry indices have shown a good correlation with visual gait assessment scores459,460. GRF 
determined using a pressure-sensitive walkway may be lower than those determined with a force 
plait, but they exhibit a similar trend, suggesting that they can be used for comparative studies461 . 
Pressure plates may provide a more practical alternative to forces plates, as they can register 
simultaneous, consecutive, and collateral foot strides in a single passage, which requires fewer trials. 
It also allows for the evaluation of load distribution among foot pads459.   
The metatarsal pad is the one experience lower forces, compensated by contralateral limb 
pads426. However, the existence of a specific kinematic signature is still debatable since kinematic 
changes differ between reports462,463, as animals with hip OA present complex changes in gait 
involving more joints than just the affected hip alone. Interestingly, GRF of the lame limb in dogs 
with hip OA can be similar to those of non-affected dogs' limbs, whereas the contralateral limb shows 
higher values464. Varying results have been found in dogs with OA when comparing kinematics and 
force plait analysis, with no differences in GRF but in joint kinematics465,466. When assessing animals 
after total hip replacement, no difference between the sensitivity of vertical impulse and PVF seems 
to exist467. Other factors may influence GRF, as carrying weight in the mouth, which likely produces 
additional stress on the forelimb joints, muscles, and connective tissues23. The knowledge of the fact 
is of particular interest in sporting and working dogs, in which a knowledge of specific tasks/miss ions 
may give insight to expected specific lesions. The calculation of a symmetry index is also a commonly 
used measure. Although a small amount of asymmetry is normal in healthy dogs, is asymmetry caused 
by pathology would is easier to detect when using a symmetry index calculation468. Symmetry indices 
can be used to detect lameness as limb symmetry is expected to change with lameness due to the force 
distribution pattern468. Research focusing on HD found subtle changes in dysplastic dogs compared 
to sound ones, including coxofemoral extension at the end of the stance phase, increased femorotib ia l 
flexion throughout the stance and early swing phase, and increased stride length with decreased 
PVF267,469,470. Significant differences were also observed in maximum angular velocity and maximum 
angle of hip joint, higher in dysplastic dogs. Even if no signs of lameness were observed in dysplastic 
dogs when trotting on a treadmill, joint kinematic alterations were observed on both pelvic and 
thoracic limbs, with more rapid extension of the hip in dysplastic German Shepherd Dog458. In 
comparison, Belgian Malinois with borderline HD had an earlier maximal flexion of the hip, along 
with less flexion and ROM of the stifle joint during the swing phase than clinically normal dogs466,471. 
Mean PVF is also lower in dogs with severe HD than mild dysplastic dogs, which suggests that HD 
degrees can affect lameness severity471,472.  
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Subtle changes in posture or weight-bearing may occur in the early stages of the disease 
process, which can be easily missed with visual assessment, and are not improved through slow-
motion video235,447,473. Weight distribution and off-loading or limb favouring at the stance are 
commonly used subjective assessments during the orthopaedic examination, yet lameness may be 
difficult to detect during gait evaluation438,474. Additionally, OA animals may not be overtly lame at 
a walk or a trot but exhibit subtle shifts in body weight distribution at a stance due to pain or instability 
associated with orthopaedic or neural disease467,475. Stance analysis has been reported as sensitive for 
detecting lameness in dogs, being more sensitive in large breed dogs (Figure 16 and Figure 17)476. If 
a dog presents pelvic limb-lameness, in general, a load redistribution occurs, more by side-to-side 
compensation rather than pelvic-to-thoracic has been described465,477. Normal weight distribution on 
the weight distribution plate is the same as for pressure-sensitive walkway total pressure index—
30/30/20/20 (left thoracic limb/right thoracic limb/ left pelvic limb/right pelvic limb)414. Weight 
distribution platforms, as pressure-sensitive walkways, can provide accurate and consistent measures 
of weight distribution with no significant difference between devices478,479. It has been proposed that 
bodyweight distribution at a stance may be an equivalent or superior measurement of pain associated 
with hip OA than both VI and PVF, with the highest sensitivity and specificity being set at a cut-off 
of 2 (thoracic limb value less than 28 or pelvic limb value less than 18)475,480. There may exist a 
tendency to see fewer improvements in male dogs concerning bodyweight distribution with pelvic 
limb pain relief, as they naturally tend to carry more weight on the thoracic limbs467. A recent report 
analysing weight distribution within the paws of dogs suffering from hip osteoarthritis concluded that 
the weight distribution compensatory mechanisms are very complex, relieving weight in the affected 
limb, counterbalanced through higher loading of the caudal quadrants in all unaffected limbs481. 
 




Figure 17 – Stance analysis results. 
 
3.3 Digital Thermography; 
Digital thermal imaging is a non-invasive, non-radiating, contact-free, physiologic diagnostic 
tool that depends on heat resulting from physiological functions related to skin temperature 
control20,482,483. It does not replace but rather augments a thorough physical examination, being an 
efficient, safe, non-invasive, and (compared with other diagnostic methods) relative low-cost. By 
correlating changes in temperature patterns with the various diseases, degenerative, or injury 
processes, digital thermography can provide a reproducible diagnostic tool, particularly in early 
phases484–486. Digital thermography uses non-ionising radiation, thus allowing for an unconstra ined 
and harmless application in patient487. Skin temperature is a reflex of a complex system that depends 
on blood-flow rate, local structures of subcutaneous tissues, and the sympathetic nervous system's 
activity. This system is so complex that, to date, the mechanism of thermoregulatory adaptation to 
exercise not fully understood20. An injury is often related to variations in blood flow, which can affect 
skin temperature488. Superficial tissue temperature changes can reflect inflammation in subcutaneous 
and deeper tissues. During the inflammatory process, skin temperature rises due to changes in blood 
vessels' diameter and blood flow rate and increased capillary permeability489,490. 
Digital thermography provides a visual map of the skin temperature distribution but does not 
quantifies absolute temperature values. Although modern cameras provide an absolute temperature 
value, it still has a significant margin of error. Nevertheless, in a given evaluation moment, a 
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difference of more than 1°C between similar areas or tissues is considered significant. The 
identification of inflammation, characterized by, among others, an increase in temperature, is a critica l 
step in determining the appropriate treatment20,491. With focal plane arrays of 320x240 pixels, high-
resolution cameras, a thermal sensitivity less than 50mK, and a spatial resolution of 25-50µm, ensure 
useful thermal and spatial details484. It allows for the acquisition of detailed infrared thermograms, 
images of the temperature distribution of the target483. A 180x180 pixel resolution has been deemed 
enough to provide reliable results, but a higher resolution (320x240) means smaller changes can be 
detected492. It is crucial to standardize image collecting procedures, to obtain relevant information. 
The International Standards Organization recommends using the rainbow scale for medical 
thermograms (in which high temperatures appear in red and low temperatures in blue colours) since 
the temperature range does not usually exceed 10°C. The temperature scale should be displayed 
alongside the final image. The merger of a digital image (a traditional picture) and an infrared image  
is also recommended, as it allows for reliable mapping of anatomical landmarks. Some camera 
models conduct this procedure automatically. For image collection, room temperature should be 
controlled, and animals should be given a period to adjust to room temperature (30minutes), and all 
images should be adequately identified20,483,492,493. Horses are an exception to this rule, which may 
require no adjustment or equilibration time for performing thermographic imaging. This point has 
been attributed to the fact that the horse is a much bigger and more even heat source than a dog494. 
Digital thermography has been used to assess soft tissue injuries, including muscle strains, 
sprains, tendinopathies, and also OA, through the identification of tissue changes involved in subtle 
performance and gait abnormalities. It is also useful to monitor rehabilitation progress or training 
stressors before an injury occurs. Unlike other medical modalities, thermography is not related to 
morphology20,495–497. It has been described as useful in several species, from humans to horses and 
cats, but its clinical utility has rarely been studied in small animals20,491,492,498. Infrared imaging has 
also been used to monitor in vitro MMPs activity, major actors in OA499. Canine thermal imaging has 
been documented only recently495. Still, a growing interest in this modality has led to an increase in 
the number of studies evaluating thermography use to assess a wide range of pathologies in the canine 
hip, stifle, elbow, intervertebral disc, and bone neoplasia492,500–504. Thermography has also been used 
to monitor body temperature in exercising dogs and is useful for detecting surface temperature 
variations of specific body regions505. Each thermographic image to assess the hip should include the 
area from the last lumbar vertebra to the first coccygeal vertebra at a minimum, from a distance of 60 
cm to simulate a clinical setting where the space around the patient could be limited (Figure 19 and 
Figure 20Figure 1)492. Fur clipping has not been proven as necessary for the thermographic evaluat ion 
of dogs' structures and can be harmful. Still, the coat's type and color are variables that must be taken 
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into account and its influence documented496,500,501,505,506. For example, short-haired dogs exhibit a 
more drastic increase in body surface temperature compared to other dogs in response to 
environmental changes507. 
 
Figure 18 – Digital thermography image collection. 
 
 





Figure 20 – A dorsoventral view of a dog with moderate osteoarthritis (left) and another with severe osteoarthritis (right), 
after image editing with the software Tools®. Arrowhead indicates cranial direction. Arrow indicates the anatomical 
location of the hip joint. An area of increased temperature is observed on the patient with moderate OA and of lower 
temperature on the patient with severe OA. 
In humans OA studies, increased temperatures have been related to even slight degenerative 
changes and low temperatures in more severe disease cases490. In knee OA, a good correlation 
between an increase in temperature and more severe radiographic changes has been described508,509. 
Thermography has also been shown to be a reliable technique to assess inflammatory arthritis pain 
and differentiate normal, rheumatoid arthritis, and osteoarthritis subjects from each other510,511. 
 
3.4 Pedometers; 
Mobility is important to health and wellbeing. Mobility impairment and decreased activity are 
associated with musculoskeletal pain in humans, and improved mobility results have been 
recommended to measure outcome253. Pedometers and accelerometers have been used in humans to 
measure ambulatory physical activity while also opening up new research opportunities. One of the 
advantages of activity monitoring includes gathering data over a prolonged period in the patient’s 
home environment349. Pedometers, in particular, are inexpensive, simple devices that measure 
ambulatory activity with acceptable accuracy512. Accelerometers have also been used in veterinary 
medicine as activity monitors513–516. They have the advantage of portability, unrestricted movement, 
and direct measurement of three-dimensional accelerations517,518, and have been used to assess 
improvements related to interventions in a canine model of OA519, serving as objective measures of 
chronic orthopaedic pain520. As inertial measurement units, other systems have been developed for 
objective lameness evaluations in horses and are based on sensor technology comprising gyroscopes, 




Unlike accelerometers, pedometers are not designed to capture the pattern, intensity, or 
physical activity type. They also do not adequately capture the intensity of specific activit ies. 
Nonetheless, several reports have pointed out that simple and inexpensive pedometers agree 
acceptably with more expensive accelerometers523. They are highly adaptable and have been used in 
several reports with animals, from dogs to cows, horses, and turkeys, to assess multiple interventions 
and behaviours524–529. In a study designed to measure physical activity in dogs, pedometers showed 
to measure it with reasonable accuracy. The amount of activity that a dog experiences, particular ly 
walking, is highly correlated with the owner’s motivations and characteristics530,531. Animals with a 
higher body condition score and less active owners had a lower number of steps per day523,532. Activity 
counts also experience a clinical influence from environmental conditions, as average temperature 
and total daylight hours533. At a walk and a trot, pedometers tended to overestimate the actual number 
of steps by 17% in large and medium dogs and underestimated by >5% the number of steps of large 
dogs when running. Using a different mounting technique to position the pedometer, another report 
registered a smaller difference in medium and large dogs, amounting to 3.3%532. While presenting 
some inaccuracy degree, results are consistently inaccurate, which allows for result correction and to 
monitor overall activity on a daily basis523. In normal dogs, pedometer steps may reasonably 
estimate distance travelled534. Recording data over several days, in opposition to single-day 
recordings, has demonstrated to help avoid anomalies in other species535.  
 
3.5 Clinical metrology instruments; 
Pain and functional ability are essential parameters in the evaluation of OA treatment 
efficacy257. Measuring and evaluating pain, in particular, is integral to assess the relevance and utility 
of any specific animal model on translation research, but also for effective pain management and a 
requirement of evidence-based medicine. Typically, OA pain is localized and related to movement or 
weight-bearing of the affected joints249,296. Historically, measuring pain intensity was the focus in 
human and veterinary medicine, but, more recently, a focus on the affective dimension of pain was 
gain emphasis. Comprehensive documentation of this component is paramount for the development 
of treatments for chronic pain296,536. Often in clinical trials and studies, questionnaires are used and 
may be completed by clients, attending veterinarian, or both537–539. They usually include a semi-
objective rating of disease parameters such as “lameness” and “pain”, on either a discontinuous 
ordinal scale or a visual analog scale540. While extremely useful in a clinical setting, subjective scales  
are more susceptible to bias, as is the case of the caregiver placebo effect, from both owners and 
assisting veterinarians, associated with the variability in emotional and cognitive components of pain 
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perception249,541. It is still important to measure the affective component of the pain experience, not 
just its intensity296. 
Several clinical metrology instruments (CMI) have been developed to measure outcome 
assessments usually completed by a proxy. The owner is the most common proxy with dogs, since 
they can identify degrees and changes of their pets' subjective states, and can interpret their signa ls. 
For these reasons, dogs are good candidates for the use of CMI to evaluate pain542,543.  A CMI 
comprises a sequence of questions or items, scored based on the person's observations or experiences 
completing it. The individual item-scores are then used to calculate an overall instrument score544. 
They show discriminatory, responsiveness, and criterion validity as pain and impairment measures in 
performing daily activities. As a whole, CMIs represent a patient-centred approach that, similar to 
what happens in human medicine, has been incorporated in veterinary assessments for different 
species111,545,546. In human medicine, they are a standard, validated, and accepted method for 
measuring chronic pain and have formed an essential part of the patient’s assessment for over 30 
years349,547. They also try to represent an alternative to force platforms, as this equipment is often 
confined to research facilities. Also, changes in PVF only detect a treatment effect on load-bearing 
through an individual limb and may not detect a change in demeanor or activity in the animal’s 
everyday environment and activities 544,548. Whereas it is certainly a positive result to have an 
increased ROM in a joint after an intervention, if the animals show no improvement in its ability to 
perform daily activities, the owner may not perceive a clinically significant benefit from the 
procedure390. Owners may often be more focused on the dogs as a whole and its ability to perform 
daily activities, rather than an increase or decrease use of a single limb at a walk or trot549. Working 
dogs, in particular, will often only display their lameness when involved in activities550. To conduct 
clinical research outside these centers, the need for standardized clinical outcome measures that are 
cost-effective and widely available has led to the development of several CMI. The best ones 
developed for dogs and that have been reported to have criterion validity are the Canine Brief Pain 
Inventory (CBPI) and the Liverpool Osteoarthritis in Dogs (LOAD)253,349,540,544.  
The Canine Brief Pain Inventory survey is often the analysis of choice in the veterinary 
literature and has been recommended to compare the overall mean or median differences in pain 
scores between groups 551,552. It is based on the human-equivalent brief pain inventory and reported 
as able to differentiate sound from OA dogs, to detect a measurable effect for individual animal 
assessment, with results correlating with PVF249,544,549,551–554. It has been used alongside objective 
lameness measurements, and results showed to correlate, making the CBPI a reliable evaluation tool, 
used in several reports235,445,555. The CBPI has been demonstrated as not being associated with 
response bias and may be used as a clinical outcome measure of chronic pain in dogs with OA treated 
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with pharmacological and non-pharmacological pain interventions556. It was also shown to be able to 
evaluate pain related to other conditions, as bone cancer557. For its data to be appropriately powered, 
a minimum of 29 subjects per group is recommended549,552. It is divided into two sections, a pain 
severity score (PSS) that assesses the magnitude of an animal's pain and a pain interference score 
(PIS) that assesses the degree to which pain affects daily activities445. Individual treatment success in 
OA dogs has been set as a decrease in PSS≥1 and PIS≥2548,549. These two components have high 
correlation coefficients, and it is reasonable to assume that “pain”, as captured by this CMI, might 
correlate with lameness544. PIS was suggested as being more sensitive than PSS in assessing treatment 
results, maybe because the interference questions are more specific548. Bodyweight has a significant 
impact on PIS, with larger dogs showing smaller improvements. This effect may be possibly due to 
the fact that smaller dogs may respond more with an improvement in pain severity rather than an 
improvement in function552. 
LOAD was initially developed to assess dogs with elbow OA. It has shown good reliabil ity, 
just lower than PVF generated by a force platform, although both results correlate540,544. Later, its 
broader use has been tested, is deemed reliable to assess canine OA in general544. With LOAD, a 
placebo effect has been detected540. The CBPI and LOAD results have a moderate correlation, likely 
due to different components of OA that are capture by each CMI, based on a reasonable 
approximation of what constitutes canine OA in the clinical sense544. A good agreement between 
CBPI and LOAD baseline scores exists, however558.  
The Canine Orthopaedic Index (COI) is a more recent CMI, developed to assess 4 domains in 
dogs with OA, stiffness, gait, function, and quality of life. It is a 4 factor, 16 item questionna ire 
designed to measure owner assessment of those four domains, shown to have excellent reliability and 
validity, and of being able to differentiate between OA and healthy subjects559,560. COI contains four 
questions that sum up to deliver a stiffness score, five questions that deliver a gait score, four 
questions that add up to a function score, and three questions that compose a quality of life score561. 
It can detect changes in all of them when an NSAID is compared to a placebo561 and has been used 
to assess police working dogs562.   
Visual Analogue Scales are used to score pain and assess its severity, allowing a comparison 
of analgesic regimens. They rely on a continuous scale, meaning that data can be modeled as a 
continuous variable455. All pain scores that include modifications to a VAS are subjective and, 
therefore, may lack validity when performed by individuals unfamiliar with signs of pain, and not all 
show concordance when compared with quantitative force platform gait analysis433,563,564. They seem 
to be more accurate, with force plate gait analysis as a reference, when lameness is severe455. It has 
also been described as of particular interest to assess the need for rescue analgesia rather than a 
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primary evaluation303. The Hudson Visual Analogue Scale (HVAS) was deemed repeatable and valid 
to assess the degree of mild to moderate lameness in dogs, compared with force plate analysis as a 
criterion-referenced standard565. 
When administering these questionnaires, it is still unknown if respondents should be 
permitted to see previous answers (dependent and independent interviewing, respectively). However, 
little difference has been observed between independent and dependent interviewing, but dependent 
interviewing resulted in increased treatment effect sizes. Therefore, by using dependent interviewing, 
increased clinical trial power may be observed558.  
 
3.6 Ultrasound; 
Ultrasound is a safe, non-ionizing radiation diagnostic method and is a mainstay of 
musculoskeletal imaging in horses and humans344. It is an accepted standard, while relative ly 
versatile, convenient, and cost-effective method, complementary to radiography for examining 
musculoskeletal structures396. When radiography does not elucidate the diagnosis, ultrasonography 
should be considered before more expensive imaging modalities, such as computed tomography and 
magnetic resonance imaging566. It also enables dynamic assessment of joints, ligaments, and tendons, 
with structures typically scanned in longitudinal and transverse planes to assess fiber alignment in 
muscles or tendons567. Most commonly, linear, high-frequency probes (9-14MHz) are used, giving 
better resolution but decreased tissue penetration. As a general principle, all examinations should be 
conducted with a higher frequency that allows sufficient penetration and best resolution344.  
Many musculoskeletal ultrasound studies can be completed without anaesthesia or sedation, 
although a still, relaxed patient facilitates a detailed and thorough examination, including scanning 
structures during passive movement. In working and sporting dogs, clipping hair is often frowned 
upon, limiting ultrasound use. Comparison scanning of contralateral structures may be necessary 
when a suitable anatomic reference is lacking566. The lateral and medial portions of the coxofemora l 
joint can be assessed with the dog in lateral recumbence and dorsal recumbence in a frog position, 
respectively. Regular joint capsule thickening with preserved hyperechoic layering is a non-specific 
US sign found in chronic OA. The inner surface of the synovium may show irregular thickening 
representing hyperplasia. Osteophytes are irregular convex hyperechoic formations at joint margins. 
With chronic joint disorders, the defective cartilage layer shows an irregular outline and increased 
echogenicity496,568. Joint effusion is also a common radiographic change seen in early OA, but there 
is usually little effusion in the hip joints, making radiographic detection difficult. Ultrasound may be 
a more sensitive approach for this assessment, and, in the canine stifle, the presence of osteophytes 
has demonstrated a good correlation with joint effusion113,569,570. It has been studied as an early 
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indicator of joint laxity in young puppies and is a common screening tool in human medicine. In 
veterinary medicine, it is useful for depicting the joint anatomy of puppies younger than 8 weeks. 
Although there is a significant association between the US measured hip distraction indices in puppies 








Analysis of SF permits classifying the sample as normal, traumatic, degenerative, or 
inflammatory (septic or immune-mediated) in nature, but has been characterized as of limited value 
in OA12,45,313. For other conditions, total and differential cell estimates can be extremely 
informative572. SF is known for its sensitive and rapid response to joint insult and injury, and changes 
are primarily joint specific2. Still, SF analysis is an underused diagnostic test in clinical practice. Joint 
fluid samples should be assessed for colour, turbidity, viscosity, and volume and submitted to a 
laboratory for cytology346. Arthrocentesis of normal joints usually yields only small volumes of SF 
(0.5ml or less), and it usually is colourless or light yellow, clear. It should form a strand of at least 
2.5cm between fingers before breaking (Figure 22). It forms a gel when placed on a tube or syringe, 
reversible when the recipient is agitated45. Typical total and differential cell counts for canine SF in 











Normal  <2 × 109 /L  94-100  0-6 
Osteoarthritis  2-5 × 109 /L  88-100  0-12 
Rheumatoid arthritis 8-38 × 109 /L  20-80  20-80 
Infective arthritis  40-267 × 109 /L  1-10 90-100 
Table 5 - Total and differential cell counts for canine synovial fluid in normal joints and different joint diseases (adapted 
from Innes, 2012). 
 
 
Figure 22 – Evaluation of a synovial fluid strand. 
In OA, early changes occur in the SF, namely increased fluid volume, cell counts 
(predominantly monocytes, usually low or within normal limits), and the colour remains clear to pale 
yellow. In the early stages of the disease, viscosity is not reduced, as the hyaluronic acid concentration 
diminishes over time573. In a study characterizing inflammatory cytokines in dogs with OA and 
rheumatoid arthritis, SF analysis of dogs with either disease showed that IL-1 and TNF-α bioactivity 
was not readily detectable at increased levels, but IL-6 was increased in both diseases189.  
The most common complication of arthrocentesis is the failure to obtain an SF sample. With 
experience, the clinician’s ability to successfully perform the technique successfully improves, but, 
on some occasions, such as markedly arthritic joints, a negative tap may be obtained. Joint sepsis, 
although perceived as a significant risk, is extremely rare45. Other authors, however, have reported 
difficulties in obtaining SF samples consistently12. The sampling method may be important and 
influence measured marker activities. Samples obtained by serial dilution of SF, as opposed to those 






OA is a common, chronic and clinical incurable condition that, despite extensive research, 
still has limited treatment options available13,111,335,574. Its management is mostly palliative, focusing 
on alleviating symptoms, mainly pain, and slowing down the progression of the disease246,575. It is a 
highly heterogenic disease characterized by varying degrees of clinical and functional impairments, 
with functional status correlating with the severity of pain rather than radiographic grading. 
Therefore, treatment should be planned according to the patient’s clinical features and functiona l 
status instead of radiological findings286,576,577. Management of OA is a lifelong commitment, and the 
standard approach often involves a multimodal perspective, from activity control, rehabilitat ion, 
weight loss, nutritional support, NSAIDs, and nutraceuticals578–581. There is evidence that, when 
targeting inflammatory mediators for OA treatment, more than one needs to be addressed582–585. This 
multi-targeted anti-inflammatory approach also has the potential to prevent cartilage loss associated 
with OA. An ideal treatment would be focused on blocking the catabolic activity of cartilage while 
enhancing the regeneration of normal cartilage586. Early intervention has the most significant potential 
for providing the most effective OA management since it provides the opportunity to start long- term 
care and disrupt the progressive vicious cycle of deterioration. However, over 50% of OA cases are 
diagnosed in dogs over 8 years339. The treatment goals are to improve joint health, overall function, 
and quality of life of affected patients. This implies relieving pain and associated muscle spasms, 
maintaining and regaining joint ROM, strengthen support muscles, address proprioceptive deficits , 
and advise on lifestyle modifications338. For sporting and working patients, an optimal treatment 
should aim to restore them to their pre-injury status in a safe, cost-effective way and as quickly as 
possible587. It is essential to realize that, in contrast to humans, dogs support themselves more with 
muscular effort and less with bony segments, making it essential to address all involved tissues of the 
joint organ during treatment588. 
Many interventions are directed at the symptoms of the disease rather than the disease process 
itself. This approach is not misguided since pain is usually the dominant symptom, and its control 
represents a fundamental goal in the management of the disease 13. In humans, relieving pain is, by 
itself, sufficient to produce an improvement in gait function but not in joint loading589.  Still, a 
growing interest in understanding the mechanisms that govern cartilage turnover has emerged, 
intending to develop treatments that preserve or restore this tissue by promoting its synthes is, 
inhibiting its breakdown, or both590. Given the limited capacity of adult articular cartilage for 
functional repair, cartilage preservation based on maintaining a balance between anabolism and 
degradation is paramount to joint function272 and a target of many treatment modalit ies. 
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Pharmacological and nutraceutical agents used in OA treatment are usually divided between two 
categories, those aimed at modifying clinical signs and those aimed at modifying joint structure579,591. 
Disease-modifying agents are defined as agents capable of delaying, stabilizing, or even repairing 
OA lesions592.  Symptom-modifying agents can be described as agents that do not affect the disease's 
progression but help to alleviate clinical signs, with pain being the most targeted one 579. Frequently, 
the first-line of treatment is mild analgesia. The next escalation of treatment consists of the lowest 
dose of non-steroids anti-inflammatory drugs (NSAIDs) for the shortest period, and weak opioids can 
also be considered. In refractory cases, full dose NSAIDs, along with intra-articular glucocortico ids 
or hyaluronan, may be used. Chondroitin sulfate and Glucosamine may provide symptomatic benefit 
but, if no response is apparent in 6 months, they should be discontinued575. There is a real need for 
effective, safe, disease-modifying therapies that treat established disease and prevent or delay 
progression593. The development of such treatments is constrained by the slow progression of the 
disease, heterogeneous clinical manifestations, and the need for long-term follow-up to detect 
structural changes16. Also, since joint health and pain status are affected by a wide range of factors, 
it is difficult to provide a specific recommendation applicable in all situations594. Due to the diversity 
of treatments, it is also difficult for practitioners to choose the most appropriate for their patients. 
Systematic reviews of the efficacy of OA treatments in dogs highlight the poor quality of study design 
and reporting, limiting their authors' ability to make strong recommendations18.  
Studies in humans have shown wide discrepancies in results can be observed between reports 
for the same treatment. These variations may be due to an enormous placebo effect, and the fact that 
prospective, randomized, double-blind, placebo-controlled studies to treat analysis are rare13. Most 
of the available data rely on symptomatic outcome measures, as the ability to identify disease-
modifying outcomes has often been challenging250. An alternative approach would be the use of 
serum or SF biomarkers 250,595. A placebo effect has also been reported in dogs, of higher degree on 
subjective evaluation tools, usually not accompanied by the same result in objective measurements23 5 . 
It has been assigned to the caregiver placebo effect, reported to occur both in owners and assessing 
veterinarians. In some instances, it was described to be as high as 41%541,596,597. It may be attributed 
to the wish of the person making the assessment for the dog to get better, and may therefore perceive 
an improvement that is not real. Another component of the placebo effect, particularly in OA cases, 
is attributed to the fact that some animals do improve during the evaluation despite not receiving any 
treatment. This improvement is attributed to the disease's natural evolution and a regression to the 
mean effect539,552,561,598. An additional consideration to keep is the degree of initial impairment, as it 
has a significant effect on several outcome measurements, with greater initial impairment being 
associated with more extensive positive changes in activity599.   
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Veterinary randomized controlled trials in dogs with OA and chronic pain might reliably 
predict treatment efficacy in humans due to the rigor of the functional outcome measures 
used552,600,601. These trials are free from the ethical objections associated with the use of experimenta l 
dog models, are aligned with the three R’s agenda, and are less expensive than using experimenta l 
dog models602. Considering veterinary randomized controlled trials as an alternative intermediary for 
the development of new therapies is reinforced by the similar clinical benefits achieved when novel 
treatments are trialed in dogs and humans, suggesting that good clinical responses in dogs with OA 
undergoing treatment might also be seen in humans111. 
 
4.1 Intra-articular modalities; 
Since OA is symptomatic only in the affected joint while lacking obvious extra-articula r 
manifestations, it is well suited to have a local therapy administered by intra-articular (IA) injection, 
reducing the total amount of drug required to produce an effect and possible side effects13–15. IA 
therapies several advantages over systemic medications. These can be physiological and practical, 
and include safety, especially when certain comorbidities are present, and bioavailability603. It can 
also be of interest in patients that present other co-morbidities, which have an increased risk of drug 
interaction and adverse effects604. Despite all this, intra-articular injections are less routinely used in 
the management of canine OA compared to their use in horses and humans. Intra-articular treatments 
are applied in the intended place of action, providing a higher concentration of the medication in the 
joint space, minimizing systemic exposure, thus avoiding several systemic side effects. It also 
addresses the difficulty that systemically administered drugs have to reach the articular cartilage, due 
to its avascular nature, raising the need for high doses15–17. However, many drugs are rapidly cleared 
from the synovial space, phenomena further accelerated by synovitis, raising the need for more stable 
presentations, such as depot formulations14,15. Novel IA approaches are being developed, include the 
creation of biomaterials encapsulating corticosteroids, designed to sustain their release locally for 
prolonged periods of time605. This directed route of treatment requires a precise diagnosis and correct 
identification of the joint to be treated. There are cases in which joint pain is attributed to peri-articular 
soft tissues and adjacent trabecular bone, that are inconsistently reached by drugs administered IA606. 
As an example, levels of pain in OA are affected by synovitis, but also osteochondral pathology and 
sensitization403.  
Frequently and true for many of the currently used IA treatments, it is uncertain if the 
treatment is having its effect noted merely by relieving the symptomatic pain associated with joint 
disease or through a positive effect on the joint environment250,607. The IA injection of any solution, 
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even saline, can produce a positive short-term effect because, since it favourably alters the abnormal 
joint environment, by diluting cytokines and cartilage degrading enzymes608. There are accounts of 
improvements in the symptoms of human knee OA for up to three months following saline 
injections609–611. A recent review of published effects of placebo saline injections shows that 
functional improvements last even longer than those reported for pain perception, up to a 6-month 
follow-up612.    
Intra-articular administrations of an anaesthetic, US-guided or not, may also be used as a 
diagnostic tool613. Using an imaging guide is not necessary for infiltrative procedures, but it can add 
extra value and provide safer and accurate treatments614,615. When done, sterile gel and probe covers 
should be used616. Failure to inject the medication in the intra-articular space is one of the possible 
causes of treatment failure617. Interestingly, a recent study concluded that accurate IA injections of 
corticosteroids do not produce a superior outcome in terms of pain when compared to inaccurate 
injection in symptomatic knee OA615. For intra-articular administration to the canine hip (Figure 23), 
animals are placed in lateral recumbency, with the side of the affected joint uppermost. The puncture 
site is clipped and aseptically prepared. With the limb parallel to the table surface and in a neutral 
position, a 22-gauge, 55 to 75mm spinal needle is then inserted closely dorsal to the greater trochanter 
and perpendicular to the long axis of the limb618. In a human study, no detrimental effect has been 
observed with variations of total injection volumes when treating OA of the hip, with practitione rs 
using from 3 to 9 ml619. 
 
 
Figure 23 – Access to the hip joint, confirmed through the collection of synovial fluid . 
Side effects of IA administrations are rare but include infection, post-injection-flare, crystal-
induced synovitis, cutaneous atrophy, and steroid arthropathy14,620.  In humans, the risk of joint 
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infections when a stringent aseptic technique is used, ranges from 1/14000, 1/50000 to 1/80000 
injections621,622. In a retrospective study, previous use of IA corticosteroids increases the risk of 
postoperative sepsis following elective arthroscopy623, although no reference to repeated IA injections 
was made.  Other factors may compromise IA treatment efficacy, as is the case of the acute synovit is 
present in OA, resulting in distension of the joint and increased synovial permeability. Inflammation 
increases synovial blood flow, and capillary permeability217, which these facts combined may lead to 
the fast removal of the applied medication from the joint space. Some authors, therefore, recommend 
preceding the administration of medication with a fluid aspiration, or even a joint lavage, to decrease 
in situ inflammation and limit the dilution effect of the eventual present effusion624–626. Joint lavage, 
by itself, contributes to the amelioration of the symptoms, as it washes out loose cartilage, 
inflammatory mediators, and collagen debris, which cause synovitis and effusion627. 
 
a. Corticosteroids (CS); 
IA CS has been used for several decades in horses and humans to successfully palliate pain 
and control inflammation associated with OA and surrounding tissues595,628. Amongst the medicat ions 
available for the treatment of OA, these are the ones with the most potent anti-inflammatory activity 
and have been the mainstay in the treatment of joint disease606. It is still the most commonly 
prescribed IA therapy in the horse, despite intense debate either concerning their beneficial or and 
potentially deleterious effects250. Proponents argue that such therapy is needed to decrease 
inflammation and musculoskeletal pain, while opponents feel that it only masks pains and leads to 
joint deterioration629. 
CS act through cytoplasmic receptors, thus reducing capillary dilation and margination62 9 . 
They reduce the number of inflammatory cells such as lymphocytes, macrophages, and mast cells, 
and also slow down the synthesis of inflammatory mediators such as IL-1β, TNF-α, and COX-2 in 
the SF227,606,630,631. In humans, CS was also described as being able to reduce macrophage infiltrat ion 
into the synovial lining, but not of some MMPs and tissue inhibitors of matrix metalloproteinase in 
the synovial membrane632. The pain relief they provide is attributed to the inhibition of prostagland in 
synthesis, specifically by inhibiting phospholipase A2 and COX-2 expression606. With time, 
pharmaceutical companies selectively modified the basic glucocorticoid molecule to develop 
analogues with more anti-inflammatory and less mineralocorticoid activity629. These molecules are 
effective for the management of chronic pain, preventing the progression of cartilage degeneration in 
the early stages of OA, particularly in patients who did not have success with NSAIDs or cannot take 
them due to side effects633.  
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Many OA animal studies have demonstrated a decrease in OA progression or a protective role 
of CS injections, based on histological and biochemical findings268,634–638. Not only the incidence and 
severity of lesions are decreased following IA CS, but also lesion size is reduced by confinement of 
cartilage erosion, reduction of fissure formation and cell clones, and preservation of matrix PG638. A 
double-blind, placebo-controlled, in vivo study, has shown that IA CS do not influence the expression 
of some essential mediators of cartilage destruction in OA632. A chondroprotective effect has been 
described in canine models, alongside some undesired effects, such as chondrocyte apoptosis and 
decreases proliferation639,640. Several animal model studies have demonstrated a cartilage-spar ing 
effect of low-dose CS without marked effects on chondrocyte health while reducing the severity of 
cartilage lesions and the size of osteophytes638,641–643. An additional limitation is that their effects have 
been described as of limited duration, due to a relatively fast clearance from the synovial space605. 
Early evaluations of their use in equine joints do not point out any direct toxic effects of 
methylprednisolone on articular tissues, even at high doses, but decreased staining for GAG content 
in the histological examination was observed644,645. Additional reports described no deleterious side-
effects to the articular cartilage, based on histology and histochemistry, and exercise also did not have 
any harmful effect in the presence of IA CS administration646. Reports presenting deleterious effects, 
mainly of methylprednisolone, usually point out the low quantity and high viscosity of SF, often are 
based on multiple injections, while a single dose does not seem to cause long-term detrimenta l 
effects647,648. 
The debate regarding the use of IA CS is a long-standing one. There is a concern that over-
use of a diseased but pain-free joint would result in accelerated cartilage degeneration, an impression 
compounded by some report of harmful effects of CS on chondrocyte metabolism606. Changes in 
articular cartilage and collagen metabolism have been described, but with one caveat, the results were 
based on the effect on normal joints595. Interestingly, several studies in humans that reported adverse 
effects of corticoids (decreased ECM synthesis or degradation after treatment) were based on 
formulations of which the vehicle excipients were shown to be toxic605. Some CS, by themselves, 
may have a deleterious effect, even when combined with hyaluronan, as is the case of dexamethasone 
and prednisolone633. High dosages of CS appear to have the most significant negative effects on GAG 
synthesis but, in the presence of inflammatory cytokines, they may limit cartilage degradation, which 
supports the potential for observing differing effects of CS in normal and disease cartilage635,649. Some 
authors measure cartilage degradation through the determination of GAG in SF. This procedure has 
been debated, as SF GAG content may be due to increased GAG release from cartilage degradation 
but also to increase synthesis635,650,651. 
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On the other hand, a long-term prospective study in humans has described no significant 
deleterious effects on follow-up radiographic evaluation following repeated IA triamcino lone 
acetonide (40mg) injections over a 2-year period652. Different animal studies have also presented 
interesting data regarding the effects of CS. In rabbits, structural and biochemical deleterious effects 
have been described, although associated with frequent administration and high doses. In dogs, 
significant beneficial effects have been described, both with methylprednisolone and triamcino lone 
hexacetonide. In horses, methylprednisolone shows detrimental effects, while triamcino lone 
acetonide was classified as having positive effects in a highly rated study653.  
 
There are some recommendations available for the use of IA CS in human medicine, which 
are thought to apply to canine medicine as well, providing varying strength of recommendation for 
the use of intra-articular CS, from weak to strong recommendation654–658. On the other hand, other 
guidelines state an inability to recommend for or against the use of intra-articular corticosteroids, in 
this case, specifically for patients with symptomatic knee OA659. The dose to be used in a specific 
joint depends on joint volume, the severity of inflammation, and the number of other joints requiring 
treatment606. In general, a period of at least 6 to 12 weeks should be respected between 
administrations, without exceeding 2 to 4 injections of the same joint within a year4,660,661. The 
recommendations for hip and knee OA stated that IA CS can be used and should be especially 
considered in patients with moderate to severe pain, non-responding to oral analgesic/NSAIDs, with 
triamcinolone hexacetonide proving pain relief and improved mobility for prolonged periods580,654,655. 
Variations in the duration of treatment may be due to disease, treatment, and patient-related factors. 
The characterization of such factors is poor, making it difficult to select patients who are the most 
likely to benefit from this approach662,663. Still, CS efficacy may be greater in early disease stages and 
when there is more significant inflammation, for example, in the presence of hip synovitis663,664. The 
individual preference of the clinician often determines the choice of CS653,665. Among the most used 
are methylprednisolone, triamcinolone acetonide, and triamcinolone hexacetonide614. A survey of the 
American College of Rheumatologists to its members found that 34.6% preferred 
methylprednisolone, 31.2% preferred triamcinolone hexacetonide, and 21.7% preferred TA666. A 
systematic review recommended that practitioners refine and individually tailor their selection of 
agent and dosing regimen to individual patient's needs and clinical response660. Some human reports 
have compared different CS. 
A systematic review has deemed triamcinolone more effective than betamethasone and 
methylprednisolone667. In humans, methylprednisolone has shown similar clinical improvements, and 
for as long as hyaluronan, both administrated IA to patients with knee OA664. It also showed the same 
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effect as triamcinolone hexacetonide in another report, with improvements in pain and function being 
sustained for up to 24 weeks, for even longer, up to 8 months617,668. When compared, triamcino lone 
hexacetonide and methylprednisolone had similar functional effects at eight weeks, with 
triamcinolone hexacetonide being more effective at week 3669. A different report comparing 
methylprednisolone (40 mg/1ml) and triamcinolone hexacetonide (40 mg/2ml) in the management of 
knee OA, concluded that both have similar efficacy in relieving pain and improving function, with 
efficacy peaking at two weeks after injection and lasting until the 24th week post-treatment670. In an 
in vitro model, methylprednisolone produced a dose and time-dependent decrease in chondrocyte 
viability after exposure to clinically relevant doses. The combination of methylprednisolone with 
lidocaine also did not mitigate the inflammatory effects of IL-1β, further potentiat ing 
chondrotoxicity671. 
Triamcinolone is presented as having an extended duration of action672, and the administrat ion 
of triamcinolone acetonide in an abnormal joint does not alter SF GAG levels as dramatically as IA 
triamcinolone acetonide in a non-fragment containing joint635.  It is addition to a culture of 
synoviocytes inhibits cytokine production and release and MMP activity, in both cartilage and 
synovial tissues. It was also able to counteract the inhibition of GAG production by synoviocytes but 
reduced GAG production in a human cartilage monoculture194. In dogs, 120h after IA injection, serum 
triamcinolone acetonide levels are diminished to undetectable levels (<0.5ng/l)605, while in horses, 
its SF levels are detectable up to 14 days post injection673. Early treatment with IA triamcino lone 
acetonide after joint injury may entirely mitigate the injury-induced increase in synovial fluid 
collagen fragments268.  It has also been described as being able to stimulate joints contralateral to a 
treated one to increase GAG production. This effect was attributed to low triamcinolone acetonide 
concentration in all joints secondary to systemic absorption, which stimulated GAG synthesis635. In 
a human report, triamcinolone acetonide was able to provide similar improvements in knee pain, 
function, and ROM when compared to a single administration of high molecular weight hyaluronan 
(G-F 20) at a 6-month follow-up. Both relieved pain and showed similar functional improvements, 
with triamcinolone acetonide having the advantage of providing better pain control in the first week 
and better knee functional improvements in the second week674. Although it provides excellent results 
concerning chronic pain, the mechanisms by which it exerts its effects are not fully elucidated. It can 
significantly suppress the expression of pain mediators induced by IL-1β in the spinal cord675. Some 
reports suggest that it may decrease chondrocyte viability and increase their oxidative stress in a dose-
dependent manner672. Several human reports have evaluated the effects of IA triamcino lone 
acetonide. A 2-year follow-up study showed that triamcinolone acetonide has long-term safety, with 
no deleterious effects being observed deriving from long-term IA administration. Patients treated had 
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significantly increases in ROM and pain652. High doses (80mg) do not have any additional benefit 
when compared to lower doses (40mg) for the treatment of knee OA676. An extended-release 
formulation of triamcinolone acetonide, in which the active principle is incorporated in poly(latic-co-
glycolic acid) microsphere, is able to provide a clinically relevant improvement in pain relief in 
patients with knee OA, compared with immediate-release triamcinolone acetonide. These effects did 
also remain relevant for a longer period of time634. Comparing triamcinolone acetonide and a different 
triamcinolone presentation, triamcinolone hexacetonide, and their elimination profiles in patients 
with knee OA, triamcinolone acetonide metabolites were detected in urine up to 48h post 
administrations, while plasma concentrations were detectable for up to 10 days post-treatment. 
Triamcinolone hexacetonide metabolites, on the other hand, were not detected in urine and while 
being detected in plasma, it was at lower concentrations677. It produces a decrease in serum cortisol 
levels after administration, reaching a peak at 24-48h. Recovery can take up to 4 weeks667. In the 
assessment of triamcinolone hexacetonide compared to a saline injection, triamcinolone hexacetonide 
(40mg) had a higher effectiveness than the placebo in the four weeks for pain in movement, pain 
scale, and ultra-sound measurement of synovial hypertrophy678. Treatment with 20mg of 40mg of 
triamcinolone hexacetonide produced equal relapse after six months in patients with chronic 
polyarthritis and when treating medium-sized joints. With that in mind, since no difference in 
outcome was found between compared doses, the lower one should be preferred, also reducing 
pharmaceutical costs and metabolic side effects679,680. Triamcinolone hexacetonide is more effective 
for managing knee pain than hyaluronan in humans up to week four post-treatment. Beyond week 8, 
however, hyaluronan has greater efficacy681. Duration of treatment efficacy also varies greatly with 
reports, raging between 1  to 2 months, 3 to 6 months, or up to one year619,667,674,682,683.  A recent 
report indicated that the combined IA use of triamcinolone hexacetonide and an NSAID (tenoxicam) 
could have a synergistic effect. With the treatment group showing significantly improved CMIs 
scores when compared to only CS and only NSAID group at 3 and 6 months follow-up, in patients 
with knee OA684. TH has higher potency, a long duration of action, and rare flare reaction when 
compared with other CS628,631. It decreases the release of COMP, which lowers cartilage 
degradation685. In a placebo-controlled trial in humans with hip OA, triamcinolone hexacetonide was 
effective in the treatment of pain, with effects lasting up to 3 months in many cases. A 2-year follow 
up randomized trial showed no loss of joint space after IA triamcinolone hexacetonide injections at 
3-month intervals652. The treatment group also had significant gains in the measurements of stiffness 
and physical function686. In another trial with humans with rapid destruction hip OA, the authors 
found no evidence that triamcinolone hexacetonide accelerated the course of the disease but did also 
fail to slow down the disease course687. Triamcinolone hexacetonide is also used to treat OA of other 
70 
 
joints, such as the interphalangeal, with clinical success, but not in the thumb carpometacarpal 
joint688,689.  
In a canine report, the authors recommended the use of triamcinolone over 
methylprednisolone690. Still, a systematic review of canine models of OA induction concludes that 
reports regarding IA CS use appear to be unanimously positive, with lower doses with sustained joint 
concentrations having a protective effect653. In contrast, triamcinolone acetonide has also been 
described as having deleterious effects on normal and OA chondrocytes and explants, with this effect 
not being counteracted by a concomitant administration of hyaluronan691. Long-action preparations 
are usually preferred for IA use4. In a Cranial Cruciate Ligament transection canine model, IA 
corticosteroid injection has shown to be able to reduce the progression of OA, associated with a 
reduction in the synthesis of stromelysin by chondrocytes. A single injection of 20mg of 
methylprednisolone produced favourable results in the structural changes of OA and, when given at 
the time of OA induction in a canine model, significantly reduces the incidence and size of 
osteophytes and histological severity of cartilage lesions639,642,692,693. This cartilage sparing effect may 
also be related to the down-regulation effects that CS have on urokinase plasminogen activator, one 
of the first enzymes in the activation cascade of MMPs636. A single administration of triamcino lone 
and lidocaine can achieve pain relief in dogs with cervical articular facet joint osteoarthritis613. This 
combination has a more prolonged action when compared with triamcinolone acetonide, being 
absorbed more slowly, with SF levels being maintained for over two weeks694. In a canine model of 
OA, IA triamcinolone hexacetonide was compared with oral prednisone and to a no-treatment group. 
Both treated groups had a significant reduction of osteophyte size, with femoral condyle cartilage 
erosion being observed in 25% of non-treated animals, 8% of those receiving oral prednisone, and in 
none of those under IA triamcinolone hexacetonide treatment. Histologically, triamcino lone 
hexacetonide significantly reduced the severity of OA structural changes of cartilage and had no 
deleterious effects on normal cartilage. No evidence of increased cell degeneration or death was 
associated with both CS638. 
In horses, a study comparing the difference between methylprednisolone and triamcino lone 
acetonide showed no difference between the two, nor between single or multiple administrations66 5 . 
methylprednisolone may, however, have a protective effect against the degradation of newly 
synthesized GAGs649. Horses that showed the most significant response to treatment are less likely 
to have had radiographically moderate or severe OA665. Another report described that neither 
methylprednisolone nor triamcinolone acetonide was able to counteract the adverse effects of IL-1 
and did not maintain cartilage metabolism at control levels. Lower doses of both were also not less 
detrimental to cartilage metabolism than higher doses695. Horses treated with IA triamcino lone 
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acetonide had lower protein and higher hyaluronan and GAG concentrations in SF. Synovia l 
membranes from treated joints also had less inflammatory cell infiltration, intimal hyperplasia, and 
subintimal fibrosis. Results show beneficial clinical effects on detectable lameness and synovial fluid, 
synovial membrane, and articular cartilage morphological parameters, with no deleterious effects on 
subchondral bone. No macroscopic, microscopic or biochemical evidence of irreversible damage 
secondary to IA triamcinolone acetonide was observed635,696. These results, along with the observed 
chondroprotective effect of triamcinolone acetonide in vitro, have given body to the recommendation 
that it is an ideal corticosteroid, particularly in high motion joints629,697,698. A systematic review 
favoured triamcinolone hexacetonide over betamethasone due to a significant difference in terms of 
pain reduction699. 
As a whole, different CS have varied in terms of benefits and deleterious effects, generalizing 
that their IA is harmful inappropriate. Their IA use has prolonged effects, hypothesized as being due 
to its interaction with cytoplasmatic receptors, which may increase with rest629. Side effects are 
mainly related to discomfort from the procedure, localized pain post-injection, and flushing676. IA CS 
can, however, cause synovitis, in a reactive reaction called a steroid flare. This event has been 
described in horses and humans, with a prevalence of 2-6%14,630,700. Other than that, very few side 
effects have been reported and may include crystal-induced synovitis, calcification, steroid 
arthropathy, amongst others. Rarely, systemic side effects have been described in humans, as fluid 
retention, hyperglycemia, and hypertension699. It is crucial to guarantee a rest period after IA 
administration. Rest after an IA corticosteroid is a common practice amongst human rheumatologis ts, 
which may lead to a substantially higher duration of effect when a gradual return to use follows rest606. 
A prolonged clinical response has been described in humans that received a 24-hour period of rest 
after administration. This effect was attributed to a reduced clearance of the medication from the joint 
due to restricted joint movement, which in turn enabled better IA tissues penetration 701. When 
compared to other therapeutic options, such as hyaluronan, CS may be a more cost-effective option 
because of its lower cost674.   
 
b. Hyaluronan; 
Hyaluronan is a high molecular GAG composed of continuously repeating molecula r 
sequences of glucuronic acid and N-acetyl-glucosamine, synthesized by chondrocytes and synovia l 
fibroblasts (type B synoviocytes) in articular cartilage and synovial intima, respectively246,624. In the 
cartilage matrix, it forms the backbone of PG aggregates that are interwoven with collagen to create 
the unique structure of hyaline cartilage702. In SF, hyaluronan provides joint lubrication and helps 
limit inflammation, pain, and cartilage degradation, while acting as a shock absorber and allowing 
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the joint to move in a smooth manner246,247. In diarthrodial joints, it is also responsible for the 
viscoelastic and lubricating properties of SF, which is primarily a dialysate of plasma703.  
Currently, its wide use as a treatment for OA is still somewhat controversial because its mode 
of action is unclear and clinical trials have provided contradictory results13. In normal stifle joints of 
dogs, a mean SF concentration of 15.3mg/ml has been reported. During the early stages of OA, SF 
hyaluronan concentrations rise due to increased synthesis in response to pathological stimuli, and 
then gradually diminishes to severely low levels in most clinically affected animals2,245. Other studies 
reported significantly reduced levels of hyaluronan in canine OA joints, with a negative correlation 
between its concentrations and disease severity704. Dogs younger than eight months tend to exhibit 
higher levels while older dogs value tend not to differ significantly from the adult animal70 5 . 
Endogenous hyaluronan is cleaved by free radicals, and its quantity and quality are affected in OA 
joints, more severely in clinically affected dogs. The fragmented, low-molecular-weight hyaluronan 
has been shown to have a pro-inflammatory effect706. Its concentration is also affected by dilut ion 
attributable to joint effusion, with aberrant forms also being produced2,79,703,707,708. Contradictory 
reports regarding the effects of unuse and immobilization on hyaluronan levels have been published7 9 . 
The rapid turnover and degradation of PG aggregates components in OA may also involve turnover 
and loss of hyaluronan709.  
The observation of decreased hyaluronan concentrations in OA patients leads to the 
hypothesis the disease resulted from increased wear and tear and that lubrication was impaired due to 
reduced hyaluronan concentration. With this in mind, the exogenous administration of hyaluronan 
seemed an obvious corrective measure, but the assumption is presently known not to be correct13. 
Hyaluronan treatment aims to reduce pain and improve function by supplementing the viscosity and 
elasticity of SF574. The full mechanism of action is not entirely known, but anti-inflammatory, anti-
nociceptive, and chondroprotective properties have been suggested, by enhancing cartilage synthes is, 
blunting response to IL-1 and TNF-α, and significantly decreasing TNF-α, prostaglandins, and IL-6 
levels. It also reduces the damage of oxygen free radicals, inhibits phagocytosis, and affect leukocyte 
function13,624,710–713. Evidence towards the role of hyaluronan in chondroprotection is less prevalent3 0 , 
even though it may suppress chondrocyte apoptosis, stabilize PG structure, and help to diminish gross 
morphological and histological damage714–716. Its direct analgesic effect has also been suggested in 
animal models, by a proposed action over the opioid receptor712,717,718. An additional proposed 
mechanism of action is the stimulation of endogenous hyaluronan through exogenous administrat ion, 
based on in vitro and in vivo studies703,715,719. In animal models, IA hyaluronan demonstrated similar 
effects inhibiting degenerative cartilage changes within chondrocytes and ECM, decreasing synovia l 
inflammation, enhancing PG content, and inducing chondrogenic differentiation720,721. Even when 
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given intravenously, hyaluronan seemed to be able to decrease chondrocyte apoptosis714. Suggest ions 
have been made that these effects are mainly due to the effect of hyaluronan on proinflammatory 
cytokines and degradative enzymes722. The injection is rapidly cleared from the joint, but maximal 
clinical improvement does not occur for several weeks and persists for much longer, although there 
are reports of improvements after only one week in humans13,710,723. In a normal joint, hyaluronan 
half-life is approximately 20h, while in an inflamed joint can be reduced to 11-12h724.  
A large number of human studies have addressed the use of hyaluronan, mainly focusing on 
pain and joint function. The conclusion presented by these studies varies widely from dramatic 
improvements in some to no beneficial effects in others13,725–727. High molecular weight products 
seem to produce better results, particularly in patients with mild radiographic disease667,728–730. A 
recent report showed that both single or 1–3 weekly injections of hylan G-F 20 at 1 year following 
the first injection for knee OA are efficacious and generally well tolerated for long-term use731. Even 
in active patients, the benefits of these presentations are still noted, particularly when added to usual 
care732. Still, in general, the majority of hyaluronan products seem to be superior to placebo726. A 2-
year randomized controlled trial has suggested its beneficial effects on cartilage volume and defect 
scores733. Recommendations for the treatment of human hip and knee OA have deemed hyaluronan 
as useful, is characterized by a delayed onset but of prolonged duration580,710, an unexpla ined 
characteristic. Other recommendations provide a weak recommendation for the use of IA HA 658, a 
conditional recommendation against 657, or that they should not be offered as an option 656. 
Comparative reports also deem hyaluronan superior to IA corticosteroids681. A recent report in 
humans determined that patients with knee OA are the ones who benefit the most from the treatment, 
in terms of pain reduction and improved function, particularly those with high levels of pain, younger, 
with higher body mass index, and with less severe structural damage725. Concerning specifically the 
hip joints in humans, efficacy seems to be greater in cases of less radiographic changes, lasting up to 
3 months after the first injection. Sub sequential administrations may sustain treatment benefits734,735. 
Another report showed similar clinical benefits between corticosteroids and hyaluronan, with those 
benefits being no different from saline at a 3-month evaluation point736. A meta-analysis concluded 
that efficacy of treatment reached its highest point at 2 months after injection, and then declined over 
time737.  
Many studies performed in canine experimental models of OA have failed to demonstrate 
clear benefits of hyaluronan supplementation578,579,594. The same results have been described in 
horses, were hyaluronan seems to be more effective in the treatment of incipient joint lesions rather 
than in established disease606. In a canine surgical model, IA hyaluronan provided clinica lly 
significant improvement in animals with stifle OA in terms of pain, function, lameness, and kinetics 
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when compared to pre-treatment and saline control. Maximum benefits were noted at 4-8 weeks and 
gradually tampered down by a 6-month evaluation time point. It was not, however, able to prevent 
the progression of OA based on radiographic, arthroscopic, and histologic assessment738 . 
Improvement in cartilage preservation has been described when using a conjugate of HA with 
autologous fibrinogen in platelet-rich plasma, compared to HA alone739.  In reports regarding dogs 
with naturally occurring OA, treatment groups have significantly better results than a control group 
by the 6th-week post-treatment, with the authors' suggestion and the effect that lasts from 6 to 12 
months740. Other reports state that IA hyaluronan delayed the onset of OA, slowed cartilage 
degradation, decreased signs of pain, and improved joint function after the onset of OA741. In a 
different canine model of arthropathy, the hyaluronan treated group had significantly less 
ultrastructural changes when compared to a placebo group. The authors described that hyaluronan 
seemed to cover cartilaginous defects and diffuse through the cartilaginous matrix to re-aggregate 
with degraded PG and re-stabilize the matrix. Due to these effects, chondrocytes seemed to have an 
increased potential for recovery and became hyperthophic742. Reports in horses show that HA 
treatment significantly inhibits the digestion of cartilage proteoglycans and SF HA breakdown, while 
also having anti-inflammatory actions. Comparing low to high molecular weight HA, the first seemed 
to be most effective in reducing the release of cytokines743. In a study with dogs, significant score 
improvement when compared with control was seen from between 60 and 90 days. Larger dogs 
achieved an improvement of 30% or more at 12 weeks555. 
Typical protocols in humans include three injections one week apart or five injections weekly. 
Horses are generally treated with a single injection or weekly injections if needed246. As a part of post 
joint surgery recovery, no difference was observed between one or two IA injections, with both 
protocols being able to improve recovery and delay OA signs744. Other reports indicate that three 
injections weekly are more effective in reducing pain in humans when compared to a single 
administration, although both protocols improved joint function745. A popular approach in horses is 
the combined administration of hyaluronan with a corticosteroid, thus providing more rapid onset of 
action, with prolonged effect and decreasing the potential side effects of IA corticosteroids665,745,746. 
This therapeutic synergy has also been reported in human patients with OA, where 
viscosupplementation results can be improved by prior joint lavage followed by corticosteroid 
administration625,700,747,748. A recent recommendation for the management of knee OA in humans 
outlines that hyaluronan administration is best in mild to moderate OA cases and that prior or 
concomitant use of TH may optimize the effect of hyaluronan749. This addition of triamcino lone 
hexacetonide improves first-week symptoms and a functional score of IA hyaluronan administrat ion, 
but not beyond this point 750. Other reports, however, found no additional advantage in using this 
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practice or even an association with lower short-term clinical success rate, and similar medium-term 
outcome compared with IA triamcinolone alone698,751. In a 1-year follow up report, patients treated 
with hyaluronan with or without a combination of triamcinolone acetonide for knee OA, showed 
similar improvements for both pain and function, with the difference of better early pain control in 
the patients that also received triamcinolone acetonide. At the 1-year follow-up evaluation point, 
magnetic resonance imaging also showed that neither group had a significant progression of cartilage 
damage752. This approach has also been described in dogs with elbow OA, with improvements in 
activity, lameness, and pain, for up to 6 months690. 
IA hyaluronan administration has been described as producing mild heat, swelling, and/or 
erythema post-injection, which resolves spontaneously within a week738. These adverse effects are 
well tolerated and usually restricted to the injected joint700. In horses, the injection is usually well-
tolerated, and has been used in the treatment of the clinical signs of OA but also as an adjunctive in 
the post-surgical period753. 
 
c. Platelet Rich Plasma (PRP); 
PRP is an autologous biologic treatment, composed of the patient’s plasma, containing growth 
factors released from platelets and endogenous fibrin scaffold. The rationale behind its use is to 
stimulate the natural healing cascade and regeneration of tissues by a supraphysiologic release of 
platelet-derived factors directly at the treatment site, without the risk of immune rejection or disease 
transmission754–756. All healing processes go through three phases: inflammation, proliferation, and 
remodelling. After an injury, which starts the inflammation phase, platelets are on the front line and 
have a critical role in mediating healing by releasing growth factors from their α granules756–758. A 
list of these growth factors is presented in Table 6. When activated, platelets also release a group of 
biologically active proteins that bind to the transmembrane receptors or their target cells, which leads 












Growth factor Function 
IGF-1 Early inflammatory phase 
Anabolic effects 
Protein synthesis, the proliferation of myoblasts and 
fibroblasts 
Enhances collagen and matrix synthesis 
May modulate swelling 
TGF-β Proinflammatory 
Immunosuppressant during the inflammatory phase 
Aids in cell migration and fibronectin binding 
Augments production of tendon sheath fibroblasts, 
expression of type I and III collagen 
Improves tendon mechanics during the healing 
Control of angiogenesis and fibrosis 
PDGF Role in the early phase of tendon damage 
Facilitates the proliferation of other growth factors 
Attracts stem cells and white blood cells 
Stimulates angiogenesis 
Contributes to tissue remodelling 
VEGF Expression peaks after the inflammatory phase 
Promotes angiogenesis-neovascularization 
b-FGF Appears to stimulate angiogenesis 
Helps in the regulation of cell migration 
Stimulates proliferation of capillary endothelial cells 
Influences fibroblasts to create collagenase 
Enhances angiogenesis 
Contributes to the production of granulation tissue 
Table 6 – Growth factors involved in the healing process (adapted from R. T. Nguyen et al., 2011). Legend: IGF-1 - 
insulin-like growth factor; TGF-β - transforming growth factor-β; PDGF - platelet-derived growth factor; VEGF - 
vascular endothelial growth factor; b-FGF - basic fibroblast growth factor. 
 
The α granules have a key role in tissue regeneration and can release more than 800 different 
proteins, including serotonin, adenosine, dopamine, calcium, histamine, adenosine diphosphate, 
adenosine triphosphate, and catecholamines758,760,761. Growth factors also signal cells to prolifera te 
and influence maturation, differentiation, and tissue repair757,762. Besides the attractive concentration 
of growth factors and anti-inflammatory cytokines, PRP also contains small concentrations of 
cytokines, such as TNF-α584,763. As a whole, PRP is seen as able to control the activities of different 
cell types that target multiple biological processes, such as apoptosis, ECM synthesis, modulation of 
angiogenesis, and inflammation764. Several studies in animal models have demonstrated the efficacy 
of PRP in accelerating the healing process after injuries in muscle, ligament, joints, and tendons762,765–
770. It has a protective and regenerative effect on the degenerative cartilage586 and can also be used as 
an adjunctive treatment, for example in ligament reconstruction, adding resistance to the grafts used, 
seen as soon as one week after reconstruction770,771. PRP also has fewer safety concerns than cell-
based regenerative therapies772. In joints, platelet growth factors appear to have chondroinductive 
effects. transforming growth factor-β contributes to chondrocyte phenotype expression and 
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mesenchymal stem cell chondrogenic proliferation. Insulin-like growth factor-1 also has anabolic 
properties in cartilage regeneration. PDGF has mitogenic action, influences chondrocyte 
proliferation, and PG614,757,773. B-fibroblast growth factor stimulates the migration of fibroblasts and 
collagen synthesis614. They also exert autocrine and paracrine functions, promoting angiogenes is, 
ECM, and aggrecan production and collagen synthesis, together with influencing tissue 
regeneration774. PRP also induces a significant decrease of MMP-13, MMP-9, and MMP-2 levels, 
decreases the chondrocyte apoptosis cascade, while increasing hyaluronan synthase-2 expression in 
chondrocytes, thus enhancing hyaluronan secretion and contributing to joint homeostasis711,775–777. It 
also alters the expression of specific target genes, particularly during the early stages of 
remodelling778. Some reports also present a direct analgesic effect, through the augmentation of 
cannabinoid receptors CB1 and CB2779.  
Different types of PRP exist, with different compositions and properties, classified according 
to its profile regarding leukocyte and fibrin levels: pure platelet-rich plasma, leukocyte, and platelet-
rich plasma, pure platelet-rich fibrin, and leukocyte and platelet-rich fibrin780. There is a belief that 
red blood cells and neutrophils should be reduced due to their inflammatory role, while the effect of 
mononuclear cells presence remains largely unknown781. The interest of preserving leucocytes in PRP 
is, as referred, a matter of an ongoing debate since some authors attribute deleterious effects due to 
protease and free radicals released by these cells, increasing the catabolic cascade. In contrast, others 
focus on their production of important cytokines and enzymes782,783. Nonactivated leukocytes in the 
formulation are also thought to contribute with antimicrobial properties784. Leukocyte rich PRP is 
produced by centrifuging whole blood and obtaining the platelet and leukocyte rich plasma. 
In contrast, leukocyte poor PRP does not contain leukocytes and has been described in humans 
as having better results when treating knee OA than leukocyte rich-PRP783. Also, in humans, the 
concentration of inflammatory cytokines in PRP is correlated with leukocyte concentration785. An 














Classification Contents Advantages Disadvantages Constituents 
P-PRP Platelets with low-density 
fibrin network after activation, 
without leukocytes 
Liquid solution or as gel 
after 
activation can be injected or 
placed on wound 
Dissolves 
quickly 
like a fibrin glue 
Platelets: 500× 103/μL; 
leukocytes: 0.2× 
103/μL 
L-PRP Platelets with low-density 
fibrin network and leukocytes 
Liquid solution or as gel 
after 
activation can be injected or 
placed on wound 
Dissolves 
quickly 
like a fibrin glue 
Platelets: 500× 103/μL; 
leukocytes: 20× 
103/μL 
P-PRF Platelets with high-density 
fibrin network and without 
leukocytes 
Only exist as a gel after 
activation 
Solid gel, cannot 
be injected 
Platelets: 400× 103/μL; 
leukocytes: 100-
600/μL 
L-PRF Platelets and half of the 
leukocytes (mainly 
lymphocytes), with a high-
density fibrin network 
Gel without anticoagulant; 
natural blood clot 
Solid gel, cannot 
be injected 




Table 7 – Classification of platelet preparations and characteristics (adapted from Huang et al., 2017). Legend: L-PRF, 
leukocyte- and platelet-rich fibrin; L-PRP, leukocyte- and platelet-rich plasma; P-PRF, pure and platelet-rich fibrin; P-
PRP, pure and platelet-rich plasma. 
 
Considering clinical effects, leukocyte rich-PRP has been described as able to promote 
cartilage healing on the stifle, at macroscopic and histologic levels in an animal model769,787. In the 
treatment of human OA, both LR and leukocyte poor-PRP showed similar safety profiles according 
to some reports, while others attribute more painful reactions to leukocyte rich-PRP782,783. Evaluation 
of functional results was marginally affected by leukocyte concentration, in favour of leukocyte poor-
PRP783. In a rabbit model, the presence of leukocytes in PRP elicited a short-lived inflammation that 
did not alter the therapeutic effect788. Detractors of leukocyte rich-PRP use point out that these 
preparations lead to increased inflammatory mediators, more MMP gene expression, and less COMP 
and decorin gene expression, effects attributed mainly to the presence of neutrophils781. Monocytes, 
in particular, are associated with increased cellular metabolism and collagen production in fibroblas ts, 
and a decrease in the release of anti-angiogenic cytokines, as interferon-γ and IL-12789,790. 
Macrophages have the role of removing debris and also to balance pro and anti-inflammatory aspects 
of healing. Since it is impossible to keep or remove different types of white blood cells from PRP, 
the absence of macrophages may be more detrimental to the healing process rather than any damage 
inflicted by neutrophils616. Interestingly, an in vitro relation between biological response was found 
with the concentration of growth factors in PRP and not with the type, with more positive roles found 
with higher concentrations. This same report indicated that leukoreduced PRP might not be more 
indicated for the treatment of OA, as leukocytes may also have an immunomodulatory capacity and 




PRP is prepared from autologous, anticoagulated whole blood, with a 3-8 fold the 
concentration of platelets, containing a hyperphysiological amount of autologous growth factors757. 
Human studies show that the ideal PRP product should have a 4 to 7-fold increase in platelets776,793–
795. Increasing platelet numbers beyond this point may not add any benefit or may even be detrimenta l, 
as they can be a source of inflammatory cytokines and potentially prevent tissue healing796–798. Good 
results have also been reported with the use of lower concentrations587. PRP at 40% volume/vo lume 
increased bone marrow-derived multipotent mesenchymal stromal cells, while PRP at 80 and 100% 
v/v concentrations suppressed their viability799. There are reports that very large volumes of PRP 
might have a cytotoxic effect on healing grafts800. Blood collection is usually performed from the 
jugular vein (Figure 25). 
 
 
Figure 24 – Collection of blood from the jugular vein. 
Commercial kits are available for the production of in-house PRP, with variable 
characteristics781,785. They vary in the amount of whole blood required, the anticoagulant used, time 
and speed of centrifugation, final volume, and the number of platelets in the final concentrate756 . 
Some require specific equipment, such as a dedicated centrifuge (as the Companion Pure PRP® 
system), while others do not (V-PET, Pall Corporation, Figure 25). V-PET is a platelet concentrate 
as well as conditioned plasma, that contains many autologous anti-inflammatory mediators and 
growth factors, reported to reduce pain and lameness scores, and increase weight bearing in dogs with 
OA690,801. It can target multiple inflammatory mediators, producing up to 6.5ml of platelet concentrate 




Figure 25 – The V-PET kit, ready to start blood platelet concentration. 
PRP can also be produced using centrifugation, with the majority of protocols comprising a 
double spin procedure780. The first spin is usually slow, to avoid spinning down platelets, whereas the 
second spin is fast so that the platelets are spun down. With this procedure, after the first spin, platelets 
are mostly concentrated right on top of the buffy coat772 (Figure 25). Similar efficacy of treatment 
has been reported with both single and double spin techniques782, and even with double-spinning 
protocols, complete separation is not possible, because of the components’ slightly overlapping 
specific gravities803.  
 
 




Excessive centrifugation speed may damage platelets and produce a bad quality PRP804. 
Additional care is necessary to guarantee sterility throughout the process805. Closed, commercial kits, 
secure the procedure sterility. After preparation, the final appearance of the platelet production 
reflects cell content (Figure 27). 
 
 
Figure 27 – Two different platelets products, V-PET® on the left, and the Companion Pure PRP® on the right. 
The anti-coagulant to be used has also been an object of study. Many kits use acid dextrose 
(ACD), which acts by binding calcium and preventing the clotting cascade initiation by the 
coagulation proteins616. Different reports indicate that Ethylenediamine tetraacetic acid may be a 
better anti-coagulant, leading to larger yields of platelets in PRP, while others attribute better results 
to sodium citrate772. There is also a continuous ongoing debate regarding the need or even the 
adequacy of PRP activation before administration. The addition of calcium chloride is frequently used 
as an activation mechanism, that triggers the prompt release of 70% of growth factors contained in α 
granules within 10 minutes, and the remaining within the hour757. Other authors defend that platelets 
will activate at the injection site, when in contact with substances as collagen type I or through 
paracrine mechanisms, which may be a more normal physiological activation614,616. Once activated, 
platelets are morphologically modified, developing pseudopods that promote platelet aggregation and 
later degranulation806. Large bore needles (>22G) should be used during blood collection to prevent 
unintentional activation. After activation at the injection site, the release of growth factors initia tes 
an inflammatory response that lasts approximately three days616. Since platelet products can present 
such a variety of preparation steps and characteristics, a group of experts outlined the minimum 
reporting requirements for clinical studies evaluating PRP807. 
There are several reports regarding the use of PRP in human OA. Three injections proved to 
be significantly more efficient than a single injection of hyaluronan in terms of reducing knee pain 
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and stiffness while improving function. Even a single injection has produced better effects than 
placebo, with effects being present at six months to 1-year post-injection737,808–810. Other studies, 
however, describe only mild improvements but lack a control group810. Specifically, regarding hip 
OA, PRP injections seem to provide significant clinical improvements without considerable side 
effects, which remain relevant and stable for 12 months, when compared to other treatments. In the 
same study, the combination of PRP with hyaluronan did not lead to significant improvements in pain 
symptoms203. In general, and in the long term, PRP seems to be more effective than hyaluronan or 
other therapeutics, as ozone780,811,812. Better results seem to be observed in younger, more active 
patients, with a lower degree of cartilage degeneration, than in those with more advanced OA737,813. 
Highly demanding patients may not see their needs fulfilled by the marked clinical improvement 
provided by PRP, observing a decrease in results over time587. 
In dogs, a single IA PRP injection has resulted in clinical improvements for 12 weeks, in some 
cases without progression of radiographic signs777,801,814. Through this period, radiographic scores 
were the same as assigned before treatment777. Multiple injection protocols have also been described, 
providing improvements in ROM, pain, lameness, and kinetics. Authors associated this response to 
treatment while the anti-inflammatory activity of PRP rather than any effect on tissue anabolism or 
catabolism769,815. It has also been used as a part of surgical protocols, leading to significant ly better 
gait performance in the postoperative period814,816,817. Additional reports, conducted in animal 
models, show that IA PRP significantly suppresses morphological and histological changes of OA, 
increasing neochondrogenesis and PG content in the ECM818.  
Currently, no ideal number of injections or intervals are set, which is usually based on clinica l 
experience or a desired improvement level757,812. Generally, patients are re-examined 2-6 weeks after 
the procedure to evaluate pain, function, the injection site, and also to discuss concerns and future 
management course616. As a whole, it is still unclear which PRP product is ideal for most uses, and 
even if one product deemed as superior for one specific treatment is ideal for all applications785.  
Post administration withhold of NSAIDs is recommended for ten days and, preferably 3-6 
weeks after the procedure, due to a theoretical assumption that they may impede or delay tissue 
healing and may even produce fibrosis819,820. In humans, PRP side effects are usually local and 
transient, consisting of injection pain, local inflammation of short duration, and reaccumulation of 
effusion, taking 2-10 days to resolve755,757,782,810,821. Usually, no systemic effects attributable to the 
local administration of PRP are noted822. A human study, however, reported systemic rather than local 






Stanozolol is a synthetic derivative of testosterone. Its properties include anabolic/androgenic 
activity, probably associated with its affinity for androgenic and, at lower doses, glucocortico id 
receptors824. Due to its potent anabolic effects, studies regarding its use in human OA are not 
performed825,826. Despite this concern, long-term, high-dose treatment with stanozolol has failed to 
produce significant changes in activity patterns and aggressiveness in treated mice827. It can induce 
fibroblasts to increase collagen production in a dose-dependent pathway, through transforming 
growth factor-1β synthesis, while decreasing NO production and stimulation of autocrine secretion 
of insulin-like growth factor-1, which induces osteoblast proliferation and collagen synthesis828–831. 
In humans, an increase of transforming growth factor-1β synthesis is related to a decrease in articular 
pain832. It also demonstrated chondroprotective effects through the downregulation of genes for pro-
inflammatory/catabolic cytokines and enzymes associated with OA, in an equine in vitro 
chondrocytes833. An additional possible mechanism of action may be related to its induction in 
aromatase expression834. It has been demonstrated that the human articular cartilage expresses 
aromatase and that reduced expression of aromatase could facilitate the development of OA835,836. 
The use of aromatase inhibitor therapy in humans to address other medical conditions might be 
associated with common musculoskeletal symptoms and with substantial functional disability837. 
In an ovine surgical OA model, IA stanozolol was able to preserve the gross anatomy of the 
stifle joint, reducing osteophyte formation, subchondral bone reaction, and promoting articular 
cartilage regeneration, evaluated at 3 and 9 months post-surgery. These results were assessed via 
digital radiography, lameness data, and histological examination. No gain weight was attributed to 
the anabolic effect of stanozolol829. In horses, a positive response in the treatment of OA was observed 
in 82.5% of patients, with acute cases presenting higher treatment success. In the majority of cases, 
this meant a complete lameness resolution. An improvement in the physical characteristics of the SF 
was also observed and overall results persisted after the end of the treatment period. In some animals, 
transient post-injection swelling was observed in the treated joint, which disappeared after a few days 
without intervention830. 
In humans, the dose demonstrated to produce anabolic effects is 10mg twice a week through 
intramuscular administration838. In dogs, a 0.3mg/kg dose has been described for IA and oral 
use839,840. In horses, after bilateral IA administration of 5mg of stanozolol, the maximal plasma 
concentration registered was 1.7ng/ml at 6 hours post-administration. Therefore, stanozolol passes 
rapidly from the joint space to systemic circulation, being eliminated rapidly and detected in plasm 




e. Stem Cells; 
Stem cells are defined as potential and undifferentiated cells, with the ability to convert into 
differentiated cells and to regenerate tissues842,843. Considerable clinical attention is currently devoted 
to mesenchymal stem cells (MSC), due to their ability to differentiate into chondrocytes, osteoblasts, 
adipocytes, and fibroblasts842,844. Pre-clinical and clinical studies have demonstrated their efficacy in 
muscle, tendon, bone, and cartilage regeneration845. They have also been described as having a 
protective and regenerative effect on degenerative cartilage586. MSC have been identified in normal 
joints, originated from the synovium846. They can be obtained from bone marrow or adipose tissue, 
and then go through a culture-expansion process847. Their mechanism of action is both contact-
mediated and contact independent, modulated by immune-modifying chemicals445. They inhib it 
activated B-cell, T-cell, and natural killer cell proliferation and downregulate the expression of major 
histocompatibility complex II on inflammatory cells848,849. They have an affinity for damaged joint 
tissue, with recent in vivo studies showing that they localize and participate in the repair of damaged 
joint structures, including cartilage lesions850,851. Still, it is not fully known if they differentiate into a 
tissue-specific cell if they improve tissue repair or a combination of both847. 
Stem cells are most commonly used in clinical veterinary medicine in therapeutic applications 
for the treatment of musculoskeletal injuries, both in horses and dogs847. IA MSC administration can 
decrease cartilage destruction, osteophyte formation, subchondral bone sclerosis, and even lead to 
regeneration of meniscal and articular cartilage852–855. The use of MSC as a treatment strategy for OA 
is increasing considerably, thanks to their capacity to improve joint function, reduce pain, improve 
mobility, increase daily activity and, therefore, the patients’ quality of life856,857. In dogs, it produces 
statistically significant improvements in lameness, pain, and ROM when compared to control 
animals858,859 or placebo860. In the treatment of hip OA, specifically, MSC improved average lameness 
score and reduced pain scores, with varying amounts of cell numbers861. The synovium may be a 
promising source for MSC for canine cartilage regeneration, with a higher chondrogenic potential 
than those from the infrapatellar fat pad, adipose tissue, and bone marrow862. 
Some concerns arise from the use of MSC, the first being the need for in vitro expansion of 
cells to obtain a sufficient number. Another major concern is the possibility of neoplastic 
transformation of cells, increased patient susceptibility to infection, embolism of cells, and acute or 
chronic immune reaction to the cells themselves445. Other challenges include the determination of the 
adequate number of cells in the tissues undergoing repair, long-term safety, and the durability of the 
benefit593,856. While the majority of reports as described as safe and elicited beneficial patient 
responses, they were also open-label, uncontrolled studies863. 
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The use of PRP, along with stem MSC, has been described and presents itself as an interest ing 
approach. PRP provides a three-dimensional scaffold for stem cells to differentiate, may prevent the 
depletion of MSC, enhance their effectiveness through the activity of GF and guide them to properly 
differentiate into chondrocytes, improving joint function and cartilage regeneration586,760,777,864. It has 
been used as an approach to hip OA in dogs, that showed improvements in kinetic outcome variables, 
reducing dog’s pain, and improving physical function850,865. The use of alternative scaffolds along 
with MSC is an interesting approach, which leads to the development of additional options, such as 
urinary bladder ECM scaffold866. 
 
f. Autologous Conditioned Serum; 
The use of Autologous Conditioned Serum, as part of the use of platelet concentrate, is based 
on its content of supra-physiological concentrations of autologous anti-inflammatory mediators and 
growth factors. Specifically, high concentrations of autologous IL-1ra and sTNF-RI, which inhib it 
the binding of IL-1β and TNF-α, leading to a reduction in inflammatory mediators such as MMP-13, 
IL-6, IL-8, NOS, and PGE2582,583,661,867. It can reduce pain and lameness scores and increase weight 
bearing when injected into OA joints690,801,868. Current cytokine-modulating therapies for OA yield 
variable clinical results and compelling in vivo mechanistic evidence is sparsely available57. In 
particular, the presence of IL-1ra is of great importance, due to its effectiveness in counteracting the 
role of IL-1. Local natural IL-1ra concentrations may be too low in degenerative diseases to inhib it 
the destruction of cartilage, muscle, and other joint structures869. Several reports of IA IL-1ra have 
been published in both animals and humans, and even by gene transfer212,260,870. The effects of 
Autologous Conditioned Serum seem to be due to the involvement of other factors rather than IL-1ra 
alone, mainly since some questions are recently being raised regarding the effectiveness of targeting 
IL-1 in the treatment of OA871,872. 
 The production of Autologous Conditioned Serum consists of the incubation of 50-60ml of 
blood in syringes that contain medical-grade glass beads, incubated at 37°C with 5% CO2 for 24h, 
and then centrifuged for ten minutes661. It has been deemed a safe and effective procedure, reducing 
pain and with sustained effect that lasts of up to 2 years, possibly through a re-establishment of a 
healthy joint homeostasis873,874. Additional reports of at least one year of improvements have been 
published, with mean improvements of 78% compared to 7% in the control group875. Autologous 
Conditioned Serum has shown to be superior to both placebo and hyaluronan in several clinica l 
outcome measures13,873. In dogs, studies have shown that it can produce improvements up to 12 
weeks, both in subjective scores (CBPI and HVAS) but also in weight-bearing (PVF and VI)235. It 
has also been described in dogs with elbow OA, with improvements in activity levels, decreased 
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lameness, and pain690. No side-effects have been related to its use, other than the possible ones derived 
from the IA route of administration875. 
 
4.2 Other therapeutic modalities; 
Many of the pharmaceutical agents included in this section act via the anti-inflammato ry 
activity. They do not, however, target most of the pro-inflammatory mediators, being unable to stop 
the catabolic state found in OA joints445. For that reason, they often provide insufficient symptomatic 
relief. 
 
a. Non-steroidal anti-inflammatory drugs; 
The term non-steroidal anti-inflammatory drugs (NSAIDs) refers to those drugs that inhib it 
one or more steps in the metabolism of arachidonic acid cascade into prostaglandins (particular ly 
those in the PGE series) and thromboxane, but are not classified as steroids876,877. NSAIDs are 
frequently the first-line of treatment in OA and are the mainstay of treatment of hip OA. Their 
popularity is probably due to a rapid efficacy in palliating pain in animals with OA and relative ease 
of administration575,594,876,878. In the USA, the cost of treating dogs with NSAIDs was estimated to 
exceed US$130 million in 2005, growing at 13% a year544.  
NSAIDs tend to be well absorbed after oral administration, and hepatic elimination is the 
primary route of elimination via biliary secretion, conjugation reactions, and metabolic reactions such 
as cytochrome P450 metabolism879. They work by inhibiting COX and, in consequence, PGE2, and 
this action relieves pain but is not considered able to ameliorate cartilage loss in persons with OA53,879. 
COX has two main isoforms, 1 and 2, with COX-1 being generally identified as involved in regulatory 
processes, while COX-2 is more linked with the inflammatory processes of OA, even though this 
division has been proven not to be so formal877,879. COX-2 is constitutively expressed in the dorsal 
horn of the spinal cord and contributes to the propagation of nociceptive stimuli, and its inhibit ion 
can also produce central analgesic effects880. Both COX-1 and -2 are up-regulated in the synovium 
of dogs with naturally occurring hip OA881. A third isoform, COX-3, has been identified primarily in 
the canine cerebral cortex, with minimal amounts found peripherally882. COX selectivity has been 
reported as not associated with the efficacy of any given NSAID879, although this claim is a matter of 
an ongoing debate. Different NSAIDs inhibit different isoforms of COX. Even though joint 
inflammation alone does not suffice for the diagnosis of OA, it has a predominant role in clinica l 
presentation, leading to pain and effusion, making it a relevant target for symptomatic treatment27 2 . 
NSAIDs, through the inhibition of prostaglandin production, can return the nociceptive threshold to 
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a normal level883. The plasticity of pain transmission pathways that leads to central sensitization may 
be reversed through COX inhibition884,885. Inhibition of COX-2 has proven to reduce OA clinica l 
signs, and also to have a chondroprotective action886,887. In humans, however, COX-2 inhibitors can 
produce a higher rate of cardiovascular adverse events888. Dogs, on the other hand, have higher basal 
levels of COX-2 expression in the kidney compared with humans. For that reason, dogs with chronic 
kidney disease show increase COX-2 expression, and the synthesis of prostaglandins shifts to the 
COX-2 pathway. For those reasons, NSAIDs that target COX-2 may be expected to adversely affect 
renal function in dogs889. 
Recommendations for the prescription of NSAIDs for the management of OA vary greatly, 
from intermittent (“as needed”) therapy to a continuous modality (long-term treatment being defined 
as 28 days or more of continuous therapy. The latter has the benefits of providing better pain control, 
better improvements in mobility, and potentially slowing down of the disease process through 
improved joint usage317. When prescribed for long-term use, the dose should be titrated to the lowest 
effective dose possible580. The continuous use of NSAIDs leads to a decrease in central sensitizat ion 
and reduction of disease progression, through the prevention of nitric oxide-induced cell 
death317,890,891. There is evidence that response to NSAIDs is significantly lower in dogs with 
lameness for six months or longer, compared with those with lameness lasting for shorter periods892. 
Carprofen is the NSAID with a higher number of published studies regarding its effectiveness 
in reducing OA signs in dogs. It is considered a preferencial COX-2 selective and can reduce pain in 
the post-surgical period, but may not provide the same amount of relief in all dogs433. In a systematic 
review, it has been attributed to a moderate level of confidence in its ability to reduce clinical signs 
of OA578. When used in working dogs with hip OA, carprofen was not able to significantly reduce 
signs of pain893, nor in companion dogs with HD, when compared to a placebo894. Carprofen has also 
been shown as able to reduce histologically graded cartilage lesions and significantly decrease 
biomarkers related to the progression of OA, as C-terminal telopeptide of collagen type II, and delay 
osteophyte progression, as observed in radiographic findings, though the reduction of osteoblasts’ 
activity895,896. Also, it has in vitro ability to stimulate the synthesis rate of GAGs897.  
Other reviews have pointed to strong evidence of the efficacy of carprofen, meloxicam, 
firocoxib, and mavacoxib579,898. In a large scale study, firocoxib was described as effective in over 
90% of animals, and with a low percentage of side effects899,900. Meloxicam is also a COX-2 selective, 
with potent anti-inflammatory activity and low gastrointestinal and renal toxicity876. Additiona l 
reports suggest that both mavacoxib and carprofen are remarkably effective in the treatment of canine 
OA, with 93.4% of mavacoxib-treated dogs and 89.1% of carprofen-treated dogs demonstrat ing 
overall improvement901. Both carprofen and meloxicam improve GRF in treated animals, but only 
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meloxicam can bring some of them to normal values, suggesting that meloxicam could improve joints 
suffering from a more severe inflammatory process537. The same systematic review has pointed to 
four studies on the use of meloxicam, which received a high level of comfort that it can reduce clinica l 
signs of OA578. As a whole, NSAIDs are all usually considered superior to placebo for pain relief, 
presenting no significant differences between them. It is also reasonable to presume that all dogs have 
a similar response to them594,902. While there are no studies that indicate that any given NSAID is 
superior to any other, it is important to keep in mind that an individual patient may have a better 
response to one NSAID than to another. A specific patient may also develop adverse side effects with 
one NSAID but not with another, while some may not tolerate them at all879. It is also established that 
NSAIDs provide only modest control over the signs and symptoms of OA. Some patients may also 
become refractory to therapy. Neuropathic pain, a component of chronic OA, is recognized as non-
responsive to NSAIDs866,903–905. Since NSAIDs block COX, an increase in the production of 
leukotrienes from arachidonic acid that would otherwise be metabolized to prostaglandin products 
occurs. Leukotriene activity, associated with hyperalgesia, may partially explain the incomplete relief 
provided by NSAIDs876. In a human study, the authors found that only 15% of patients with knee OA 
for whom an NSAID was prescribed were still taking the same drug 12 months latter906. A novel class 
of pharmaceuticals, the pripants, has been developed due to their role as prostaglandin receptor 
antagonists. By inhibiting just the EP4 receptor, primarily responsible for the pain and inflammation 
associated with OA, the homeostatic function of PGE2 is better maintained907. Gapripant, a drug of 
this group, as shown to be safe for long-term oral administration and effective for decreasing OA 
signs, when compared to a placebo908–910. Different approaches aim at neutralization of key factors 
involved with pain, as is the case of nerve growth factor. A recent report has presented a vaccine, 
which was able to generate anti- nerve growth factor antibodies in a mice surgical model, thus 
reversing pain behaviours334. 
Particularly when given for long periods, NSAIDs have well-documented side-effects, with 
the most common being gastrointestinal tract disturbances578. Gastrointestinal complications may 
occur in some individuals with their use, and it is most likely that is this perception of this risk that 
restricts their long-term use, even though there are no accurate and controlled estimates for the 
incidence of adverse effects with long-term NSAID use in dogs317. Newer veterinary-approved 
NSAIDs have a lower incidence of gastrointestinal side effects, which may be attributed to differentia l 
effects on the COX isoforms879. Renal and hepatic adverse effects are reported at a lower frequency, 





b. Other analgesic drugs/modalities; 
The combination of other analgesic drugs with NSAIDs is a common practice. It has the goal 
of helping control refractory pain but also to reduce total NSAID dose and, consequently, the risk of 
potential side effects913. Examples of these drugs include, but are not restricted to, tramadol, 
amantadine, or gabapentin879,913. In humans, the efficacy of treatment with NSAIDs or pure analges ics 
does not provide enough pain relief for patients with OA to be considered a solo adequate 
treatment589.  
Tramadol is an opiate-like agonist with µ-receptor activity, used in the management of mild 
to moderate acute pain, and as an adjunctive analgesic in the management of chronic pain resulting 
from OA or neoplasia. Its mechanism of action is through weak inhibition of opioid receptors, along 
with the interference of the release and reuptake of noradrenaline and serotonin, in the descending 
inhibitory pathways594,914. Other opioids can also be used, normally pure µ agonists. Morphine is one 
of the available possibilities, which has inclusively been described in IA administrations. Its effects 
were comparable with triamcinolone915. Opioids have also been administered IA as a form of 
analgesia, both as a treatment of OA and for postoperative analgesia. This route is effective due to 
the high density of opioid binding sites found in the inflamed canine joint tissues916. In a recent study 
with 25 dogs, ten days of treatment with tramadol, as administered at 5 mg/kg, given three times a 
day per os, provided no clinical benefit for dogs with osteoarthritis of the elbow or stifle joint917. On 
the other hand, the combination of tramadol with low dose ketoprofen showed interesting results918.  
Amantadine inhibits the N-methyl-D-aspartate receptors that, found in the dorsal spinal horn, 
and whose activation is associated with chronic pain594,919). It is not likely to be effective when 
administered as the only analgesic, but together with an NSAID as meloxicam, for example, and in 
cases refractory to opioids, it might be beneficial914,920. Gabapentin is beneficial in the treatment of 
neurogenic pain, although the mechanism by which gabapentin exerts its analgesic action is not  
entirely understood. It appears to bind to a specific modulating protein of the voltage-gated calcium 
channels, resulting in a decreased release of excitatory neurotransmitters594,914. It can be administe red 
along with an NSAID or not. 
Biophosphonates are commonly used to inhibit bone resorption, osteophyte formation, 
cartilage degeneration, and reduction in bone turnover. In OA, subchondral bone sclerosis is preceded 
by its resorption921–923. Tiludronate has demonstrated the ability to decrease structural changes and 
also an anti-inflammatory effect in the canine Cranial Cruciate Ligament pain model924,925. It has a 
positive effect on gait disability and joint symptoms, when compared to a placebo, most likely due to 
its ability to improve some of the structural changes that occur with OA, and also by reducing the 
synthesis of catabolic and inflammatory mediators925. The effect on pain and function is likely due to 
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a reduction of synovial effusion size, synovitis, and level of inflammatory mediators (PGE2, NO, and 
also MMPs)921. It also reduces pronociceptive substance P and concurrently increases transthyret in, 
a specific spinal cord peptide compared to placebo, keeping treated animals without peripheral or 
central sensitization even at 56 days post-surgery926. An in vitro study suggested that a 30-day course 
of treatment lowers PGE2 release from tissues, with neutral effects on tissue chondrocyte content and 
matrix composition927. While being able to reduce pain, it is not efficient against central 
sensitisation926. A long-term study evaluating the effect of risedronate in a rabbit model of OA 
showed no positive effect on the reduction of cartilage damage, and a failure to prevent subchondral 
bone changes and osteophytogenesis928. Zoledonate, on the other hand, was able to reduce 
histological joint degradation in a rodent model, and its inhibition of subchondral bone lesions 
alleviates both joint pain and central nociceptive activation921,929,930. 
Mesotherapy (from the greek mesos, referring to the mesoderm of the early embryo that 
develops into tissues such as muscle and cartilage) is a drug administration technique developed by 
the French physician Michel Pastor in the 1950s 931,932. It consists of local intradermal therapy, with 
pharmaceuticals being given in small amounts through multi-punctures in the skin over the area of 
the pathological condition to be treated. This process creates a deposit of the drug in the skin, which 
is released over time into overlying tissues (Figure 28).  
 
 
Figure 28 – The microdeposits created following a mesotherapy session, in a dog being treated for back pain. 
It has a rapid onset of action, since a short time to reach the intended site is necessary, a 
prolonged local action and a drug-sparing effect931–934. It has been described in humans, horses, and 
dogs 935–939. A human review study described that mesotherapy shows an excellent effect to reduce 
acute and chronic musculoskeletal pain while being a well-tolerated treatment940. In dogs, a 
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combination of an NSAID or CS with lidocaine and thyocolchicoside was able to significantly reduce 
pain when compared to carprofen, with effects lasting through several months with a single 
session935,936.  
Prolotherapy is a form of regenerative therapy with “proliferants” injected into diseased joints 
or periarticular area, intending to provoke an inflammatory response and increase proliferation of 
tissues during repair941,942. It consists of injecting a hyperosmolar dextrose solution into the area to 
be treated943. Dextrose is an irritant causing, inflammation with the release of growth factors, or act 
as a sclerosing vascular tissue factor, creating a regeneration process944. Practitioners that started 
using PRP for tendinopathies in the early 1990s were primarily trained in the use of prolotherapy61 6 . 
In dogs, it has been described for the treatment of animals with elbow or stifle OA, with improvements 
in lameness scores and ROM, while lowering pain levels, compared to a placebo942. 
Medical ozone is a mixture of ozone and oxygen, administered at low concentrations, and has 
been used for knee, hip, and shoulder OA in humans, and also for other painful conditions such as 
disc herniation945,946. It can reestablish cellular redox balance, increase adenosine availability through 
an ozone oxidative conditioning mechanism, and activation of enzymes responsible for protecting 
against the overproduction of superoxides947,948. It acts by reducing inflammation, IL-1β, TNF-α 
levels, and ROS (NO and H2O2), through the production of interferon and interleukins948–950.  The 
analgesic action is thought to be based on stimulation of the antinociceptive apparatus mediated by 
endogenous opioids and serotonin, raising the pain threshold946. As it has a strong analgesic effect 
and almost no side effects, it has been suggested as a good alternative to CS injections, but not for 
hyaluronan812.  
Other therapeutic options have been described, such as botulinum toxin Type A. The botulin 
toxin has a marked analgesic activity independent of its neuromuscular activity, contributing to block 
peripheral sensitization which, indirectly, reduces central sensitization951. Its IA use is hypothes ized 
as having antinociceptive and possibly anti-inflammatory action593. Glycosylated undenatured type-
II collagen, given daily to dogs with OA, is also able to ameliorate signs and symptoms of OA 
similarly to an NSAID, but signs return upon withdrawal952,953. Agmantine, a ubiquitous compound 
formed during the process of arginine decarboxylation, is also able to significantly improve GRF in 
dogs with hip OA, compared with carprofen and placebo954. Oral cannabidiol is gaining interest in 
the management of pain in humans and animals, particularly in dogs with OA. Even at low doses, 
cannabidiol can increase comfort and activity in dogs with OA, without observable side effects, while 
significantly attenuating the production of proinflammatory cytokines IL-6 and TNF-α and elevating 
levels of anti-inflammatory IL-10955–957. The use of these substances is based on the findings that 
changes in the endocannabinoid system are pivotal in joint functioning and pathological processes958.  
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Targetting the inhibition of endocannabinoid degradative enzymes or receptor agonisms are possible 
pathways to reduce inflammation and pain959,960. A recent study showed that the addition of 
cannabidiol to a standard multimodal pharmacological approach to OA led to a significant reduction 
n pain scores, in addition to an improvement in the quality of life scores961. 
The existence of such a wide variety of therapeutic options or approaches for the treatment of 
OA reflects the complexity of the disease, the impact it has on a patient’s life, and how complex it is 
to manage, points to an impossible task for a single therapeutic option. 
 
c. Nutraceuticals; 
Nutraceuticals (a term derived from the combination of the words nutrition and 
pharmaceutical) have enjoyed growing popularity over the last years in veterinary medicine962. They 
are defined as “a substance produced in purified or extracted from which, when administered orally 
to patients, aims to provide them with the necessary elements for their structure and normal function 
to better their health and wellbeing”963.  
 Prevention of cartilage degradation in OA is an important treatment objective, which requires 
long-term use of safe modalities. Amongst performance or working dog owners, there is also an 
increasing interest in alternative therapeutic modalities for the medical management of OA and 
slowing the process of cartilage breakdown and promotion of cartilage turnover. Such prevention and 
alternative solutions could come from nutrition and more particularly from dietary supplements310,581. 
Specific nutrients used in the management of OA may provide a reduction in inflammation and pain, 
enhance cartilage repair, slow the degenerative process, complement prescribed medications, and 
provide tangible improvements in clinical signs347. Despite this growing interest, there is still a lack 
of good-quality clinical trials to help determine if nutraceuticals, and glucosamine/ chondroit in 
supplements specifically, are better then an NSAID such as carprofen in reducing clinical signs of 
OA964. Unlike steroids and NSAIDs, these treatments do not exert an instantaneous effect but are 
widely used due to their ease of administration, high level of safety, and the possibility of 
administration with few side effects, mainly related to gastrointestinal upsets171,965. There is a need 
for additional well-designed studies to conclude about the safety and efficacy of these compounds as 
a whole, as the evidence for their efficacy is still poor581,962. There are, however, some evidence that 
the symptomatic relief they provide is often insufficient to address the demands of sporting or 
working animal606,893, as dogs with moderate to severe OA, which may be too seriously affected to 
benefit optimally from some of this components966.  
Chondroitin sulfate and glucosamine hydrochloride are the major components of many oral 
joint supplements on the market. They act as a preferred substrate for the biosynthesis of GAG chains, 
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and subsequently for the production of aggrecan, with reported tropism for articular cartilage. They 
also exert anti-inflammatory and anticatabolic effects, in addition to prophylactic prevention against 
synovitis, even though several studies have reported no significant differences, compared to 
placebo537,578,581,967. Despite limited and conflicting evidence, the natural products glucosamine 
hydrochloride and chondroitin sulfate are commonly recommended by veterinarians for treating 
osteoarthritis in dogs968. Some studies presented statistically significant improvements in pain scores, 
weight-bearing, and lameness severity965, while others described no significant reduction of pain was 
observed or increase in activity counts when compared to NSAIDs893,969. In vitro reports have 
presented chondroprotective effects of both chondroitin sulfate and glucosamine695,970, without this 
effect being observed in vivo studies971,972. A protective effect against synovitis and associated bone 
remodelling has been reported to a combination of glucosamine and chondroitin sulfate, attributed to 
an enhanced synthesis and turnover of proteoglycan 973,974. In a Pond-Nuki model, IA and oral 
administered glucosamine sulfate significantly reduced histological signs of OA, with the IA 
application being more effective compared to oral administration975. Chondroitin sulfate has been 
presented as able to inhibit the action of IL-1β on osteoblast, reducing the release of PGE2, MMP-3, 
and MMP-13976, and polysulfated GAGs alone have produced improvements in orthopaedic scores 
in dogs with HD977. In humans, some studies have shown that glucosamine is as efficient as a placebo, 
and is not adequate for the treatment of chronic, severe, OA related pain813,978. Other reports 
concluded that chondroitin sulfate has several beneficial effects, reducing pain, improving articular 
function, reducing joint swelling and effusion while preventing joint space narrowing979–981. The 
recommendations for human hip and knee OA stipulate that treatment with glucosamine and/or 
chondroitin sulfate may provide symptomatic benefit, but should be discontinued if no apparent 
response is observed within six months. Structure-modifying effects have also been attributed to the 
compounds, although a 2-year study showed no significant reduction in joint space nor a clinica lly 
relevant improvement in pain and joint function580,888,972.  
New Zealand green-lipped mussels have a quantitative composition of GAGs, omega-3 fatty 
acids, vitamins, and minerals, which have been suggested to act synergistically in reducing 
inflammation, limiting cartilage breakdown, and supporting cartilage regeneration982,983. The 
evidence for the efficacy of green-lipped mussel is moderate578. It has been described as able to 
alleviate chronic orthopaedic pain in dogs, although it is not as effective as carprofen966. At a cellular 
level, it can inhibit COX activity, and also decrease IL-1, IL-2, and TNF-α levels984. Other reports 
indicate contradictory findings, with green-lipped mussels being unable to reduce IL-1β but able to 
downregulate the expression of MMPs985. Long term administration (8 weeks or longer) has been 
described as able to alleviate clinical signs of dogs presumptively diagnosed with mild to moderate 
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OA, in terms of veterinary-assessed mobility, owner-evaluated pain index, pain, and 
locomotion596,986,987.  
Polyunsaturated fatty acids are classified as omega-3, omega-6, and omega-9, depending on 
the position of the last bond along the fatty acid chain581. COX can metabolize the ω -3 and ω-6 into 
distinct eicosanoids, and ω-6-derived eicosanoids tend to be pro-inflammatory while the ω-3-derived 
eicosanoids tend to be anti-inflammatory988. In humans, both eicosapentaenoic acid and 
docosahexaenoic acid ω-3 polyunsaturated fatty acids can reduce pain, improve clinical signs of joint 
diseases. Also, eicosapentaenoic acid and arachidonic acid can decrease several inflammatory 
markers. To maintain an appropriate balance of both ω-3 and ω -6 fatty acids in dietary interventions 
is a point to keep in mind985,989,990. Fish oil and corn oil supplementation decrease the formation of 
pro-inflammatory prostanoids which, in excess, increase inflammation, and also monocytes, 
basophils, and ROS associated with cytokines and prostaglandins991. Supplementation with fish oil 
has also demonstrated the ability the beneficially change heart rate at rest and after exercise, while 
also improving muscle mass gain in response to exercise992. Several studies reported the ability of 
polyunsaturated fatty acids to decrease the degree of lameness, increased PVF, and ability to rise from 
a resting position310,993–995. At a molecular level, polyunsaturated fatty acids s can reduce 
inflammatory markers concentration, such as PGE2, IL-1, and IL-6996,997. Different sources of ω-3 
have different cartilage-protecting properties, with krill oil having greater/equal potential than fish 
oil, which, in turn, has a greater effect than green-lipped mussel985. eicosapentaenoic acid in dogs can 
alter the expression of genes responsible for the progression of cartilage degradation and can be 
applied in the design of pet foods347. In juvenile growing dogs with HD, a less severe grade of 
osteoarthritis at 12 months was observed in supplemented dogs, compared with a control group998. 
The combined used of fatty acids and NSAIDs seems to be more effective than their isolated use999. 
Avocado-soybean unsaponifiable are plant extracts derived from unsaponifiable residues of 
avocado and soya bean oils, which contain fat-soluble vitamins, sterols, triterpene alcohols, and 
possibly furan fatty acids1000. In vitro, these compounds have been shown to reduce several pro-
inflammatory mediators, such as TNF-α, IL-1β, COX and PGE2 synthesis, and anticatabolic cytokine 
expression, mainly MMP-3 and MMP-131001,1002. They also stimulate the synthesis of matrix 
components by chondrocytes by increasing TGF production and decreasing MMP production693. In 
a canine model of OA, patients treated with avocado-soybean unsaponifiables had smaller and less 
severe macroscopic cartilage lesions, with lower scores of histological parameters, as decreased loss 
of subchondral bone1003. 
Other substances, such as curcumin have also been described as having antioxidant, anti-
inflammatory, and antiseptic properties, with similar ability as NSAIDs to reduce IL-1β and TNF-α 
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levels, both in vitro and in vivo1004,1005. Green tea extract, in conjunction with curcuminoids extract, 
did not also produce significant changes in GRF, although a slight reduction of pain may have been 
registered1006. There are no controlled studies in dogs assessing the efficacy of dietary antioxidants in 
OA, but there is a growing scientific rationale for their use as adjuncts in the treatment of OA347. 
Dietary vitamin E, in dogs with surgically induced OA, produced consistent lower visual analogue 
scale and numerical rating scale scores, due to the vitamin’s ability to affect the synthesis of PGE2  
and NO in SF, by inhibiting the activation of transcription nuclear factor kappa B. Even though it 
does not reduce IL-1β concentration levels, it was able to reduce histological lesions in the articular 
cartilage1007. Vitamin C and selenium also have powerful antioxidant effects, quenching free radicals 
and defending tissues against oxidative stress. Homoeopathic preparations have also been studied, 
with some showing beneficial effects in the management of OA related pain, such as Traumeel® and 
Zell®1008–1010. 
The majority of commercially available formulations are multicomponent, with the idea that 
several compounds may interact with multiple targets to trigger interdependent activities to achieve 
optimal effects1011. In human trials, nutraceuticals have recently been shown to have potential in 
relieving OA pain. Emerging evidence indicates that they may represent interesting alternatives for 
the relief of OA pain. However, future studies should prioritize elucidating the mechanisms of action 
of nutraceuticals in OA and developing nutraceuticals that not only relieve OA pain but also mitiga te 
OA pathology and may decrease radiographic sign progression998,1012. 
 
d. Rehabilitation; 
Rehabilitation is the treatment of diseases and injuries with physical agents, such as heat, cold, 
US, electricity, massage, and exercises. It involves, as athletic training, the application of controlled 
forces to musculoskeletal system structures, to stimulate and facilitate adaptions suited to a specific 
therapeutic objective. In many cases, it helps to reduce the dose of analgesics necessary to mainta in 
a patient comfortable29,594. Even though rehabilitation for animals is a growing field, a limited number 
of studies have been conducted to address the effectiveness of these methods and their effect on the 
biomechanics of joints and muscles464,1013. There are many nonpharmacologic treatment options 
available for the conservative management of OA,  which are often recommended by veterinaria ns, 
with client education being an important component of the management protocol878,1014,1015. The 
recommendations for non-pharmacological modalities of treatment for OA in humans stress the 
importance of lifestyle changes, exercise, the pacing of activities, weight reduction, and other 
measures to unload damaged joints580. It is through movement that fluid goes from the ECM to the 
synovial fluid and vice versa, the mechanism by which nutrients are delivered to chondrocytes. 
96 
 
For this reason, early mobilization and controlled loading are one of the focus during 
rehabilitation following joint trauma and/or surgery29. Management of body weight is one the most 
important of medical therapies, with dogs of appropriate body weight living an average of 22 months 
longer, with the later onset and less chronic disease, with fewer signs of OA1016,1017. Adipose tissue 
in obesity secretes pro-inflammatory cytokines (TNF-α and IL-1), which results in increased 
inflammation in OA1018. This reduction of body weight should be obtained through a combination of 
caloric restriction and an exercise program1019. The inclusion of a controlled exercise plan, in 
combination with a dietary weight loss program in these animals, helps prevent the loss of lean body 
mass1020. A therapeutic approach to dogs with hip pain due to OA usually focus on multi-modal pain 
relief and strengthening of the gluteal muscles.  
Rehabilitation options for pain relief may include thermal modalities, laser therapy, 
transcutaneous electrical nerve stimulation, massage, acupuncture, and others338,1016,1021. Thermal 
modalities are routinely incorporated in the treatment of OA. Cryotherapy is used in acute 
inflammation, and promotes vasoconstriction, skeletal muscle relaxation, and decreases nerve 
conduction. It helps to reduce inflammation, minimizes oedema through vasoconstriction, decreases 
enzyme activity, and metabolism on tissues while providing analgesia919,1022–1024. Heat is mostly used 
after the acute inflammation phase has been resolved, and is often applied before stretching, massage, 
passive ROM exercises, or active exercises594. Heat therapy can also relieve pain, provide muscle 
relaxation, and increase the extensibility of articular or ligamentous collagen1022. The therapeutic US 
can be used to heat deeper tissues and to help control pain and improve tissue extensibility. While 
superficial heating agents only penetrate soft tissues to a depth of approximately 1 cm, deep heating 
agents can elevate tissue temperatures at depths of 2 cm or more. The therapeutic US also promotes 
a non-thermal phenomenon shown to accelerate the inflammatory phase of wound healing, promote 
ion transport, to increase cellular permeability, and promote healing by stimulating fibroblast ic 
activity, increasing cellular metabolism and circulation594,1025. It is considered an effective treatment 
modality for rehabilitating musculoskeletal conditions such as a restricted range of motion (ROM) 
resulting from joint contracture, pain and muscle spasm, and wound healing1026,1027.  
Laser therapy, or photobiomodulation, has been increasingly incorporated into rehabilitat ion 
programs for a variety of conditions, like muscle, tendon, and ligament injuries, OA, and pain1028 
Lasers used in rehabilitation help to modulate cellular functions. This process, known as 
photobiomodulation, is defined as the nonthermal interaction of monochromatic radiation with a 
target site. This photobiostimulation upregulates the production of ATP, NO, and reactive oxygen 
species within cells, alters gene transcription, and leads to an increase in cell proliferation, cellular 
motility, and growth factor production1029. Also, acute and chronic pain control has been reported 
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using this type of low-energy photon therapy. Treatment of chronic and acute oedema, neurologic 
conditions, to reduce pain and postoperative care are some other prevalent conditions treated with 
laser therapy341,594,1030–1032. Its affect is affected by coat color and in unshaved treatment areas, making 
it necessary to adjust the treatment dose to the particular animal1033. In dogs, its use is associated with 
improvement in PVFs of pelvic limbs orthopaedic surgery and shortened duration to ambulat ion 
following hemilaminectomy1034,1035. Its effects have been compared to a placebo, leading to 
significant improvements and lower NSAID doses required to managed patients with OA1036. It is 
important to use it in conjunction with other modalities, as exercise, massage, and pharmacologic 
options. It may give patients enough comfort to allow patients to initiate or increase specific exercise 
protocols, such as increasing the range of motion of a stiff joint1037 (Figure 29). 
 
 
Figure 29 – A dog with hip osteoarthritis, with associated back pain, being treated with laser therapy. 
Electrical stimulation is another commonly used modality in physical therapy, useful for many 
purposes, including increasing muscle strength, muscle re-education, increasing ROM, enhancing 
function, pain control, accelerating wound healing, reduce oedema, muscle spasm reduction, and 
enhancing transdermal administration of medication (iontophoresis). transcutaneous electrical nerve 
stimulation (Figure 30) is a particular type of electrical stimulation, used to increase muscle strength, 
improve joint ROM, re-educate muscles, and decrease oedema and pain594,1038,1039. Different reports 
show that treated dogs have increased ROM and a 'positive slope' when compared to dogs in a control 
group1040,1041. This positive effect is also true in humans, where the benefit over placebo for certain 
aspects of OA has been described, making it an adjunct therapy for the treatment of patients with 




Figure 30 – A transcutaneous electrical nerve stimulation equipment. 
In a systematic review, weak evidence to support the use of electrostimulated acupuncture and 
the extracorporeal shockwave was observed579. Radial shock wave therapy has also shown to increase 
mean PVF and VI values in treated limbs of dogs with hip OA, in contrast to no significant differences 
found in control limbs1043. In humans, it has also helped to decrease pain in patients with knee OA1044. 
Pulsed electromagnetic field therapy is a non-invasively treatment modality, used to treat a variety of 
conductions by delivering electric and magnetic fields to tissues via inductive coils. In OA, it assists 
in the reduction of pain, inflammation, and edema1045. The combination of acupuncture and manual 
therapy has shown to provide immediate short-term improvement in comfort and mobility1046 . 
Differing results have been obtained when comparing acupuncture with placebo and carprofen, with 
neither of the therapeutic options providing significant improvements in dogs with HD894. Other 
reports describe the use of acupuncture alone or in combination with analgesics reduced pain and 
improved quality of life in dogs with musculoskeletal diseases1047. Thermal modalit ies, 
transcutaneous electrical nerve stimulation, and acupuncture have all demonstrated their ability in 
relieving symptoms, particularly pain580,1048.  
In human medicine, the benefit of referral to a physical therapist for evaluation and instruct ion 
in appropriate exercises to reduce pain and improve functional capacity is well established58 0 . 
Therapeutic exercise is a cornerstone of rehabilitation and is used to improve active joint range of 
motion (ROM), improve weight-bearing and limb use, build strength and muscle mass, and increase 
conditioning (endurance, speed, and others), joint health, proprioception and overall functioning 




Figure 31 – A dog with hip OA during a rehabilitation session, performing balance exercises . 
Hydrotherapy (swimming or using an underwater treadmill), is an increasingly popular 
modality for the rehabilitation of dogs and also shows benefits in the management of OA, being one 
the most elected modalities of the management of this condition1050–1053. A single hydrotherapy 
session increases ROM in both sound and animals with OA, to a greater degree in OA animals1054 . 
This beneficial effect was also observed after joint surgery1055. Aquatic exercises, in particular, have 
been praised for OA patients due to the buoyance effect of water, which allows exercise to be 
conducted without significant joint impact338,580,1056,1057. In the post-surgical period, exercise leads to 
ticker repair tissue, but not necessarily of better histological quality1058. Aerobic exercise, in 
conjunction with a range of motion exercises, can effectively enhance the function of joints, reduce 
pain, and also improve joint function in patients1022,1059. Massage therapy can also be used to relieve 
pain and in orthopaedic rehabilitation, but the techniques described are initially intended for use in 
humans, and scientific data supporting anecdotal. The description of beneficial effects in domestic 
animals is still lacking1060. Stretching exercises are commonly used in companion animal 
rehabilitation programs and a critical aspect of the management of joint contractures1061. 
Animals with hip OA should undertake a low impact exercise program to help strengthen the 
hips, like swimming or hill walking, to build muscle mass, improve comfort, and increase ROM. 
Rehabilitation can also help reduce the progression of osteoarthritis in the post-surgical period. 
Targeted exercise therapy aids in the management or prevention of many of the consequences of 
immobility and decreased joint use and loading, including atrophy of soft and bony tissues, stiffening 
or fibrosis, while maintaining proper proteoglycan matrix and stimulating the synovium to replenish 
joint fluid997,1062.  There are reports that physiotherapy improves kinetic parameters in different dogs 
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treated with the same surgical technique for ACL ruptures at four months postoperatively81 4 . 
Moderate exercise has been shown to improve cartilage GAG content in humans at risk of developing 
OA338,1063. In dogs, regular walks or light jogs in soft surfaces, and hilly terrains should be 
encouraged, as it builds different muscle groups and may help decrease the risk of developing 
radiographically detectable hip dysplasia338,573,1064. Moving uphill, in particular, increases extension 
of the hip joint, to a level similar to non-lame dogs (Figure 32). Moving downhill, on the other hand, 
significantly decreases ROM464. Passive ROM exercises can be effective in restoring a more normal 
joint motion in patients, to advance to a more comfortable ROM, improve blood and lymphatic 
circulation, and stimulate sensory awareness594. Used in combination with other therapeutic options, 
such as PRP, rehabilitation enhances obtained results for more extended time periods1065. 
 





Juvenile pubic symphysiodesis is a preventative, minimally invasive surgical intervention for 
dogs between 12 and 16 weeks of age, which are at risk of development of hip dysplasia and, 
consequently, OA. It consists of the premature surgical closure of the pubic symphysis induced by 
thermal destruction of the symphyseal growth plate. This procedure results in an increase in the 
ventral rotation of the acetabulum during growth, providing better congruity, and preventing 
secondary OA1066. A two-year follow-up report indicated that juvenile pubic symphysiodesis surgery 
at 12–24 weeks of age significantly improved hip conformation and decreased laxity in at-risk HD 
dogs. At this timeframe, juvenile pubic symphysiodesis offers greater benefits than surgery performed 
at 19- to 24-weeks-old1067. Long-term reports indicate that the procedure does not eliminate the hip 
joint laxity, characteristic of hip dysplasia, or the progression of degenerative changes. Still, it 
increases the odds of arresting or limiting the progression of HD in mild to moderate grades1068,1069.  
Total hip replacement and femoral head and neck osteotomy are the key surgical options for 
managing chronic coxofemoral joint pain313. Femoral head and neck osteotomy is a salvage 
procedure, intended to eliminate most of the pain caused by OA in the mature dog. It can be performed 
in dogs of any age, but likely produces better results in dogs under 20kg. The goal is to elimina te 
bone-on-bone contact of the diseased acetabulum and the femoral head and to permit the formation 
of a pseudo-arthrosis1066,1070,1071. With femoral head and neck osteotomy, the outcome is variable and 
unpredictable, depending on surgical skill, length of time that OA has been present, and severity of 
the pathology. However, if removal of the entire femoral neck is achieved, in conjunction with 
appropriate postoperative rehabilitation and analgesia, many dogs achieve satisfactory limb 
function313,1071. 
 
Figure 33 – Ventrodorsal extended view of a dog following femoral head and neck osteotomy, with 
incomplete removal of the femoral neck. 
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Total hip replacement is a salvage procedure, involving the replacement of the diseased 
acetabulum and femoral head with implants. The goal is to return a chronically lame dog, that is 
nonresponsive to medical treatment, to near-normal or normal function, including athletic, sporting, 
and working activities1066,1071,1072. It is a costly surgical option, with no guarantee of success, but most 
dogs return to full function by eight weeks after surgery. A 6-year follow-up described a high surviva l 




II. MATERIALS AND METHODS 
 
Study design and patient selection 
In this experimental, randomized, double-blind study, we aimed to evaluate the effectiveness 
of 4 different intra-articular treatments in the management of osteoarthritis, using the species Canis 
familiaris as an OA naturally occurring canine model.  The major goals of the study were: 
1. Determine the effect of 4 substances delivered by IA, in patients with hip joint 
osteoarthritis; 
2. Evaluate the variation in the synovial fluid of patients with hip joint OA of 
inflammatory markers levels such as CRP and IL-1 through time after the IA 
administration of the different substances used for the OA treatment; 
3. Assess the relationship between laboratory and imaging medicine data, and the 
patient's objective medical examination; 
4. Validate the use of digital thermography and weight bearing evaluation in OA 
assessement; 
5. Outline a therapeutic for IA treatment protocol for patients with hip OA using the dog 
as an animal model, under the general concept of One Health. 
 
The study protocol was approved by the ethical review committee of the University of Évora 
(Órgão Responsável pelo Bem-Estar dos Animais da Universidade de Évora, approval 
nº GD/32055/2018/P1, September 25th, 2018). Written, informed consent was obtained from the 
Institution responsible for the animals (Guarda Nacional Republicana, Portuguese Gendarmerie) 
through dispatch of the Doctrine and Training Commander nº327/16, dated September 16th, 2016. 
Animals included in this study were recruited from the police working dog population of the Grupo 
de Intervenção Cinotécnico, Guarda Nacional Republicana (Portuguese Gendarmerie Canine Unit). 
They constituted a convenience sample, similar in size to previous reports concerning this subject, 
comprising 100 joints (n=1 joint)586,686,738,898,969. Animals selected presented clinical signs of 
osteoarthritis of the coxo-femoral joint, of natural progression, with clear identifiable clinical signs , 
namely: loss of performance, pain during joint manipulation, decrease amplitude during the swing 
phase of the movement, and muscle atrophy, confirmed through digital radiography and without any 
other illness. Animals without clinical signs were not included in the study, and those selected for the 
study presented mild to severe OA. The control group was also composed of animals with naturally 
occurring hip OA. 
Inclusion criteria comprised the following items: 
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- Mobility impairment, as described by the trainer and detect by the assisting veterinarian; 
- Bodyweight ≥20kg; 
- Age ≥2 year; 
- Radiographic evidence of bilateral hip OA; 
- Not to be on any medication or nutritional supplements for the previous six weeks or more. 
Exclusion criteria comprised the following items: 
- Suspected or diagnosed neurological/musculoskeletal disorder other than hip OA; 
- Documented or suspected presence of concomitant disease; 
- Being on any other treatment or drugs; 
- Results of routine blood testing outside normal limits. 
 
Study design protocol 
After the selection, sample animals were randomly distributed into the 5 following groups: 
- Control group (CG): IA administration of NaCl 0.9% (n=20); 
- Treatment with triamcinolone hexacetonide group (THG): IA administration of TH  
     (Bluxam, Laboratórios Farmacéuticos ROVI) (n=20); 
- Treatment with stanozolol group (SG): IA administration of stanozolol   
     (Estrombol, Laboratório Fundacion) (n=20); 
- Treatment with Hylan GF-20 group (HG): IA administration of high-density hyaluronan 
     (Synvisc, Sanofi) (n=20); 
- Treatment with platelet concentrate (PCG): IA administration of platelet concentrate 
     (V-PET, PALL) (n=20); 
 
Animals were evaluated on 6 different time-points (ranging from day 0 until day 180) using a 












Modality Evaluation moment 
T0            
treatment day 
T1                       
8th day  
T2                       
15th day  
T3                      
30th day  
T4                       
90th day  
T5                      
180th day  
Treatment X         
Goniometry X X X X X X 
Thigh girth 
measurement 
X X X X X X 
HVAS X X X X X X 
CBPI X X X X X X 
COI X X X X X X 
LOAD X X X X X X 
Digital Thermography X X X X X X 
Pedometer X X X X X X 
Stance analysis X X X X X X 
Digital radiography X   X X X 
SF CRP X X  X X X 
SF IL-1 X X  X X X 
Routine blood testing X     X X X 
Table 8 – Evaluation modalities used in each evaluation moment. Days are counted from treatment day. Legend: CBPI – 
Canine Brief Pain Inventory; COI – Canine Orthopedic Index; CRP – C-Reactive Protein; HVAS – Hudson Visual 
Analogue Scale; IL-1 – Interleukin 1; LOAD – Liverpool Osteoarthritis in Dogs; SF – Synovial fluid. 
Radiographic studies, IA administrations, and SF collections were conducted under light 
sedation, using a combination of medetomidine (0.01mg/kg) and buthorphanol (0.1mg/kg), given 
intravenously. Radiographic studies were based on the ventrodorsal extended legs and frog views, as 
described previously. For intra-articular administration to the hip and SF collection, animals were 
placed in lateral recumbency, with the affected joint uppermost. The area of interest, a 4x4cm window 
surrounding the greater trochanter was clipped and aseptically prepared, using a chlorhexid ine 
solution followed by the application of 70% alcohol. For these procedures, the operator used sterile 
gloves and 10x10cm gauzes, and the area of interest was covered with a surgical drape. With the limb 
parallel to the table surface and in a neutral position, a 22-gauge, 55 to 75mm spinal needle was then 
inserted closely dorsal to the greater trochanter and perpendicular to the long axis of the limb618. 
 
For each considered study group, the specific treatment dose was determined based on the 
manufacturer’s recommendation or previous reports. For dogs, a 0.3mg/kg dose of stanozolol has 
been described for IA use839,840. Hylan GF-20 was administered at the dose of 1 pre-loaded 2ml 
syringe/joint. TH was administered at a dose of 1 vial/joint (20mg). V-PET was prepared following 
the manufacturer’s instructions. Briefly, 55 ml of whole blood was collected from the jugular vein of 
the patient and then introduced into the provided closed system. The blood then flowed by the action 
of gravity through the filter, where platelets were concentrated. The final product, 6ml of platelet 
concentrate, was obtained, with 3ml/joint being administered within 10 minutes without activation.   
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Dog’s handlers were blinded for the group in which their dogs were allocated. Following 
treatment, all animals were prescribed a 3-day rest period606. Due to their nature and specific mission, 
all animals are followed daily by their trainers and veterinarians. Any need for additional treatment 
for symptomatic disease control, namely pain, was determined and registered by the assisting 
veterinarian.  
 
At each evaluation moment, an online copy of the HVAS, CBPI, COI, and LOAD was 
completed by the trainers. Before completion, handlers received the published instructions for each 
of them. The CMIs were completed in sequence by the same handler in each of the follow-up 
assessments, without knowledge of their previous answer, in a quiet room with as much time as 
needed to answer all items.  
 
For the collection of digital thermography images, the procedure followed the protocol 
described by M. H. Vainionpää et al., 2013. Dogs were allowed to walk around and calmly adjust to 
room temperature for approximately 30 min before imaging, in a room with a steady temperature, set 
at 21°C. They were then positioned standing in an upright position, as symmetrically as possible, 
without the trainer or veterinarian touching the dog’s torso. If needed, the trainer could help position 
the dog by holding it under the abdomen. Each thermographic image included the area from the last 
lumbar vertebra to the first coccygeal vertebra at a minimum. All images were taken with a FLIR 
ThermaCAM E25 at a distance of 60 cm, to simulate a clinical setting where the space around the 
patient could be limited.  
 
The weight distribution platform (Companion Stance Analyzer; LiteCure LLC, Newark, 
Delaware, United States) was placed in the centre of a room,  at least 1-meter from the walls. 
According to the manufacturer’s guidelines, the platform was calibrated at the beginning of each day 
and zeroed before each data collection. Animals were then encouraged to stand on to the weight 
distribution platform, and allow to acclimate, and its trainer helped to ensure the patients placed one 
foot on each quadrant of the platform and maintained a natural stance with their centre of gravity and 
stability (measured by the platform) near the middle of the platform475. Gentle restraint was used to 
maintain the patient’s head in a natural, forward-facing position For all animals, at least 20 
measurements were performed, and the mean value determined. A left-right symmetry index (SI) was 
calculated with the following formula: SI=[(WBR-WBL)/((WBR+WBL)x0.5)]x100468,544, where WBR 
is the value of weight-bearing for the right pelvic limb, and WBL is the value of weight-bearing for 
the left pelvic limb. Negative values were made positive. Weight-bearing for a pelvic limb is 20%475, 
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so deviation from this value was also considered, calculated by subtracting WB to 20.  Determination 
of thigh girth was made with a Gullick II measuring tape, and obtained at a distance of 70% thigh 
length, as measured from the tip of the greater trochanter, with the leg in an extended position while 
in lateral recumbency, and the dog relaxed353. ROM of the hip joints was obtained at extension and 
flexion with a flexed stifle1075. Both measurements were made in triplicate, and the mean value was 
calculated. Pedometers were worn around the dog’s neck, attached to an adjustable lightweight collar 
so that they detected and counted forelimb steps only523. They were placed one week before the first 
evaluation moment, to determine a baseline value, and then maintained up to the 30th-day post-
treatment. For the 90th and 180th post-treatment days evaluation, the animals worn the pedometer 
for a week before that evaluation moment. 
 
Determination of SF CRP and IL-1β concentrations were made using the DuoSet Ancilla ry 
Canine IL-1β Reagent kit (R&D Systems, United Kingdom), read with a FLUOstar OPTIMA (BMG 
Labtech),  and Fuji Dri-Chem Slides VC-CRP PS (FUJIFILM Europe GmbH), read with a DRIChem 
NX500i (FUJIFILM Europe GmbH). 
 
Statistical analysis 
Multiple variables were considered for data collection, for posterior use in statistical analysis 
work. The variable operational plan is described in the following table 9:  
 
Name Description Type Definition Source 
Breed  Breed of the animal 
 Categorical 
Nominal 
 0 = German 
Shepherd Dog 
1 = Belgian Malinois 
Shepherd Dog 
2 = Dutch Shepherd 
Dog 








Sex of the animal Categorical 
Nominal 
0 = male 








 0 = control 
1 = triamcinolone 
hexacetonide 
2 = Hylan G-F 20 
3 = Stanozolol 
4 = V-PET 
Clinical 
software  
Bodyweight  Weight of the animal 
Numerical 




 Number of steps registered by the 
pedometer 
Numerical 
 Steps  Pedometer 
LTL 
Percentage of body weight exerted 






 Percentage of body weight 
exerted on the right thoracic limb 
Numerical  Percentage Stance 
Analyzer 
TLs 
 Percentage of body weight 
exerted on both thoracic limbs 
Numerical  Percentage Stance 
Analyzer 
LPL 
Percentage of body weight exerted 
on the left pelvic limb 
Numerical  Percentage Stance 
Analyzer 
RPL 
Percentage of body weight exerted 
on the right pelvic limb 
Numerical  Percentage Stance 
Analyzer 
PLs 
Percentage of body weight exerted 
on both pelvic limbs 
Numerical  Percentage Stance 
Analyzer 
TermoDV-L 
Skin temperature at the level of 
the left greater trochanter, 
registered with a thermographic 
camera, on a dorsoventral view  
Numerical 





Skin temperature at the level of 
the right greater trochanter, 
registered with a thermographic 
camera, on a dorsoventral view   
Numerical 





Skin temperature at the level of 
the left greater trochanter, 
registered with a thermographic 
camera, on a lateral view 
Numerical 





Skin temperature at the level of 
the right greater trochanter, 
registered with a thermographic 
camera, on a lateral view 
Numerical 




MGirth   Thigh muscle girth 
Numerical 
Centimetres  
 Gullick II 
tape measure 
GonioFlex  Flexion angle of the hip joint 
Numerical 
 Degrees  Goniometer 
GonioExt  Extension angle of the hip joint 
Numerical 
 Degrees  Goniometer 
XRayVD-a 
Presence of a misshapen femoral 
head, with a, lose of its rounded 




0 = no 
1= yes  Digital X-ray 
XRayVD-b 
 Presence of a flattened or shallow 
acetabulum, with an irregular 




0 = no 
1= yes  Digital X-ray 
XRayVD-c 
 Presence of caudolateral 
curvilinear osteophyte (CCO) on a 
radiograph ventrodorsal view 
Categorical 
Nominal 
0 = no 
1= yes  Digital X-ray 
XRayVD-d 
 Presence of new bone formation 
on the acetabulum and femoral 




0 = no 
1= yes  Digital X-ray 
XRayVD-e 
 Presence of a worn away angle, 
formed at the cranial effective 




 0 = no 




Presence of subchondral bone 
sclerosis along the cranial 




0 = no 
1= yes  Digital X-ray 
XRayVD-g 
Presence of circumferential 
femoral head osteophyte (CFHO) 
on a radiograph ventrodorsal view 
Categorical 
Nominal 
0 = no 
1= yes  Digital X-ray 
OFA 
Hip grade, according to the 




A = Excelent 
B = Good 
C = Fair 
D = Borderline 
E = Moderate 
F = Mild 
G = Severe  Digital X-ray 
XRayFL-CCO 
 Presence of caudolateral 
curvilinear osteophyte (CCO) on a 
radiograph frog-leg view 
Categorical 
Nominal 
 0 = no 
1= yes  Digital X-ray 
XRayFL-
CFHO 
 Presence of circumferential 
femoral head osteophyte (CFHO) 
on a radiograph frog-leg view 
Categorical 
Nominal 
 0 = no 
1= yes  Digital X-ray 
IL-1 
 The concentration of interleukin 
1 in the synovial fluid 
Numerical 
 pg/mL  ELISA test 
CRP 
Concentration of C-reactive 
protein in synovial fluid 
Numerical 
 mg/dL  ELISA test 
CRP-S 
The concentration of C-reactive 
protein in the blood serum 
Numerical 
 mg/dL  ELISA test 
HVAS 
The score obtained in the Hudson 
Visual Analogue Scale clinical 
metrology instrument 
Numerical 




The score obtained in the Pain 
Severity Score section of the 
Canine Brief Pain Inventory 
clinical metrology instrument 




The score obtained in the Pain 
Interference Score section of the 
Canine Brief Pain Inventory 
clinical metrology instrument 




The score obtained in the Stiffness 
dimension of the Canine 
Orthopedic Index clinical 
metrology instrument 




The score obtained in the 
Function dimension of the Canine 
Orthopedic Index clinical 
metrology instrument 




The score obtained in the Gait 
dimension of the Canine 
Orthopedic Index clinical 
metrology instrument 




The score obtained in the Stiffness 
dimension of the Canine 




Orthopedic Index clinical 
metrology instrument 
COI 
The overall score obtained in the 
Canine Orthopedic Index clinical 
metrology instrument 
Numerical Not applicable 
 Inquiry 
Answers 
TABLE 9 – Evaluation modalities used in each evaluation moment. Days are counted from treatment day. Legend: CBPI 
– Canine Brief Pain Inventory; COI – Canine Orthopedic Index; CRP – C-Reactive Protein; HVAS – Hudson Visual 
Analogue Scale; IL-1 – Interleukin 1; LOAD – Liverpool Osteoarthritis in Dogs; SF – Synovial fluid. 
According to its characteristics, each variable was referred to as dependent and independent. 
Thus:  
Dependent variables: 
- Evidence of OA signs; 
- Evolution of hip grade; 
- Changes in thigh muscle girth and joint range of motion; 
- Scores obtained with different clinical metrology instruments; 







- Treatment Group. 
 
All results were analyzed with IBM SPSS Statistics version 20. Several statiscal tests were 
conducted, according to the intended analysis: Paired Samples T-Test, Repeated Measures ANOVA, 
with a Huynh-Feldt correction, or Wilcoxon Signed Ranks Test. Kaplan-Meier estimators were 
conducted and compared with the log-rank test. Cox proportional hazard regression analysis was 
performed to determine treatment survival. A significance level of P<0.05 was set. 
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III. RESEARCH & DISCUSSION 
 
For the study results presentation, we decided to use the manuscripts already published and 
submitted to different international index journals. This chapter consists of six sections, one for 
preliminary research and each main objective. 
 
1. PRELIMINARY RESEARCH 
 
Police working dogs with hip naturally occurring osteoarthritis used as animal model to study 
the efficacy of a single intra-articular administration of two drugs: methylprednisolone acetate and 
triamcinolone acetonide - Submitted to Topics in Companion Animal Medicine, Impact factor 0.410, 
Quartile 2.  
A Pilot Study on the Efficacy of a Single Intra-Articular Administration of Triamcino lone 
Acetonide, Hyaluronan, and a Combination of Both for Clinical Management of Osteoarthritis in 
Police Working Dogs - Published in Frontiers in Veterinary Science – Impact factor 2.140, Quartile 
1. 
A report on the use of a single intra-articular administration of autologous platelet therapy in 
a naturally occurring canine osteoarthritis model - a preliminary study - Published in BMC 







Manuscript submitted to Topics in Companion Animal Medicine. 
Impact factor 0.410 
Quartile 2 
 
Police working dogs with hip naturally occurring osteoarthritis used as animal model to study 
the efficacy of a single intra-articular administration of two drugs: methylprednisolone 
acetate and triamcinolone acetonide 
 
Alves, J. C.1,2,*, DVM, MSc; Santos, A.1, DVM, MSc; Jorge, P.1, DVM; Lavrador, C. DVM, PhD2; 
Carreira, L. Miguel DVM, PhD3,4,5 
 
1Divisão de Medicina Veterinária, Guarda Nacional Republicana (GNR). Rua Presidente Arriaga, 9 
1200-771 Lisbon, Portugal.  
2MED – Mediterranean Institute for Agriculture, Environment and Development, Instituto de 
Investigação e Formação Avançada, Universidade de Évora, Pólo da Mitra, Ap. 94, 7006-554 
Évora, Portugal;  
3Faculty of Veterinary Medicine, University of Lisbon (FMV/ULisboa) – Portugal; 
4Interdisciplinary Centre for Research in Animal Health (CIISA) – University of Lisbon, 
(FMV/ULisboa) – Portugal. 








We aimed to compare the effectiveness of intra-articular (IA) methylprednisolone-acetate 
(MPA) and triamcinolone acetonide (TA) in the management of naturally occurring hip osteoarthrit is 
(OA) in police working dogs. Twenty police working dogs (N=20) were divided into two groups 
according to the drug injected per joint: GT (20mg of triamcinolone acetonide, TA) and GMPA 
(40mg of methylprednisolone, MPA). Animals were treated at T0 (treatment day), and further 
evaluations conducted at T1 (15 days after treatment), T2, T3, T4, T5, T6, and T7 (1, 2, 3, 4, 5 and 6 
months after treatment respectively). Response to treatment was measured using the Canine Brief 
Pain Inventory (CBPI) and Hudson Visual Analogue Scale (HVAS). Significant was set at p<0.05. 
Treatment was successful in reducing pain severity score (PSS) in two animals of GT at T1 
(20%), three at T2-T3 (37.5%) and two at T4-T7 (28.6%). For GMPA, treatment was successful in 
two animals at T1 (20%), four at T2 (40%), three at T3 (30%) and two at T4-T5 (20%). When 
considering pain interference score (PIS), treatment was a success in two animals in both GT and 
GMPA from T1-T7. No significant differences were registered with CBPI and HVAS when 
comparing each moment with T0 nor between groups.  
Intra-articular TA and MPA injection may be a treatment option for some patients. While 
some patients may benefit from IA with TA and MPA, further studies, aimed at determining better 
candidates, are required.  
Keywords: Osteoarthritis, Pain, Dog, Animal Model. 
 
Introduction 
Osteoarthritis (OA) is a species transversal degenerative joint disease. It is difficult to treat, 
causing pain and dramatic changes in patient activity and overall performance [1–4].  In the dog, it 
presents an estimated prevalence of 20% with a trend for rising in the future [5–8]. 
Different types of animal models have been used to study OA, in it all its modalities and stages 
[9,10]. Considering the dog´s tame nature, the fact that their cartilage thickness is less than half the 
size of humans, and the occurrence of slowly progressing OA [10–12], it is considered a nearly ideal 
species for translation research of human OA and, for those reasons, the most used model for research. 
It has the advantages of being anatomically, biochemically, genomically and molecularly similar to 
humans, with clinical progression and treatment similarities [12–15]. This specie has been one of the 
preferred animal model to study, in particular, the progression of natural occurring OA and the 
efficacy of drugs in its treatment [11,12,16]. 
For the management of OA, intra-articular (IA) steroids (CS) have mainly been used in 
humans and horses (despite the doubts of their beneficial or potentially deleterious effects [17]), 
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aiming to control and decrease pain and inflammation levels present in cartilage, bone and soft-tissues 
surrounding the affected joint [18,19,28,20–27]. Amongst the most used CS, methylpredniso lone 
acetate (MPA) and triamcinolone acetonide (TA) have been pointed out by the clinicians of the 
American College of Rheumatologist as their preference for OA IA treatment (34.6% and 21.7%, 
respectively) [29,30]. The primary concern associated with these drugs is the limited duration of their 
effects as a result of their fast clearance from the synovial space [31].  
In animal models, gait and lameness analysis are used items to access pain levels. Multip le 
pain scales are already validated and routinely used in dogs [32].  The Canine Brief Pain Inventory 
(CBPI) is one of those validated tools, developed to access owner’s opinion regarding their perception 
of the impact and level that chronic pain assumes in their pet [33]. It is divided into two sections, a 
pain severity score (PSS), that evaluates the magnitude of the pain of an animal, and a pain 
interference score (PIS), that measures the degree in which pain affects daily activities [34]. The 
Hudson Visual Analogue Scale (HVAS) is repeatable and a valid tool in the assessment of mild to 
moderate pain level in dogs, using force plate analysis as a criterion-reference standard [35].  
We hypothesize that a single IA administration of MPA and TA can reduce pain scores in 
police working dogs with naturally occurring hip OA. We also aimed to describe and compare the 
use and effectiveness of intra-articular injection of TA or MPA. 
 
Materials and Methods 
This doubled blinded, prospective study, is a part of a project approved by the ethical review 
committee of the University of Évora (Órgão para o Bem Estar Animal da Universidade de Évora, 
approval nº GD/32055/2018/P1, September 25th, 2018). Written, informed consent was obtained 
from the Institution responsible for the animals (Guarda Nacional Republicana) through the dispatch 
nº327/16, dated September 16th, 2016.  
A sample of 20 police working dogs (N=20) was selected from the population of police 
working dogs. It constituted a convenience sample, with patients signalled based on trainer 
complaints, physical exam and pelvic radiographic evaluation consistent with bilateral hip OA. 
Animals with other diseases were ruled out through physical examination, complete blood count and 
basic serum chemistry profile (BUN, Creat, ALT, AST, Gluc), and/or under any treatment, were not 
included in the study. Signed informed consent was obtained for all animals participating in the study. 
Dogs were randomly divided into two groups using the statistical analysis software,  according to the 
type of drug used for hip joint intra-articular administration, namely: GT (treated with 20mg of TA 
per hip joint - Trigon depot, Bristol-Myers Squibb®, Spain) and GMPA (treated with 40mg of 
methylprednisolone acetate per hip joint - Depo-medrol, Pfizer®, Portugal). 
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All intra-articular procedures were performed by the same researcher and conducted under 
light sedation using medetomidine (0.01mg/kg) and butorphanol (0.1mg/kg), both given 
intravenously. Animals were placed in lateral recumbency, with the affected joint uppermost. A small 
window of 4x4cm area surrounding the greater trochanter was clipped and aseptically prepared, using 
a chlorhexidine solution 0,2% followed by 70% alcohol scrub, with sterile gloves and 10x10cm 
gauzes. With the limb parallel to the table surface and in a neutral position, the operator inserted a 
22-gauge 75mm length spinal needle, closely dorsal to the greater trochanter and perpendicular to the 
long axis of the limb [36]. Confirmation of correct needle placement was obtained through the 
collection of synovial fluid. After the treatment session, animals were rested for three consecutive 
days and resumed their regular activity over five days. 
Signs of exacerbated pain, persistent stiffness of gait and changes in posture exhibited by the 
dogs, were evaluated by the veterinarian on the days 1 and 3 after the IA procedure. If no complaints 
were reported, the animal could resume regular activity [37,38]. 
To evaluate response to treatment and compare it with an initial clinical condition, two 
validated tools for dog pain assessment were used: the CBPI (Appendix A) and the HVAS (Appendix 
B). Seven different time points were considered: T0 (before IA treatment), T1 (15 days after IA 
treatment), T2, T3, T4, T5, T6 and T7 (1, 2, 3, 4, 5 and 6 months after IA treatment respective ly). 
During and after the six months, all animals remained in active service. 
Collected data were analyzed with IBM SPSS Statistics version 20, and a significance level 
of p<0.05 was set. Normality was assessed with a Shapiro-Wilk test, and results of both groups by 
time points were compared using a Mann-Whitney Test. When comparing each instant with T0 within 
each group, a Paired Samples T-Test was used. 
 
Results 
The sample comprised animals of both genders (5 females and 15 males), with a mean age of 
6±2.4 years and the bodyweight of 33.3±4.14 kg, and body condition score of 4/9. Four breeds were 
represented, German Shepherd Dogs (n=15), Belgian Malinois Shepherd Dogs (n=3) and Labrador 
Retriever (n=2), all with naturally occurring bilateral hip OA. GT included animals of both genders 
(2 females and 8 males), with a mean age of 6.2±2.3 years old and the bodyweight of 32.8±3.8 kg, 8 
German Shepherd Dogs, 1 Belgian Malinois Shepherd Dogs and 1 Labrador Retriever. They were 
graded with mild (n=3) and moderate (n=7) hip OA. GMPA also included animals of both genders 
(3 females and 7 males), with a mean age of 6.1±0.7 years old and a bodyweight of 33.8±3.4 kg, 7 
German Shepherd Dogs, 2 Belgian Malinois Shepherd Dogs and 1 Labrador Retriever. They were 
graded with mild (n=2) and moderate (n=7) hip OA. Of all animals enrolled in the study, three from 
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GT were excluded - two after T2 due to the development of unrelated medical conditions, and one 
after T3 due to inability to keep it medical follow-up. No side effects were detected in both GT and 
GMPA. No significant changes in body weight were recorded throughout the study. 
A reduction of ≥1 in PSS and ≥2 in PIS has been defined as individual treatment success 
achieved, as measured by the CBPI [39]. Treatment was successful in reducing PSS in two animals 
treated with TA at T1 (20%, n=10), three at T2 and T3 (37.5%, n=8), and two at T4-T7 (28.6%, n=7). 
Improvements were registered in four animals at T1 (50%, n=10), three at T2 (30%, n=10), four at 
T3 (50%, n=9) and three at T4-T7. For the GMPA, results showed that treatment was successful in 
two animals at T1 (20%, n=10), four at T2 (40%, n=10), three at T3 (30%, n=10) and two at T4-T5 
(20%, n=10). Scores improved in six animals at T1-T2 (60%, n=10), seven at T3 (70%, n=10), and 
four at T4-T5 (40%, n=10).  
Considering PIS, treatment was a success in two animals in GT and two in GMPA; in GT 
from T1-T7 and in GMPA from T1-T5. Also, scores increased in the same proportion that PSS. When 
comparing results for each time moment with T0 or between groups, no significant differences were 
found. Overall CBPI score evolution can be observed in figure 1. 
 
Figure 1 – Overall Canine Brief Pain Inventory scores, by section and instant for 
methylprednisolone acetate (MPA) and triamcinolone acetonide (TA). Box plots represent the 
median, 25th and 75th percentiles, and whiskers represent 10th and 90th percentiles. 
 
When comparing each moment with T0 or between groups, no significant differences were 
registered in the results of the HVAS. However, individual results showed an improvement in results 
observed in two animals of the GT at T1 (20%), eight at T2-T3 (62.5%) and three at T4-T7 (57.1%). 
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In GMPA, an improvement in scores was observed in seven animals at T1 (70%), six at T2 (60%), 
five at T3-T4 (50%) and four at T5 (40%). 
 
Discussion 
The main focus of OA treatment is to control and decrease pain levels [40,41]. This study 
results show that intra-articular CS could be an effective therapeutic option for some animals since a 
majority of treated animals showed improved results, which may last for months. The 
recommendations for human hip and knee OA state that intra-articular CS can and should be used, 
especially in patients with moderate to severe pain, non-responding to oral analgesic/NSAIDs [42,43]. 
These recommendations may also be adequate for dogs.  
The PSS assesses the magnitude of pain of an animal, and the PIS the level in which pain 
affects a dog´s daily activities, are the body of the CBPI, used for comparisons of overall mean or 
median differences in pain scores between groups [33,34,44]. It has the advantage of quantifying the 
dog’s activity in its environment and over a more extensive period using the owner’s assessment. 
Treatment success in OA dogs has been set as a decrease in PSS≥1 and PIS≥2 [39,45]. Both TA and 
MPA were able to reduce significantly scores of some individuals, particularly PSS. In some cases of 
GT, beneficial results spread up to the last evaluation point, while the majority of improvements in 
both groups declined around T4-T5, especially in GMPA.  
Triamcinolone is presented as having an extended duration of action. In some canine reports, 
the authors recommended the use of TA over MPA [46,47]. In horses, a study comparing the 
difference between TA and MPA registered no difference between both drugs used [48]. According 
to our results, significant individual improvements lasted longer in GT, even though more animals 
showed significant improvements in the GMPA. This difference may be associated with the total 
amount of drug administrated in each joint. 
Both drugs – TA and MPA, are approved for IA use and, since both hip joints were to be 
treated in each animal, we divided the content of one vial equally between joints. Therefore, 20mg of 
TA and 40mg of MPA were administered per joint in each animal sample. Further studies, involving 
different total doses, are required to determine if different doses would provide different results. 
Individual results for PIS registered less marked improvements, similar for both treatment 
groups. Some factors may influence this. Considering that OA pain results not only from the joint 
tissues and structures, but also from adjacent tissues like muscles, tendons, and ligaments, it is 
possible that IA therapies do not completely address all of these pain sources. Besides, the fact that 
animals enrolled in the study are active police working dogs, their musculoskeletal structures are 
under great physical stress and may require a more comprehensive multi-modal approach to OA. It 
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may be reasonable to assume that a companion animal will need a less marked and continued pain 
control, thus achieving better results that can also remain significant for more prolonged periods post-
treatment.  
To compare different analgesic protocols, visual analogue scales are usually used to address 
pain scores and severity. As they rely on a continuous scale, data can be modelled as a continuous 
variable [49]. The HVAS is beneficial to assess lameness in dogs varying from mild to moderate, 
having force plate analysis as a criterion-referenced standard [35]. According to our results, no 
significant variations were observed in HVAS scores, even though individual results seemed to 
improve in almost all animals. This can be due to one of the limitations pointed out to visual analogue 
scales, the fact that they are more sensitive in detecting and recording changes in more obvious cases 
of lameness. Since the majority of animals included in the study showed only mild signs, HVAS 
might not be able to record subtle changes resulting from TA and MPA treatments. 
Described side effects for IA CS use are mainly related to discomfort from the procedure, 
specifically localized pain and flushing [49]. However, no side effects were observed during the 
study.  
Although no significant variations were observed when comparing the results of the groups, 
several animals showed improvements in both GT and GMPA. Future studies should include a larger 
number of animals since the sample size is a limitation of this study.  ON the other side, animals 
included had similar conformations and sizes, where kept in identical housing conditions, fed the 
same food and submitted to similar workloads. As such, the information present may be of interest in 
the treatment of human and canine OA.  
The lack of a control group is a further limitation and, even though both the CBPI and HVAS 
are validated tools for pain and lameness assessment in dogs, further studies should include other 
evaluation methods, such as Force Plait Gait or Stance Analysis. The determination of individua l 
characteristics of the animals that improve with this treatment may help elect the most suitable 
candidates for IA CS. The effect of different treatment frequencies has also to be addressed. 
 
Conclusions 
Intra-articular CS may be a treatment option for some dogs with naturally occurring OA, being 
particularly useful in terms of reducing pain and return to function, with an added cost-effectiveness 
when compared to other therapeutic options. Further studies are required, aimed at determining which 







[1] Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: A disease of the joint as an 
organ. Arthritis Rheum [Internet]. 2012;64:1697–707. Available from: 
http://doi.wiley.com/10.1002/art.34453 
[2] Venable RO, Stoker AM, Cook CR, Cockrell MK, Cook JL. Examination of synovial fluid 
hyaluronan quantity and quality in stifle joints of dogs with osteoarthritis. Am J Vet Res [Internet]. 
2008;69:1569–73. Available from: http://avmajournals.avma.org/doi/abs/10.2460/ajvr.69.12.1569 
[3] Evans CH. Novel Biological Approaches to the Intra-Articular Treatment of Osteoarthrit is. 
BioDrugs [Internet]. 2005;19:355–62. Available from: http://link.springer.com/10.2165/00063030-
200519060-00003 
[4] Gigante A, Callegari L. The role of intra-articular hyaluronan (Sinovial®) in the treatment of 
osteoarthritis. Rheumatol Int [Internet]. 2011;31:427–44. Available from: 
http://link.springer.com/10.1007/s00296-010-1660-6 
[5] Allan GS. Radiographic signs of joint disease in dogs and cats. Thrall, D E, Textb Vet Diagnost ic 
Radiol. 5th ed. St. Louis: Saunders Elsevier; 2007. p. 317–58.  
[6] Innes JF. Arthritis. In: Tobias KM, Johnson SA, editors. Vet Surg Small Anim. St. Louis: Elsevier 
Saunders; 2012. p. 1078–111.  
[7] Smith G, Karbe G, Agnello K, McDonald-Lynch M. Pathogenesis, Diagnosis, and Control of 
Canine Hip Dysplasia. In: Tobias K, Johnston S, editors. Vet Surg Small Anim. 1st ed. Saunders; 
2011. p. 824–48.  
[8] Anderson KL, O’Neill DG, Brodbelt DC, Church DB, Meeson RL, Sargan D, et al. Prevalence, 
duration and risk factors for appendicular osteoarthritis in a UK dog population under primary 
veterinary care. Sci Rep [Internet]. 2018;8:5641. Available from: 
http://www.nature.com/articles/s41598-018-23940-z 
[9] Lampropoulou-Adamidou K, Lelovas P, Karadimas E V., Liakou C, Triantafillopoulos IK, Dontas 
I, et al. Useful animal models for the research of osteoarthritis. Eur J Orthop Surg Traumato l 
[Internet]. 2014;24:263–71. Available from: http://link.springer.com/10.1007/s00590-013-1205-2 
[10] Bendele AM. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact [Internet]. 
2001;1:363–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15758487 
[11] McCoy AM. Animal Models of Osteoarthritis. Vet Pathol [Internet]. 2015;52:803–18. Availab le 
from: http://journals.sagepub.com/doi/10.1177/0300985815588611 
[12] Kraus VB, Huebner JL, DeGroot J, Bendele A. The OARSI histopathology initiative - 
recommendations for histological assessments of osteoarthritis in the guinea pig. Osteoarthr Cartil. 
2010;  
[13] McCoy AM. Animal Models of Osteoarthritis: Comparisons and Key Considerations. Vet 
Pathol. 2015;52:803–18.  
120 
 
[14] Garner B, Stoker A, Kuroki K, Evans R, Cook CR, Cook J. Using Animal Models in 
Osteoarthritis Biomarker Research. J Knee Surg [Internet]. 2011;24:251–64. Available from: 
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0031-1297361 
[15] Lascelles BDX, Brown DC, Maixner W, Mogil JS. Spontaneous painful disease in companion 
animals can facilitate the development of chronic pain therapies for humans. Osteoarthr Cartil 
[Internet]. 2018;26:175–83. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S1063458417313298 
[16] Meeson RL, Todhunter RJ, Blunn G, Nuki G, Pitsillides AA. Spontaneous dog osteoarthritis — 
a One Medicine vision. Nat Rev Rheumatol [Internet]. 2019; Available from: 
http://www.nature.com/articles/s41584-019-0202-1 
[17] Clegg PD. Investigating the efficacy of articular medications in the horse: The science behind 
clinical practices. Equine Vet J [Internet]. 2010;42:484–6. Available from: 
http://doi.wiley.com/10.1111/j.2042-3306.2010.00210.x 
[18] Céleste C, Ionescu M, Poole AR, Laverty S. Repeated intraarticular injections of triamcino lone 
acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid. J Orthop Res 
[Internet]. 2005;23:602–10. Available from: http://doi.wiley.com/10.1016/j.orthres.2004.10.003 
[19] Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of 
relative efficacy of various corticosteroids. Clin Rheumatol [Internet]. 2014;33:1695–706. Availab le 
from: http://link.springer.com/10.1007/s10067-014-2572-8 
[20] Kumar A, Bendele AM, Blanks RC, Bodick N. Sustained efficacy of a single intra-articular dose 
of FX006 in a rat model of repeated localized knee arthritis. Osteoarthr Cartil [Internet]. Elsevier Ltd; 
2015;23:151–60. Available from: http://dx.doi.org/10.1016/j.joca.2014.09.019 
[21] Frisbie DD, Kawcak CE, Trotter GW, Powers BE, Walton RM, McIlwraith CW. Effects of 
triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine Vet J 
[Internet]. 1997;29:349–59. Available from: http://doi.wiley.com/10.1111/j.2042-
3306.1997.tb03138.x 
[22] Augustine AJ, Oleksyszyn J. Glucocorticosteroids inhibit degradation in bovine cartilage 
explants stimulated with concomitant plasminogen and interleukin-1<alpha>. Inflamm Res [Internet]. 
1997;46:60–4. Available from: http://link.springer.com/10.1007/s000110050073 
[23]. Pelletier JP, Martel-Pelletier J. In vivo protective effects of prophylactic treatment with 
tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog 
model. J Rheumatol Suppl [Internet]. 1991;27:127–30. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/2027112 
[24] Pelletier J-P, Martel-Pelletier J. Protective effects of corticosteroids on cartilage lesions and 
osteophyte formation in the pond-nuki dog model of osteoarthritis. Arthritis Rheum [Internet]. 
1989;32:181–93. Available from: http://doi.wiley.com/10.1002/anr.1780320211 
[25] Sieker JT, Ayturk UM, Proffen BL, Weissenberger MH, Kiapour AM, Murray MM. Immedia te 
Administration of Intraarticular Triamcinolone Acetonide After Joint Injury Modulates Molecular 
Outcomes Associated With Early Synovitis. Arthritis Rheumatol [Internet]. 2016;68:1637–47. 
Available from: http://doi.wiley.com/10.1002/art.39631 
121 
 
[26] Williams JM, Brandt KD. Triamcinolone hexacetonide protects against fibrillation and 
osteophyte formation following chemically induced articular cartilage damage. Arthritis Rheum. 
1985;28:1267–74.  
[27] Pelletier J, DiBattista J, Raynauld J, Wilhelm S, Martel-Pelletier J. The in vivo effects of 
intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1, and oncogene 
protein synthesis in experimental osteoarthritis. Lab Invest [Internet]. 1995;72:578–86. Availab le 
from: http://www.ncbi.nlm.nih.gov/pubmed/7745952 
[28] Pelletier JP, Martel-Pelletier J, Cloutier JM, Woessner JF. Proteoglycan-degrading acid 
metalloprotease activity in human osteoarthritic cartilage, and the effect of intraarticular steroid 
injections. Arthritis Rheum [Internet]. 1987;30:541–8. Available from: 
http://doi.wiley.com/10.1002/art.1780300508 
[29] Barile A, La Marra A, Arrigoni F, Mariani S, Zugaro L, Splendiani A, et al. Anaesthetics, steroids 
and platelet-rich plasma (PRP) in ultrasound-guided musculoskeletal procedures. Br J Radiol 
[Internet]. 2016;89:20150355. Available from: 
http://www.birpublications.org/doi/10.1259/bjr.20150355 
[30] Centeno LM, Moore ME. Preferred intraarticular corticosteroids and associated practice: A 
survey of members of the American College of Rheumatology. Arthritis Care Res (Hoboken) 
[Internet]. 1994;7:151–5. Available from: http://doi.wiley.com/10.1002/art.1790070309 
[31] Rudnik-Jansen I, Colen S, Berard J, Plomp S, Que I, van Rijen M, et al. Prolonged inhibition of 
inflammation in osteoarthritis by triamcinolone acetonide released from a polyester amide 
microsphere platform. J Control Release [Internet]. 2017;253:64–72. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0168365917301190 
[32] Reid J, Scott M, Nolan A, Wiseman-Orr L. Pain assessment in animals. In Pract [Internet]. 
2013;35:51–6. Available from: http://inpractice.bmj.com/lookup/doi/10.1136/inp.f631 
[33] Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the canine brief pain inventory to detect 
response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc [Internet]. 2008;233:1278 –
83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19180716 
[34] Upchurch DA, Renberg WC, Roush JK, Milliken GA, Weiss ML. Effects of administration of 
adipose-derived stromal vascular fraction and platelet-rich plasma to dogs with osteoarthritis of the 
hip joints. Am J Vet Res [Internet]. 2016;77:940–51. Available from: 
http://avmajournals.avma.org/doi/10.2460/ajvr.77.9.940 
[35] Hudson JT, Slater MR, Taylor L, Scott HM, Kerwin SC. Assessing repeatability and validity of 
a visual analogue scale questionnaire for use in assessing pain and lameness in dogs. Am J Vet Res 
[Internet]. 2004;65:1634–43. Available from: 
http://avmajournals.avma.org/doi/abs/10.2460/ajvr.2004.65.1634 
[36] Van Vynckt D, Samoy Y, Mosselmans L, Verhoeven G, Verschooten F, Van Ryssen B. The use  
of intra-articular anesthesia as a diagnostic tool in canine lameness. Vlaams Diergeneeskd Tijdschr. 
2012;81:290–7.  
[37] Caron JP. Intra-Articular Injections for Joint Disease in Horses. Vet Clin North Am Equine Pract 




[38] Chakravarty K, Pharoah PDP, Scott DGI. A randomized controlled study of post-injection rest 
following intra-articular steroid therapy for knee synovitis. Rheumatology [Internet]. 1994;33:464–
8. Available from: https://academic.oup.com/rheumatology/artic le -
lookup/doi/10.1093/rheumatology/33.5.464 
[39] Brown DC, Bell M, Rhodes L. Power of treatment success definitions when the Canine Brief 
Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in 
dogs with osteoarthritis. Am J Vet Res [Internet]. 2013;74:1467–73. Available from: 
http://avmajournals.avma.org/doi/abs/10.2460/ajvr.74.12.1467 
[40] Mobasheri A, Henrotin Y. Identification, validation and qualification of biomarkers for 
osteoarthritis in humans and companion animals: Mission for the next decade. Vet J [Internet]. 
2010;185:95–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1090023310001899 
[41] Kuroki K, Cook JL, Kreeger JM. Mechanisms of action and potential uses of hyaluronan in dogs 
with osteoarthritis. J Am Vet Med Assoc [Internet]. 2002;221:944–50. Available from: 
http://avmajournals.avma.org/doi/abs/10.2460/javma.2002.221.944 
[42] Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI 
recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, 
expert consensus guidelines. Osteoarthr Cartil [Internet]. 2008;16:137–62. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S1063458407003974 
[43] Park KD, Kim TK, Bae BW, Ahn J, Lee WY, Park Y. Ultrasound guided intra-articular ketorolac 
versus corticosteroid injection in osteoarthritis of the hip: a retrospective comparative study. Skeletal 
Radiol [Internet]. 2015;44:1333–40. Available from: http://link.springer.com/10.1007/s00256-015-
2174-9 
[44] Webster RP, Anderson GI, Gearing DP. Canine Brief Pain Inventory scores for dogs with 
osteoarthritis before and after administration of a monoclonal antibody against nerve growth factor. 
Am J Vet Res [Internet]. 2014;75:532–5. Available from: 
http://avmajournals.avma.org/doi/abs/10.2460/ajvr.75.6.532 
[45] Brown DC, Boston RC, Farrar JT. Comparison of Force Plate Gait Analysis and Owner 
Assessment of Pain Using the Canine Brief Pain Inventory in Dogs with Osteoarthritis. J Vet Intern 
Med [Internet]. 2013;27:22–30. Available from: http://doi.wiley.com/10.1111/jvim.12004 
[46] Franklin SP, Cook JL. Prospective trial of autologous conditioned plasma versus hyaluronan 
plus corticosteroid for elbow osteoarthritis in dogs. Can Vet J = La Rev Vet Can [Internet]. 
2013;54:881–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24155495 
[47] Suntiparpluacha M, Tammachote N, Tammachote R. Triamcinolone acetonide reduces viability, 
induces oxidative stress, and alters gene expressions of human chondrocytes. Eur Rev Med Pharmacol 
Sci [Internet]. 2016;20:4985–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27981533 
[48] Labens R, Mellor DJ, Voûte LC. Retrospective study of the effect of intra-articular treatment of 
osteoarthritis of the distal tarsal joints in 51 horses. Vet Rec [Internet]. 2007;161:611–6. Availab le 
from: http://www.ncbi.nlm.nih.gov/pubmed/17982139 
[49] Popma JW, Snel FW, Haagsma CJ, Brummelhuis-Visser P, Oldenhof HGJ, van der Palen J, et 
al. Comparison of 2 Dosages of Intraarticular Triamcinolone for the Treatment of Knee Arthrit is : 
123 
 
Results of a 12-week Randomized Controlled Clinical Trial. J Rheumatol [Internet]. 2015;42:1865–
8. Available from: http://www.jrheum.org/cgi/doi/10.3899/jrheum.141630. 
 
 
Fronti e rs in Veterin a ry Science | www. fro n ti e rsi n. o rg 124 Nov ember 2020 | Volume 7 | Article 512523   
 
ORIGINAL RESEARCH 
published: 06 Nov ember 2020 doi: 10.3389/f v ets.2020.512523 
 
 
A Pilot Study on the Efficacy of a Single Intra-Articular Administration  of Triamcinolone Acetonide, 




A Pilot Study on the Efficacy of a     
Single Intra-Articular Administration        
of Triamcinolone Acetonide,    
Hyaluronan, and a Combination of     
Both for Clinical Management of 





Edited by: Pablo Martín -V a s allo , 
University of La Laguna, Spain 
Reviewed by: 
Nicole Buote, VCA West Los Angele s 
Animal Hospit al , United States 
Alexan d ri n a Ferreira Mende s, Universit y 
of Coimbra , Portug al 
*Correspondence: 
João C. Alves alves.jca@g nr. pt 
 
Specialty section: This article was 
submitted to Comp a rati v e and Clinical  
Medici ne , 
a section of the journal Frontiers in 
Veterin a ry Scien ce 
Received: 15 November 2019 
Accepted: 12 October 2020 
Published: 06 November 2020 
Citation: Alves JC, Santos A, Jorge P,  
Lavrador C and Carreira LM (2020) A 
Pilot Study on the Efficacy of a Single 
Intra-A rti cul a r Administ rati o n of 
Triam ci n ol o n e Acetoni d e, Hyalu ro n a n, 
and a Combination of Both for Clinical 
Manag e m e n t of Oste o a rt h riti s  in 
Police Worki n g Dogs. Front. Vet. Sci. 
7:512523. 
doi: 10.3389/fvets.2020.512523 
João C. Alves 1,2*, Ana Santos 1 , Patrícia Jorge 1 , Catarina Lavrador 2 and 
L. Miguel Carreira 3,4,5 
 
1 Divisão de Medicina Veterinária, Guarda Nacional Republicana (GNR), Lisbon, Portugal, 2 MED—Mediterranean Institute for 
Agriculture, Environment and Development, Instituto de Investigação e Formação Avançada, Universidade de Évora, Évora, 
Portugal, 3 Faculty of Veterinary Medicine, University of Lisbon (FMV/ULisboa), Lisbon, Portugal, 4 Interdisciplinary Centre for 
Research in Animal Health (CIISA), University of Lisbon (FMV/ULisboa), Lisbon, Portugal, 5 Anjos of Assis Veterinary Medicine Centre 
(CMVAA), Barreiro, Portugal 
 
Objectives: To describe and compare the use and effectiveness of a single intra-articular injection 
(IA) of triamcinolone acetonide (TA), hyaluronan (HA), and a combination of both (TA+HA) in police 
working dogs with natural occurring hip osteoarthritis (OA). 
Study Design: Prospective, randomized, single-blinded study. 
Sample Population: Thirty animals with naturally occurring hip OA. 
Methods: Animals were randomly divided in three groups: GT, treated with 20 mg of 
TA per hip joint; GH, treated with treated 20 mg of HA per hip joint; and GTH, treated 
with a combination of 20 mg of TA and 20 mg of HA per hip joint. Response to treatment,  
measured by the Canine Brief Pain Inventory (divided in Pain Interferenc e Score—P IS and 
Pain Severity Score—PSS) and the Hudson Visual Analog Scale (HVAS), was evaluated in 
seven different time points: T0 (before treatment), T1 (after 15 days), T2, T3, T4, T5, and 
T6 (after 1, 2, 3, 4, and 5 months, respectively). Results were compared using a 
Kruskal-Wallis test or a Wilcoxon signed ranks test, and p < 0.05 was set. 
Results: Comparing results of the different time points considered with T0, significant  
differences were registered in GH at T1 for HVAS (p = 0.03) and PIS (p = 0.04);  and 
in GTH at T1  (p  =  0.05  for  HVAS  and  p  < 0.05  for  PIS),  T2  (p  < 0.04 for PIS),  
T3 (p < 0.03 for HVAS  and p = 0.05  for PIS),  T4 (p < 0.03 for  HVAS  and p < 0.05),  
and T5 (p < 0.05 for HVAS). No significant differences were found 
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between groups when comparing scores in each time point. Individual treatment is 
considered successful with a reduction of ≥1 for PSS or ≥2 for PIS. In GTH, treatment 
was successful in four animals between T1 and T5 (40%, n = 10) and three at T6–T7 
(30%, n = 10) for PSS and three animals of GTH at T1 (30%), two at T2 (20%), three 
between T3 and T4 (30%), and two between T5 and T7 (20%). 
Conclusions and Clinical Relevance: This study provides direct information on the 
use of these treatment modalities in patients with hip OA. Intra-articular injection with 
TA and HA may be a treatment option for dogs with naturally occurring OA, particularly 
when simultaneously used, as they provide significant improvements of PIS and HVAS 
scores. Individual scores improved in some animals with PIS, PSS, and HVAS. 
 
Keywords: animal model, osteoarthritis, pain, triamcinolone, hyaluronan  
 
INTRODUCTION 
Osteoarthritis (OA) is a complex joint disease with a high negative 
impact on patient’s quality of life and a high financial burden. 
Characterized by its inflammatory character and degradation of 
cartilage layers, it is a source of chronic pain, which affects all 
mammals, including humans and dogs (1–3). In adult active dogs, 
OA presents a prevalence around 20% (4–6). This value is 
expected to rise, due to a simultaneous increase in life expectancy 
and obesity. Both surgical and natural occurring canine models 
have been widely studied, and since pathologic process, clinical 
presentation and response to treatment  are  very similar in both 
species—humans and dog, this animal model  is  the  closest  to  a  
gold  standard  (7–10).  The  changes that occur in slowly 
progressive spontaneous dog OA closely match those of human 
OA, in contrast with those seen in  rapidly advancing experimental 
surgical induced OA (11). The grades of canine hip OA are similar 
to those in the classification of human OA (mild/minimal, 
moderate, and severe) (12, 13).   In addition, companion animals 
share the same environment and suffer similar co-morbidities as 
humans, with OA usually being present for prolonged periods. 
Therefore, these naturally occurring painful disease models may 
better reflect the complex genetic, environmental, temporal, and 
physiological influences present in humans (12). Exploring 
spontaneous dog OA under the One Medicine concept can promote 
new insight on the disease, improving therefore the health and well-
being of both species, humans, and dogs (12, 13). 
Intra-articular (IA) corticosteroids  (CS)  have  been  u sed for 
several decades in humans and horses to successfully palliate pain 
and control inflammation  associated  with  OA  and surrounding  
tissues  (14,  15).  Different  guidelines  for the management of 
human OA provide varying strength of recommendation for the use 
of intra-articular CS, from weak to strong recommendation (16–
20). On the other hand, other guidelines state an inability to 
recommend for or against the   use of intra-articular corticosteroids, 
in this case specifically   for patients with symptomatic knee OA 
(21). Corticosteroids reduce the number of inflammatory cells such 
as lymphocytes, macrophages and mast cells, and also slow down 
the synthesis of inflammatory mediators such as interleukin 1β, 
Tumor necrosis 
 
factor  α,  and  Cycloxygenase  2  in  the  synovial  fluid  (22–25). 
The pain relief they provide is attributed to the inhibition of 
prostaglandin synthesis (24). Triamcinolone is recommended over 
other CS due to an  extended  duration  of  action  (26,  27). 
Hyaluronan (HA), the high molecular glycosaminoglycan, occurs 
naturally in synovial fluid, and provides joint lubrication, helps 
limit inflammation, pain and cartilage degradation while acting as  
a  shock  absorber,  allowing  the  joint  to  move  in  a smooth 
manner (16, 17). Its mechanism of action is not completely 
understood, but anti-inflammatory, anti-nociceptive, and 
chondroprotective properties have been suggested, through the 
enhancement of cartilage synthesis, blunting response to interleukin 
1, protection from the damage of oxygen free radicals,  and  
protection  of  chondrocytes  from  apoptosis  (28– 31). Guidelines 
for the management of OA provide a weak recommendation for the 
use of IA HA (20), a conditional recommendation against (19) or 
that they should not be offered as an option (18). The choice to use 
IA HA or a CS, or which CS to use, is often determined by individual 
preference of the clinician (18, 19). A popular approach is their 
combined administration, thus providing rapid onset of action 
(obtained from the CS), with prolonged effect and decreasing the 
potential side effects of intra-articular CS therapy (obtained from 
HA) (20, 21). Being an incurable chronic disease, treatment 
success in OA is often defined as the ability to manage its 
symptoms, mainly pain.   The similarities in neurophysiology 
across mammals strongly suggest that the type of pain experienced 
by humans and animals is analogous (22). The Canine Brief  Pain  
Inventory  (CBPI) was developed to assess the impact of chronic 
pain in the patient’s life. It is divided in two sections, a pain 
severity score (PSS)  that  assesses  the  magnitude  of  the  animal’s  
pain,  and  a pain interference score (PIS) that assesses the degree 
in which pain affects daily activities (23). The Hudson Visual 
Analog Scale (HVAS) has been  validated for  the assessment of  
mild  to moderate lameness in dogs, using force plate analysis as a 
criterion-reference standard (24). 
With this study, we aimed to determine (1) if the intra - articular 
administration of triamcinolone acetonide (TA) or HA can 
reduce pain scores in a naturally occurring canine osteoarthritis 
model and if (2) the combined administration of both substances 
provides better results for longer periods of time. 
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The study used a sample of 30 working dogs (N = 30) from the 
Guarda Nacional Republicana (Portuguese Gendarmerie Canine 
Unit) of both genders (6 females and 24 males), with a mean age of 
6 ± 2.4 years old and body weight of 33.3 ± 6.65 kg. Breeds 
included German Shepherd Dogs (n = 20), Belgian Malinois 
Shepherd Dogs (n = 5), Labrador Retriever (n = 4), and Dutch 
Shepherd Dog (n = 1). All had bilateral naturally occurring mild 
and moderate hip OA, classified according to the Orthopedic 
Foundation for Animals scoring, This method was chosen due to 
the unavailability of other evaluation methods, such as PennHip. 
Radiographic evaluation was performed by one of the authors 
(JCA), not a board radiologist but with extensive training and 
experience in radiographic examination. 
Patients were included based on trainer complaints, physical 
examination, and standard pelvis radiographic evaluation consistent 
with bilateral hip OA. Animals with other diseases were ruled out 
through physical examination, complete blood count, and basic 
serum chemistry profile (BUN, Creat, ALT, AST, Gluc) were not 
included in the study. Patients under any treatment, therapy or 
supplement were also excluded. Written, informed consent was 

















FIGURE 1 | Overall Pain Severity Scores, by section and instant for triamcinolone acetonide (TA), hyaluronan (HA), and TA+HA. Box plots represent median, 25th and  













FIGURE 2 | Overall Pain Interference Scores, by section and instant for triamcinolone acetonide (TA), hyaluronan (HA), and TA+HA. Box plots represent median, 25th 
and 75th percentiles, and whiskers represent 10th and 90th percentiles. 
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Dogs were randomly divided in three groups according to the type 
of drug used for hip joint IA administration, namely: GT (treated 
with 20 mg of TA per hip joint—Trigon depot, Bristol-Myers  
Squibb§R  ,  Spain),  GH  (treated  with  20 mg  of hyaluronan per 
hip joint—Hyalart, Grunenthal§R  , Portugal), and GTH (treated with 
the combination of both substances per hip joint). Breeds were 
similarly distributed amongst groups: GT had 7 German Shepherd 
Dogs, 2 Belgian Malinois Shepherd Dog and 1 Labrador Retriever; 
GH had 6 German Shepherd Dogs,    2 Belgian Malinois Shepherd 
Dogs, 1 Labrador Retriever and 1 Dutch  Shepherd Dog; and GTH 
had 7 German Shepherd Dogs, 1 Belgian Malinois Shepherd Dogs 
and 2 Labrador Retrievers. 
The  IA  administration  was  always  made  by  the  same 
clinician and conducted with dogs under light sedation using 
medetomidine (0.01 mg/kg) and buthorphanol (0.1  mg/kg),  both 
administered intravenously, and with intravenous fluids of NaCl 
0.9% in the dose of 2 ml/Kg/h. Animals were placed in lateral 
recumbency, and a small window of 4 cm × 4 cm area surrounding 
the greater trochanter was clipped and aseptically prepared, using 
a chlorhexidine solution 0.2% followed by 70% alcohol 
application, using sterile gloves and 10 cm × 10 cm gauzes. With 
the limb parallel to the table surface and in a neutral position, the 
operator inserted a 22-gauge with 75 mm length spinal needle, 
closely dorsal to the greater trochanter and perpendicular to the 
long axis of the limb (32). Confirmation of correct needle 
placement was obtained through the collection of synovial fluid. 
Both hips were treated with the same treatment in all animals. After 
treatment, animals were rested for 3 consecutive days. Signs of 
exacerbated pain during daily activities 
or physical examination (pain during joint mobilization, stiffness, 
and reduced range of motion), persistent stiffness of gait and 
changes in posture exhibited by the dogs, were evaluated by the 
veterinarian on the days 1 and 3 after the IA procedure. With IA 
treatments, some side effects were documented, and include local 
pain and inflammation, swelling and infection. These are usually  
self-limiting, and take 2–10 days to resolve (33, 34). If no 
complaints were registered, the animal could resume its normal 
activity over a period of 5 days (35, 36). 
To evaluate the response to treatment and comparing it with the 
initial clinical condition, two validated tools for dog pain 
assessment were used: the CBPI (Appendix A) and the HVAS 
(Appendix B). These were completed by the trainers, who were 
unaware of which treatment the animal received. Evaluations were 
conducted at T0 (before IA treatment), T1 (15 days after IA 
treatment), T2, T3, T4, T5, T6, and T7 (1, 2, 3, 4, 5, and 6 months 
after IA treatment, respectively). 
From all the  sampled  individuals,  three  dogs  from  the GT were 
excluded—two after T2 due to having developed unrelated medical 
conditions (one developed gastric dilatation volvulus and the other 
suffered  a  third  phalanx  avulsion), and one after T3 due to an 
inability to maintain medical follow-up. Data collected from these 
animals was considered  up  to  the  point  of  their  exclusion. 
Data  was  analyzed   with IBM SPSS Statistics  version  20,  and  
a  significance level  of  p <  0.05  was  set.   Normality  was  
accessed  with a Shapiro-Wilk test and results of all  groups  in  
each  time point considered were compared using a Kruskal-Wallis 



















FIGURE 3 | Overall Hudson Visual Analog scores, by instant for triamcinolone acetonide (TA), hyaluronan (HA), and TA+HA. Box plots represent median, 25th and 
75th percentiles, and whiskers represent 10th and 90th percentiles. *indicates  significant differences within the group, when compared with T0. 
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In GT, when comparing clinical results from T1 to T7 with patient 
initial condition (T0), no significant differences were recorded. In  
GH, significant differences were observed only at T1 (p = 0.03 for 
HVAS and p = 0.04 for PSS). In GTH, significant differences were 
observed at T1 (p < 0.05 for HVAS and p < 0.05 for PSS), T2 (p 
< 0.04 for PSS), T3 (p < 0.03 for HVAS and p < 0.05 
for PSS), T4 (p < 0.03 for HVAS and p < 0.05 PSS), and T5  (p 
< 0.05 for HVAS). Comparing results of the three groups in each 
evaluation moment, no significant differences were found. 
Evolution of PSS, PIS, and HVAS scores can be observed in 
Figures 1–3, respectively. Evolution of mean PSS, PIS, and HVAS 
scores (±standard deviation), p values and percentage variations in 
each group, are presented in Table 1. 
During the study, no side effects were detected in any of the 




OA is a chronic disease with no cure, but with the possibility to 
be effectively managed in a largely palliative approach, aiming to 
relieve symptoms and especially pain (17, 29). Non-steroidal 
anti-inflammatory drugs (NSAIDs) are often considered as the 
first line of OA treatment. For active patients, or with more  
advanced OA stages, the control they provide over signs and 
symptoms may be insufficient (30, 31, 37). Since OA is 
symptomatic only in the affected joint, while lacking obvious 
extra-articular manifestations, it is well-suited to have a local 
therapy administered by intra-articular injection, reducing the 
total amount required to produce an effect, compared with a 
systemic  administration  (38–40).  Still,  this  approach  presents 
some disadvantages, as the need of a precise diagnosis, the 
learning curve inherent to the execution of the procedure 
(particularly when considering hips), better conducted with the 
assistance of fluoroscopy or ultrasound, and the need of placing 
the patient under sedation or general anesthesia. Results showed 
that both TA and HA, when administered through intra-articular 
injection, are able to reduce pain levels to some degree and up to 
certain time points, in a naturally occurring canine osteoarthritis 
model. The combination of both substances, in particular, can be 
an effective therapeutic option, with a majority of treated patients 
showing improved results in their clinical condition, lasting for 
several months. 
Limitations of this study are associated with sample size and the 
lack of a control group. Additionally, even though both the CBPI 
and HVAS have been validated as tools for the assessment of pain, 
lameness, and response to treatment in dogs, further studies should 
include another evaluation method such as Force Plait Gait or 
Stance Analysis. 
The CBPI is often the analysis of choice in the veterinary literature, 
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groups (41, 42). In this study, significant variations were observed in 
GH only at the first follow up, and for PSS. In GTH, improvements 
were also observed in PSS scores, but for a longer period. It was in 
GTH that the biggest improvement was observed, with a 44.7% 
improvement at T3. Individual treatment success has been set as a 
decrease in PSS ≥ 1 and in PIS ≥ 2 (28, 43). Both IA treatments with 
HA and TA were able to significantly reduce individual scores in 
naturally occurring canine OA model, particularly PSS, while 
improving the results for  the majority of patients. In some cases 
of GT and in one patient of GH, beneficial results spread up to the 
last evaluation point, while most improvements in both groups 
declined around T4-T5. Results for PIS showed no significant 
variations, considering group results. Individual resu lts registered 
some improvements, but less marked than PSS results. This may 
be because, for some patients, PIS scores were low to begin with, 
making it difficult to reach a significant reduction. In addition, 
these are dogs with very high prey drive and work motivation, 
which may lead to a good performance and low perception of pain 
interference during daily activities. Individual HVAS results 
improved in almost all animals. However, when considering group 
results, significant  improvements  were  observed  only in GH (at 
T1) and GTH, in this case up to T5. In  GTH, similarly to PSS 
scores, improvements reached a highest of 25.5% at T3, and 
declined from this point, reaching an 18.2% improvement at T5. 
The IA use of HA  for the treatment of    OA is still somewhat 
controversial due to its mode of action being unclear and clinical 
trials have provided contradictory results (38). The results of our 
study showed improvements in some animals at T1, with the 
maximal number of significant improvements obtained at  T2,  and  
maintained  for  a  couple of months. Additional administrations, 
compared to a single injection, may be required in order to obtain 
sustained results. IA CS have been used for several decades in 
humans to successfully palliate pain and control inflammation 
associated with OA and surrounding tissues (14, 15). A systematic 
review has deemed triamcinolone more effective in relieving pain 
and improving function than betamethasone and 
methylprednisolone acetate (44). The choice to use IA HA or CS, or 
which CS to use, is often determined by individual preference of 
the clinician (18, 19). There are reports presenting deleterious 
effects of IA CS, as they may induce the production of a low 
quantity and high viscosity synovial fluid. These results are often 
based on multiple injections, particularly of methylprednisolone, 
while a single dose does not seem to cause long-term detrimental 
effects (45, 46). In a canine model of OA, animals treated with IA 
triamcinolone showed a significant reduction of osteophyte size 
compared with a control group. At the histological level, it 
significantly reduced the severity of OA structural changes of 
cartilage and had no deleterious effects on normal cartilage (47). 
Our results show that a single IA TA is effective in reducing pain 
scores in some animals, but not the majority of them. For those that 
it was, benefits were detected for several months, in some cases up     
to the last evaluation point. We did not observed any clinical side-
effects in the animals treated with TA,  and this seems to be a safe 
therapeutic options in patients with hip OA. As we   did  not 
performed a follow-up radiographic evaluation of the 
joints, we cannot comment on the evolution of radiographic signs 
in the three considered groups, but it should be addressed in 
future studies. 
Results observed in GTH support the hypothesis that combined 
administration of HA and TA is superior in positive effects when 
comparing to the individual use of each one. PSS scores show 
significant improvements until T3, raising from a 25.3% at T1 
to a 44.7% improvement at T3. Individual  PSS scores improved 
in several patients up to the six -month evaluation point. HVAS 
in GTH also improved significantly from T1 to T5, in contrast 
to what was observed in GT and GH. This result is in accordance 
with what was observed with PIS, reflecting increased mobility, 
presumably due to decreased pain. 
According  to  the  author’s  knowledge,  this  is  the  first  study that 
presents the description of the clinical effect of IA CS, HA and 
the combined use of both products in a naturally occurring 
canine model. The study was  able  to  establish that all 
therapeutic approaches are safe, since no side effects were 
observed after the  IA  procedure  in  all  animals  of  the three 
groups considered. All treatments can be effective for the 
treatment of OA, particularly the combined use of both products 
(TA + HA). Future studies should enroll a larger sample and 
considered the effect of different doses and administration 
frequency. 
 
CONCLUSIONS AND CLINICAL RELEVANCE 
Intra-articular administration of TA and HA may  be  a treatment 
option  for  natural  occurring  OA,  particularly  when used 
simultaneously. This  study  provides  information  on the use  of  
these  treatment  modalities  in  patients  with  hip OA. Further 
studies are required, involving  a  larger number of patients and 
the use of  a  more  objective  evaluation method. 
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Abstract  
and poses 
a large healthcare cost. We aimed to describe the use of a single intra-articular (IA) injection of an autologous platelet 
therapy in the management of osteoarthritis  (OA) in a naturally occurring canine model. 
 Fifteen police working dogs with bilateral hip OA were treated with 3 ml of platelet concentrate per hip 
were compared with T0 with a Paired Samples T-Test, and a 
p < 0.05 was set. 
PSS, Function and Gait; p = 0.01 for COI; and p < 0.05 for PIS). 
produced significant improvements, which lasted several months, and therefore warrants further study.  
 







Osteoarthritis (OA) represents a significant burden to 
societies, as it affects quality of life, performance and poses 
a large healthcare cost [1]. It is also the most prevalent 
musculoskeletal disease in dogs, with an ex- pected increase, 
due to a simultaneous increase in life expectancy and obesity 
[2]. For these reasons, it raises major welfare challenges and 
concern [3]. Translational research is a critical step towards 
understanding the long-term effects of OA, and animal 
models provide relevant ways to study the  natural  history 
and response to treatment [4]. Canine OA models have the 
advantages of being anatomically, biochemically , 
genomically and molecularly similar to humans, with close 
clinical pro- gression and response to treatment. These 
naturally oc- curring models may better reflect the complex 
genetic, environmental, temporal and physiological 
influences present in humans, being the closest to a gold 
standard [4–9]. Therefore, exploring spontaneous OA in  
dogs under the One Medicine initiative can help improve the 
health and well-being of both humans and dogs [9, 10]. 
Pain and functional  ability  are  important  parameters in the 
evaluation of OA treatment efficacy [11]. The gold standard 
for the evaluation of lameness is through gait analysis [12] 
but this equipment is often confined to re- search facilities  
[9]. Several clinical metrology instru- ments (CMI) have 
been developed in order to measure outcome assessments, 
which for dogs are normally com- pleted by a proxy. In 
human medicine, they are a stand- ard, validated and 
accepted method for measuring  chronic pain, and have 
formed an important part of the patient clinical assessment 
for over 30 years  [13,  14]. The best ones developed for 
dogs, and that have been reported to have criterion validity, 
are the Canine Brief Pain Inventory (CBPI) and  the 
Liverpool Osteoarthritis  in Dogs (LOAD) [9, 14–16]. The 
CBPI is divided in two sections, a pain severity score (PSS), 
that assesses the magnitude of the animal pain, and a pain 
interference score (PIS), that assesses the degree in which 
pain affects daily activities [17]. The Canine Orthopaedic 
Index  (COI) was developed to assess four domains  in  dogs  
with OA: stiffness, gait, function and quality of life (QOL). 
It has been shown to have excellent reliability and validity, 
and has been used to evaluate working dogs [18, 19]. Visual 
Analogue Scales are one of the tech- niques used to score 
pain and assess its severity, allow- ing the comparison of 
analgesic protocols. The Hudson Visual Analogue Scale 
(HVAS) has been deemed as re- peatable and valid to assess 
the degree of mild to moder- ate lameness in dogs, compared 
with force plate analysis as a criterion-referenced standard 
[20]. 
Autologous platelets are a regenerative treatment modality for 
OA, used with the aim to stimulate the natural healing cascade 
and regeneration of tissues by a supraphysiologic 
release of platelet derived factors directly at the treat- ment 
site, without the risk of immune rejection or dis - ease 
transmission [21–23]. Growth factors affect nearly every 
biological process [24] and, in platelets concen- trates, 
insulin-like growth factor (IGF-1), transforming growth 
factor-β (TGF-β), platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (b-FGF), signal cells to proliferate 
and influence their maturation, differenti- ation and tissue 
repair [25, 26]. Growth factors can be obtained from other 
sources, such as autologous condi- tioned plasma, and are 
able to reduce pain  and  lame- ness scores, and increase 
weight bearing when injected into OA joints [27–29]. In 
dogs, a single intra-articular (IA) PRP injection has resulted 
in clinical improve- ments for 12 weeks, in some  cases 
without progression of radiographic signs [27, 30, 31]. 
Through this period, radiographic scores were the same as 
assigned before treatment [30]. Multiple injections protocols 
have also been described, providing improvements in ROM, 
pain, lameness and kinetics. Authors associated this response 
to treatment to an anti-inflammatory activity of PRP ra- ther 
than any effect on tissue anabolism or catabolism [32]. It has 
also been used as a part of surgical proto-   cols, leading to a 
significant improvement in gait per- formance in the 
postoperative period [31, 33]. V-PET is   a platelet 
concentrate as well as conditioned plasma, which contain 
many autologous anti-inflammatory me- diators and growth 
factors, reported to reduce pain and lameness scores and 
increase weight bearing in  dogs  with OA [27, 28]. 
The objective of this report is to describe the use of the 
platelet concentrate V-PET in the management of OA in   a 
naturally occurring canine model. We hypothesize that a 
single IA administration of platelet concentrate can reduce 
pain scores in police working dogs with naturally occur- ring 
hip OA for a long period of time. 
 
Methods 
The sample comprised animals selected from the popu- 
lation of police working dogs of the Guarda Nacional 
Republicana (Portuguese Gendarmerie Canine Unit). Se- 
lection was made by the assisting veterinarian, based on the 
dog’s history, trainer complaints, physical and radio- graphic 
findings consistent with bilateral naturally oc- curring mild  
and moderate hip OA, classified according to the Orthopedic 
Foundation for Animals scoring. Ani- mals with other 
illnesses or under any other treatment were not included in 
the study, and were ruled out through physical examination,  
complete  blood  count  and serum chemistry profile. Written, 
informed consent was obtained for all animals. 
The animals were placed under light sedation using 
medetomidine (0.01 mg/kg) and buthorphanol (0.1 mg/ 









kg), both given intravenously, and then positioned in lat- eral 
recumbency with the affected joint uppermost. A small 
window of 4x4cm area surrounding the greater trochanter 
was clipped and aseptically prepared. The  limb was then 
placed parallel to the table surface and in    a neutral position 
by an assistant, and the clinician (the same in all procedures) 
inserted a 21-gauge with 2.5″ length needle, just dorsal to the 
greater trochanter and perpendicular to the long axis of the 
limb [34]. Confirm- ation of correct needle placement was 
obtained through the collection of synovial fluid. All animals  
received 3 ml of platelet concentrate per hip joint, prepared 
with the commercially available V-PET kit (PALL 
Corporation), according to the manufacturer’s instructions. 
Fifty-five milliliters of whole blood were collected from the 
jugular vein of the patient, and then introduced into the  pro-  
vided closed system. The blood then flowed by action of 
gravity through the filter, where platelets where concen- 
trated. The final product was collected using the pro- vided 
syringe. After treatment, animals were rested for 3 
consecutive days and resumed their normal activity over   a 
period of 5 days. Signs of exacerbated pain, persistent 
stiffness of gait and changes in posture exhibited by the dogs, 
were evaluated by the veterinarian on the days 1   and 3 after 
the IA procedure. If no complaints were reg- istered, the 
animal could resume its normal activity [35, 36]. 
Response to treatment, as measured by the CBPI 
(Additional file 1), COI (Additional file 2), LOAD (Add- 
itional file 3) and HVAS (Additional file 4) was evaluated 
before treatment (T0), after 15 days (T1) and 1 (T2), 2 (T3), 
3 (T4), 4 (T5), 5 (T6) and 6 (T7) months after ini- tial 
treatment. These were completed by the  trainers, who were 
unaware of which treatment the animal re- ceived, and after 
receiving the published instructions for each for them. 
Normality was assessed with a Shapiro- Wilk test and each 
instant was compared with T0 with a Paired Samples T-Test. 
All results were analyzed with IBM SPSS Statistics version 
20 and a significance level of p < 0.05 was set. 
 
Results 
All animals enrolled were followed during a 6-month  
evaluation period. The sample included 15 working dogs (N 
= 15) of both genders (8 females and 7 males), with a mean   
age of 7 ± 2.4 years old and body  weight  of 31.1 ± 
4.57 kg. Four breeds were represented: German Shep- herd 
Dogs (n = 10), Labrador Retriever (n = 3), Belgian Malinois  
Shepherd Dogs (n = 1) and Catch Dog of São Miguel (n = 
1). These were use of force, product and hu- man scent dogs 
in active work at the time of treatment and during the follow 
up period, and where in similar kennels of the Portuguese 
Gendarmerie Canine Unit.  Each  animal  received  an  
average  total  solution volume 
 
of 6 ml of platelet was produced with V-PET, divided in   3 
ml per hip joint. Increased lameness after the IA ad- 
ministration was observed in four dogs, which was spon- 
taneously resolved within 48 h. 
When comparing results between each time moment and T0, 
significant differences were observed in all mo- ments and 
with different CMIs. With HVAS, significant improvements  
were observed at T1 (p < 0.01), T2 (p = 0.02) and T3 (p < 
0.01). When considering individual re- sults, improved  
results  were observed  in 12 animals at  T1 (80%), 11 at T2 
(73.3%), 14 at T3 (93.3%), 9 at T4-T6 
(60%) and 8 at T7 (53.3%). 
With CBPI, significant differences were observed at T1 (p < 
0.01 for PSS and p = 0.01 for PIS), T2 (p < 0.01 for PSS and 
PIS), T3 (p < 0.01 for PSS and PIS), T4 (p < 0.01 
for PSS and p = 0.03 for PIS), T5 (p = 0.03 for PSS and PIS), 
T6 (p < 0.01 for PSS and p = 0.04 for PIS) and T7  (p < 0.01 
for PSS and p < 0.05 for PIS). Evolution of PSS and PIS 
scores can be observed in Fig. 1. Individual treatment 
success, as measured by the CBPI, has been defined as a 
reduction of ≥1 in PSS and ≥ 2 in PIS [37]. Treatment was 
successful in reducing PSS  in 8 animals  at T1 (53.3%), 11 
at T2 (73.3%), 10 at T3 (66.7%), 9 at 
T4 (60%) and 8 at T5-T7 (53.4%). In addition, scores im- 
proved for 10 animals at T1 (66.7%), 12 at T2 (80%), 11 
at T3 (73.3%), 10 at T4 (66.7%), 12 at T5 (80%) and 11 
at T6-T7 (73.3%). Considering PIS, treatment was a suc- 
cess in 4 animals at T1 (26.7%), 5 at T2 (33.3%), 4 at T3 
(26.7%), 3 at T4-T5 and T7 (20%,) and 4 at T6 (26.7%). 
Treatment also improved scores for 10 animals at T1 
(66.7%), 11 at T2-T3 (73.3%), 9 at T4 (60%), 10 at T5 
(66.7%) and 8 at T6-T7 (53.3%). 
With COI, significant differences were observed at T1 (p < 
0.01 for COI, Gait and QOL, p = 0.02 for Function and p < 
0.05 for Stiffness), T2 (p < 0.01 for Gait, p = 0.01 for COI, 
p = 0.02 for Function and  QOL,  and p = 0.04 for  Stiffness),  
T3  (p < 0.01  for  Function  and  Gait, p = 
0.01 for COI, and p = 0.02 for QOL), T4 (p = 0.03 for Gait ), 
T5 (p < 0.01 for COI, Function and Gait, and p = 
0.03 for Stiffness), T6 (p < 0.01 for Function  and Gait and 
p < 0.05 for COI) and T7 (p < 0.01 for Function and Gait and 
p = 0.01 for COI). Evolution of COI scores can be observed 
in Fig. 2. When considering individual re- sults, an 
improvement was observed in all dimensions in all 
evaluation points. Regarding stiffness, 7 animals re- corded 
better  scores  at T1 (46.7%), 6 at T2-T4 (40%)  and 7 at T5-
T7 (46.7%). Function scores improved in 6 animals at T1-T2 
(40%), 8 at T3-T4 (53.3%), 11 at T5 (73.3%), 9 at T6 (60%) 
and 8 at T7 (53.3%). Gait scores also improved in a large 
majority of animals, with better results  when comparing to 
baseline being  registered in  13 animals at T1 (86.7%) at T1, 
11 at T2 (73.3%), 10 at T3 (66.7%), 9 at T4 (60%) and 10 at 
T5-T7 (66.7%). Re- garding  QOL,  11  animals  recorded  
better  scores  at T1 











(73.3%),  7  at  T2  (46.7%),  9  at  T3  (60%),  7  at T4-T5 
(46.7%) and 6 at T6-T7 (40%). Several animals also showed 
better overall COI scores, namely 13 animals re- corded  
better  scores at T1 (86.7%), 10 at T2 (66.7%), 11 
at T3 (73.3%), 10 at T4-T6 (66.7%) and 11 at T7 (73.3%). 
No significant differences were registered in the LOAD 
scores when comparing each moment with T0. When 
considering individual results, an improvement in res ults 
was observed in 8 animals at T1 (53.3%), 10 at T2 (66.7%),  
11  at  T3  (73.3%),  12  at  T4  (80%),  11  at T5 
(73.3%) and 10 at T6-T7 (66.7%). 
Discussion 
OA is a common, incurable condition that, despite ex- 
tensive research, still has limited treatment options avail- 
able [10, 38, 39]. Its management is largely palliative, 
focussing on the alleviation of symptoms, mainly pain, and 
slowing down the progression of  the  disease  [40, 41]. The 
results show that the animals included in this sample 
experienced significant improvements for several months, as 
measured with several validated CMI. Since there is a 
similarity in neurophysiology paths across mammals, which 
















Fig. 1 Overall Canine Brief Pain Inventory scores, by section and instant. Box plots represent median, 25th and 75th percentiles, and whiskers 













Fig. 2 Canine Orthopedic Index scores, by domain and instant. Box plots represent median, 25th and 75th percentiles, and whiskers represent 
10th and 90th percentiles  









humans and animals in similar ways [42], it is reasonable 
that these results could also be observed in humans. 
Previous reports in dogs have described that a single IA 
autologous platelet therapy injection has resulted in clin- ical 
improvements for 12 weeks, in some cases without 
progression of radiographic signs [27, 31]. Our results show 
that significant improvements, when compared to baseline 
values, are still present at the 6-month evaluation point, a 
considerably longer period. 
The CBPI survey is often the test of choice to evaluate 
chronic pain in veterinary medicine [43, 44]. Treatment  
success in OA dogs has been set as a decrease in PSS ≥ 1 and 
in PIS ≥ 2 [37, 45]. Our results show that IA autolo- gous 
platelet therapy was able to significantly  reduce  pain levels 
in dogs, in some cases up to 6 months. Inter- estingly, it was 
also able to significantly reduce pain interference scores, in 
contrast to other treatment mo- dalities, such as NSAIDs and 
nutraceuticals [46]. 
LOAD was initially developed to assess dog with elbow OA, 
but was latter deemed as reliable to asses canine OA in 
general [16]. It has shown good reliability, just lower than 
peak vertical force generated by a force platform, al- though 
both results correlate. CBPI and LOAD results  have a 
moderate correlation [15, 16]. Even though im- provements 
in individual LOAD scores have been  ob- served, no 
significant differences when considering the entire sample 
was considered. A possible explanation to this fact may be 
in the nature of the dogs included in the sample and of the 
CMI itself. Many of the LOAD items focus on the level of 
activity of the dog, its willingness or ability to exercise. 
Since the animals included in this study are working dogs 
with a very high work drive, it is possible that the constant 
willingness of these animals to exercise, even in cases of 
overt lameness and pain, may have led to smaller variations 
in LOAD scores, when compared to other CMIs. This may  
also be true for PIS scores,  in addition to the fact that were 
low to begin with for many patients, making it harder to 
reach a significant reduction. Considering COI results, it was 
also interesting to ob- serve that significant improvements 
were observed up to the last evaluation point, specifically in 
overall score but also gait and function, two areas 
particularly affected by OA. Individual results in all 
dimensions improved for 
most animals, in many cases up to T7. 
Visual analogue scales are one of the techniques used to score 
pain and assess its severity, allowing to compare dif- ferent 
analgesic protocols. The Hudson Visual Analogue Scale 
(HVAS) has been deemed as repeatable and valid to assess the 
degree of mild to moderate lameness in dogs, compared with 
force plate analysis as a criterion- referenced standard [20]. In 
this study, significant varia- tions in HVAS scores were 
observed, up to T3, even  though individual results improved 
for a majority of ani- mals during the 6-month evaluation 
period. 
 
The obtained results give strength the concept that dif- 
ferent components of OA are captured by different CMI 
[16], and reinforce the advantage of using more than one 
of them when monitoring patients and response to treat- 
ment. As a whole, CMIs represent a patient-centred ap- 
proach, similar in human and veterinary medicine [10]. It is 
still unknown if respondents should be permitted or not to 
see previous answers. Previous reports show little dif- 
ference has been observed between both approaches, but 
allowing responders to see previous answers results in in- 
creased treatment effect sizes, which may increase clinical 
trial power [47]. In this study, in order to reduce bias, 
trainers were not allowed to see previous answers, as it  
might influence their responses, particularly with a long  
follow-up period. 
Increased lameness was observed in four dogs, which 
spontaneously  resolved within 48 h. This is in contrast  to 
what is observed with NSAIDs, often the first line of 
treatment but with well documented side-effects, par- 
ticularly when for long periods [48]. It was, however, in line 
with what has been described in humans, were platelet 
concentrates can produced local and transient side-effects, 
such as injection pain and local inflamma- tion, that take 2–
10 days to resolve [26, 49, 50]. No add- itional medication  
was administered to the  animals during the follow up 
period. 
This study presents some limitations, namely the lack of   a 
control group. Even though the validity of the results is 
reinforced by the use of several CMIs, further studies should 
include other evaluation method such as Force Plait Gait 
Analysis or Stance Analysis. Future studies should also 
evaluate the effect that both different cell composition and 
administration frequencies have on clinical results. 
 
Conclusions 
Autologous platelet therapy showed to be a promis ing  
treatment option for the treatment of OA, as this natur- 
ally occurring canine model experienced significant im- 
provements, up to the 6-month follow up moment. Further 
studies are required, particularly to determine the clinical 
effect of different administration frequencies. 
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Clinical and diagnostic imaging findings in police working dogs referred for hip osteoarthritis  
Abstract 
Background: Osteoar thr itis (OA) is the most commonly diagnosed joint disease in veterinary medicine, with at   least 
80%  of the cases of lameness and joint diseases in companion animals being classified as OA. Sporting and working 
animals are more predisposed to develop OA since they are exposed to chronic fatigue injuries, leading to bone and 
muscular tissue damage and failure, resulting in clinical signs. To character ize the clinical signs and diagnostic 
findings of Police working dogs presenting with bilateral hip OA at the time of diagnosis. Fifty animals were evaluated 
with a bodyweight ≥ 15 kg, be older than two years, and without any medication or nutritional supplements for ≥ 6 
weeks. 
Results: Weight distribution, joint range of motion at flexion and extension, thigh girth, digital thermography, and 
radiographic signs were collected. Data from different Clinical Metrology Instruments (CMI) were collected: Canine 
Brief Pain Inventory, Liverpool Osteoar thritis in Dogs, Canine Orthopedic Index, and the Hudson Visual Analogue 
Scale. Results were compared by breed, age, sex, and Orthopaedic Foundation for Animals hip grades with the 
Independent Samples T-Test, ANOVA followed by a Bonferroni post hoc test, and Pearson correlation coefficient, with 
p < 0.05. The sample included 30 males and 20 females, with a mean age of 6.5 ± 2.4 years and a bodyweight of 26.7 
± 5.2 kg. Animals with weight distribution below normal levels had significant variations of joint extension  and function 
scores. This evaluation was the only not correlated with at least one breed. Animals with caudolateral curvilinear 
osteophy te showed a poorer clinical presentation and worse scores in all considered CMIs. Radiographic changes 
correlated with age and corresponded to worse CMIs scores and weight d istribution. Dutch Shepherd  Dogs showed 
better CMI scores than the other considered breeds. 
Conclusions: Police working dogs presented with complaints related to hip OA at an early stage of the disease. Hip 
scores influenced clinical presentation, with moderate cases showing lower thigh girth and worse pain interference 
and severity, and function scores than mild cases. Patients with severe OA had lower thermographic evaluations 
than patients with moderate OA. Age was the primary variable influencing considered CMI scores. 
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Osteoarthritis (OA) is the most commonly diagn o sed 
joint disease in both human and veterinary medic i n e, 
with at least 80% of the cases of lameness and joint 
conditions in companion animals being classified as 
OA [1–3]. Risk factors include breed, neutering, high er 
body weight, and being older than eight years [4]. Police 
and working animals are at increased risk of 
developing an orthopaedic disease than compani o n 
animals , and OA is common amongst these anima l s 
[5]. Hip OA is commonly bilateral and a consequen c e 
of canine hip dysplasia, being influenced by many 
genes specific for every breed [6–9]. 
Pelvic radiographs are frequently performed in dogs to 
screen hip dysplasia and OA. They have been used for 
over four decades in several screening mechan i sm s 
worldwide. They are also a significant determination of 
clinical and experimental outcome [10–12]. The most 
common radiographic view is the ventrodorsal hip 
extended view. The ventrodorsal flexed view (also called 
frog-legged view) enhances the visibility of the crani a l 
and caudal aspects of the femoral head and neck. This 
feature helps assess the presence of circumferential fem- 
oral head osteophyte (CFHO) and caudolateral curvilin - 
ear osteophyte (CCO). These two features represent 
early radiographic signs that predict the development of 
the clinical signs of hip OA [9, 13–15]. 
Weight distribution and off-loading or limb favouring at 
stance is a commonly used subjective assessment dur- ing 
orthopaedic examination [16]. Animals with OA may 
not be overtly lame at a walk or a trot but exhibit subt l e 
shifts in body weight distribution at a stance due to pain 
or instability [17, 18]. Stance analysis has been report ed 
as sensitive for detecting lameness in dogs, with better  
results in large breed dogs [19]. Digital thermal imaging 
is a non-invasive, non-radiating, contact-free, physiolo g i c 
diagnostic tool that depends on heat result- ing from 
physiologic functions related to skin tempera t ur e 
control [20–22]. It has been described as useful in 
several species, from humans to horses and cats, but 
its clinical utility has rarely been studied in small 
animals [21, 23, 24]. Animals with OA present a vari et y 
of clinical signs, which can vary significantly. Muscul a r  
atrophy is a consistent finding and is evident within a few 
weeks of OA onset [8, 25]. Restricted range of motion 
(ROM), including flexion and extension, is usually 
present [8]. The evaluation of asymmetry, assess- ment of 
muscle atrophy level, measurement of static weigh t -
bearing, and ROM measurement have been descri bed 
as the most valid and sensitive physiothera- peut i c 
evaluation methods [26, 27]. 
Pain and functional ability are also important parame- 
ters in the evaluation of OA treatment efficacy [28]. Pain is 
a multi-dimensional experience with sensory, evaluative, 
and affective components [29]. Several clinical metrology 
instruments (CMI) have been developed to measure out- 
come assessments to approach these different dimensions. In 
dogs, CMIs are typically completed by a proxy. The ones 
developed and validated for dogs are the Canine Brief Pain 
Inventory (CBPI) and the Liverpool Osteoarthritis in Dogs 
(LOAD) [30–33]. The CBPI allows to rate a dog’s pain 
and is divided into two sections, a pain severity score (PSS) 
that assesses the magnitude of the animal pain, and a pain 
interference score (PIS) that evaluates the degree to which 
pain affects daily activities [34]. The Canine Ortho- paedic 
Index (COI) was developed for clinical research in canine 
orthopedics or individual outcomes in four domains: 
stiffness, gait, function, and quality of life. It has been 
shown to have excellent reliability and validity [35]. The 
Hudson Visual Analogue Scale (HVAS) has been 
deemed repeatable and valid to assess the degree of mild 
to moderate lameness in dogs, compared with force plate 
analysis as a criterion-referenced standard [36]. By collect- 
ing information from different CMIs, it possible to 
characterize the disease in all dimensions, a patient’s level 
of pain, the degree of lameness, the ability to enjoy life, 
and perform daily activities. It also allows characterizi n g 
the effect of a treatment in each of those dimensions. 
This study aimed to characterize the clinical signs and 
diagnostic findings of Police working dogs presen t i n g 
with bilateral hip OA. We hypothesized that differen c es 
occur when comparing breeds commonly used as Police 
working dogs. 
 
  Results 
The sample included 50 Police working dogs, of both 
genders (all intact, 30 males and 20 females), with a 
mean age of 6.5 ± 2.4 years, bodyweight of 26.7 ± 5.2 kg, 
and a body condition score of 4 (70%) or 5/9 (30%). Four 
breeds were represented: German Shepherd Dogs (GSD, n 
= 17), Belgian Malinois Shepherd Dogs (BM, n = 15), 
Labrador Retriever (LR, n = 10), and Dutch Shepherd 
Dog (DSD, n = 8). Fifteen patients did not meet the in- 
clusion criteria. 
Considering OFA hip grading, 35 animals were classi - 
fied as mild (70%), 10 as moderate (20%), and 5 as severe 
(10%). Comparing animals classified as mild and moder- 
ate, significant differences were observed in thigh girth 
(p = 0.01), frequency of CCO in the frog-legged view 
(p < 0.01), and scores of PIS (p = 0.01), PSS (p = 0.02) and 
Function (p = 0.01), with moderate cases presenting 
worse evaluations. With digital thermography, signifi cant 
differences were observed comparing moderate and 
severe OA in the dorsoventral (p = 0.03, 25.0 ± 1.8 and 
24.0 ± 1.7, respectively) and lateral views (p = 0.04, 
26.1 ± 2.5 and 25.5 ± 2.4, respectively). 
Measured values of overall age, body weight, weigh t 
distribution, digital thermography, thigh girth, and joint 







range of motion, and divided by breed and sex, are 
presented in Table 1. Comparing males to females, sig- 
nificant differences were observed in weight and thigh 
girth (p < 0.01), with male dogs having higher values. 
Comparing breeds, GSD were significantly heavier 
than BM (p < 0.01) and LR (p < 0.01) and also had sig- 
nificantly higher thigh girth than BM (p < 0.01), LR 
(p < 0.01), and DSD (p = 0.02). LR were significantly 
older and had lower thigh girth than GSD (p < 0.01 
for both), BM (p < 0.01 and p = 0.05, respectively), and 
DSD (p < 0.01 for both). DSD were significantly heav- 
ier than BM (p < 0.01). DSD also had higher measured 
values with digital thermography on the dorsovent ra l 
view than GSD (p = 0.02 for both) and on the lateral 
view than BM (p = 0.04). Thigh girth showed a correl- 
ation with breed (r=-0.34, p < 0.01), weight (r=-0.47, p 
< 0.01) and sex (r=-0.72, p < 0.01). Age correlated 
with joint extension (r=-0.31, p < 0.01), and thermo- 
graphic measurem ent on the dorsoventral view corre- 
lated with breed (r=-0.30, p < 0.01). The weight 
distribution of both pelvic limbs correlated with joint ex- 
tension (r=-0.36, p < 0.01), while considering the left pelvic 
limb, a higher value was observed (r=-0.43, p < 0.01). Vari- 
ables considered in multiple regression statistically signifi- 
cantly predicted thigh girth F(5,84) = 26.33, p = 0.000, 
R2 = 0.610, with breed (p < 0.01), bodyweight (p < 0.01) , 
and OFA hip score (p = 0.01) adding statistically signi fi - 
cantly to the prediction. 
 
With a cut-off of weight distribution of individual limbs 
set at 18%, significant variations were observed on joint 
extension (p = 0.02) and the frequency of an irregu l a r, 
misshapen femoral head (p = 0.03). At the 20% cut-of f 
point, besides the differences in joint extension (p < 
0.01) and on the frequency of an irregular, misshap en 
femoral head (p = 0.02), significant variations were 
observed in joint flexion  (p < 0.01) and HVAS (p = 0.03) . 
For both pelvic limbs with the 36 and 40% cut-of f s , 
significant variations were observed in joint exten si o n 
(p < 0.01), function (p = 0.03), presence of CCO (p = 0.03 
at 40), and of a misshapen femoral head (p = 0.02). 
Absolute frequencies and percentages of radiographi c 
findings, presented by overall, by breed, and by sex, in 
the ventrodorsal and frog-leg views, are outlined in 
Table 2. Each joint was analyzed individually, for a total 
of 100 joints. Considering specific radiographic signs, 
patients with irregular wear on the femoral head were 
older (p < 0.01), with worse weight distribution (p < 0.01) 
and CMI scores (p < 0.01). Animals with a flattened or 
Table 1 Mean values (± standard deviation) of overall weight, age, stance analysis (per pelv ic limb and of the combination of both), 
thermography (ventrodorsal and lateral  v iews),  thigh  girth  and  range  of  motion  (extension  and  flex ion)  measurements,  and  by 
breed, sex and OFA score, of left and right pelv ic limbs 
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29.9 ± 6.3    5.7 ± 1.8    19 ± 0.6 38.4 ± 4.3 24.5 ± 1.7 25.6 ± 2.5 32.2 ± 2.7    151.3 ± 6.9 56.2 ±3.6 
 
24.3 ± 4.1    6.5 ± 2.5    18.3 ± 5.6 37.6 ± 7.6 24.6 ± 1.5 27.6 ± 2.2 29.9 ± 2.4    148.6 ± 6.3 55.2 ±5.4 
Labrador Retriev er   24.3 ± 2.5   8.7 ± 2.4    19.3 ± 4.1 38.5 ± 5.6 25.1 ± 1.6 26.6 ± 2.5 28.5 ± 2.3 147.8 ± 12.4 55.1 ±3.5 
Dutch Shepherd 
Dog 
27.5 ± 3.9    5.3 ± 1.3    18.2 ± 3.5 36.4 ± 4.6 26.0 ± 2.5 26.9 ± 2.2 30.4 ± 2.0    152.0 ± 8.1 57.5 ±4.2 
Male 29.0 ± 5.4    6.2 ± 2.3    19.2 ± 5.1 38.3 ± 6.4 24.8 ± 1.9 25.9 ± 2.7 31.5 ± 2.7    150.1 ± 6.4 56.1 ±4.3 
Female 23.5 ± 2.8   6.9 ± 2.8   18.7 ± 3.2 37.2 ± 4.6 24.9 ± 1.7 26.1 ± 2.1 28.9 ± 2.1   149.6 ± 4.3 55.5 ±4.3 
Mild 27.4 ± 5.3    6.1 ± 2.1    18.9 ± 4.2 38.1 ± 4.1 24.9 ± 1.5 26.0 ± 2.1 31.2 ± 2.9    150.9 ± 7.4 55.8 ±4.1 
Moderate 25.4 ± 3.7   7.0 ± 3.4   18.4 ± 5.6 36.8 ± 6.6 25.0 ± 1.8 26.1 ± 2.5 29.7 ± 2.5 146.7 ± 11.7     56.1 ±3.1 
Sev ere 27.1 ± 4.9    7.6 ± 1.6    18.2 ± 1.5 36.4 ± 2.3 24.0 ± 1.7 25.5 ± 2.4 29.1 ± 2.6    144.9 ± 6.2 55.0 ±4.3 




Table 2 Overall, by breed and by sex, absolute frequencies and percentag es within group of radiographic findings in the                                                            
ventrodorsal and frog leg v iews, of hip joints. For each animal, both joints were considered, representing one hundred joints 
Radiographic finding Overall GSD   BM   LR   DSD   Male   Female  
 Total/ 
% 
Total %  Total %  Total %  Total %  Total %  Total % 
Irregular w ear on the femoral head, making it misshapen 95 34 100,  30 100,  17 85,0  16 100,  28 46,7  20 50,0 
and w ith a loss of its rounded appearance   0   0      0       
Flattened or shallow  acetabulum, w ith irregular outline 60 23 67,6  15 50,0  13 65,0  9 56,3  35 58,3  25 62,5 
Caudolateral curv ilinear osteophy te (CCO) 35 18 52,9  13 43,3  4 20,0  4 25,0  24 40,0  15 37,5 
New  bone formation on the acetabulum and on femoral 
head and neck 
86 31 91,2  25 83,3  19 95,0  15 93,8  51 85,0  37 92,5 
The angle formed at the cranial effectiv e acetabular rim is 77 26 76,5  23 76,7  20 100,  12 75,0  45 75,0  34 85,0 
w orn aw ay          0          
Subchondral bone sclerosis along the cranial acetabular 98 34 100,  30 100,  20 100,  16 100,  60 100,  40 100, 
edge   0   0   0   0   0   0 
Circumferential femoral head osteophy te (CFHO) 28 13 38,2  10 33,3  6 30,0  1 6,3  18 30,0  14 35,0 
CCO on the Frog Leg v iew  33 14 41,2  12 40,0  8 40,0  5 31,3  20 33,3  17 42,5 
CFHO on the Frog Leg v iew  88 32 94,1  25 83,3  19 95,0  16 100,  55 91,7  35 87,5 
            0       
Legend: GSD German Shepherd Dog, BM Belgian Malinois Shepherd Dog, LR Labrador Retriever, DSD Dutch Shepherd Dog 
 
shallow acetabulum, with an irregular outline, had lower 
weight distribution values (p = 0.03). Animals with CCO, 
on both the ventrodorsal and frog-legged views, were 
older (p < 0.01), had lower weight distribution values 
(p = 0.04), and had worse CMI scores (for all, p < 0.01). 
Those with new bone formation on the acetabulum and 
femoral head and neck were older (p < 0,01) and had 
worse PSS, Function, quality of life (p < 0.01), and PIS 
(p > 0.05) scores. Animals with a worn away angle at the 
cranial effective acetabular rim had lower thigh girth (p 
< 0.01) and joint flexion (p = 0.04). When CFHO was 
observable on the ventrodorsal, animals were heavi er 
(p = 0.04) and had worse stiffness, function (p = 0.02), 
Gait, COI (p < 0.01), quality of life (p = 0.03) scores. The 
presence of CCO on the ventrodorsal was correlated 
with its presence on the frog-legged view (r = 0.51, p 
< 0.01). On the frog-legged view, the presence of 
CCO correlated with age (r = 0.47, p < 0.01) and joint 
extension (r=-0.51, p < 0.01). 
 
Overall scores, by breed and sex, of the considered 
CMI, are presented in Table 3. While no significant dif- 
ferences were observed between male and female ani- 
mals, the opposite was observed between breeds. GSD 
had lower function scores than LR (p = 0.04), while DSD 
had better results when compared to other breeds with 
HVAS (p < 0.01 for GSD and p = 0.02 for LR), LOAD 
(p = 0.02 for GSD, and p = 0.02 for BM and p < 0.01 for 
Table 3 Median (range) for CBPI, HVAS, LOAD and COI, by breed, sex and OFA score, of different Clinical Metrology Instruments 
 CBPI  HVAS  LOAD  COI  
PIS PSS      Stiffness Function Gait QOL Total 
(0–10) (0–10)  (0–10)  (0–52)  (0–16) (0–16) (0–20) (0–12) (0–64) 
Overall 2.9 (1.9–9.1) 2.8 (2.1-9.0)  6.2 (2.3–8.2)  10 (1–39)  3 (1–12) 2 (1–16) 4 (1–17) 3 (-12) 13 (1–54) 
German Shepherd Dog 3.0 (1.8–9.4) 3.1 (1.3-9)  6.4 (2.1-8)  9 (1–39)  4 (1–11) 2 (1–11) 6 (1–17) 3 (0–4) 18 (3–50) 
Belgian Malinois Shepherd Dog 2.5 (1.2-6.0) 2.4 (1.8–6.0)  7.0 (4.8–7.7)  8 (3–39)  3.5 (1–12) 1 (0–16) 3.5 (1–17) 4 (1–9) 9 (3–54) 
Labrador Retriev er 2.7 (1.0-8.2) 2.8 (1.5–7.8)  6.9 (4.1–7.9)  16 (4–36)  3.5 (1–10) 4.5 (0–10) 6 (1–15) 4 (1–12) 16.5 (2–47) 
Dutch Shepherd Dog 2.2 (1.0-6.2) 2.0 (1.0-7.3)  7.3 (5.1–8.3)  5.5 (1–17)  2 (0–4) 0.5 (0–4) 1 (0–9) 2.5 (0–7) 5 (0–23) 
Male 2.7 (1.2–8.6) 2.5 (1.3–7.3)  6.2 (4.3–8.3)  9.5 (1–39)  4 (0–12) 2 (0–16) 4.5 (1–17) 4 (0–9) 13.5 (4–54) 
Female 2.3 (1.0-9.4) 2.9 (1.5-9.0)  6.1 (2.1–8.3)  10 (1–39)  1 (1–11) 3 (0–12) 4 (1–17) 3 (0–12) 11 (2–54) 
Mild 6.5 (1.5–6.2) 2.1 (1.4–6.3)  6.3 (4.-8.3)  10.5 (1–36)  3 (0–12) 2.5 (0–16) 4.5 (0–17) 3.5 (0–12) 13 (0–47) 
Moderate 5..0 (1.0-8.6) 5.0 (1.0-7.8)  5.7 (4.1–7.7)  16 (1–36)  4 (1–12) 4.5 (0–16) 6.6 (1–17) 5.0 (0–12) 20 (3–50) 
Sev ere 5.0 (1.0-9.4) 5.0 (1.0–9.0)  5.7 (2.1–7.9)  23 (1–39)  5 (1–12) 6 (0–16) 8 (1–17) 6.0 (0–12) 25 (3–54) 
Legend: GSD German Shepherd Dog, BM Belgian Malinois Shepherd Dog, LR Labrador Retriever, DSD Dutch Shepherd Dog, CBPI Canine Brief Pain  Inventory,  PIS  Pain 
Interference Score, PSS Pain Severity Score, HVAS Hudson Visual Analogue Scale, LOAD Liverpool Osteoarthritis in Dogs, COI Canine Orthopedic Index, QOL Quality of Life 







LR), stiffness (p = 0.05 for GSD, and p = 0.01 for BM and 
LR), function (p < 0.01 for GSD, BM and LR), Gait (p < 0.01 
for GSD and LR, and p = 0.02 for BM) and COI scores 
(p = 0.02 for GSD, and p < 0.02 for BM and LR). Age 
was the considered variable adding statisti- cally 
significance (p < 0.01) for the prediction of PSS F(5,82) 
= 2.498, p = 0.04, PIS F(5,82) = 3.177, p = 0.01, 
R2 = 0.162, LOAD F(5,82) = 7.873, p < 0.01, R2 = 0.324, 
stiffness F(5,82) = 4.637, p < 0.01, R2 = 0.220, functi o n 
F(5,82) = 11.160, p < 0.01, R2 = 0.405, gait F(5,82) = 
4.074, p < 0.01, R2 = 0.199, QOL F(5,82) = 3.691, p < 0.01, 
R2 = 0.184 and COI F(5,82) = 6.046, p < 0.01, R2 = 0.269. 
Besides age, only the OFA hip score contributed to the 
prediction of PIS (p = 0.03). Correlation of age, joint 
extension, and CCO on a VD are presented in Table 4. 
Comparing animals at several cut-off points for PSS 
(scores of 4, 6, and 8), the same significant differen ce s 
being observed consistently, with animals above the cut- 
off having worse joint extension (p < 0.01) and higher fre- 
quency of CCO on the ventrodorsal and frog-legged views (p 
< 0.01). When comparing the same cut-offs for PIS, at the 
4 and 6 cut-offs, animals had to have a worse joint 
extension (p < 0.01) and higher frequency of CCO on the 
ventrodorsal and frog-legged views (p < 0.01). On the 8 
cut-off point, the occurrence of all other radiograph i c 
signs was significantly higher (p < 0.01), and weight distri- 
bution on the left pelvic limb and both limbs was worse 
(p < 0.01). 
 
 
  Discussion 
Hip OA is very common in large breeds such as Germ an 
Shepherd Dogs and Labrador. In working dogs, it has a 
toll on performance and quality of life [37, 38]. To our 
knowledge, this is the first study to describe the clinica l 
presentation of Police working dogs first diagnosed with 
hip OA. It presents a wide variety of physical exami n - 
ation results and several diagnostics to provide an in- 
depth description of affected animals. 
Radiographic examination is a staple in OA evaluati on . 
Still, it is also well established that radiographic sign s 
develop later than the structural changes associated with 
OA, and clinical symptoms do not always correlate with 
radiographic signs [9, 39, 40]. CFHO and CCO are con- 
sidered the radiographic predictors of future OA devel- 
opment [9]. Animals presenting with these radiographi c 
signs had a significantly worse clinical presentation, par- 
ticularly with CCO, with animals showing worse results 
in all considered CMIs scores, ranging from pain to 
lameness level and functionality. If the presence of CCO, 
or other radiographic findings, influences response to 
treatment is still to be determined. Several differen c es 
were found between OFA grades, specifically consideri n g 
pain and function scores and thermographic evaluati on . 
The sequence of these differences may occur alongsi d e 
the course of OA. From mild to moderate, structural 
changes occur and are detected on radiographic examin- 
ation, specifically CCO, one of the predictive signs of 
OA developm ent [13–15]. These structural changes are 
then reflected in clinical signs, such as muscular atrophy 
and pain, which takes a toll on daily activities . With se- 
vere OA, a corresponding loss of functional tissue and 
muscle masses surrounding the joint occurs [21, 41]. 
These facts may account for the decrease in thermo- 
graphic evaluation observed in severe hip grades com- 
pared to moderate hip grades. OFA hip was also one of 
the variables, alongside age, adding statistically signifi - 
cantly to the prediction of PIS scores. 
Some of the differences observed during the physical 
examination, as the fact that GSD were significan tl y 
heavier than other breeds (such as BM and LR), also 
having greater thigh muscle masses, were expected. This 
relation also applies to male dogs being heavier than fe- 
males and with higher thigh girth. Multiple regress i o n 
analysis showed the effect of breed and bodyweight in 
predicting thigh girth, confirming these findings. It also 
showed that OFA hip significantly influenced thigh girth, 
making it a useful measure in evaluating hip OA. These 
variables combined may lead to a positive correlation 
 
Table 4 Correlation of age, joint extension and presence of caudolateral curv ilinear osteophyte (CCO) on a ventrodorsal v iew with 
different Clinical Metrology Instruments 
Measure  Score  
  PSS PIS LOAD COI Stiffness Function Gait QOL 
Age rs 0,56 -0,32 0,5 0,48 0,43 0,59 0,38 0,40 
 Sig. 0,10 < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* 
Joint ex tension rs 0,33 0,41 0,44 0,5 0,48 0,49 0,44 0,40 
 Sig. < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* < 0,01* 
CCO rs -0,45 -0,35 0,42 0,33 -0,37 0,07 -0,36 -0,31 
 Sig. < 0,01* < 0,01* 0,23 0,56 < 0,01* 0,12 < 0,01* < 0,01* 
Legend: PIS Pain Interference Score, PSS Pain Severity Score, LOAD Liverpool Osteoarthritis in Dogs, COI Canine Orthopedic Index, QOL Quality of Life. * indicates 
significant difference 







observed between thigh girth, weight, sex, and breed . 
The role that weight exerts in the developm ent of hip 
dysplasia, and consequent hip OA, has been intensive l y 
studied, with heavier dogs showing to be more prone to 
develop OA earlier in life [42, 43]. This role is parti cu - 
larly true in dogs with higher body condition scores [4]. 
All of the animals included in this sample had either a 4 
or 5 body condition score. Still, the fact that male dogs 
tend to be heavier than females (a tendency confi rm ed 
in this study) may place them under greater risk of 
developing OA and may account for the higher number 
of males observed. However, the OFA hip score was not 
predicted based on breed, age, sex, or bodyweight, so 
future studies should clarify these facts. Hip OA, when 
compared with OA in other joints, seems to be better 
tolerated by animals. This ability is mainly due to the 
higher amount of muscle masses surrounding this joint 
[8]. The quadriceps muscle group is particularly pron e 
to atrophy secondary to decreased limb function. There- 
fore, measuring thigh girth helps make an initial assess- 
ment and measure patient evolution and treat m en t 
outcome [44]. In this study, we described thigh girth 
measurements of dogs initially diagnosed with hip OA, 
specifically of the breeds most commonly used as work- 
ing and sporting dogs. However, it would be of interest 
to also have healthy subjects’ values to compare both 
groups. 
The evaluation of joint ROM is a standard measure- 
ment, with OA joints usually exhibiting ROM rest r i c - 
tions. In the hip joint, specifically, a ROM decrease and 
particularly during extension, can also be present, even 
though this is not a universal finding [33, 39]. It showed a 
correlation with age, which may be attributed to dis- 
ease progression since some of the older animals had 
worse OFA scores. Normal ROM of the hip joint for 
some breeds have been described. In military worki n g 
GSD, a normal ROM of 44°±6 at flexion and 155°±6 at 
extension, and in LR of 50°±2 at flexion and 162°±3 at 
extension have been reported [45–47]. Our study mea- 
sured lower values in both breeds, which could be 
expected due to OA. Still, it would be interesting to have a 
group of disease-free dogs to compare these values and 
describe normal values in the other two conside red 
breeds. 
The mean age of animals included in this sample was 
6.5 years, which is earlier than the commonly considered 
risk factor for OA of > 8 years [4]. GSD and DSD were 
even younger than 6.5 years, with only LR being beyo n d 
this point and significantly older than the other breed s. 
Multiple regression analysis showed that age was the pri- 
mary variable adding statistically significantly to CMI 
scores’ prediction. All of the animals included in the sample 
were screened before starting training and active work, so 
the earlier diagnosis may be attributed to the high demand 
and stress that these animals’ musculoskeletal structures 
are under and the subsequent toll on performance [48]. 
Since these animals are active working dogs, it is possibl e 
that the disease actually develops or is simply detected earl- 
ier than in other dogs. The reason leading to a later diagno- 
sis of LR is not clear. It may be due to breed characteristi cs , 
with LR being less explosive and less driven than BM, for 
example. Also, a less physically demanding mission of these 
dogs (most were product detection dogs) compared with 
the remaining animals included in the sample (mostly 
involved in search and rescue and use of force activiti es) 
might be an important factor to consider. 
Normal weight distribution on the weight distribution 
plate is the same as for pressure-sensitive walkway total 
pressure index—30/30/20/20 (left thoracic limb/right 
thoracic limb/left pelvic limb/right pelvic limb) [49, 50]. 
For the evolution of hip OA, bodyweight distribution at 
a stance may even be a superior measurement to VI and 
PVF since dogs present different standing postures to 
increase acetabular coverage. Sensitivity and specificity 
seem to be higher with a cut-off point of 18% for pelvic 
limbs [8, 18, 51]. We considered both the 20% and 18% 
cut-off, with more differences being found at 20%. Mean 
values were below the 20% value but showed some dis- 
persion. Since included animals had bilateral disease, it 
is quite possible that at any given point, they would be 
overloading one side to protect the other, leading to very 
different weight distribution values when comparing 
contralateral limbs in the same animal. Dogs presenting 
with pelvic limb-lameness tend to distribute weight 
more side-to-side than pelvic-to-thoracic compensation 
[52, 53]. For that reason, we also analyzed weight distri- 
bution for both pelvic limbs, with two different cut-off 
points. This analysis may be an interesting approach 
since it accounted for significant joint extension and 
function scores and CCO variations. It would be inter- 
esting to see the importance of these cut-off points in 
evaluating response to treatment. It should be the sub- 
ject of further research, mainly since it did not show 
associated breed variations. It has been described that 
male dogs tend to carry more weight on the thoracic 
limbs naturally and may exhibit fewer improvements in 
response to treatment [17]. No significant variation com- 
paring males and females in weight distribution was 
found, but future studies should evaluate this hypothesis. 
Canine thermal imaging has been documented only 
recently. Still, a growing interest in this modality has led 
to an increase in the number of studies evaluating its 
use to assess the canine hip, stifle, elbow, and interverte- 
bral disc [24, 54–58]. To our knowledge, this is the first 
study describing values for dogs with hip OA. The coat’s 
type and color are variables that must be taken into 
account, and its influence documented [55, 56, 59, 60]. 
Our results seem to confirm this fact since DSD showed 







significantly different values than other breeds, and this 
may be due to its brindle coat, in opposition to lighter 
coats in the other breeds. In humans OA studi e s , 
increased temperatures have been related to even slight 
degenerative changes and low temperatures in more se- 
vere disease cases [61]. In this study, this effect was not 
found, but it may be due to the coat variation effect . 
Still, its value in evaluating response to treatment has to 
be determined. 
CMIs represent a patient-centred approach that, simi- lar 
to what happens in human medicine, has been incor- 
porated in veterinary assessments in different speci es  
[62–64]. They may also capture a different dimension of 
OA since owners may often be more focused on the 
dog’s ability to perform daily activities, rather than an 
increase or decrease of ROM or use of a single limb at a 
walk or trot [65, 66]. While no differences were observed 
when comparing animals by sex, several differences were 
observed between breeds and reported values for the 
same breeds’ pet dogs. One of the reasons for this may 
be the nature of the specific mission of the animals. 
When involved in a more physically challenging task, it 
is more likely that complaints or limitations arise. 
Another reason may be age (which correlated with sev- 
eral scores), since older animals tend to be more experi - 
enced and able to manage the effort, making them less 
prone to injury [67]. Also, since these animals are 
selected based on working predisposition, they presen t 
high drive, which may mask some complaints and lead, 
for example, to relatively low PSS. We also aimed to see if 
different cut-off points of pain scores (measure with the 
PIS and PSS) presented significant differences. The main 
finding was that, as could be expected, animals with 
higher PIS scores had significantly lower weigh t 
distribution, but also had higher frequencies of all radio- 
graphic signs. 
This study presents some limitations, namely the lack of 
a control group with non-lame dogs. This limitation is 
mainly related to the sample’s convenience nature, 
comprised of dogs specifically presenting for treatment . 
Some of the previous report results of similar evalua - 
tions were conducted in the same breeds included in our 
sample, which is still useful. Since data was only col- 
lected in a single moment, we cannot comment on the 
interest of each of the findings for the prognosis or 
treatment monitoring of OA, which should be addressed 
in future studies. 
 
  Conclusions 
To our knowledge, this study first describes several clin- 
ical and radiographic findings of working dogs of differ- 
ent breeds to hip OA. Police working dogs presented 
complaints related to hip OA at an early stage of the dis- 
ease and a younger age than non-working dogs. LR were 
significantly older than other considered breeds. Hip 
scores influenced clinical presentation, with modera t e 
cases showing lower thigh girth and worse PIS, PSS, and 
function scores than mild cases. Patients with severe OA 
had lower thermographic evaluations than patients with 
moderate OA. Age was the primary variable influen ci n g 
considered CMI scores. 
 
  Methods 
The sample comprised fifty (N = 50) Police working dogs 
with bilateral hip OA. It was a convenience sample, 
composed of patients presented at the Clínica Veteri - 
nária de Cães (Portuguese Gendarmerie Canine Clinic) 
to undergo hip OA treatment after initial diagnosis. Sub- 
sequent treatment was randomly determined, as the ani- 
mals took part in a study evaluating intra-articular 
treatments for OA. Patients were active police worki n g 
dogs of the Guarda Nacional Republicana (Portugue se 
Gendarmerie Canine Unit). The diagnosis was based on 
the dog’s history, trainer complaints (difficulty risin g, 
jumping and maintaining obedience positions, stiffness 
and decreased overall perform ance), physical exami n - 
ation (pain during joint mobilization, stiffness and 
reduced range of motion), and radiographic findin g s 
(OFA hip scores of mild, moderate or severe) consist e nt 
with bilateral hip OA. Inclusion criteria were: body- 
weight ≥ 15 kg, animal older than 2 years and witho ut 
any medication or nutritional supplements for 6 weeks 
or more before the beginning of the study. Animals sus- 
pected or with any other orthopaedic or concomi t ant 
disease (ruled out through physical examination, 
complete blood count, and serum chemistry profile) and 
not tolerant of data collection were excluded. All evalua - 
tions were perform ed at the same moment by the same 
researcher, which had extensive experience in the con- 




For the collection of digital thermography images, dogs 
were allowed to walk around in a large, plain wall room 
and adjust to room temperature (set at 21 °C) in a 
relaxed way for approximately 30 min before imagi n g. 
They were then positioned in an upright standing pos- 
ition, as symmetrically as possible, without the trainer or 
veterinarian touching its torso. A dorsoventral and two 
lateral images (one for each limb) were obtained from 
every animal. Every dorsoventral thermographic image 
included the last lumbar vertebra area to the first coccy- 
geal vertebra at a minimum, at a distance of 60 cm 
(Fig. 1) [23]. Lateral views had the greater trochanter in 
the centre of the image, also at a distance of 60 cm. All 
images were captured with a FLIR Therm aCAM E25® 
camera model and kept when the anatomical landmarks 






were included, and the image was steady enough to de- 
termine their location. The free software Tools (FLIR 
Systems, Inc) was used to analyse the images, with a 
rainbow color pallet. Temperature boxes of equal size 
were placed on the hip joint’s anatomical area on both 





Stance analysis was conducted with a weight distribut io n 
platform (Companion Stance Analyzer; LiteCure LLC®, 
Newark, Delaware, United States). According to the 
manufacturer’s guidelines, it was placed in the centre of a 
room, at least 1 meter from the walls. It was calibrated at 
the beginning of each day, and zeroed before each 
data collection. Animals were encouraged to stand on to 
the weight distribution platform. Its trainer helped 
ensure the patients placed one foot on each quadrant of 
the platform while maintaining a natural stance with the 
centre of gravity and stability (measured by the platform ) 
near the platform’s middle. Gentle restraint was used to 
keep the patient’s head in a natural, forward-facing pos- 
ition when needed. For all animals, at least 20 measur e- 
ments were performed, and the mean value was 
determined. Normal weight distribution for each pelv i c 
limb was considered 20% of the total weight [18]. Since 
all animals included had bilateral OA, weight distri b u - 
tion on both pelvic limbs was also considered and set at 
40% (20% left pelvic limb + 20% right pelvic limb). 
 
Clinical Assessment 
Determination of thigh girth was made with a Gullick II 
measuring tape at a distance of 70% thigh length, mea- 
sured from the tip of the greater trochanter, with the leg 
in an extended position while in lateral recumbency, and 
the dog relaxed [44]. With the patient in the same 
position, hip joint ROM was obtained with a goniom et e r 
(Veterinary Instrumentation, United Kingdom) at exten- 
sion and flexion, with a flexed stifle [68]. These measure- 




Radiographic studies were conducted under light 
sedation, using a combination of medetomidine  (0.01 
mg/kg) and butorphanol (0.1 mg/kg), given intra- 
venously. A ventrodorsal extended legs view and a frog- 
legged view were obtained. Hips were graded accordi n g 
to the OFA hip grading scoring scheme[69] by the 
researcher, blinded to the patient’s identification. A mild 
score corresponded to a partially subluxated femo ra l 
head, causing an incongruent and widened joint space, 
with a shallow acetabulum, only partially covering the 
femoral head. In young dogs (24 to 36 months), OA 
lesions may not be present. Moderate grades were attrib- 
uted when significant subluxation was present, and the 
femoral head was barely seated into a shallow acetabu - 
lum. Secondary remodeling along the femoral neck and 
head, acetabular osteophytes, and subchondral sclero si s 
were present. In severe cases, the femoral head was 
partly or completely out of a shallow acetabulum, with 
extensive secondary arthritic bone changes along the 
femoral head and neck head, acetabular rim chan ges, 
and large amounts of abnormal bone pattern changes. A 
full description of the OFA hip grading scheme is avail- 
able online (https://www.ofa.org/diseases/hip-dysplasi a/ 
grades). The presence of specific radiographic signs was 
also recorded: irregular wear on the femoral head, mak- 
ing it misshapen and with a loss of its rounded appea r- 
ance; a flattened or shallow acetabulum, with irregu l a r 
outline; CCO; new bone formation on the acetab u l um 
and femoral head and neck; a worn away angle form ed 
















sclerosis along the cranial acetabular edge; and CFHO 
[9, 39, 70, 71]. In the frog-legged view, the presence of 
CCO and CFHO was also recorded. 
 
Clinical metrology instruments 
At the evaluation moment, an online copy prepared for 
the effect of the HVAS, CBPI, COI, and LOAD was 
completed by the trainers. The same trainer compl et ed 
all CMIs for each dog. 
 
Statistical Analysis 
Normality was assessed with a Shapiro-Wilk test. Each 
measured parameter was compared with an Indepen den t 
Samples T-Test (when two groups were considered, like 
sex) or ANOVA, followed by a Bonferroni post hoc test 
for multiple comparisons (when more than two groups 
were considered). CMI scores were compared with a 
Wilcoxon signed-rank test. Different score cut-off points 
(4, 6, and 8) were analyzed for PIS and PSS. 20% and 
18%[18] pelvic limb percentages cut-off points were con- 
sidered for weight distribution. Since hip OA is often 
bilateral, results for the combination of both pelvic limbs 
were also analyzed, at 36% (18% left pelvic limb + 18% 
right pelvic limb) and 40% (20% left pelvic limb + 20% 
right pelvic limb). The correlation between paramet ers  
was assessed with the Pearson correlation coeffici en t . 
Multiple regression was run to predict evaluated param- 
eters from age, sex, breed, body weight, and OFA hip 
score. All results were analyzed with IBM SPSS Statistics 
version 20, and a significance level of p < 0.05 was set. 
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Objective 
This study aimed to compare the symmetry of clinical and radiographic signs of right and left 
pelvic limbs of dogs with bilateral hip osteoarthritis (OA) and evaluate the association of 
physical findings and radiographic abnormalities. 
 
Patients and methods 
One hundred pelvic limbs of police working dogs with bilateral hip OA were evaluated, fol- lowing 
a screening program. Weight distribution, joint range of motion at flexion and exten- sion, thigh 
girth, and radiographic signs were recorded and compared with the results of the contralateral 
limb and by breed, age, and sex with the Paired Samples T-Test and Pearson correlation 
coefficient, with p<0.05. 
 
Results 
The sample mean age was 6.5±2.2 years, and the bodyweight of 26.7±5.3kg. No significant 
differences were observed when comparing weight distribution, joint range of motion, and thigh 
girth of left and right limbs. Weight distribution and age showed a statistically significant 
correlation with joint extension. The right limbs showed a significantly higher frequency of 
circumferential femoral head osteophyte (CFHO) regarding radiographic signs. Limbs with 
CFHO or caudolateral curvilinear osteophyte had significantly larger joint flexion angle (p = 
0.02) and smaller extension angle (p<0.01), respectively, compared to those that did not. 




Clinical and radiographic signs occur symmetrically in naturally occurring hip OA in police 
working dogs. Several correlations were observed between the evaluations performed and 
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Osteoarthritis (OA) poses significant welfare challenges and concerns, as it affects the quality of 
l ife, performance and implies a considerable cost in terms of healthcare [1, 2]. It is the most 
prevalent musculoskeletal disease in the dog and is estimated to affect around 200 000 dogs 
annually in the United Kingdom [3]. At least 80% of lameness cases and joint disease in com- 
panion animals are classified as OA, with 20% of middle-aged and 90% of older dogs having 
OA in one or more joints [4–7]. Risk factors include breed, neutered, higher bodyweight, and 
older than eight years [3]. Sporting and working animals are at increased risk, being exposed to 
repetitive loading and chronic fatigue injuries, leading to tissue damage, wear, tear, and ulti- 
mate tissue failure, resulting in clinical signs [8]. Chronic fatigue injuries are a critical predis - 
posing condition for hip OA development, a disease commonly diagnosed in dogs, with 
various degrees of severity [9, 10]. 
Imaging plays a key role alongside the clinical review of patients with joint disease and can be 
done repeatedly and safely within recognized limits, which is important for the follow up of 
chronic conditions [11, 12]. The most common radiographic view for evaluating the hip is the 
ventrodorsal  (VD) hip extended view, for which sedation is required for most dogs [13–15]. 
Main radiographic changes include femoral periarticular osteophyte formation, subchondral  
sclerosis of the craniodorsal acetabulum, osteophytes on the cranial/caudal acetabular margin, 
remodeling of the cranial and caudal acetabulum, flattening of the femoral head, and irregular 
widening of the femoral neck [16, 17]. The features that have been deemed of significant 
importance are the circumferential femoral head osteophyte (CFHO), caudolateral curvilinear 
osteophyte (CCO), and subchondral bone sclerosis, early radiographic signs that predict the 
development of the clinical signs of hip OA [18–21]. The ventrodorsal  flexed view (also called 
frog-legged view, FL) enhances the visibility of the cranial and caudal aspects of the femoral 
head and neck, helping in the assessment of CFHO and CCO [21]. 
Weight distribution and off-loading, or l imb favoring at the stance, is a commonly used 
subjective assessment during the orthopedic examination, but the subtle changes in posture or 
weight-bearing may occur in the early stage of the disease process can be easily missed with 
visual assessment only [22–25]. Stance analysis and weight-bearing distribution have been 
reported as sensitive for detecting lameness in dogs, with better results in large breed dogs [26]. 
Muscular atrophy is a consistent finding in OA patients and may be evident within a few weeks 
[10, 14, 16, 27]. The evaluation of the joint range of motion (ROM) can also be per - formed, 
including flexion and extension [10]. The evaluation of asymmetry, assessment of muscle 
atrophy, measurement of static weight-bearing, and ROM measurement have been described as 
the most valid and sensitive physiotherapeutic evaluation methods [28, 29]. 
This study aimed to compare the symmetry of clinical and radiographic signs of right and left 
pelvic limbs of police working dogs with bilateral hip osteoarthritis, and evaluate the asso- ciation 
of physical findings and radiographic abnormalities, at the time of diagnosis. We hypothesize 
that multiple asymmetries are present in several of the evaluation parameters. 
 
Materials and methods 
The study protocol was approved by the ethical review committee of the University of Évora (Ó 
rgão Responsável pelo Bem-estar dos Animais da Universidade de Évora, approval n˚ GD/ 
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32055/2018/P1, September 25th, 2018) and comply with ARRIVE guidelines. Written, 
informed consent was obtained from the Institution responsible for the animals. 
This study’s sample constituted a convenience sample, similar in size to previously pub - 
l ished reports on this topic [30–32]. The sample comprised 100 hips of 50 police working dogs 
with bilateral hip OA, from the population of police working dogs of the Guarda Nacional  
Republicana (Portuguese Gendarmerie Canine Unit), scheduled to undergo treatment of hip 
OA. Patients were active police working dogs, selected after screening of the Portuguese Gen- 
darmerie Canine Unit, based on history (difficulty rising, jumping and maintaining obedience 
positions, stiffness and decreased overall  performance), physical (pain during joint mobiliza - 
tion, stiffness, and reduced range of motion), orthopedic, neurological  and radiographic (OFA 
hip scores of mild, moderate or severe) examinations compatible with bilateral  hip OA. 
All  patients underwent medical evaluation before acquisition from multiple breeders and 
trainers, and starting active training to become police working dogs. Additional inclusion cri - 
teria comprised a bodyweight 15kg, age over 1 year should not have received any medication nor 
nutritional supplements for six weeks or more. Animals that did not tolerate the data col- 
lection procedures, which had any other suspected or diagnosed neurological/musc ulos kel etal  
disorder, had a diagnosis of suspected concomitant disease (ruled out through physical exami- 
nation, complete blood count, and serum chemistry profile), were excluded. Subsequent treat- 
ment was randomly determined, as the animals took part in a study evaluating intra-articular 
therapies for OA. Two-hundred and eighty-one dogs were screened, and 231 were excluded. 
Sixty-three due to suspected or documente d orthopedic, neurological, or concomitant disease, 
50 due to having a bodyweight <20kg, 25 for having received medication in <6 weeks, and 13 
for not being tolerant of data collection, and 80 due to an inability to maintain medical follow-
up throughout the study, for work-related reasons. 
Radiographic studies were conducted under l ight sedation, using a combination of medeto- 
midine (0.01mg/kg) and buthorphanol (0.1mg/kg), given intravenously. A VD extended legs  
view and an FL view were obtained. In the VD view, the presence of the following radiographic 
hip OA findings was recorded [21]: irregular wear on the femoral head, making it misshapen 
and with a loss of its rounded appearance; flattened or shallow acetabulum, with irregular out- 
l ine; CCO; new bone formation on the acetabulum and on femoral head and neck; acetabular 
rim wear; subchondral  bone sclerosis along the cranial acetabular edge; CFHO. In the FL view, 
the presence of CCO and CFHO was recorded. An example of CCO and CFHO, in VD and FL 
views, are presented in Figs 1 and 2, respectively. 
Stance analysis was conducted with a weight distribution platform (Companion Stance 
Analyzer; LiteCure LLC, Newark, Delaware, United States). The equipment was placed in the 
center of an observation room, at least 1-meter feet from the walls. Complying with the manu- 
facturer’s guidelines, the platform was calibrated at the beginning of each testing day and 
zeroed before each data collection. After an acclimatization period, animals were then encour- 
aged to stand on to the weight distribution platform. To secure a correct position, the patient’s 
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trainer helped ensure it placed one foot on each quadrant of the platform while 
maintaining a natural stance with its center of gravity and stability (measured by the platform) 
near the plat- form’s middle. When required, gentle restraint was used to maintain the 
patient’s  head in a natural, forward-facing position. Normal pelvic limb evaluation is 
considered 20% of the total weight [33]. A Gulick II measuring tape was used to determine 
thigh girth. Measurements were made at a distance of 70% thigh length, measured from the 
greater trochanter’s  tip, with the leg in an extended position. Animals were placed in lateral 
recumbency in a relaxed posi- tion [34]. ROM of the hip joints was obtained with a 
goniometer at extension and flexion with a flexed stifle [35]. 
 
Statistical analysis 
Normality was assessed with a Shapiro-Wilk test, and each measured parameter was 
compared with the contralateral l imb with a Paired Samples T-Test. Measured parameters by 
breed and sex were compared with an Independent Samples T-Test. Evaluation of the results 
of radio- graphic imaging, digital thermography, and physical examinations were conducted 
without knowledge of the results of the remaining evaluations. Correlation between parameters 
was assessed with Pearson correlation coefficient. All  results were analyzed with IBM SPSS 
Statis- 
tics version 20, and a significance level of p<0.05 was set. 
 
Results 
A sample of 50 police working dogs, of both genders (30 males and 20 females), with a 
mean age of 6.5±2.2 years and bodyweight of 26.7±5.3kg, were analyzed. Four breeds were 
repre- sented: German Shepherd Dogs (GSD, n = 17), Belgian Malinois Shepherd Dogs (BM, n 
= 15), Labrador Retriever (LR, n = 10), and Dutch Shepherd Dog (DSD, n = 8). They were used 
for four different purposes: Use of force (n = 20), drug detection (n = 14), search and rescue 
(n = 7), explosives detection (n = 5), and tactical  intervention (n = 4). Considering OFA 
grad- ing of hip joints, 35 animals were classified as mild (70%), 10 as moderate (20%), and 5 
as severe (10%). 
Measured age and weight values, individual limb weight distribution, thigh girth, and joint 
range of motion are presented in Table 1. No significant differences were observed when com- 
paring overall measurements of left and right l imbs. Significant differences were observed in 
weight and thigh girth in both right and left pelvic l imbs (p<0.01) when comparing males to 
females, with male dogs having higher values. Comparing breeds, LR were significantly older 
than other animals (p<0.01), and GSD were significantly heavier than BM (p<0.01) and LR 
(p<0.01). GSD also had a significantly higher left thigh girth than BM (p<0.01), LR (p<0.01) 
and DSD (p = 0.04), and right thigh girth than BM (p<0.04) and LR (p<0.01). DSD had higher 
left joint flexion than BM and GSD (p = 0.04), while LR had a larger joint flexion angle 
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Table 1. Mean scores (±standard deviation) of overall weight and age, individual stance analysis, thigh girth and range of motion (extension and flexion) measure- 
ments, and by breed and sex, of left and right pelvic limbs. 
 Weight Age Stance Analysis Thigh Girth Joint Extension Joint Flexion 
 (kg, mean±SD) (yrs, mean±SD) (%, mean±SD) (cm, mean±SD) (˚, mean±SD) (˚, mean±SD) 
   Left Right Left Right Left Right Left Right 
Overall 26.7±5.3 6.5±2.2 19.2±4.8 18.7±4.2 30.6±2.9 30.4±2.6 149.2±9.5 150.6±7.1 55.6±4.1 56.2±4.6 
German Shepherd Dog 29.9±6.4 5.7±1.8 20.0±3.9 18.4±3.6 32.5±3.5 31.8±2.7 151.1±8.1 151.6±5.9 55.2±3.5 57.1±3.5 
Belgian Malinois Shepherd Dog 27.5±4.1 5.3±1.4 17.8±5.5 19.8±5.9 29.9±2.7 29.9±2.2 146.7±7.1 150.6±4.9 54.3±4.6 56.1±6.1 
Labrador Retriever 24.3±2.5 8.7±2.5 19.9±5.5 18.6±3.2 28.5±2.5 28.5±2.3 147.0±14.4 148.5±10.8 55.8±3.8 54.3±3.7 
Dutch Shepherd Dog 27.5±4.1 5.3±1.4 19.0±4.4 17.4±2.9 30.2±2.1 30.7±2.1 152.5±8.8 151.5±7.9 58.5±3.7 56.5±4.2 
Male 29.3±5.4 6.2±2.4 19.0±5.5 19.3±4.8 31.7±2.9 31.2±2.5 149.2±7.6 151.1±4.9 55.2±3.8 57.0±4.7 




(p = 0.05). Sex showed a correlation with weight (r = 0.5, p<0.01). Breed showed a 
moderate correlation with thigh girth (r = 0.4, p<0.01 for the left pelvic l imb and r = 0.3, p = 
0.04 for the right pelvic l imb), as did sex (r = 0.5, p<0.01 for both limbs) and high correlation 
with weight (r = 0.8, p<0.01 for both limbs). A correlation was observed between joint 
extension and age (r = -0.4, p<0.04 for the left pelvic l imb and r = 0.3, p<0.02 for the right 
pelvic l imb) and weight distribution (r = 0.5, p<0.01 for the left pelvic l imb). 
Regarding radiographic findings, absolute frequencies and percentages in the VD and FL 
views of the left and right pelvic l imbs are presented in Table 2. Breed variations in Orthopedic 
Foundation for Animals hip scores are shown in Table 3. Comparing contralateral l imbs, only 
the presence of CFHO, observed in the VD view, was significantly different (p = 0.03). DSD 
had significant differences in the frequency of CFHO in the VD view compared to GSD 
(p = 0.03) and BM (p = 0.04) (left and right pelvic l imbs, respectively). On the FL view, 
differ- ences were observed in the frequency of CFHO of BM and GSD (p = 0.02) and DSD 
(p = 0.04), both on the left pelvic l imb. 
A difference in the frequency of the presence of a worn cranial effective acetabular rim 
angle was observed in the right pelvic l imb of GSD and LR (p = 0.04). Breed showed a moder- 
ate correlation with the presence of CFHO in the VD view (r = 0.302, p<0.05 for the left pelvic 
l imb). A moderate correlation was observed between age and the presence of CCO on the FL 
view (r = -0.408, p<0.01 for both pelvic l imbs), an irregular, misshapen femoral  head 
(r = 0.302, p = 0.02 for the left pelvic l imb), and new bone formation on the acetabulum 




Table 2. Absolute frequencies and percentages of radiographic findings in the ventrodorsal and frog-leg views of the left and right pelvic limbs. 
Radiographic finding Left Right 
Present Absent Present Absent 
Irregular wear on the femoral head, making it misshapen and with a loss of its rounded appearance 48 96% 2 4% 47 94% 3 6% 
Flattened or shallow acetabulum, with irregular outline 32 64% 18 36% 28 56% 21 42% 
Caudolateral curvilinear osteophyte (CCO) 17 34% 33 66% 18 26% 32 64% 
New bone formation on the acetabulum and on femoral head and neck 41 82% 9 18% 45 90% 5 10% 
The angle formed at the cranial effective acetabular rim is worn away 36 72% 14 28% 41 82% 9 18% 
Subchondral bone sclerosis along the cranial acetabular edge 49 98% 1 2% 49 98% 1 2% 
Circumferential femoral head osteophyte (CFHO) 18 36% 32 64% 40 80% 10 20% 
CCO on the Frog Leg view 18 36% 32 64% 15 30% 35 70% 
CFHO on the Frog Leg view 45 90% 5 10% 43 86% 7 14% 
https://doi.org/10.1371/journal.pone.0248767.t002 
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Table 3. Breed variations in Orthopedic Foundation for Animals hip scores. 
 OFA hip grade 
 Mild Moderate Severe 
Overall 35 70% 10 20% 5 10% 
German Shepherd Dog 9 53% 5 29% 3 18% 
Belgian Malinois Shepherd Dog 13 87% 2 13% 0 0% 
Labrador Retriever 7 88% 1 13% 0 0% 




high or moderate correlated with the presence of CCO in an FL view (r = -0.506, p = 0.01 for 
the left pelvic l imb and r = -0.439, p<0.01 for the right pelvic l imb) and on the VD view(r = 
-0.315, p<0.04 for the right pelvic limb). Joint flexion was moderate correlated with the pres- 
ence of CFHO in the VD view on both limbs (r = -0.312, p = 0.02 for the left pelvic l imb and r 
= -0.304, p<0.04 for the right pelvic l imb). 
Considering animals that did or did not present CCO or CFHO on the left pelvic l imb, sig- 
nificant differences were observed in joint extension when CCO was present in both the VD 
and FL views (p<0.01 for both) and joint flexion when CFHO was present in a VD view 
(p = 0.02). On the right pelvic l imb, a significant difference was observed in joint extension 





Hip OA is common in large breeds such as German Shepherd Dogs and Labrador, amongst 
others [36]. This study describes and compares several clinical and radiographic findings of 
different individuals in each individual and between breeds with hip OA. It also describes as,  
in these animals, disease derived changes occur in similar degree in both limbs since no signifi- 
cant differences were observed when comparing contralateral l imbs. The reason for this find- 
ing is unclear and may be associated with the natural progression of the disease or with a  
relatively early diagnosis, the effect of a possible unilateral, or even intermittent overloading is 
sti l l  not noticeable. 
Most hip OA signs are observed in the older population, usually in animals over 8 years, 
with the disease now at a chronic stage [3]. The mean age of animals included in this study was 
lower (6.5) years, except for LR. This result is not in l ine with published studies and may be 
associated with the fact that these animals are active working dogs, where complaints due to 
musculoskeletal disease are noticed early on, from its toll  on gait and performance [37]. The 
difference in age of LR is less apparent and may be due to breed conformation, leading to a bet- 
ter disease tolerance, as hip OA seems to be better tolerated by animals than OA in different 
joints [10]. Additional reasons may be related to a less physically demanding mission of these 
dogs (most were product detection dogs) than the remaining animals included in the sample 
(mostly in search and rescue and Use of force activities). 
Some of the other registered differences could be expected. GSD were significantly heavier 
than other breeds (BM and LR) and with higher thigh girth. Male dogs also heavier than  
females and with higher thigh girth. This may account for a positive correlation between thigh 
girth, weight, sex, and breed. The effect of weight and growth rate has been studied concerning 
hip dysplasia from an early stage, with heavier dogs showing a higher incidence of OA at matu- 
rity and an earlier age [38, 39]. This can partially account for the higher number of males  
included in this sample since they tend to be heavier and, therefore, possibly more prone to 
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develop OA. Measuring thigh girth is also be a useful measurement, not only in the initial  
assessment but also as an outcome measure [34]. We have presented thigh girth measurements 
in dogs with hip OA, but further studies should include a control  group with disease-free dogs 
to compare both groups’ values. Coxofemoral  ROM may also be diminished, particularly dur- 
ing extension, although this is not a universal  finding [14, 40]. Normal ROM of the hip joint in 
military working German Shepherd Dogs are described as 44˚±6 at flexion and 155˚±6 at 
extension [41]. In Labrador Retrievers, normal ROM been described as 50˚±2 at flexion and 
162˚±3 at extension in one report, and 49˚ at flexion and 159˚ at extension in another [35, 42]. 
We have measured lower values in GSD and LR, which could be expected due to OA. Exercise 
has been described as having a positive effect on the severity of lameness in LR with hip dyspla- 
sia, which increased with longer exercise duration [43]. Since the animals included in the sam- 
ple are all  active working dogs, this inverse relationship can be present. The joint extension 
was one of the measurements made with higher dispersion, which may confirm the fact that 
ROM changes are not a consistent finding. It showed a correlation with age, which may be 
attributed to disease progression, as joint extension appears to be limited by the joint capsule 
fibrosis. This reduction in joint extension in older dogs has been described before [43]. On the 
other hand, hip joint flexion seems to be related to muscle mass and could increase in dogs  
with OA due to a loss in muscle masses [44]. As the patients in our sample did not exhibit a  
high degree of muscle atrophy, this increase was not observed. 
Normal weight distribution for the stance analyzer is the same as for a pressure-sensitive 
walkway—30/30/20/20 (left thoracic l imb/right thoracic l imb/ left pelvic l imb/right pelvic  
limb) [45, 46]. It has been proposed that bodyweight distribution at a stance may be an equiva- 
lent or superior measurement of pain associated with hip OA than both VI and PVF [33, 47], 
and dogs presenting with the disease often have slightly abducted pelvic l imbs, easily notice- 
able when the animal is standing, increasing acetabular coverage [10]. Overall weight distribu- 
tion values per limb recorded in this study were lower than the described 20% expected level. 
When analyzing weight distribution in individual breeds, the exception was registered in the 
left pelvic l imb of GSD, but this may be a compensation mechanism. No significant variations 
were observed between breeds. This measurement’s  value, particularly in response to treat- 
ment, should be the subject of further research since it was the measured parameter that 
recorded the least breed associated variations. 
It is well established that radiographic signs’ development occurs later than the structural 
changes associated with OA, and symptoms must be severe before being observed on the X- 
ray [14, 48]. CFHO is a marked radiopaque line encircling the junction between the femoral 
neck and the epiphysis, along with the insertion of the joint capsule [49]. When comparing 
radiographic findings between contralateral l imbs, only the frequency of CFHO on the VD 
view was significantly different. Since this is one of the radiographic predictors of future OA 
development [21], and these animals were only now being diagnosed, future studies will have 
to address whether further asymmetries between limbs develop if it was only an incidental 
finding. Since CFHO is usually better observed on an FL view, and the same asymmetry was  
not observed on the FL, this might be the case. CFHO also correlated with joint flexion, which 
can be explained by the changes that occur in the joint capsule during OA progression, making 
it less flexible. GSD also had significantly higher frequencies of this finding than BM and DSD. 
Interestingly, no correlation was found between weight and any of the radiographic findings 
considered, as could be expected, and they may rather be linked to breed variations. 
CCO arises at the femoral  neck’s  caudodorsal part due to traction on the hip joint capsule, 
and it manifests as a radiopaque line. It correlates with hip subluxation and, therefore, repre -  
sents a risk factor for OA development at a later stage in l ife [15]. A correlation between CCO 
and age of an irregular femoral head and new bone formation was observed and can further 
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attest to the relationship between CCO and OA signs’ development. It also correlated with  
joint extension and, as seen with CFHO, may be due to the changes that occur in the joint cap- 
sule. This possibility is also reflected when considering the animals that presented CFHO or  
CCO and comparing them with those that did not, with significant differences in ROM evalua- 
tion, flexion, and extension. 
This study presents some limitations. Ideally, a control group with non-lame dogs 
should be included. The interest of each of the findings in the prognosis or treatment 
monitoring of OA could not be determined since data was collected in a single evaluation 
moment. Future studies are required to evaluate these points. Additionally, the sample 
included a majority of dogs with mild OA. For that reason, further studies should include a 




The present study showed that clinical and radiographic signs occur symmetrically in naturally 
occurring hip OA in police working dogs. It also describes the correlation between the evalua- 
tions performed, which can be useful in evaluating and early diagnosing hip OA, as differences 
between the most commonly used working dogs breeds. 
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We aimed to evaluate IL-1 and C-reactive protein (CRP) levels in the synovial fluid (SF) in a 
naturally occurring canine osteoarthritis (OA) model, and its relation with animals' clinica l, 
radiographic and thermographic disease signs. 
One hundred (N=100) joints of active police working dogs with hip OA were evaluated. SF 
IL-1 and CRP levels, weight distribution, joint range of motion, thigh girth, digital thermography and 
radiographic signs were recorded. Data from four Clinical Metrology Instruments (CMI) was 
collected.  Results were compared by age, sex and OFA scores with the Independent Samples T-Test, 
ANOVA and Pearson correlation coefficient, with p<0.05. 
The sample included 100 pelvic limbs, equally distributed between left and right pelvic limbs 
30 males and 20 females, with a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg.  IL-1 
levels, particularly above 200pg/mL, may be related to the development of caudolateral curvilinear 
osteophyte, which then expresses a toll on the patient's levels of pain and activity. It was unclear if 
the CRP levels were a consequence of inflammatory activity within the joint or a reflection of better 
prognosis. Increasing body weight was related to worse CMI scores. 
We described the relation of IL-1 and CRP synovial concentrations levels with several clinica l 
signs, diagnostic imaging, laboratorial findings and clinical metrology instruments results of animals 
with OA. Further studies are required to determine and possibly quantify the interest of each 
parameter for the prognosis and treatment monitoring. 
  
Keywords: Dog; Osteoarthritis; Interleukin-1; C-reactive protein; Stance Analysis; Digita l 
Thermography; Clinical Metrology Instruments. 
 
Introduction 
Osteoarthritis (OA) affects all mammals and is an important and costly disease, representing 
a significant burden to societies, as it affects the quality of life, performance and healthcare, posing 
significant welfare challenges and concern (Loeser et al., 2012; Venable et al., 2008). OA is a 
relatively low-grade inflammatory disease, where the inflammatory process affects the progression 
of the disease, frequently without systemic manifestation (Calich et al., 2010; Goldring and Goldring, 
2004). Interleukin 1 (IL-1) has been pointed out as the most critical pro-inflammatory cytokine 
responsible for the catabolism in OA, with a relation with lameness duration (Fujita et al., 2006). 
However, some studies have reported low or undetectable IL-1 levels in OA animals (Vincent, 2019). 
C-reactive protein (CRP) is an acute-phase protein, produced during inflammatory reactions or tissue 




the most useful acute-phase protein in the dog, as in humans, with the advantage of its shifts being 
noted from a very early stage of the disease process (Bennett et al., 2013). 
The dog is a frequent model for the study of OA, since the pathologic process, clinica l 
presentation and response to treatment are very similar to that of humans, making it the closest to a 
gold standard. The naturally occurring canine model has the advantage of presenting a faster disease 
progression, with equivalent life stages to those of humans, while sharing many of the environmenta l 
variations that also influence human OA (Gregory et al., 2012; Kol et al., 2015; Meeson et al., 2019). 
Exploring dog OA in translation treatment under the One Medicine initiative will help improve the 
health and well-being of both species (Cimino Brown, 2017; Meeson et al., 2019).  
Pelvic radiographs are a part of screening programs for hip dysplasia, but also the clinica l 
assessment of OA and determination of treatment outcome (Puckler et al., 2016). The most common 
radiographic views are ventrodorsal (VD) hip extended view and the ventrodorsal flexed view (called 
frog-legged view, FL). The particular interest of the FL view is that it augments the visibility and 
assessment of the circumferential femoral head osteophyte (CFHO) and caudolateral curvilinear 
osteophyte (CCO), early radiographic signs related with the development of the clinical signs of hip 
OA (Mayhew et al., 2002; Powers et al., 2004). Weight distribution, off-loading or limb favouring at 
the stance is a standard assessment during the orthopaedic examination, as animals tend to bear less 
weight on a painful limb (Gordon-Evans, 2012). Stance analysis has been reported as a sensitive 
evaluation for detecting lameness in dogs (Clough and Canapp, 2018). Digital thermal imaging relies 
on heat generated during physiologic functions and its relation with skin temperature control 
(Hildebrandt et al., 2012). It is a reliable technique to assess inflammatory arthritis pain and able to 
differentiate normal from osteoarthritis subjects (Fokam and Lehmann, 2019). Pain and functiona l 
ability are the most relevant parameters in the evaluation of OA animals and for assessment of 
treatment efficacy (Wiegant et al., 2015).  For that purpose, several clinical metrology instruments 
(CMI) have been developed. The most commonly used are the Canine Brief Pain Inventory (CBPI) 
and the Liverpool Osteoarthritis in Dogs (LOAD) (Lascelles et al., 2018; Walton et al., 2018). The 
CBPI is divided into two sections, a pain severity score (PSS) that assesses the magnitude of the 
animal pain, and a pain interference score (PIS) that assesses the degree in which pain affects daily 
activities (Upchurch et al., 2016). It has been demonstrated as not being associated with response bias  
(Essner et al., 2020). Other CMIs are also used to evaluate different dimensions of OA, like the Canine 
Orthopaedic Index (COI, divided into four scores: stiffness, gait, function and quality of life – QOL), 
and the Hudson Visual Analogue Scale (HVAS), developed assess the degree of lameness in dogs  
(Brown, 2014; Hudson et al., 2004). Mobility impairment and activity levels are associated with 




recommended as measures of outcome (Lascelles et al., 2018). Pedometers are simple and 
inexpensive devices, capable of measuring ambulatory activity with acceptable accuracy(Tudor -
Locke et al., 2002). Additional evaluated parameters include the examination of muscle masses since 
muscular atrophy is a consistent finding in OA animals, and also the joint range of motion (ROM), 
including flexion and extension, with a restricted ROM being usually present (Hyytiäinen et al., 
2013).  
The goal of this study is to evaluate IL-1 and CRP levels in the synovial fluid (SF) in a 
naturally occurring canine OA model, and its relation with animals' clinical, radiographic and 
thermographic signs. We hypothesize that increased levels of IL-1 and CRP are related to more severe 
signs. 
 
Materials and Methods 
The study protocol was approved by the ethical review committee of the University of Évora 
(Órgão Responsável pelo Bem-Estar dos Animais da Universidade de Évora, approval nº 
GD/32055/2018/P1, September 25th, 2018). Written, informed consent was obtained from the 
Institution responsible for the animals.  
The sample comprised one hundred (N=100) joints of active police working dogs with hip 
OA. For the diagnosis, a complete history, physical, orthopaedic, neurological and radiographic 
examinations were obtained and had to be consistent with bilateral hip OA. Additionally, animals 
should have a bodyweight ≥15kg, be over two years and must not have received any medication or 
nutritional supplements for six weeks or more. Animals were excluded if suspected to have any other 
orthopaedic or concomitant disease, or if they were not tolerant of data collection. All evaluat ions 
were performed at the same moment by the same researcher. 
Stance Analysis 
Stance analysis was conducted with a weight distribution platform (Companion Stance 
Analyzer; LiteCure LLC®, Newark, Delaware, United States). According to the manufacture r's 
guidelines, the equipment was placed in the centre of a room, at least 1 meter from the walls. It was 
calibrated at the beginning of each day and zeroed before each data collection. Trainers encouraged 
animals to stand on the platform while ensuring the patient placed one foot on each quadrant of the 
platform. If required, gentle restraint was used to keep the patient's head facing forward. The left -
right symmetry index (SI) was calculated with the following formula: SI=[(WBR-
WBL)/((WBR+WBL)x0.5)]x100 (Volstad et al., 2017; Walton et al., 2013), where WBR is the value 
of weight-bearing for the right pelvic limb, and WBL is the value of weight-bearing for the left pelvic 




(Clough et al., 2018), deviation from this value was also considered, calculated by subtracting WB to 
20.  
Digital thermography 
Digital thermography images were collected after 30 minutes, during which animals were 
allowed to calmly walk in a controlled temperature room (set at 21°C). With the animal positioned in 
a symmetrical upright standing position, a dorsoventral thermographic image was obtained, includ ing 
the area from the last lumbar vertebra to the first coccygeal vertebra at a minimum at a distance of 
60cm(Vainionpää et al., 2013).  A lateral view was also obtained, at a distance of 60cm, with the 
greater trochanter in the centre. All images were produced with a FLIR ThermaCAM E25® model. 
The range of temperature was set at 15-40°CC and emissivity at 0.98. Data from the thermographic 
images were analyzed with the free software Tools (FLIR Systems, Inc), and the Rainbow HC colour 
pallet was used. 
Clinical Assessment 
For the determination of thigh girth and joint ROM, the patient was placed in lateral 
recumbency, with the affected limb uppermost. With an extended leg, thigh girth determination was 
made with a Gullick II measuring tape, at a distance of 70% thigh length, measured from the tip of 
the greater trochanter. Hip joint ROM was obtained with a goniometer at extension and flexion with 
a flexed stifle.  
Pedometers 
Pedometers were worn around the patient's neck, attached to an adjustable lightweight collar. 
They were placed one week before the evaluation moment, and mean daily counts were considered 
and calculated by dividing the register number of steps by the number of days considered. 
Clinical metrology instruments 
At the evaluation moment, trainers received the published instructions for HVAS, CBPI, COI 
and LOAD, and then completed an online copy of each for them. The CMIs were completed in 
sequence by the same handler in a quiet room with as much time as needed to answer all items. 
Radiographic examination 
Radiographic studies were conducted under light sedation, using a combination of 
medetomidine (0.01mg/kg) and butorphanol (0.1mg/kg), given intravenously. VD extended legs and 
FL views were obtained. The presence of seven radiographic OA signs was assessed: irregular wear 
on the femoral head, making it misshapen and with a loss of its rounded appearance; a flattened or 
shallow acetabulum, with irregular outline; CCO; new bone formation on the acetabulum and femoral 




sclerosis along the cranial acetabular edge and CFHO(Armbrust, 2009; Fortrie et al., 2015; Puckler 
et al., 2016; Smith et al., 2011). In the FL view, the presence of CCO and CFHO was also recorded. 
Determination of synovial IL-1 and CRP concentrations 
With the patient positioned in lateral recumbency with the affected joint uppermost, a small 
window of 4x4cm area surrounding the greater trochanter was clipped and aseptically prepared. An 
assistant positioned the limb in a neutral, parallel to the table position. For the collection of synovia l 
fluid, a 21-gauge with 2.5" length needle was introduced just dorsal to the greater trochanter and 
perpendicular to the long axis of the limb, until the joint was reached. Determination of CRP and IL-
1β concentrations were made using the DuoSet Ancillary Canine IL-1β Reagent kit (R&D Systems, 
United Kingdom), read with a FLUOstar OPTIMA (BMG Labtech),  and Fuji Dri-Chem Slides VC-
CRP PS (FUJIFILM Europe GmbH), read with a DRIChem NX500i (FUJIFILM Europe GmbH). 
Statistical Analysis  
Normality was assessed with a Shapiro-Wilk test, and each measured parameter was 
compared with an Independent Samples T-Test or ANOVA. Correlation between parameters was 
assessed with the Pearson correlation coefficient. Multiple regression was run to predict evaluated 
parameters from CRP serum and synovial IL-1 and CRP concentrations and to predict synovial IL-1 
and CRP concentrations from age, sex, body weight and OFA score. All results were analyzed with 
IBM SPSS Statistics version 20, and a significance level of p<0.05 was set. 
Data availability 
The data used in this study is a property of the Guarda Nacional Republicana, a governmenta l 
police force from Portugal and, by law, confidential. The authors obtained specific approval in order 
to use the data. The data request may be sent to the Divisão de Medicina Veterinár ia 
(cari.dsad.dmv@gnr.pt). Other researchers, who meet the criteria for access to confidential data, can 
access data in the same manner as the authors. 
 
Results 
The sample included 100 pelvic limbs of police working dogs, equally distributed between 
left and right pelvic limbs, with a mean age of 6.5±2.4 years and a bodyweight of 26.7±5.2kg. 
Considering OFA hip grading, 70 joints were classified as mild (70%), 20 as moderate (20%) and ten 
as severe (10%). Both genders were represented (60 limbs from males and 40 from females), and 
male dogs showed significantly higher mean temperature on the lateral view than females (p=0.05) 
and also higher flexion values (p=0.05). 
Overall IL-1 concentration in the synovial fluid was 161.8pg/mL (±66.5) and of CRP was 




off points for IL-1 and CRP concentration in synovial fluid are presented in table 1. CMI results are 
presented in Table 2. Variables considered in multiple regression statistically significantly predicted 
IL-1 synovial concentration F(5,85)=2.826, p=0.03, R2=0.117, with OFA hip score (p<0.01) adding 
statistically significantly to the prediction. Considering a 100ng/ml cut off point for IL-1 
concentration, no significant differences were observed. With a 200ng/ml cut off, animals with higher 
values showed higher frequency in the presence of CCO on the VD view (p<0.01), worse OFA hip 
grades (p<0.01) and lower serum CRP concentration (p=0.02). Considering a 0.3ng/dL cut off point 
for CRP concentration, animals below this range had worse PSS (p=0.04), PIS (p<0.01) and function 
scores (p<0.01). With a 1ng/dL cut off, animals with higher values had higher pedometer counts 
(p=0.02), lower CFHO frequency (p<0.01), better OFA hip grade (p<0.01), PIS (p<0.01) and function 
scores (p<0.01). Considering a 2ng/dL cut off value, animals with higher values had higher pedometer 
counts (p=0.02), higher mean and maximal thermography values on the lateral view (p=0.05 and 
p<0.01, respectively), increased frequency of CCO and CFHO on the VD view (p<0.01, for both), 
better OFA hip grade (p<0.01), and higher serum CRP concentration (p=0.02). IL 1 synovial levels 
added statistically (p<0.01) significantly to the prediction of thigh girth F(3,59)=11.019, p<0.01, 
R2=0.359 and joint extension thigh girth F(3,58)=3.367, p=0.03, R2=0.148. 
Clinical findings for different OFA hip grades, according to the presence of CCO and CFHO, 
with different cut off points for weight, are presented in table 3. CMI results are presented in Table 
4. Grouping joints by OFA hip grading, animals with a severe grade were significantly older than 
those with mild (p<0.01) and moderate (p<0.01) grades, and worse SI and deviation than mild (p=0.03 
and p=0.01, respectively). On the digital thermography DV view, mild hip grades showed higher 
values than moderate grades (p=0.03). Mild grades had higher IL-1 concentration than moderate 
grades (p<0.01), and better HVAS scores than moderate (p<0.01) and severe (p<0.01) hip grades. 
They also had better PSS (p<0.01), PIS (p<0.01), LOAD (p<0.01), function (p<0.01), gait (p<0.01), 
QOL (p<0.01) and COI (p<0.01) scores than severe hip grades. Also, lower frequencies of CCO on 
the VD (p=0.05 and p<0.01 for moderate and severe, respectively) and FL (p=0.03 and p<0.01 for 
moderate and severe, respectively) views. Moderate had better LOAD (p<0.01), stiffness (p=0.02), 
function (p<0.01), gait (p=0.02), QOL (p<0.01) and COI (p<0.01) scores than severe hip grades. IL 
1 synovial levels added statistically (p=0.01) significantly to the prediction of OFA hip grade 
F(1,90)=6.332, p=0.01. 
Joints which exhibited CCO on the VD view had worse OFA hip grade (p<0.01), lower levels 
of synovial IL-1 concentration (p=0.02), higher serum CRP (p<0.01), and worse PSS (p=0.05), 
LOAD (p<0.02), function (p=0.05), gait (p=0.01) and COI (p=0.04) scores. IL 1 synovial levels added 




F(3,59)=11.019, p=0.01. Joints with CFHO on the VD view showed lower pedometer counts 
(p=0.02), worse OFA hip grade (p<0.01), and worse HVAS (p<0.01), PSS (p<0.01), PIS (p<0.01), 
LOAD (p=0.02), stiffness (p=0.02), function (p<0.01), gait (p=0.02), QOL (p=0.02) and COI 
(p<0.01) scores. Considering the FL view, joints where CCO was identified had worse SI (p<0.01), 
deviation (p=0.03) and OFA hip grade (p<0.01). IL 1 synovial levels added statistically (p<0.01) 
significantly to the prediction of the presence of CCO on an FL view F(3,59)=3.047, p=0.01. No 
significant variations were observed when CFHO was considered in this view. 
Different cut off points were considered in regard to weight. With a 25kg cut-off, heavier 
animals had lower pedometer counts (p=0.03), higher SI (p<0.01), lower mean and maximal 
temperature on the lateral view (p<0.01 for both), and worse HVAS (p<0.01), PSS (p<0.01), PIS 
(p<0.01), LOAD (p<0.01), stiffness (p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01) and 
COI scores (p<0.01). Setting a 30kg cut-off, value heavier animals had lower mean and maximal 
temperature on the lateral view (p<0.01 for both), worse flexion (p<0.01) and lower IL-1 
concentration level (p=0.04). For a 35kg cut-off, heavier animals had lower SI (p<0.01), lower mean 
and maximal temperature on the lateral view (p<0.01 for both), worse flexion (p<0.01), higher 
frequency of CCO on a FL view (p<0.01), lower IL-1 concentration level (p<0.01) and CRP serum 
concentration (p<0.01), and worse HVAS (p=0.05), LOAD (p=0.05), stiffness (p=0.03), gait 
(p<0.01), QOL (p=0.03) and COI scores (p=0.03). 
Correlations between measured parameters are presented in Table 5. In Table 6, the correlation 















Table 1 – Mean values (±standard deviation) of overall weight, age, symmetry index (SI), deviation from normal weight-bearing, mean 
and maximal thermography values on ventrodorsal and lateral views, thigh girth, range of motion (extension and flexion) measurements, and 
synovial interleukin-1 (IL-1) and C-Reactive Protein (CRP), by different cut-off values for synovial IL-1 and CRP concentration. 
  





Thigh Girth Joint Flexion 
Joint 
Extension 










cm degrees degrees    
IL-1  with 100pg/ml cut 
off 
above 6.6±2.4 441.5±462.5 14.5±20.9 1.9±2.2 25.4±1.3 26.8±1.2 28.3±2.1 30.6±2.2 33.8±19.3 50.7±3.4 150.7±11.3 - 0.2±0.9 0.6±0.5 
bellow 6.6±1.9 325.7±261.7 16.5±20.9 3.0±5.3 26.0±0.8 27.5±0.8 27.9±1.1 30.2±0.9 32.1±2.3 51.6±2.6 153.3±2.1 - 0.5±0.6 0.4±0.3 
IL-1  with 200pg/ml cut 
off 
above 6.5±2.3 407.5±522.2 14.4±21.2 2.3±2.8 25.9±1.1 27.2±1.1 28.4±1.6 30.6±1.8 48.3±45.1 50.1±5.7 145.0±27.4 - 0.0±0.0 0.4±0.3 
bellow 6.7±2.4 439.5±442.5 14.7±20.8 2.0±2.6 25.4±1.3 26.8±1.2 28.2±2.1 30.6±2.2 48.3±45.1 50.9±2.8 151.8±3.3 - 0.2±0.9 0.6±0.5 
CRP with 0.3 mg/dL cut 
off 
above 5.0±2.4 814.0±1114.4 3.1±2.9 1.0±0.7 26.2±1.4 27.6±1.2 28.6±0.5 31.0±0.7 32.5±3.1 50.8±1.1 151.8±3.0 113.5±25.6 - 0.9±0.8 
bellow 6.5±2.2 458.4±477.0 12.5±19.7 1.7±2.6 25.4±1.3 26.8±1.3 28.2±2.0 30.4±2.1 36.3±22.7 50.8±3.3 150.7±13.3 169.3±69.1 - 0.6±0.5 
CRP with 1mg/dL cut off 
above 5.5±2.5 1602.0±450.2 3.9±2.6 1.3±0.5 26.2±1.4 27.6±1.2 28.7±0.5 31.0±0.7 31.6±2.7 50.5±1.0 150.8±2.2 117.3±27.9 - 1.1±0.8 
bellow 6.4±2.3 443.48±475.3 12.3±19.8 1.7±2.6 25.4±1.3 26.8±1.3 28.2±2.0 30.4±2.1 35.3±22.5 50.8±3.3 150.8±13.2 168.2±69.1 - 0.6±0.5 
CRP with 2mg/dL cut off 
above 4.0±1.4 1602.0±450.3 2.7±3.8 1.0±0.0 26.3±1.9 27.5±1.6 29.0±0.3 31.6±0.1 30.8±1.1 52.0±1.4 150.5±3.5 132.3±28.3 - 1.5±1.1 









Table 2 – Mean values (±standard deviation) of clinical metrology instruments scores by different cut-off values for synovial IL-1 and CRP 
concentration. CBPI – Canine Brief Pain Inventory; PIS – Pain Interference Score; PSS – Pain Severity Score; HVAS – Hudson Visual Analogue 
Scale; LOAD – Liverpool Osteoarthritis in Dogs; COI – Canine Orthopedic Index; QOL – Quality of Life. 
  HVAS CBPI LOAD COI 
  
 PSS PIS  Stiffness Function Gait QOL Total 
  (0-10) (0-10) (0-10) (0-52) (0-16) (0-16) (0-20) (0-12) (0-64) 
IL-1  with 100ng/ml cut off 
above 6.6±1.5 3.3±2.3 3.3±2.6 13.2±11.2 3.5±4.1 3.7±4.6 4.9±5.4 3.9±2.9 16.1±16.8 
bellow 6.8±1.5 2.9±2.3 3.2±2.4 12.0±11.9 3.5±4.2 3.8±4.3 4.7±5.5 3.8±3.2 15.8±16.9 
IL-1  with 200ng/ml cut off 
above 7.0±1.0 2.8±1.8 2.6±1.7 10.4±7.5 2.6±3.1 2.3±2.8 3.0±3.8 3.1±2.1 11.1±11.1 
bellow 6.6±1.5 3.4±2.4 3.5±2.7 13.6±11.7 3.7±4.3 4.0±4.8 5.2±5.6 4.0±3.1 16.9±17.4 
IL-1  with 300ng/ml cut off 
above 7.5±0.9 1.7±1.1 1.7±1.5 4.1±3.4 0.3±0.5 0.0±0.0 0.0±0.0 2.0±2.0 2.3±1.9 
bellow 6.6±1.5 3.4±2.4 3.5±2.6 13.9±11.3 3.8±4.2 4.1±4.6 5.3±5.4 4.0±2.9 17.2±16.8 
CRP with 0.3 mg/dL cut off 
above 7.7±1.1 1.6±1.3 1.3±0.6 5.2±6.1 0.8±1.8 0.4±0.9 1.8±4.0 2.2±1.1 5.2±7.7 
bellow 6.8±1.3 3.2±2.1 3.2±2.3 11.9±10.3 3.1±3.7 2.9±3.9 4.3±4.9 3.4±2.7 13.8±14.9 
CRP with 1 mg/dL cut off 
above 7.5±1.2 1.7±1.4 1.4±0.7 5.5±7.0 1.0±2.0 0.4±1.0 2.3±4.5 2.5±1.0 6.3±8.5 
bellow 6.8±1.3 3.1±2.1 3.1±2.3 11.8±10.2 3.1±3.7 2.9±3.9 4.2±4.9 3.4±2.7 13.6±14.9 
CRP with 2 mg/dL cut off 
above 7.0±1.7 2.4±1.9 1.7±0.9 9.0±9.9 2.0±2.8 1.0±1.4 4.5±6.4 3.0±1.4 10.5±12.0 









Table 3 – Mean values (±standard deviation) of overall weight, age, symmetry index (SI), deviation from normal weight-bearing, mean 
and maximal thermography values on ventrodorsal and lateral views, thigh girth, range of motion (extension and flexion) measurements, and 
synovial interleukin-1 (IL-1) and C-Reactive Protein (CRP), by different OFA hip grades, presence of caudolateral curvilinear osteophyte (CCO) 


























cm degrees degrees   
Mild   6.3±2.1 567.6±525.5 11.2±17.7 1.5±1.9 25.7±1.2 27.1±1.1 28.4±1.7 30.7±1.8 35.8±23.7 51.0±3.3 150.9±13.8 178.3±78.6 0.3±1.0 
Moderate  
6.4±2.5 294.0±270.5 16.6±21.6 2.4±3.5 24.9±1.1 26.5±1.2 27.9±2.3 30.6±2.3 31.7±3.5 51.1±3.5 151.7±3.6 130.6±30.5 0.1±0.2 
Severe  
8.4±2.7 281.0±350.4 25.1±27.2 3.5±2.9 25.4±1.5 26.6±1.4 28.1±2.9 30.2±3.2 28.9±2.1 49.5±2.9 149.3±3.4 144.7±22.9 0.0±0.0 
CCO in a VD view 
absent 6.1±2.3 437.5±423±.5 13.5±20.4 1.9±2.2 25.6±1.2 26.9±1.2 28.5±1.9 30.8±1.8 35.6±2.4 50.7±3.5 150.3±13.8 174.6±75.1 0.1±0.4 
present 7.1±2.6 428.4±503±.9 16.5±21.5 2.3±3.2 25.3±1.4 26.8±1.2 27.8±2.3 30.2±2.5 30.8±3.4 50.9±3.1 151.7±3.7 141.8±45.8 0.3±1.3 
CFHO in a VD view 
absent 5.9±2.1 653.9±556.2 10.3±16.7 1.6±1.9 25.6±1.2 27.0±1.1 28.5±1.9 30.7±1.8 37.8±27.6 50.8±3.7 150.1±16.2 163.7±70.9 0.4±1.1 
present 7.2±2.5 327.5±353.7 18.0±23.0 2.4±2.9 25.4±1.3 26.7±1.3 28.0±2.2 30.5±2.4 30.6±3.2 50.8±3.1 151.5±3.5 160.3±64.0 0.0±0.1 
CCO in a FL view 
absent 4.2±1.7 425.7±458.6 6.8±9.9 1.3±4.5 25.7±1.2 26.9±1.2 28.6±2.0 30.8±2.1 37.8±27.7 51.1±3.8 150.5±16.3 172.5±78.2 0.1±0.5 
present 7.1±2.7 440.8±454.2 20.1±24.4 2.5±3.0 25.4±1.3 26.8±1.2 28.0±2.0 30.4±2.2 30.6±2.9 50.6±2.9 151.1±3.4 154.8±57.4 0.3±1.1 
BW  with 25kg cut off 
above 6.8±2.3 359.7±414.8 16.7±22.3 2.3±2.8 25.5±1.2 26.8±21.2 27.8±1.9 30.1±2.0 35.1±2.1 50.9±3.6 150.5±12.1 163.0±65 0.2±0.9 
bellow 6.4±2.6 701.6±496.7 5.9±8.2 0.9±1.3 25.6±1.6 27.0±1.3 29.9±1.7 32.3±1.6 28.7±1.7 50.4±2.2 152.2±2.3 160.3±75.4 0.32±0.9 
BW  with 30kg cut off 
above 5.9±1.7 189.6±149.1 11.3±16.4 1.6±1.9 25.4±1.2 26.9±1.3 27.3±1.9 29.6±1.9 33.0±2.4 51.8±2.2 152.5±3.1 144.9±56.7 0.3±1.2 
bellow 7.2±2.6 501.8±483.9 16.9±23.1 2.3±2.9 25.6±1.3 26.9±1.1 28.7±1.9 31.1±2.0 34.2±2.4 50.1±3.8 149.7±13.8 174.2±71.8 0.1±0.5 
BW  with 35kg cut off 
above 7.0±0.0 101.0±0.0 2.3±2.5 1.5±0.9 25.3±0.4 26.5±0.5 26.1±1.2 28.6±1.3 35.8±1.7 52.8±2.6 154.5±2.1 135.8±21.9 0.0±0.0 







Table 4 – Mean values (±standard deviation) of clinical metrology instruments scores, by different OFA hip grades, presence of caudolateral 
curvilinear osteophyte (CCO) and circumferential femoral head osteophyte (CFHO) and different cut-off values for weight. CBPI – Canine Brief 
Pain Inventory; PIS – Pain Interference Score; PSS – Pain Severity Score; HVAS – Hudson Visual Analogue Scale; LOAD – Liverpool 
Osteoarthritis in Dogs; COI – Canine Orthopedic Index; QOL – Quality of Life. 
  HVAS CBPI LOAD COI 
  
 PSS PIS  Stiffness Function Gait QOL Total 
  (0-10) (0-10) (0-10) (0-52) (0-16) (0-16) (0-20) (0-12) (0-64) 
Mild   7.0±1.1 2.9±2.1 2.7±2.1 10.1±8.3 2.6±3.2 2.4±3.3 3.5±4.2 3.1±2.3 11.6±12.4 
Moderate  
6.3±1.6 3.5±2.3 3.8±2.7 13.1±11.7 3.8±4.3 4.3±5.3 5.3±5.9 3.9±3.2 17.3±18.4 
Severe  
5.5±1.6 4.7±2.8 5.1±3.2 24.6±12.9 7.0±5.4 8.3±4.9 9.6±6.5 6.7±3.6 31.6±19.8 
CCO in a VD view 
absent 6.8±1.5 2.9±2.1 2.9±2.3 11.0±9.3 2.9±3.7 3.0±4.9 3.7±4.6 3.5±2.6 13.2±14.3 
present 6.4±1.3 3.9±2.5 3.9±2.8 16.4±12.9 4.6±4.6 4.9±5.4 6.6±6.1 4.5±3.3 20.6±18.9 
CFHO in a VD view 
absent 7.1±1.1 2.5±1.8 2.4±1.7 9.9±7.5 2.4±2.9 2.1±2.9 3.3±4.0 3.0±2.0 10.8±11.3± 
present 6.3±1.6 3.9±2.5 4.1±2.9 15.6±12.3 4.5±4.7 5.1±5.2 6.1±6.1 4.6±3.4 20.2±19.0 
CCO in a FL view 
absent 6.9±1.2 2.9±2.1 2.8±2.1 12.4±8.7 3.1±3.1 2.9±3.4 4.4±4.5 3.4±2.3 13.8±12.9 
present 6.4±1.6 3.5±2.5 3.7±2.8 13.7±12.8 3.9±4.8 4.4±5.2 5.2±6.1 4.2±3.4 17.8±16.7 
BW  with 25kg cut off 
above 6.4±1.5 3.7±2.4 3.8±2.6 14.7±11.7 4.2±4.3 4.4±4.8 5.7±5.6 4.4±3.0 18.8±17.4 
bellow 7.6±0.8 1.6±0.9 1.4±0.5 6.8±4.8 1.0±1.4 1.1±1.9 1.4±2.8 1.8±1.3 5.3±6.2 
BW  with 30kg cut off 
above 6.7±1.4 3.2±2.1 3.2±2.3 12.6±10.7 3.1±3.4 3.2±3.8 4.9±4.9 4.1±2.5 15.2±14.2 
bellow 6.6±1.5 3.3±2.4 3.4±2.7 13.4±11.5 3.9±4.5 4.1±5.0 4.9±5.8 3.8±3.2 16.6±18.2 
BW  with 35kg cut off 
above 5.8±1.0 4.4±1.9 4.0±2.0 17.8±6.7 5.2±2.0 5.0±3.4 8.0±2.4 5.2±1.7 23.4±9.3 






 Table 5 – Correlation between measured parameters 
 
Measure   






Thigh girth Flexion Extension CCO VD SF IL-1 SF CRP 
Age rs 1 -0.08 -0.08 0.29 0.32 0.27 0.24 0.22 0.26 -0.07 -0.17 -0.03 0.19 0.22 -0.15  
Sig.  0.47 0.47 0.01* 0.01* 0.02* 0.03* 0.04* 0.02* 0.49 0.11 0.76 0.06 0.84 0.24 
Weight rs -0.08 1 -0.32 0.14 -0.34 -0.02 0.00 -0.43 -0.42 0.07 0.19 0.061 0.03 -0.15 -0.05  
Sig. 0.47  0.03* 0.21 0.74 0.83 0.97 0.01* 0.01* 0.49 0.06 0.57 0.89 0.17 0.71 
Pedometer rs -0.08 -0.32 1 -0.32 -0.32 -0.32 0.13 -0.43 0.42 -0.18 0.19 0.06 0.03 -0.12 0.37 
 Sig. 0.47 0.03*  0.03* 0.03* 0.03* 0.41 0.00* 0.00* 0.24 0.07 0.57 0.79 0.43 0.04 
SI rs 0.29 0.14 -0.32 1 0.71 -0.26 -0.22 -0.31 -0.23 -0.13 -0.18 -0.01 0.071 0.04 0.09 
 Sig. 0.01* 0.21 0.03*  0.00* 0.02* 0.04* 0.01* 0.04* 0.25 0.10 0.96 0.52 0.73 0.46 
Deviation rs 0.32 -0.34 -0.32 0.71 1 -0.09 -0.08 -0.21 -0.12 -0.07 -0.09 -0.03 0.08 -0.06 -0.05 
 Sig. 0.01* 0.74 0.03* 0.00*  0.40 0.52 0.07 0.31 0.53 0.43 0.81 0.46 0.57 0.69 
Termo DV rs 0.27 -0.02 -0.32 -0.26 -0.09 1 0.91 0.39 0.30 -0.02 0.12 0.03 -0.11 0.09 0.05 
 Sig. 0.02* 0.83 0.03* 0.02* 0.40  0.00* 0.00 0.00* 0.85 0.31 0.77 0.32 0.41 0.72 
Termo DV max rs 0.24 0.00 0.13 -0.22 -0.08 0.91 1 0.38 0.33 0.03 0.07 -0.01 -0.06 0.07 0.06 
 Sig. 0.03* 0.97 0.41 0.04* 0.52 0.00*  0.00* 0.00* 0.81 0.53 0.99 0.59 0.51 0.66 
Termo Lat rs 0.22 -0.43 -0.43 -0.31 -0.21 0.39 0.38 1 0.94 -0.12 -0.11 -0.10 -0.17 0.03 0.07 
 Sig. 0.04* 0.01* 0.00* 0.01* 0.07 0.00 0.00*  0.00* 0.29 0.32 0.93 0.12 0.79 0.60 
Termo Lat max rs 0.26 -0.42 0.42 -0.23 -0.12 0.30 0.33 0.94 1 -0.15 -0.14 0.01 -0.14 0.04 0.09 
 Sig. 0.02* 0.01* 0.00* 0.04* 0.31 0.00* 0.00* 0.00*  0.18 0.22 0.89 0.22 0.69 0.46 
Thigh girth rs -0.07 0.07 -0.18 -0.13 -0.07 -0.02 0.03 -0.12 -0.15 1 -0.48 -0.90 -0.13 0.46 0.05 
 Sig. 0.49 0.49 0.24 0.25 0.53 0.85 0.81 0.29 0.18  0.01* 0.00* 0.23 0.00* 0.63 
Flexion rs -0.17 0.19 0.19 -0.18 -0.09 0.12 0.07 -0.11 -0.14 -0.48 1 0.65 0.02 -0.15 0.02 
 Sig. 0.11 0.06 0.07 0.10 0.43 0.31 0.53 0.32 0.22 0.01*  0.00 0.83 0.15 0.89 
Extension rs -0.03 0.061 0.06 -0.01 -0.03 0.03 -0.01 -0.10 0.01 -0.90 0.65 1 0.06 -0.31 -0.01 
 Sig. 0.76 0.57 0.57 0.96 0.81 0.77 0.99 0.93 0.89 0.00* 0.00  0.57 0.00* 0.93 
CCO VD rs 0.19 0.03 0.03 0.07 0.08 -0.11 -0.06 -0.17 -0.14 -0.13 0.02 0.06 1 -0.24 0.13 
 Sig. 0.06 0.89 0.79 0.52 0.46 0.32 0.59 0.12 0.22 0.23 0.83 0.57  0.02* 0.29 
SF IL-1 rs 0.22 -0.15 -0.12 0.04 -0.06 0.09 0.07 0.03 0.04 0.46 -0.15 -0.31 -0.24 1 -0.12 




Table 6 – Correlation between measured parameters and Clinical Metrology Instruments. 
Measure   






Thigh girth Flexion Extension CCO VD SF IL-1 SF CRP 
HVAS rs -0.36 -0.19 -0.19 -0.25 -0.32 0.09 0.14 0.20 0.16 0.12 0.09 -0.01 -0.13 0.12 0.13 
 Sig. 0.01* 0.07 0.19 0.02* 0.00* 0.43* 0.21 0.07 0.16 0.28 0.39 0.95 0.22 0.26 0.29 
PSS rs 0.39 0.16 0.13 0.24 0.27 0.00 -0.12 -0.12 -0.09 -0.14 -0.06 0.04 0.21 -0.09 -0.15 
 Sig. 0.00* 0.12 0.40 0.03 0.02* 0.99 0.27 0.27 0.41 0.18 0.61 0.74 0.05* 0.37 0.23 
PIS rs 0.41 0.19 0.06 0.30 0.31 -0.04 -0.1 -0.1 -0.06 -0.14 -0.09 0.01 0.19 -0.09 -0.17 
 Sig. 0.00* 0.08 0.71 0.00* 0.01* 0.74 0.37 0.37 0.62 0.19 0.39 0.98 0.07 0.36 0.18 
LOAD rs 0.51 0.14 0.01 0.35 0.39 0.09 0.05 -0.05 -0.04 -0.13 -0.07 -0.01 0.24 -0.14 -0.14 
 Sig. 0.00* 0.19 0.95 0.00* 0.00* 0.41 0.65 0.68 0.70 0.25 0.54 0.94 0.02* 0.21 0.28 
COI rs 0.58 0.16 0.05 0.32 0.39 0.14 0.09 -0.01 -0.02 -0.13 -0.11 -0.01 0.22 -0.14 -0.11 
 Sig. 0.00* 0.15 0.75 0.00* 0.00* 0.22 0.41 0.94 0.89 0.23 0.30 0.93 0.04 0.21 0.37 
Stiffness rs 0.58 0.12 0.11 0.30 0.39 0.13 0.08 0.02 0.05 -0.09 -0.12 -0.03 0.19 -0.10 -0.13 
 Sig. 0.00* 0.27 0.45 0.01* 0.00* 0.24 0.48 0.85 0.65 0.36 0.26 0.79 0.06 0.36 0.31 
Function rs 0.62 0.93 -0.05 0.35 0.39 0.13 0.09 0.05 0.08 -0.14 -0.15 -0.02 0.21 -0.15 0.14 
 Sig. 0.00* 0.39 0.73 0.00* 0.00* 0.24 0.42 0.64 0.46 0.21 0.18 0.89 0.05* 0.18 0.28 
Gait rs 0.52 0.19 0.05 0.27 0.36 0.13 0.08 -0.05 -0.04 -0.14 -0.09 0.01 0.26 -0.15 0.09 
 Sig. 0.00* 0.08 0.75 0.01* 0.00* 0.27 0.49 0.59 0.74 0.21 0.41 0.96 0.01 0.18 0.45 
QOL rs 0.55 0.22 0.11 0.33 0.38 0.18 0.13 -0.06 -0.05 -0.14 -0.07 0.00 0.16 -0.11 -0.08 








Osteoarthritis is the most commonly diagnosed joint disease both in human and veterinary 
medicine(Anderson et al., 2018). To our knowledge, this is the first study to describe the influence of 
IL-1 and CRP synovial concentrations levels in several clinical signs, diagnostic imaging, laboratoria l 
findings and clinical metrology instruments results of animals with OA, characterizing the mult ip le 
dimensions of the disease.  
It is well established that OA is a complex low-grade inflammatory process, which affects the 
progression of the disease (Loeser et al., 2012). IL-1 drives this process and increases the expression 
of inflammatory genes and mediators, with median detected concentrations of IL-1β concentrations 
of 109pg/mL in knees with mild OA and 122pg/mL in moderate OA, in an animal model(McNulty 
et al., 2013). We have recorded mean values of 178.3pg/mL for joints with mild OA, 130.6pg/mL for 
joints with moderate OA and 144.7pg/mL for joints with severe OA. Concentration levels were 
significantly higher in mild cases comparing with moderate ones, which may account for the also 
significantly higher thermographic evaluation. Regression analysis determined that the OFA hip score 
could be determined from IL-1 levels. The reason for higher levels in less severe OA grades is still 
unclear, but maybe an indicator of higher inflammatory activity in the early stages of the disease. 
This, however, did not translate in more significant disease-related impairment, since animals with 
mild OA exhibited better scores in several CMIs. This is line with what has been previously described, 
with no relationship being identified between pro-inflammatory and anti-inflammatory biomarker 
concentrations and gait asymmetry in dogs with OA (Allen et al., 2019). 
In some cases, even if in cases without overt lameness, subtle shifts in body weight distribution 
at a stance may be present (Clough et al., 2018; Seibert et al., 2012). This was observed in the present 
sample, with severe OA cases showing worse SI and deviation than mild and moderate cases. 
Synovial IL-1 concentration showed no correlation with measured clinical parameters other than a 
weak, significant correlation with joint extension, but significantly added to the prediction of thigh 
girth and joint extension. It also correlated with the presence of CCO on a VD view and added to the 
prediction of its occurrence in both considered radiographic projections. CCO, in turn, correlated with 
PSS, LOAD and function scores. Cases were CCO was present had higher IL-1 and serum CRP levels, 
and also worse several CMI scores. IL-1 levels may be related to the development of this radiographic 
sign, which then expresses a toll on the patient's levels of pain and activity. This relation is also 
observed when comparing animals with an IL-1 concentration cut off point of 200pg/mL since 
animals with higher concentrations showed a higher frequency of CCO and worse hip grades.  
The potential interest in determining CRP levels is the advantage of it being an objective and 




(Bennett et al., 2013; Borer et al., 2003; Kjelgaard-Hansen et al., 2013; Kum et al., 2013). It has been 
measure in dogs with stifle OA, with concentration levels being higher in cases of OA secondary to 
natural occurring cranial cruciate ligament rupture when compared to normal stifles. However, in 
cases of OA from other anatomical locations, synovial CRP levels were lower (Boal and Miguel 
Carreira, 2015). In this study, we have observed CRP synovial levels, similar to what has previous ly 
recorded in dogs with knee OA (2.5mg/dL in this study vs 2.22 mg/dL) (Boal and Miguel Carreira, 
2015). Registered serum levels were higher than what has been recorded in a cohort of dogs with OA 
(0.8mg/dL in this study vs 0,05mg/dL) (Fujiki et al., 2007). It was interesting to observe that higher 
values of synovial CRP corresponded to better OFA hip grades, higher activity levels as measure with 
the pedometer and PIS and function scores. However, they also had higher thermography values, 
which is usually related to increased inflammatory activity. We also reported higher serum CRP 
concentration levels than what has been previously reported (Fujiki et al., 2007). In the same study, 
CRP levels increased after treatment (Fujiki et al., 2007). It is unclear if higher CRP levels are a 
consequence of high activity levels, micro-lesions within the joint and inflammatory activity within 
the joint, thus leading to the progression of the disease in animals still at an early stage or, on the 
other hand, if higher CRP levels reflect a better prognosis since higher levels after treatment have 
been previously recorded. Further studies must address this question.    
Pain is the most relevant clinical sign of OA and a hallmark of the disease (Piel et al., 2014). 
Together with functional ability, they are of the most critical parameters in the evaluation of OA 
treatment efficacy, with canine studies offering valuable data that may translate to humans  
(Robertson-Plouch et al., 2019; Wiegant et al., 2015). An additional observation was related to the 
relationship between increasing body weight and worse scores with different CMIs, evaluat ing 
different components of OA. At the 35kg cut-off value, the highest considered, animals additiona lly 
showed worse clinical and imaging findings, higher thermography values, worse flexion and higher 
frequency of CCO.  
Further studies, including a control group, with non-lame dogs, would be of interest to validate 
this comparison. Also, we only collected data in a single moment, and therefore cannot comment on 
the interest of each of the findings for the prognosis or treatment monitoring of OA. These aspects 
should be addressed in future studies. 
 
Conclusions 
Intra-articular CS may be a treatment option for some dogs with naturally occurring OA, being 




when compared to other therapeutic options. Further studies are required, aimed at determining which 
are the better candidates for the treatment, and to evaluate alternative drugs and drug dosages. 
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Abstract 
Background: In dogs, thermal imaging has been documented only recently, but a growing interest in this 
modality has led to studies using thermography to assess pathologies in the canine hip, stifle, elbow, intervertebral  
disc, and bone neoplasia. This study aimed to evaluate the use of digital  thermography in assessing and 
evaluating treatment response in dogs with hip osteoarthritis (OA) and comparing its results with an objective 
measure and two clinical metrology instruments. In an experimental, randomized, double-blinded study, one 
hundred hip joints of fifty police working dogs with bilateral hip OA were evaluated. A dorsoventral and lateral 
thermographic image were obtained on days 0, 8, 15, 30, 90, and 180. Mean and maximal temperatures were 
determined. Additionally, the animal’s weight-bearing distribution and radiographic examination of the hip joint 
(extended legs ventrodorsal  
obtained. Results were analyzed by ANOVA, followed by an LSD post-hoc test, and 
correlations were assessed with Spearman correlation coefficient, with p < 0.05. 
Results: Values recorded on the lateral view were higher than those on the dorsoventral view. No differences or  
correlations were found between Orthopedic Foundation for Animals hip grades and temperature. D igital  
         
for 
gait). It also correlated with radiographic findings, specifically the circumferential femoral head osteophyte and  
caudolateral  curvilinear osteophyte. 
Conclusion: To our knowledge, this is the first study presenting the digital  thermography assessment of Police 
working dogs submitted to treatment for hip OA. Digital  thermography, mainly based on a lateral  view evaluation, 
showed a weak significant correlation with stance analysis and clinical metrology instruments scores. 
Alves et al. BMC Veterinary 
Research 









Digital thermography is a contact-free, non-invasi ve 
screening tool that can assess soft tissue injuries, includ- ing 
muscle strains, sprains, tendinopathies, and OA in 
humans, horses, cats, and dogs [1–3]. It relies on identi- 
fying changes in heat in tissue due to disruptions of tissue 
morphology and physiological functions, which in turn 
relate to skin temperature control [4–6]. The rational e 
behind its use is that an injury is often associ- ated with 
variations in blood flow on the affected site, changing the 
skin temperature [7]. Changes in blood flow rate, local 
structures of subcutaneous tissues, and the sympath et i c 
nervous system’s activity are reflected on skin 
temperature through a complex system [1]. Inflammat io n 
in subcutaneous and deeper tissues re- flects temperat ure 
changes in superficial tissues. These changes are a 
product of the inflammation mechanism, which influences 
blood vessels’ diameter, blood flow rate, and capilla ry 
permeability [8, 9]. Digital thermog- raphy can provide a 
reproducible screening tool by describing the specif i c 
changes in each disease process [10, 11]. It has been 
described as useful in humans, horses, and cats [1, 3, 12, 
13]. There has been a growing interest in thermal imaging 
in dogs, with recent reports on thermography use to assess 
pathologies in the canine hip, stifle, elbow, intervertebra l 
disc, and bone neoplasia published [2, 13–18]. These 
studies have described nor- mal thermal imaging of 
different body areas or diseases. Still, there are no studies 
available to our knowledge comparing the results of 
thermal imaging with other evaluation modalities and in 
the evaluation of response to treatment. 
OA is the most prevalent joint disease in dogs, with an 
estimated prevalence of 20% [19–22]. Since the disease 
lacks obvious extra-articular manifestations, it is well  
suited to use a local therapy by intra-articular (IA) injec- 
tion [23]. Commonly used IA treatment modalities in- 
clude corticosteroids (as triamcinolone hexacetoni de) , 
hyaluronan, and autologous platelets [24–26]. Pain is the 
most relevant clinical sign of OA and a hallmark of the 
disease [27, 28]. Several clinical metrology instrum en t s 
have been developed to assess pain and evaluate treat- 
ment response [29]. One of the best clinical metrolo gy 
instrument created for dogs is the Canine Brief Pain In- 
ventory (CBPI), divided into a pain severity score (PSS), to 
evaluate the overall pain magnitude and a pain inter- 
ference score (PIS), to assesses the degree to which pain 
affects daily activities [30–34]. The Canine Orthopaedi c 
Index (COI) is an additional clinical metrology instru- 
ment to evaluate other dimensions of OA’s impact. It is 
divided into stiffness, gait, function, and quality of life 
scores [35–38]. A typical assessment performed during 
the orthopedic examination is evaluating weight distri- 
bution, off-loading, or limb favoring at the stance [39]. 
OA patients exhibit subtle shifts in body weight distribu- tion 
at a stance due to pain or instability [40, 41]. Stance analysis, 
which evaluates individual limb weight-bearing, is an 
objective measure, reported as sensitive for detect- ing 
lameness in dogs [41], and equivalent or superio r 
measurement of hip OA-related pain associated with hip 
OA than vertical impulse and peak vertical force [41]. 
This study aimed to evaluate the use of digital therm- 
ography in assessing and evaluating treatment response in 
dogs with hip OA. As OA is a disease involving mul- tiple 
dimensions, from changes in limb function, ability to 
conduct daily activities, and demeanor [32], we also aimed 
to compare the results of digital thermography to an 
objective measure (weight-bearing evaluation) and two 
clinical metrology instruments (the CBPI and the COI). We 
hypothesize that digital thermography results will correlate 
with the weight-bearing assessment results, the considered 




The sample from this study included 100 limbs of 50 
Police working dogs with bilateral hip OA: 17 German 
Shepherd Dogs, 15 Belgian Malinois Shepherd Dogs, 10 
Labrador Retriever, and 8 Dutch Shepherd Dog, 30 from 
males and 20 females, with a mean age of 6.5 ± 2.2 years, 
bodyweight of 26.7 ± 5.3 kg and body condition score of 4/9 
[42]. Joints were classified as mild (n = 70), moderate (20), 
and severe (10), according to the Orthopedic Foun- dation 
for Animals hip grading scheme [43, 44]. Three images (1 
DV and 2 LT, to have a DV and LT view from each joint) 
were obtained from each animal in six differ- ent 
evaluation moments (days 0, 8, 15, 30, 90, and 180), 
amounting to 900 images. All patients were followed up to 
the last evaluation day. At the initial evaluation (day 0), 
the mean and maximal temperature on the DV were 
24.7 °C ± 1.7 and 25.8 °C ± 1.7, respectively. On the LT 
view, mean and maximal temperatures were 26.1 °C ± 2.3 and 
28.1 °C ± 2.4, respectively. The thermographic evalu- ation 
results in each view by the Orthopedic Foundation for 
Animals hip grades are presented in Table 1. No sig- 
nificant differences or correlations were found between 
OFA hip grade and temperature. 
 
Table 1 Mean and maximal thermographic evaluation values (± 
standard deviation ) of ventrodors al and lateral views, by Orthoped ic 
Foundation for Animals hip grades at the initial evaluation 
 
OFA hip grade Dorsoventral view  Lateral view 
 (°C, mean ± SD)  (°C, mean ± SD) 
 Mean Max Mean Max 
Mild (n = 70) 24.9 ± 1.6 25.9 ± 1.6 26.2 ± 2.2 28.2 ± 2.1 
Moderate (n = 20) 24.9 ± 1.8 25.9 ± 1.9 26.1 ± 2.6 28.2 ± 2.4 
Severe (n = 10) 24.0 ± 1.8 25.0 ± 1.7 25.5 ± 2.6 27.2 ± 2.3 
Alves et al. BMC Veterinary 
Research 









Mean and maximal values of ventrodorsal and lateral  
views on each evaluation day are presented in Table 2. 
Compared to the initial evaluation, significant variations in 
the thermographic evaluation were recorded mainly on 
the lateral view. During follow-up evaluati o n s, 
significant differences in the result of treatment were 
registered with SI (p < 0.01) and deviation (p < 0.01). 
Correlations between thermography evaluation and 
weight-bearing evaluation, on the initial assessment and 
during the follow-up period, are presented in Table 3. 
Correlations between thermography evaluation and clin- 
ical metrology instrument scores on the first assessm en t 
and during the follow-up period are shown in Table 4. 
Considering radiographic findings, at the initial evalu- 
ation, maximal DV, mean and maximal LT therm o - 
graphic evaluations showed a weak correlation with the 
presence of caudolateral curvilinear osteophyte on the 
ventrodorsal view (r = − 0.2, p = 0.05; r = − 0.3, p < 0.01 and 
r = − 0.2, p = 0.04, respectively). 
 
Discussion 
Digital thermal imaging can be used to assess musculo - 
skeletal conditions, including OA, based on the 
variations in blood flow that injury and inflammat io n 
generate, which can affect the skin temperature [7–9]. To 
our knowledge, this is the first study to describe the use 
of digital thermography in the initial evaluation and to 
monitor treatment outcome in dogs with OA. 
Pain is the most relevant clinical sign of OA [27, 28], and 
it is a multi-dimensional experience with functional, sensory, 
evaluative, and affective components [45]. To capture 
information regarding this wide-ranging nature of the 
disease, we choose to compare digital thermog- raphy to 
an objective measure, stance analysis [41], directed at 
evaluating the function, and two different clinical 
metrology instruments, to assess pain and the ability to 
conduct specific daily activities. Previous re- ports 
indicate that SI is reliable indicators of clinical 
Table 2 Mean and maximal thermographic evaluation 
temperature values (±standard deviation) of ventrodorsal and 
lateral views, on each evaluation moment. * indicates significant 
differences when compare d with day 0 evaluation (p < 0.01). 
Negative values represent negative correlations between values 
 
Instant Dorsoventral view  Lateral view 
 (°C, mean ± SD)  (°C, mean ± SD) 
 Mean Max Mean Max 
0 24.9 ± 1.7 25.8 ± 1.7 26.1 ± 2.3* 28.1 ± 2.4* 
8 24.0 ± 2.3 25.5 ± 2.2 30.9 ± 2.3* 34.6 ± 1.6* 
15 26.6 ± 2.2 25.9 ± 2.3 29.5 ± 3.1* 34.3 ± 1.6* 
30 24.8 ± 2.3 26.3 ± 2.3 29.6 ± 2.6* 33.6 ± 1.9* 
90 25.8 ± 1.3 27.1 ± 1.4* 28.5 ± 2.1* 30.7 ± 2.3* 
180 25.5 ± 1.3 26.9 ± 1.2* 28.2 ± 2.1* 30.6 ± 2.1* 
 
Table 3 Correlation coefficients between thermography 
evaluation and weight-bearing evaluation (symmetry index and 
deviation from the normal 20% weight-bearing), on the initial 
evaluation and during the follow-up period. COI – Canine 
Orthopedic Index; PIS – Pain Interference Score; PSS – Pain 
Severity Score; QOL – Quality of Life; SI – Symmetry Index. a 
indicates a significant correlation 
 
 
Initial evaluation Follow up period 
 
Measure SI Deviation  SI Deviation 
Dorsoventral mean rs 0.22 0.06  −0.05 −0.03 
Sig. 0.83 0.59  0.27 0.49 
Dorso ventral max rs 0.48 0.04  −0.12 −0.05 
Sig. 0.65 0.73  0.01a 0.27 
Lateral mean rs 0.04 0.05  0.08 0.09 
Sig. 0.97 0.65  0.08 0.04a 
Lateral max rs 0.03 0.07  0.13 0.10 
Sig. 0.75 0.51  < 0.01a 0.04a 
 
lameness in dogs [46]. Considering a cut-off point of 
18% of weight-bearing for pelvic limbs seems to increase 
sensitivity and specificity [41, 47, 48]. For that reason, we 
compared thermography scores with both SI and 
deviation from the normal value of 20%. During the 
follow-up period, digital thermography results based on 
the lateral view, specifically the maximal value, showed 
low but significant correlations with stance analysis re- 
sults, which provides evidence favoring using a lateral  
view rather than a dorsoventral when monitoring OA 
treatment. Still, the dorsoventral maximal value also  
showed a week significant correlation with SI. This is not 
entirely unexpected, as inflammatory mediators drive OA 
within the joint, and thermography has shown to be a 
reliable technique to assess inflammatory pain and 
differentiate normal from human osteoarthritis pa- tients 
[49–51]. The use of the maximal temperature value may 
better reflect this inflammatory process and nature. It 
may also present an additional advantage for less 
experienced operators than mean values. This last 
approach requires a more precise determination of ana- 
tomical areas of interest and is influenced by incorrect  
inclusion of measurements from non-affected tissues. It is 
also well established that the perception of pain and 
overall joint function is influenced by sensory innerv- 
ation of the tissues that compose the joint, from the 
subchondral bone, periosteum, synovium to the capsule, and 
surrounding tissues, such as muscles [52, 53]. As LT views 
include a more significant amount of muscle masses 
than DV views, which are also involved in the disease 
process and under inflammation, this may ac- count for 
higher mean and maximal temperature values regist ered 
on a lateral view [51, 54]. It may also account for the weak 
significant correlation between LT evalua- tions and pain 
severity scores during the follow-up 
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Table 4 Correlation coefficients between thermography evaluation and clinical metrology instrument scores, on the initial evaluation 
and during the follow-up period. COI – Canine Orthope d ic Index; PIS – Pain Interference Score; PSS – Pain Severity Score; QOL – 
Quality of Life; SI – Symmetry Index. a indicates a significant correlation 
Evaluation Measure  Score  
moment   PSS PIS COI Stiffness Function Gait QOL 
T0 Dorso ventral mean rs −0.01 −0.03 −016 −0.21 −0.11 −0.22 −0.03 
  Sig. 0.89 0.78 0.13 0.04a 0.28 0.04a 0.78 
 Dorso ventral maxi mal rs −0,02 −0.03 −0.14 – 0.17 −0.11 – 0.19 −0.01 
  Sig. 0.89 0.81 0.19 0.10 0.31 0.06 0.97 
 Lateral mean rs −0.04 −0.06 −0.12 – 0.10 −0.41 – 0.21 −0.02 
  Sig. 0.73 0.59 0.28 0.32 0.69 0.04a 0.84 
 Lateral maximal rs −0.01 −0.01 −0.09 – 0.84 −0.07 – 0.17 0.03 
  Sig. 0.99 0.98 0.36 0.42 0.48 0.09 0.81 
Follow up period Dorso ventral mean rs −0.04 −0.04 −0.06 – 0.05 −0.04 – 0.06 −0.07 
  Sig. 0.42 0.36 0.25 0.32 0.38 0.23 0.16 
 Dorso ventral maxi mal rs 0.06 −0.01 −0.01 0.02 0.01 −0.06 −0.01 
  Sig. 0.23 0.91 0.77 0.70 0.91 0.22 0.97 
 Lateral mean rs −0.10 −0.01 0.04 0.03 0.06 0.01 0.08 
  Sig. 0.03a 0.82 0.37 0.59 0.22 0.79 0.08 
 Lateral maximal rs −0.25 −0.06 −0.01 −0.01 – 0.01 −0.1 0.3 
  Sig. < 0.01a 0.22 0.94 0.86 0.79 0.79 0.5 
 
evaluations. An additional reason for these weak but sig- 
nificant correlations (also reflected in the scatter plot) may 
be related to the fact that different evaluation methods 
are capturing different dimensions of OA [32]. 
The thermographic evaluation also correlated with clinical 
metrology instruments scores, specifically gait and 
function, at the initial assessment. This can be explain ed 
by the fact that inflammation, whose effect is recorded by 
digital thermography, reflects affected tissues, their 
contribution to pain perception, and loss of normal function. 
These signs, related to an inability to perform norma l 
daily activities, are most likely to present a patient for 
consultation [29]. As most joints represented in this 
sample were classified as mild OA, they are likely 
expressed mainly on scores that aim to measure 
functionality rather than overall demeanor, such as QOL. 
A weak significant correlation was ob- served with the 
PSS, but not with PIS, and only during the follow-up 
period. This is not entirely unexpected, as patients in this 
study high-drive working dogs, which tend to be stoic and 
usually show only subtle signs of pain, making its 
evaluation more challenging [55, 56]. 
In a human OA study, increased temperatures have 
been related to even slight degenerative changes and low 
temperatures with more severe disease cases [9]. In other 
reports, a correlation between increasing temperature and 
more severe radiographic changes has been descri bed 
[57, 58]. Although no differences were found in the 
thermographic evaluation of different OFA hip grades, 
hip joints classified as severe did have lower values in all 
considered thermographic evaluations, which may signa l 
a trend. With severe OA, a loss of the tissues that 
surround the joint also occurs [1, 51]. These factors may be 
responsible for the decrease in temperature ob- served in 
severe hip grades than moderate hip grades. The evaluati on 
of more hips classified as severe would help clarify this 
fact, as the large majority of joints considered in this study 
were classified as mild. The circumferential femoral head 
osteophyte and the caudolateral curvilinear osteophyte are 
the two features that represent early radio- graphic signs 
that predict the development of the clinical symptoms of 
hip OA [43, 59–61]. This is supported by our results, as 
both showed a correlation with digital thermography 
evaluation and may be linked to the inflam- matory process 
that drives OA and is responsible for producing clinical 
signs. 
This study evaluated digital thermography’s ability to assess and 
assess treatment response in dogs with hip OA by com- paring 
digital thermography results with other commonly used and 
validated evaluation modalities. A limitation of the study is 
related to the fact that evaluated dogs were working dogs, 
which tend to be stoic, making it more challenging to assess 
these patients using the CBPI [55, 56]. Also, the majority of 
animals had mild or moderate OA. It would be of interest to 
include disease-free patients and a larger proportion of 
animals representing the remaining hip grades to describe 
their digital thermography evaluation and this evaluation 
technique’s ability to differentiate between them. 
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To our knowledge, this is the first study presenting the 
digital thermography assessment of Police working dogs 
submitted to treatment for hip OA. Significant variation s 
were observed in the thermographic evaluation of pa- 
tients between initial and follow-up evaluations. Digital 
thermography, mainly based on an LT view evaluati on , 
correlated with weight-bearing distribution and clinical 
metrology instruments scores. It also correlated with the 
presence of caudolateral curvilinear osteophyte on the 
ventrodorsal view at the initial assessment, a finding 
associated with the development of clinical symptoms of 
hip OA. Digital thermography may be an option for the 
screening of dogs with hip OA. 
 
Methods 
The sample comprised one hundred (N = 100) hip joints from 
fifty active police working dogs with naturally occurri n g 
bilateral hip OA, constituting a convenience sample of 
patients presenting for treatment in the Clinica Veteriná ri a 
de Cães of the Guarda Nacional Republicana (Portuguese 
Gendarmerie), after they were first diagnosed. All patients 
were active working dogs and remained in ac- tive work 
during and after this study’s conclusion. For this report, data 
from a longitudinal double-blinded, negative controlled 
study was used. Animals were signaled based on a 
diagnosis consistent with bilateral hip OA. For the 
diagnosis, the dog’s history was considered, in addition to a 
difficulty to perform specific exercises (as rising, jump- ing, 
or maintaining obedience positions, leading to a worse 
performance), a physical examination consistent with hip 
OA (joint pain and stiffness, with a reduced range of 
motion), and an OFA hip scores of mild, moderate or 
severe. Additionally, they should be over 2 years and have a 
bodyweight ≥20 kg [62, 63]. They could not be on any 
medication or nutritional supplements for 6 weeks or 
more to allow a washout period [64]. Animals with any 
other suspected or documented orthopedic, neurological, or 
concomitant disease were excluded. Other conditions were 
ruled out through physical and radiographic examin- ation, 
complete blood count, and serum biochemistry. The same 
researcher examined all patients. 
Using a statistical analysis software, patients were randomly 
assigned to a group and, on day 0 (treatment day), either re- 
ceived an intra-articular administration of 0.9% NaCl (control 
group) or treatment (a platelet concentrate - VPET®, Hylan G-
F 20, stanozolol or triamcinolone hexacetonide), the same to 
both hips, according to the assigned group. All groups had the 
same number of joints (n = 20), and all administrations were 
performed by the same researcher, blinded to the given group. 
No other medications/treatments were administered during 
the follow-up period. 
Thermographic images, CBPI, COI, and weight-bea ri n g 
evaluation results were recorded on days 0, 8, 15, 30, 90, 
and 180, corresponding to the day when the IA treatment  
response was evaluated. These evaluations were con- 
ducted before the IA administration. On each assessment, 
three images were taken sequentially: a dorsoventral view, a 
right lateral view, and a left lateral view, with a FLIR 
ThermaCAM E25® camera. A single researcher, blinded to 
the patient’s assigned group, performed the thermographic 
evaluation. Before image collection, dogs were introduced in 
a room with a controlled temperature, set at 21 °C. They 
were allowed to walk calmly to adjust to room 
temperature for 30 min. During the actual image collec- tion, 
animals were positioned standing in an upright pos- ition, as 
symmetrically as possible. When required, the dog’s 
trainer assisted in maintaining the animal’s position. They 
were allowed to touch the dog’s abdomen but not its torso. 
Each dorsoventral image included the last lumbar vertebra 
area to the first coccygeal vertebra (Fig. 1). This procedure 
has high repeatability between observers and cameras [13]. 
For the lateral views, the greater trochanter was located and 











Fig. 1 A dorsoventral view of two dogs with moderate (left) and severe (right) osteoarthritis. Images include the area from the last lumbar 
  the         distance     indicates the   the   
indicates the anatomical location of the hip joint. Increased temperature areas are observed on the hip joint, but with surrounding lower 
temperatures on the patient with severe OA 
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Figure 3 shows a dog at the time of initial evaluation and 
30 days post-treatment. No fur clipping was performed befo re 
image collection since it can be harmful for 
thermographic evaluation, affecting reading stability for at 
least 60 min after clipping [14]. Image settings were ad- 
justed to include a range of 15–40 °C and emissivity of 
0.98. Thermographic images were analyzed with Tools 
(FLIR Systems, Inc), a Rainbow HC color pallet was se- 
lected, and equal-sized temperature boxes were placed on the 
hip joint’s anatomical area. Mean and maximal tem- 
peratures were determined. 
After image collection, handlers received the publish ed 
instructions for CBPI and COI and completed an online 
copy of each for them. These were completed in sequence by 
the same handler, which was blinded to the group his/ her 
dog was assigned, in each of the follow-up assessments, 
without knowledge of their previous answer. Weight - 
bearing distribution was obtained with the Companion 
Stance Analyzer (LiteCure LLC, Newark, Delaware, United 
States). The equipment was placed on a flat surface in the 
center of a room, at least 1 m from the walls, calibrated at 
the beginning of each day, and zeroed before each evalu- 
ation moment. Animals were encouraged by their handlers to 
stand on to the weight distribution platform, with one foot 
on each quadrant. Gentle restraint was used to main- tain 
the patient’s head in a natural, forward-facing position. For 
each patient, 20 measurements were conducted, and a mean 
value was obtained. Normal weight distribution for each 
limb is considered 20% of the total weight [41], and we also 
considered the deviation from this value, obtained by 
subtracting the weight-bearing of the limb to 20. 
Additionally, a left-right symmetry index (SI) was calcu- 
lated, using the following formula: SI = [(WBR-WBL)/ ((WBR 
+ WBL)× 0.5)]× 100 (WBR = weight-bearing of the right pelvic 
limb and WBL = weight-bearing for the left pelvic limb) [32, 
65]. Negative symmetry index values were transformed to 
positive values. Radiographic images were conducted under 
light sedation, using a combination of medetomidine (0.01 
mg/kg) and buthorphanol (0.1 mg/kg), given intravenousl y. 
A ventrodorsal extended view was obtained, as described 
elsewhere [43]. Since sedation can influence blood 
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anatomical location of the hip joint. Increased temperature areas are observed on the hip joint, but with surrounding lower temperatures on the 









Fig. 3 A dorsoventral view of the same dog at the time of initial evaluation (left) and 30-days post-treatment (right). Arrowhead the direction of 
   indicates the cal   the    indicates the    the   
temperatures are observed at 30-days post-treatment 
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procedure was conducted after weight-bearing and digital 
thermography evaluations. On day 0, the body condi ti o n 
score was determined, according to the Laflamme 
scale [42]. 
Normality was assessed with a Shapiro-Wilk test. Mean 
and maximal values obtained on the dorsoventral view at 
the initial evaluation and during the follow-up period were 
compared with those obtained on the lateral view with 
ANOVA, followed by an LSD post-hoc test, or the Wilcoxon 
test, as appropriate for the data distribu- tion. 
Correlations were assessed with the Spearman cor- 
relation coefficient. Results were analyzed with IBM SPSS  
Statistic s version 20, p < 0.05. 
Abbreviatio ns 
CBPI: Canine Brief Pain Inventor y; COI: Canine Orthope dic Index; DV: Dorsoven tr al 
view; OA: Osteoar thri ti s; PIS: Pain Interferen ce Score; PSS: Pain Severity Score 
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Thermographic imaging of police working 
dogs with bilateral naturally occurring hip 
osteoarthritis 
João Carlos Agostinho Alves1,2* , Ana Margarida Moniz Pereira dos Santos1, Patrícia Isabel Figueiredo Jorge1, Catarina 
Falcão Trigoso Vieira Branco Lavrador2 and L. Miguel Carreira3,4,5 
Thermographic imaging of police working dogs with bilateral naturally occurring hip osteoarthrit is 
 
Background 
Hip osteoarthritis (HOA) is a common problem in the 
canine population. The severity of clinical signs is vari- 
able, and many cases are subclinical [1]. Hip dysplasia is a 
significant predisposing factor, and other factors include 
age, prior joint injury, obesity, genetic predisposition, and 
activity levels. Overall, osteoarthritis accounts for at least 
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80% of cases of lameness and joint diseases in companion 
animals [2–5]. 
Digital thermal imaging is a physiologic, non-invasive, 
contactless, and non-radiating diagnostic tool that relies on 
heat resulting from physiological functions related to skin 
temperature control [6–8]. Skin temperature reflects a 
complex system that depends on blood-flow rate, local 
structures of subcutaneous tissues, and the sympathetic 
nervous  system’s  activity.  Inflammation  in subcutane ous 
and deeper tissues can be reflected by superficial tissue 
temperature changes due to changes in blood ves- sels’  
diameter,  blood  flow  rate,  and  increased  capillary 
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permeability [9, 10]. Digital thermal imaging can be used 
to assess a wide range of musculoskeletal condi- tions, 
including OA, by identifying tissue’s tempera - ture 
changes. It is also useful to monitor rehabilitation progress, 
and, unlike other medical modalities, it is no t related to 
morphology [7, 11, 12]. A 180 × 180 pixel reso- lution has 
been deemed enough to provide reliable results for medical 
uses, but a higher resolution (320 × 240) means smaller 
changes can be detected [13]. It has been described as 
useful in several species, from humans to horses and cats, 
but its clinical utility has rarely been studied in companion 
animals [7, 13–15]. By correlating changes in temperature 
patterns with various diseases, degenerative, or injury 
processes, digital thermography can provide a 
reproducible diagnostic tool, particularly in early disease 
phases [16–18]. Canine thermal imag- ing has been 
documented recently [11], with a growing interest 
reflected in an increase in the number of studies assessing 
thermography use. These reports present this diagnostics 
modality to evaluate a wide range of patholo- gies in 
different joints and the inter-vertebral disc. Type and coat 
colour are variables that must be taken consid- ered, as its 
influence on the evaluation results has been documented 
[12, 13, 19–23]. 
 
Methods 
This study aimed to compare a dorsoventral (DV) and a 
lateral (LT) thermography image views of police work- ing 
dogs presenting with HOA. We hypothesize that both 
views present similar results.  The  study  proto- col was 
approved by the ethical review committee of the 
University of Évora (Órgão Responsável pelo Bem- estar 
dos Animais da Universidade de Évora, approval nº 
GD/32,055/2018/P1, September 25th, 2018). Writ- 
positioned standing in an upright position, as sym- 
metrically as possible. If needed, the trainer could help 
place the dog by holding the dog under the abdomen but  
without  touching  the  dog ’s  torso.  Each  thermo- graphic 
image included the area from the last lumbar vertebra to 
the first coccygeal vertebra at a minimum   at a distance 
of 60 cm (Fig. 1). This procedure has been previously 
described, with high repeatability between observers and 
cameras [14]. Each lateral view was set with the greater 
trochanter in the centre, also at a dis- tance of 60 cm. The 
range of temperature was set at 15–40°C and emissivity 
at 0.98. 
Data from the thermographic images was analyzed with 
the free software Tools (FLIR Systems, Inc), and the  
Rainbow  HC  collor  pallet  was  used.  Both  hips’ mean 
temperatures on the two views were evaluated   by placing 
temperature boxes of equal size on the ana- tomical area 
of the hip joint (Fig. 2). The maximal tem- perature within 
the box was also registered since the goal was to record 
signs of inflammation, a hallmark of OA. Normality was 
assessed with a Shapiro–Wilk test, and mean values 
obtained on the dorsoventral view were compared with 
those obtained on the lateral view with ANOVA, followed 
by an LSD post-hoc test. The same procedure was 
conducted for maximal tempera- tures. Temperature 
values were compared by age, sex, breed, and body weight 
using a paired samples t-test. For weight, cut-off values of 
20, 25, 30, and 35 kg were evaluated. Correlations were 
assessed with the Pearson correlation coefficient. All 
results were analyzed with IBM SPSS Statistics version 
20, and a significance level of P < 0.05 was set. 
ten, informed consent was obtained from  the institution         
responsible for the dogs (Guarda Nacional Republicana, 
Portuguese Gendarmerie). The sample comprised 50 
active police working dogs with naturally occurring bilat- 
eral HOA, signaled from the population of police work- 
ing dogs of the Guarda Nacional Republicana. These 
animals were submitted  to  treatment  for  HOA  and  to 
be included in the study, they should have a body- weight 
≥ 15 kg, be over 2 years, and on no medication or 
nutritional supplements for six weeks or more. The study 
was conducted over 180 days, with images collected on 
days 0, 8, 15, 30, 90, and 180. On each day, three images 
were taken sequentially from each animal: a dorsoventral 
view, a right lateral view, and a left lateral view. All images 
were obtained with a FLIR ThermaCAM E25® camera. 
Before the images were obtained, dogs were allowed to 
walk calmly around a room with a steady tem- perature, 
set at 21 ºC, to adjust to room temperature   for 30 min. 
For the dorsoventral view, animals were 
Fig. 1 Ex ample of a digital thermography  dorsov entral v iew . Each 
image included the area from the last lumbar v ertebra to the first 
coccy geal v ertebra at a minimum at a distance of 60 cm. Arrow head 
indicates cranial direction 












The sample included 50 police working, and four breeds 
were represented: German Shepherd dogs (GSD, n = 17), 
Belgian Malinois Shepherd dogs (BM, n = 15), Labrador 
Retriever (LR, n = 10), and Dutch Shepherd dog (DSD, n 
= 8). Thirty were males and 20 females, with a mean age of 
6.5 ± 2.2 years and bodyweight of 26.7 ± 5.3 kg. Each joint 
was considered a sample unit and evaluated indi- vidually, 
and classified as mild (n = 70), moderate (20), and severe 
(10) according to the Orthopedic Foundation for Animals 
scoring [24]. Three images were obtained from each 
animal in six different evaluation moments, amounting to 
900 images. Mean and maximal values of overall body 
weight and age, by breed and sex, are pre- sented in Table 
1. Mean and maximal values of overall, left, and right 
pelvic limbs thermography values on the DV and LT 
views, by breed and sex, are presented in Table 2. 
 
 
Table 1 Mean and maximal values ( standard deviation) of 
overall body weight and age by breed and sex 
Overall mean values observed in the  DV  and  LT  views 
were significantly different (P < 0.01), and so were maximal 
values (P < 0.01). Mean and maximal values showed low 
correlations (r = 0.10, P = 0.03 and r = 0.15, P < 0.01, 
respectively). Comparing mean and maximal temperatures 
by individual pelvic limb, significant dif- ferences were 
observed on the left hip on the DV and    LT views (P < 
0.01). The same was true for the right hip (P < 0.01). Sti ll, a 
correlation was found between left hip mean values on DV 
and LT views (r = 0.43, P < 0.01), left hip ’s  maximal  values  
on  DV  and  lateral  views  (r = 0.16, P < 0.01), and right hip 
maximal values on DV and LT views (r = 0.14, P = 0.02). 
When comparing male and female dogs, significant 
differences were observed for mean values of the left and right 
hips on the LT view (P < 0.01 and P = 0.03, respec- tively). 
When animals were grouped by body  weight,  with the cut -
off set at 20 kg, significant differences were observed on the 
left hip maximal value on the DV view (P = 0.04), on the 
mean and maximal values of the left hip on the LT view (P < 
0.01 for both), and on the mean and maximal values of the 
right hip on the LT view (P < 0.01 and P = 0.03, respectively). 
Similar results were observed with the cut-off set at 25 kg, 30 
kg, and 35 kg, with sig- nificant differences observed on the 
mean and maximal values of the left hip on the LT view (P < 
0.01 for both) and on the mean and maximal values of the right 
hip on the LT view (P < 0.01 for both). Bodyweight showed a 
cor- relation with mean and maximal values recorded on the 
left LT view (r = −0.34, P < 0.01 and r = −0.30, P < 0.01, 
respectively), and  on  the  right  LT  view  (r =  −0.30,  P < 
0.01 and r = −0.23, P < 0.01, respectively). 
Comparing animals by breed, mean and maximal val - ues for 
the left hip on the DV view was significantly dif- ferent for 
GSD and BM than all other breeds (P < 0.01). No differences 
were observed between RL and DSD. A similar trend was 
observed on the LT for mean values, with significant 
differences observed between all breeds (P < 0.01), except 
DSD and RL and BM. For maximal val- ues, GSD registered 
different values compared to all other breeds (P < 0.01). For 
the right hip on the DV view, no sig- nificant differences were 
observed between breeds. For  the maximal value, significant 
differences were observed between GSD and all other breeds 
(P < 0.01), and BM and RL (P = 0.02). On the lateral view, 
GSD’s mean val- ues were again significantly different from 
other breeds (P = 0.01). Differences were also observed 
between BM and RL (P < 0.01) and RL and DSD (P = 0.03). 
For maxi- mal values, GSD registered different values 















 Bodyweight (kg, Age (yrs, 
mean ± SD) mean ± SD) 
Ov erall 26.7 ± 5.3 6.5 ± 2.2 
German Shepherd dog 29.9 ± 6.4 5.7 ± 1.8 
Belgian Malinois Shepherd dog 27.5 ± 4.1 5.3 ± 1.4 
Labrador Retriev er 24.3 ± 2.5 8.7 ± 2.5 
Dutch Shepherd dog 27.5 ± 4.1 5.3 ± 1.4 
Male 29.3 ± 5.4 6.2 ± 2.4 

















Table 2 Mean and maximal (± standard deviation) values of overall, left, and right pelvic limbs thermography values on the DV and LT views by breed and sex 
Dorsoventral view (º, mean ± SD)   Lateral view (º, mean ± SD)    
Overall        Overall max     Left Left max     Right Right max     Overall       Overall max     Left Left max     Right Right max 
Ov erall 25.3 ± 9.1 26.3 ± 1.9 24.9 ± 1.9 26.3 ± 1.9 25.6 ± 1.2 26.2 ± 2.0 28.4 ± 2.8 31.9 ± 3.1 28.7 ± 2.9 31.9 ± 3.2 29.0 ± 2.8 32.1 ± 2.9 
German Shepherd dog 24.1 ± 1.9 25.3 ± 1.8 24.1 ± 1.8 25.3 ± 1.8 24.0 ± 1.9 25.3 ± 1.8 27.1 ± 2.6 30.8 ± 3.4 26.7 ± 2.5 30.6 ± 3.6 27.4 ± 2.6 31.1 ± 3.1 
Belgian Malinois Shepherd dog 26.0 ± 2.0 26.4 ± 1.9 24.8 ± 1.8 26.4 ± 1.9 27.2 ± 2.3 26.4 ± 1.9 29.1 ± 2.6 32.3 ± 3.0 28.9 ± 2.6 32.2 ± 3.0 29.2 ± 2.6 32.4 ± 2.9 
Labrador Retriev er 25.8 ± 1.7 27.1 ± 1.7 25.8 ± 1.6 27.1 ± 1.6 25.8 ± 1.7 27.1 ± 1.7 30.7 ± 2.4 32.7 ± 2.7 30.6 ± 2.4 32.6 ± 2.7 30.8 ± 2.4 32.9 ± 2.7 
Dutch Shepherd dog 25.7 ± 2.1 26.9 ± 2.1 25.7 ± 2.0 26.9 ± 2.1 25.7 ± 2.1 26.9 ± 2.1 29.7 ± 2.4 32.7 ± 2.7 29.7 ± 2.3 32.7 ± 2.7 29.6 ± 2.5 32.6 ± 2.7 
Male 24.9 ± 2.1 26.1 ± 2.1 24.8 ± 2.1 26.1 ± 2.1 24.7 ± 2.1 26.1 ± 2.1 28.6 ± 2.9 31.8 ± 3.2 28.4 ± 2.9 31.7 ± 3.3 28.7 ± 2.9 31.9 ± 3.1 

























Digital thermography provides a visual map of the skin 
temperature distribution.  A  difference  of  more  than 1 
°C between similar areas or tissues is considered sig- 
nificant, and the identification of inflammation, charac- 
terized by, among others, an  increase in  temperature, is 
a critical step in determining the appropriate treat- ment 
[7, 15]. In dogs, thermography has been able to identify 
animals with dysplastic elbows and cranial cruciate 
ligament deficiency, compared with sound animals [20, 
22]. All animals included in this study had bilateral HOA, 
and therefore we only evaluated con- tralateral 
differences. When comparing values for the hip joint ’s 
anatomical region on the DV and LT views, significant 
differences were observed. The main reason for this 
difference may be the larger amount of muscle masses 
included in the LT view area, thus contributing to higher 
temperature values. Still, the values observed on different 
views showed some correlation. This effect was also 
observed when comparing dogs with different cut-off 
points for bodyweight and males and females (male dogs 
being heavier), with increasing body weight always 
accounting for higher temperature levels. These 
differences were observed on mean and maximal scores. 
A thermographic value of 28.47 °C ± 0.45 on an LT view 
has been described in healthy LR. However, this value 
was for a region of interest that encompassed the most 
proximal third of the pelvic limb and not the hip joint area 
specifically [19]. Similar values (28.4 °C ± 2.8) were found 
when the overall sample was considered, but higher values 
in the LR dogs (30.7 °C ± 2.4). This difference  may  be  
associated  with  OA’s  changes,  but further studies should 
address this hypothesis. 
Working and sporting dog owners and trainers are 
frequently reluctant to clip their dogs, and it has not been 
proven as necessary for the thermographic evalu- ation of 
structures in dogs. Fur clipping can be harmful during a 
thermographic evaluation since a minimum   of 60 min 
after clipping is required for stable readings to be 
acquired [19]. Still, the coat’s type and color are variables 
that must be taken into account, and their influence 
evaluated, as it tends to be predictable [12, 20, 23]. All of 
the breeds included in this study had short hair, and some 
had a double coat. The majority   of GSD included were 
sable, BM fawn, LR yellow, and DSD bridle. Comparing 
thermography evaluation by breed, the most consistent 
difference was the lower val- ues observed in GSD, even 
though these were heavier dogs. The reason for this is 
unclear but may be related to coat characteristics since 
GSD usually have a very thick undercoat. Some coats can 
also  make  it  harder to locate the area of interest, mainly 
when the hair is 
very long and/or thick [14, 25]. Strong knowledge of the  
area  of  interest’s  anatomical  landmarks  is  para- mount 
to obtain valuable and correct information from the 
thermographic images [13]. This identification was not 
particularly problematic in this study but would 
undoubtedly be more challenging in longhaired or 
overweight/obese dogs. These variations in coat further 
stress the importance of guaranteeing an adjustment 
period in a temperature-controlled room. In horses, it has 
been suggested that there is no need for such an 
adjustment or equilibration time before thermographic 
imaging. This could be because a horse is much bigger 
and produces more heat than a dog [26], and also, with 
less variation in coat types. For those reasons, this sug- 
gestion probably cannot be applied to dogs. We also chose 
to register and analyse maximal scores as higher 
temperature levels could be related to inflammation.  For 
that reason, it may better reflect the events that occur 
during OA development. 
Conclusions 
This is the first study presenting two different digital ther- 
mography views of dogs diagnosed with HOA. Signifi- 
cantly higher values were recorded on an LT view. Coat 
characteristics influenced thermographic evaluations. 
Further  studies  are  required  to  determine  each  view’s 
interest and the influence of different coats in HOA treat- 
ment monitoring. 
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We aimed to test construct and criterion validity of four Clinical Metrology Instruments 
(CMIs) for the evaluation of naturally occurring canine OA model. Fifty Police working dogs with 
bilateral hip OA were assessed in a prospective, randomized, double-blinded study. Patients were 
evaluated using a stance analyzer in six different moments, divided over a 180-day period. Pedometer 
step count, weight-bearing symmetry index and deviation from normal weight-bearing were 
calculated and used as criterion validity. In each evaluation moment, a copy of the Hudson Visual 
Analogue Scale, Canine Brief Pain Inventory, Liverpool Osteoarthritis in Dogs and Canine 
Orthopedic Index were completed by the dogs’ handlers. Correlations between CMIs were evaluated 
as construct validity. Further evaluation was performed with the Kaiser-Meyer-Olin measure of 
sampling adequacy, Eigenvalue and scree-plot analysis.  Internal consistency was tested with 
Cronbach’s α. 
A significant weak correlation was found between all CMIs and stance analysis symmetry 
index measure and deviation, indicating criterion validity. A significant weak correlation was also 
found between pedometer count and LOAD plus COI. Cronbach’s α was 0.80 for HVAS, 0.98 for 
CBPI, 0.97 for LOAD and 0.98 for COI. A significant strong correlation was observed between CMIs, 
indicating construct validity.  
We presented criterion and construct validity of these CMIs, which are able to capture various 
dimensions of OA. They can be used for the evaluation of naturally occurring canine osteoarthrit is 
models.  
Keywords: Osteoarthritis, Pain, Dog, Animal Model, Clinical Metrology Instruments. 
 
Introduction 
Osteoarthritis (OA) is an important and costly disease in humans and dogs [27,45], being the 
most commonly diagnosed joint disease both in human and veterinary medicine. It represents a 
significant burden to societies, as it affects the quality of life, performance and implies a high cost in 
terms of healthcare [12,52]. The dog is the closest to a gold standard model, due to anatomica l 
resemblance, disease progression, same shared environment and lifestyle, with the advantage of 
providing a faster disease progression [16,23,29–31,33,37]. Exploring spontaneous dog OA under the 
One Medicine initiative can help improve the health and well-being of both humans and dogs [31]. 
Pain is the most relevant clinical sign of OA and a hallmark of the disease [38,52]. Since it is 
central in both human and veterinary clinical practice, the current therapeutic goal for both is the 
management of pain and associated loss of function [7,9]. Several clinical metrology instruments 




discriminatory, responsiveness and criterion validity as measures of pain and impairment in 
performing daily activities, and represent a patient-centred approach [17,31,42]. Two of the most 
widely used are the Canine Brief Pain Inventory (CBPI) and the Liverpool Osteoarthritis in Dogs  
(LOAD) [18,25,48,49]. The CBPI encompasses two sections, a pain severity score (PSS) and a pain 
interference score (PIS). The first assesses the magnitude of the pain of the animal and the second 
assesses the degree in which pain affects daily activities [44]. The Canine Orthopaedic Index (COI) 
has been developed to assess 4 dimensions of OA in dogs: stiffness, gait, function and quality of life  
[3]. The Hudson Visual Analogue Scale (HVAS) has been compared with force plate analysis, shown 
to be repeatable and valid to assess the degree of mild to moderate lameness [21]. 
Weight distribution and off-loading or limb favouring at the stance is a commonly used 
subjective assessment during orthopaedic examination [26]. Patients with OA may not be overtly 
lame but exhibit subtle shifts in body weight distribution at a stance [11,41]. Stance analysis has been 
reported as sensitive for detecting lameness in dogs [10]. It has been proposed that bodyweight 
distribution at a stance may be an equivalent or superior measurement of hip OA pain than both 
vertical impulse and peak vertical force [11,24]. Mobility impairment and decreased activity are 
associated with musculoskeletal pain in humans, and improved results in regards to mobility have 
been recommended as measures of outcome [25]. Pedometers are inexpensive, simple devices that 
measure ambulatory activity with acceptable accuracy [43]. 
The aim of this study was to compare HVAS, CBPI, LOAD and COI with each other, to 
evaluate construct validity. We also aimed to compare these CMIs to objective measures (weight-
bearing and pedometers step counts) to test criterion validity and compare changes in a follow-up 
study. In addition, we wanted to test factor analysis of the CMIs.  We hypothesized that correlation 
would be found between the four considered CMIs, and also between them and the considered 
objective measures. 
 
Materials and Methods 
The study protocol was approved by the ethical review committee of the University of Évora 
(Órgão Responsável pelo Bem-estar dos Animais da Universidade de Évora, approval nº 
GD/32055/2018/P1, September 25th, 2018), and comply with relevant institutional and nationa l 
guidelines for the care and use of animals. Written, informed consent was obtained from the 
Institution responsible for the animals. A sample of 50 Police working dogs (N=50) of both sexes 
was used, a convenience sample selected for a longitudinal double-blinded, negative controlled study, 
evaluating intra-articular treatment modalities in a naturally occurring canine OA model. Data from 




evaluation being used as a cross-sectional cohort, while follow-up evaluations, assessing response to 
treatment, constituted the longitudinal cohort. Inclusion and exclusion criteria were defined by 
research activity other than that currently reported and are summarized in table 1. 
Table 1 – Inclusion and exclusion criteria. 
Inclusion criteria Exclusion criteria 
Mobility impairment, as described by the trainer and 
detect by the assisting veterinarian; 
Suspected or diagnosed neurological/musculoskeletal 
disorder other than hip OA; 
Bodyweight ≥15kg; Documented or suspected presence of concomitant disease; 
Age ≥1 year; Receiving any other drugs; 
Radiographic evidence of bilateral OA of the hip 
joint; 
Results of routine blood testing outside normal limits; 
Not to be on any medication or nutritional 
supplements for six weeks or more; 
 
The study was conducted over a period of 180 days, and data was gathered on days 0, 8, 15, 
30, 90 and 180. On day 0 (treatment day), patients either received an intra-articular administration of 
0.9% NaCl (control group) or a treatment (a platelet concentrate, Hylan G-F 20, triamcino lone 
hexacetonide or stanozolol), according to the assigned group. All groups had the same number of 
animals. No other medications/treatments were administered during the follow-up period. In all 
evaluations moments, a copy of all CMIs was completed by the handlers, stance analysis was 
performed, and pedometer count was recorded. 
Before completion of an online copy of the HVAS, CBPI, COI and LOAD, handlers received 
the published instructions for each of them. The CMIs were completed in sequence by the same 
handler in each of the follow-up assessments, without knowledge of their previous answer, in a quiet 
room with as much time as needed to answer all items. As CBPI has two sections (PSS and PIS), and 
COI has four dimensions (stiffness, function, gait and QOL), were considered all sections and 
dimensions in the analysis. 
Stance analysis was conducted with a weight distribution platform (Companion Stance 
Analyzer; LiteCure LLC®, Newark, Delaware, United States). According to manufac turer’s 
guidelines, the platform was placed in the center of a room, at least 1 meter from the walls, and 
calibrated at the beginning of each day and zeroed before each data collection. After a period of 
familiarization with the space, animals were encouraged by their handlers to stand on to the weight 
distribution platform, with one foot on each quadrant of the platform, while maintaining a natural 
stance with their centre of gravity and stability (measured by the platform) near the middle of the 




position. Evaluations were conducted in the morning, and no exercise or activity was performed 
before it, as exercise can exacerbate pelvic limb lameness and a potential factor of variation during 
gait evaluation [1]. For all animals, at least 20 measurements were performed, and the mean value 
determined. Handlers were unaware of the evaluation results before completing the CMIs. Normal 
weight distribution for the pelvic limbs was considered 40% (20% right pelvic limb + 20% left pelvic 
limp) of the total weight [11].  
Pedometers were worn around the dog’s neck, attached to an adjustable lightweight collar, so 
that they detected and counted forelimb steps only, associated with greater accuracy at a walk, trot or 
run [8]. They were placed one week before the first evaluation moment, in order to determine a 
baseline value, and then maintained up to the 30th-day post-treatment. For the 90th and 180th post-
treatment days evaluation, the animals worn the pedometer for a week before that evaluation moment. 
Mean daily counts were considered and calculated by dividing the register number of steps by the 
number of days considered. 
To test criterion validity, CMI scores were compared with the left-right symmetry index (SI), 
calculated with the following formula: SI=[(WBR-WBL)/((WBR+WBL)x0.5)]x100 [46,47,49], 
where WBR is the value of weight-bearing for the right pelvic limb, and WBL is the value of weight-
bearing for the left pelvic limb. Negative values were made positive. As normal weight-bearing for 
the pelvic limbs is 40%, we also considered the deviation from this value, obtained subtracting 
WBR+WBL to 40.  To additionally test validity, we compared CMI scores against changes in activity, 
considered as changes in mean daily step count with the pedometers. 
We compared results of the CMIs using repeated-measures ANOVA, with a Huynh-Feld t 
correction and tested construct validity by comparing individual CMI scores against all others. The 
correlation was assessed with Spearman’s rank correlation coefficient, with p<0.05. Additionally, we 
performed factor analysis for all CMIs, using the Kaiser-Meyer-Olin (KMO) measure of sampling 
adequacy, with adequacy considered >0.6. Eigenvalue and scree-plot analysis were used to assess 
extracted values, and item loading on the extracted components was based on a varimax-rota ted 
model of factor analysis. A communality cut-off value of 0.4 was considered. Internal consistency 
for all CMIs was tested with Cronbach’s α. 
 
Results 
The sample included 50 Police working dogs, of both sexes (30 males and 20 females), with 
a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg. Four breeds were represented: German 




Dutch Shepherd Dog (n=8). In the six considered evaluation moments, a response for all CMIs was 
obtained for every animal, accounting to 300 responses for each CMI. 
Correlations for the cross-sectional cohort are presented in table 2. A significant strong 
correlation was observed between all CMIs. A significant weak correlation was observed between SI 
and COI, and its dimensions Stiffness, Function and Gait.  A significant moderate correlation was 
also observed pedometer step count and LOAD, COI, Stiffness, Function, Gait and QOL. Scatterplot 
of COI versus SI is presented in figure 1. Correlations for the longitudinal cohort between changes of 
different evaluations performed are presented in table 3.  
Significant strong correlations were observed between all CMIs. Additional, significant weak 
correlations were observed between SI and all other evaluations except pedometer step count. The 
same was found for deviation. Scatterplot of LOAD versus HVAS, PIS, PSS and COI are presented 
in figures 2, 3, 4 and 5, respectively. Scree plots for HVAS, CBPI, LOAD and COI are presented in 
figures 6, 7, 8 and 9, respectively. 
Comparing CMI results, Mauchly’s test rejected the present of sphericity (χ2(35)=5189, 
p<0.01). The difference between mean scores was significantly different, with F(1.18, 
320548)=257845, p<0.01. Cronbach’s α was 0.80 for HVAS, 0.98 for CBPI, 0.97 for PIS, 0.98 for 
PSS, 0.97 for LOAD, 0.98 for COI, 0.97 for stiffness, 0.97 for function, 0.96 for Gait and 0.85 for 
QOL. Kaiser-Meyer-Olkin factor analysis was 0.88 for HVAS, 0.94 for CBPI, 0.96 for LOAD and 
0.96 for COI. As all values were above 0.8, factor analysis was conducted for the four CMIs. Scree 
plots for HVAS, CBPI, LOAD and COI are presented in figures 6, 7, 8 and 9, respectively. For HVAS, 
two factors with eigenvalues>1 were extracted. These factors accounted for 60.2% and 13.3%, 
respectively, of the total variance. Based on the varimax-rotated solution, loading for these items was 
performed. All items loaded heavily on the first component, with communalities ranging between 
0.68 and 0.91. For the second component, not all items showed significant communalities, with values 
ranging from -0.39 to 0.65.  For CBPI, a single factor was extracted, which accounted for 90.9% of 
the total variation. All other items loaded heavily on this component, with communality being >0.93. 
For LOAD, two factors were extracted and were responsible for 76.1% and 10.5% of the total 
variance, respectively. Other items loaded mainly on the first component, with commonalties ranging 
from 0.71 to 0.94. For COI, also only one factor was extracted, accounting for 79.5% of the total 





Table 2 – Correlations for the cross-sectional cohort. CBPI – Canine Brief Pain Inventory; COI – Canine Orthopedic Index; HVAS – Hudson 1 
Visual Analogue Scale; LOAD – Liverpool Osteoarthritis in Dogs; PIS – Pain Interference Score; PSS – Pain Severity Score; QOL – Quality of 2 
Life; SI – Symmetry Index. * indicates significant correlation.  3 
 4 
Measure   SI Deviation Pedometer HVAS PIS PSS LOAD COI Stiffness Function Gait QOL 
SI rs 1.00 .072 -.040 -.203 .036 .196 .300 .324 .026 .367 .324 .177  
Sig.  .617 .823 .161 .300 .178 .036* .023* .318 .010* .023* .224 
Deviation rs .072 1.00 -.200 -.151 .198 .210 .169 .240 .180 .233 .229 .265  
Sig. .617  .256 .200 .174 .147 .245 .096 .216 .107 .114 .066 
Pedometer rs -.040 -.200 1.00 .326 .-323 -.323 -.425 -.523 -.531 -.499 -.427 -.530 
 Sig. .823 .256  .060 -.063 .078 .012* .002* .000* .003* .012* 0.01* 
HVAS rs -.203 -.151 .326 1.00 -.806 -.775 -.698 -.643 -.640 -.578 -.577 -.652 
 Sig. .161 .200 .060  .000* .000* .000* .000* .000* .000* .000* .000* 
PIS rs .036 .198 .-323 -.806 1.00 .966 .831 .842 .808 .774 .793 .801 
 Sig. .300 .174 -.063 .000*  .000* .000* .000* .000* .000* .000* .000* 
PSS rs .196 .210 -.323 -.775 .966 1.00 .784 .811 .772 .722 .770 .800 
 Sig. .178 .147 .078 .000* .000*  .000* .000* .000* .000* .000* .000* 
LOAD rs .300 .169 -.425 -.698 .831 .784 1.00 .936 .918 .910 .854 .848 
 Sig. .036 .245 .012* .000* .000* .000*  .000* .000* .000* .000* .000* 
COI rs .324 .240 -.523 -.643 .842 .811 .936 1.00 .964 .937 .954 .905 
 Sig. .023* .096 .002* .000* .000* .000* .000*  .000* .000* .000* .000* 
Stiffness rs .026 .180 -.531 -.640 .808 .772 .918 .964 1.00 .885 .907 .836 
 Sig. .318 .216 .001* .000* .000* .000* .000* .000*  .000* .000* .000* 
Function rs .367 .233 -.499 -.578 .774 .722 .910 .937 .885 1.00 .830 .810 
 Sig. .010* .107 .003* .000* .000* .000* .000* .000* .000*  .000* .000* 
Gait rs .324 .229 -.427 -.577 .793 .770 .854 .954 .907 .830 1.00 .809 
 Sig. .023* .114 .012* .000* .000* .000* .000* .000* .000* .000*  .000* 
QOL rs .177 .265 -.530 -.652 .801 .800 .848 .905 .836 .810 .809 1.00 





Table 3 – Correlations for the longitudinal cohort. CBPI – Canine Brief Pain Inventory; COI – Canine Orthopedic Index; HVAS – Hudson Visual 6 
Analogue Scale; LOAD – Liverpool Osteoarthritis in Dogs; PIS – Pain Interference Score; PSS – Pain Severity Score; QOL – Quality of Life; SI 7 
– Symmetry Index. * indicates significant correlation.  8 
Measure   SI Deviation Pedometer HVAS PIS PSS LOAD COI Stiffness Function Gait QOL 
SI rs 1.00 .261 -.040 -.152 .196 .130 .230 .211 .177 .227 .195 .202  
Sig.  .000* .823 .013* .001* .033* .000* .001* .004* .000* .001* .001* 
Deviation rs .261 1.00 -.200 -.127 .141 .112 .133 .174 .129 .156 .191 .179  
Sig. .000*  .256 .038* .021* .068 .030* .004* .035* .010* .002* .003* 
Pedometer rs -.040 -.200 1.00 .063 -.147 -.118 -.168 -.183 -.167 -.260 -.135 -.122 
 Sig. .823 .256  .412 .055 .125 .028* .017* .029* .001* .078 .111 
HVAS rs -.152 -.127 .063 1.00 -.830 -.814 -.736 -.716 -.695 -.057 -.677 -.732 
 Sig. .013* .038* .412  .000* .000* .000* .000* .000* .355 .000* .000* 
PIS rs .196 .141 -.147 -.830 1.00 .956 .844 .853 .828 .805 .808 .813 
 Sig. .001* .021* .055 .000*  .000* .000* .000* .000* .000* .000 .000* 
PSS rs .130 .112 -.118 -.814 .956 1.00 .807 .817 .792 .755 .783 .785 
 Sig. .033* .068 .125 .000* .000*  .000* .000* .000* .000* .000* .000* 
LOAD rs .230 .133 -.168 -.736 .844 .807 1.00 .954 .928 .919 .912 .863 
 Sig. .000* .030* .028* .000* .000* *  .000* .000* .000* .000* .000* 
COI rs .211 .174 -.183 -.716 .853 .817 .954 1.00 .966 .952 .965 .916 
 Sig. .001* .004* .017* .000* .000* .000* .000*  .000* .000* .000* .000* 
Stiffness rs .177 .129 -.167 -.695 .828 .792 .928 .966 1.00 .906 .919 .847 
 Sig. .004* .035* .029* .000* .000* .000* .000* .000*  .000* .000* .000* 
Function rs .227 .156 -.260 -.643 .805 .755 .919 .952 .906 1.00 .872 .836 
 Sig. .000* .010* .001* .000* .000* .000* .000* .000* .000*  .000* .000* 
Gait rs .195 .191 -.135 -.677 .808 .783 .912 .965 .919 .872 1.00 .965 
 Sig. .001* .002* .078 .000* .000* .000* .000* .000* .000* .000*  .000* 
QOL rs .202 .179 -.122 -.732 .813 .785 .863 .916 .847 .836 .965 1.00 






Figure 1 – Scatterplot of COI (Canine Orthopedic Index) versus SI (symmetry index) in the cross-
sectional cohort. A significant weak correlation was observed (r=0.21, p<0.01). 
 
 
Figure 2 – Scatterplot of LOAD (Liverpool Osteoarthritis in Dogs) and HVAS (Hudson Visual 






Figure 3 – Scatterplot of LOAD (Liverpool Osteoarthritis in Dogs) and PIS (Pain Interference Score) 
in the longitudinal cohort. A significant strong correlation was observed (r=-0.844, p<0.01).  
 
Figure 4 – Scatterplot of LOAD (Liverpool Osteoarthritis in Dogs) and PSS (Pain Severity Score) in 





Figure 5 – Scatterplot of LOAD (Liverpool Osteoarthritis in Dogs) and COI (Canine Orthopedic 
Index) in the longitudinal cohort. A significant strong correlation was observed (r=-0.954, p<0.01).  
 
Figure 6 – Scree plot of factor analysis of HVAS (Hudson Visual Analogue Scale). Two factors had 





Figure 7 – Scree plot of factor analysis of CBPI. One factor had Eigenvalues >1, with a discernib le 
“shoulder” observed. 
 










A good understanding and evaluation of canine pain, and its toll on daily activities, is 
paramount to the development of treatments of chronic conditions, such as OA [15,22]. To our 
knowledge, this study first presents evidence of criterion validity for HVAS and COI. It has been 
described for LOAD and CBPI [49] but, for the first time, we compared the scores of these four CMIs 
with stance analysis and mean daily step count, as an outside measure of disease. We also presented 
construct validity for all of the instruments, as well as their internal consistency. 
The evaluation of instrument validity provides evidence that it measures what it is supposed 
to measure. One of the assessments to make is construct validity, which can be performed by testing 
the agreement of the instrument with a recognized “gold standard” [40,49]. Weight distribution 
platform, as a pressure-sensitive walkway, can provide accurate and consistent measures of weight 
distribution with no significant difference between devices [2]. It has been proposed that bodyweight 
distribution at a stance may be an equivalent or superior measurement of pain associated with hip OA 
than both vertical impulse and peak vertical force [11,24]. Previous reports indicate that SI is reliable 
indicators of clinical lameness in dogs [36]. The CBPI has been reported as being able to detect a 
measurable effect for individual animals assessment, with results correlating with PVF [4–




platform [18,49], as has the HVAS [39]. Significant weak correlations of LOAD and CBPI with SI 
peak vertical force have also been described, but these dogs had OA of a single joint [49]. In the 
present report, all animals had bilateral disease, and we used as an external measure of disease weight-
bearing using a stance analyzer. We found a significant but weak correlation between SI and COI, 
stiffness, function and gait scores in the cross-sectional cohort longitudinal cohort. In the longitud ina l 
cohort, this significant weak correlation was observed with all CMI. The fact that the correlations 
found are weak is not completely unexpected, as CMIs aim to evaluate OA as a whole, from its signs 
to the impact it has on the animal’s life, while stance analysis is directed at evaluating function. This 
may explain why, in the cross-sectional cohort, correlations occur precisely with the scores that aim 
to evaluate more functional parameters of the disease. An additional possibility is the fact that all 
animals exhibited bilateral disease, which may lead to less marked asymmetries between contralatera l 
limbs. We still chose to use this evaluation, as even bilateral disease does not necessarily show equal 
signs in both limbs. Also, and since all animals had bilateral hip OA, we performed a second analys is 
with the stance analyzer, to measure the deviation from the normal weight distribution on the pelvic 
limbs. This evaluation also showed a significant weak correlation with all CMIs scores, except for 
PSS. The weight-bearing evaluation also has the advantage of allowing comparisons between 
different breeds and can still evaluate dogs that are unable to trot [49]. A second external measure of 
disease, which was mean daily step counts, was used. Mobility impairment and decreased activity are 
associated with musculoskeletal pain in humans, with improved results regarding mobility have been 
recommended as measures of outcome [25]. Pedometers have the advantage of activity monitor ing 
over a prolonged period in the patient’s home environment [8,48]. In normal dogs, pedometer steps 
can reasonably estimate distance travelled, and recording data over several days, in opposition to 
single-day recordings, has demonstrated to help avoid anomalies in other species [13,50]. We 
observed a significant moderate correlation with LOAD and COI in the cross-sectional cohort and a 
weak correlation with the same CMIs in the longitudinal cohort. The reason for a weaker correlation 
on the longitudinal cohort may be associated with the fact that the animals of this sample are active 
working dogs. This means that the overall activity of these animals is not only voluntary activity but 
also varies with operational activity. For example, if one of the search and rescue dogs is engaged in 
a real situation, and not just training, during the pedometer evaluation week, it will increase the 
activity count. This “individual” effect may be balanced in this analysis with the fact that the 
work/training/rest routines are quite balanced within the population so that the animals do not go 
through long periods where they kennelled or under intense workloads. We anticipated that an 
increase in patient complaints (reflected in CMI scores) would correspond to higher activity levels 




and pedometer counts followed the significant variations observed in these two CMIs scores, meaning 
that activity levels (measured by the pedometer count) increase, CMIs scores reduce (corresponding 
to better scores). A possible explanation for this may be an increase in spontaneous and playing 
activity, since an animal that has less pain will probably move more and be more willing to play with 
the handler, which is also more likely to engage in these activities, seeing the animal more active.  
Construct validity can be assessed through factor analysis or by comparing the results of 
different instruments. Internal consistency is most frequently tested using Cronbach’s α [40,42,49]. 
A strong correlation was observed between CMIs in both cohorts. Previous reports have observed 
moderate to good correlation between LOAD and CBPI [34,49]. Each CMI was designed based on 
different animal populations, encompassing different breeds, sizes and OA in different joints. In 
addition, OA is a multidimensional disease, and different CMIs may evaluate or capture different 
components of the disease. Factor analysis for some of the CMIs extracted a different number of 
components when compared with previous reports: of LOAD, 2 components were extracted, 
compared with the 3 described components [49]; of CBPI, 1 component was extracted, similar to one 
report [49], but differing with the 2 components in another [5]; and of COI, 1 component was 
extracted, in contrast with 4 component in a previous study [3]. Different factor analysis with a 
different population is not unusual. In terms of composition, our sample is homogeneous compared 
with those of previous reports, with fewer breeds, similar in size and conformation, all with bilatera l 
OA of the same joint, and with similar levels of activity. Another possible explanation may be relate d 
to the proxy completing the CMIs. It has been described that quantifying pain and attributing it a 
score is subjective and, therefore, may lack validity when performed by individuals unfamiliar with 
signs of pain [19,20]. In our study, the proxy for all dogs were experience handlers, used to observe 
working and sporting dogs, particularly their own, and detect changes in movement pattern, 
performance losses and, possibly, changes in response to treatment. Alternative construct validity was 
performed through factor analysis. Factors extracted with eigenvalues greater than one or through 
scree-plot analysis were the same: two for HVAS and COI and one for CBPI and COI. Item loading 
of the components for HVAS and LOAD identified items that could be described with “ability to 
exercise/how often does the dog stop during exercise”, “mobility/attitude” and “stiffness/disability”. 
Even though CBPI and COI share some similar items with HVAS and LOAD, as the ability to rise or 
jump, stiffness and demeanour, this has not resulted in the extraction of more components. For CBPI, 
this has been described before [49]. Still, we presented enough data that shows that these CMIs 







In this study, we determined criterion and construct validity of four different CMIs. These 
instruments were able to capture the various aspects of what constitutes the multi-dimensiona l 
experience that is OA. Therefore, they are valid tools to be used for the evaluation of naturally 
occurring canine osteoarthritis models. 
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Osteoarthritis (OA) is the most commonly diagnosed joint disease in veterinary medicine, and 
weight distribution, off-loading or limb favouring at the stance is a commonly used subjective 
assessment during the orthopaedic examination. To describe the weight-bearing compensation that 
occurs in police working diagnosed with bilateral hip OA, fifty police working dogs with bilatera l 
hip OA were evaluated with a weight distribution platform at the time of initial evaluation and after 
different intra-articular treatments. Six evaluation sessions were performed, spread by 180 days. 
Results were compared by breed, age, sex, weight and OFA scores with the Independent Samples T-
Test, one-way ANOVA and Pearson correlation coefficient, with p<0.05. 
Animals had a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg. No significant 
differences were observed when comparing weight-bearing for different breeds, sex, hip grades or 
different cut-offs for weight during the initial evaluation. A weight shift from pelvic to thoracic limbs 
was observed, with a weak significant correlation found between a pelvic limb and the opposing 
contralateral thoracic limb. During the follow-up period, Labrador Retrievers showed higher 
symmetry index and deviation from normal values than German Shepherd Dogs and Dutch Shepherd 
Dogs, as did male comparing with females dogs. At this period, the symmetry index showed a 
significant, week correlation with body weight. Weight-bearing of all limbs correlated with the 
remaining limbs, reflecting a more balanced weight distribution. 
This study describes weight-bearing redistribution in dogs with bilateral hip OA, providing 
important information for the evaluation of this prevalent condition, but also in response to treatment.  
Keywords: Dog; Osteoarthritis; Hip; Weight bearing; Stance Analysis. 
 
Introduction 
Gait analysis, and the measurement of ground reaction forces (GRF), are a well-established 
method to describe gait and severity of an existing lameness, with a 90% sensitivity and specificity[1 –
3]. It is an area of increasing interest, to assess response to surgical procedures, treatment outcome, 
orthopaedic conditions and breed differences[4–8]. Osteoarthritis (OA) represents at least 80% of the 
cases of lameness and joint diseases in companion animals, making it the most frequently diagnosed 
joint disease in veterinary medicine. There are several described risk factors, as having higher 
bodyweight, being of a specific breed, neutered and older than eight years[9–12]. Sporting and 
working animals are under increased risk, as they are exposed to chronic fatigue injuries, leading to 
tissue damage and ultimate failure[13]. Although measuring changes in limb function do not directly 
correlate to changes due to joint pain, one could expect function in the limb to have comparable 




reflecting pain-related functional impairments in the context of OA, being abnormally lower[15–17]. 
The use of weight distribution platforms has been described, and presented as accurate and repeatable 
measurement, with a pressure-sensitive walkway as a reference[18]. Weight distribution platforms 
consist of a scale, with four different quadrants, in order to independently assess the four limbs[19]. 
When a limb is affected, significant adaptations occur on all limbs both at stance and swing 
phases. The described compensation mechanism is that most pronounced changes occur in the 
affected limb, followed by the contralateral limb, opposing the contralateral limb and, to a lesser 
extent, the opposing ipsilateral limb [20]. Animals with hip OA present complex changes in gait, 
which involve more joints than just the affected hip alone GRF of the lame limb in dogs with hip OA 
can be similar to those of the limbs of non-affected dogs, whereas the contralateral limb shows higher 
values[21]. Weight distribution, and off-loading or limb favouring at the stance is a commonly used 
subjective assessment during the orthopaedic examination, yet lameness may be difficult to detect 
during gait evaluation[22]. Stance analysis has been reported as being sensitive for detecting lameness 
in dogs, particularly in large breed dogs[23]. 
The study aims to describe weight-bearing compensation that occurs in police working 
diagnosed with bilateral hip OA. We also aimed to describe weight-bearing redistribution in response 
to treatment. We hypothesise that different breeds and patients with different hip grades, classified 
according to the Orthopedic Foundation for Animals (OFA) grading scheme, would show a different 
redistribution of body weight. 
 
Materials and Methods 
Fifty (N=50) active police working dogs, with bilateral hip OA, comprised the sample. They 
were selected from the population of police working dogs of the Guarda Nacional Republicana 
(Portuguese Gendarmerie Canine Unit) to take part in a longitudinal double-blinded, negative 
controlled study, evaluating the use of intra-articular treatments (platelet concentrate, Hylan G-F 20, 
triamcinolone hexacetonide, stanozolol and saline as a control) in the management of osteoarthrit is. 
Patients were divided into five groups, of ten patients each, according to the treatment being 
administered: 2ml of 0.9%NaCl per hip joint; 20mg/1ml (Bluxam, Riemser Pharma GmbH) of 
triamcinolone hexacetonide per hip joint; stanozolol (Estrombol, Laboratório Fundacion) at 0.3mg/kg 
per hip joint; 2ml of Hylan G-F 20 (Synvisc®, Sanofi, Portugal) per hip joint; and 3ml of platelet 
concentrate per hip joint. A single administration was carried out, on day 0. At the time of the initia l 
evaluation, dogs were scheduled to undergo treatment for hip OA. Diagnosis based on dog’s history 
(difficulty rising, jumping and maintaining obedience positions, stiffness and decreased overall 




motion) and radiographic findings (OFA hip scores of mild, moderate or severe) consistent with 
bilateral hip OA. In order to be included in this study, the dog must have a bodyweight ≥15kg, be 
over two years and should not have received any medication or nutritional supplements for at least 
six weeks. The need for additional rescue analgesia was evaluated by the assisting veterinarian and 
recorded. Animals with suspect or confirmed orthopaedic disease other than OA or concomitant 
disease were excluded.  Dogs not tolerant of data collection were also excluded. The same researcher 
performed all evaluations on days 0, 8, 15, 30, 90 and 180. 
Weight-bearing distribution was performed with a weight distribution platform (Companion 
Stance Analyser; LiteCure LLC®, Newark, Delaware, United States). Following manufacturer’s 
instructions, it was placed in the centre of a room, at least 1 meter from the walls, and calibrated at 
the beginning of each day and zeroed before each data collection. For data collection, animals were 
then encouraged by its trainers to stand on to the weight distribution platform, while ensuring that the 
patient placed one foot on each quadrant of the platform and maintained a natural stance with their 
centre of gravity and stability near the middle of the platform (measured by the platform). When 
required, gentle restraint was used to maintain the patient’s head in a natural, forward-facing position. 
Normal weight distribution for each thoracic limb was considered as 30% of total weight, and 20% 
for each pelvic limb[19]. A left-right symmetry index (SI) was calculated for thoracic and pelvic 
limbs, with the following formula: SI=[(WBR-WBL)/((WBR+WBL)x0.5)]x100[24, 25]. WBR is the 
value of weight-bearing for the right limb, and WBL is the value of weight-bearing for the left limb. 
Negative values were made positive. We also considered deviations from normal weight-bearing for 
both thoracic and both pelvic limbs, considered as 60% and 40%, respectively. This was obtained 
subtracting WBR+WBL to 60 for the thoracic limbs and 40 for the pelvic limbs.   
For each animal, a ventrodorsal radiographic view was obtained, to determine OFA hip grade. 
All radiographic studies were conducted under light sedation, using a combination of medetomid ine 
(0.01mg/kg) and buthorphanol (0.1mg/kg), given intravenously.  
Normality was assessed with a Shapiro-Wilk test, and measured parameters were compared 
with an Independent Samples T-Test or one-way ANOVA. Correlation between parameters was 
assessed with the Pearson correlation coefficient. All results were analysed with IBM SPSS Statistics 
version 20, and a significance level of p<0.05 was set. 
 
Results 
The sample for this study included 50 active police working dogs, 30 males and 20 females, 
representing four breeds: German Shepherd Dogs (GSD, n=17), Belgian Malinois Shepherd Dogs 




mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg, with both genders being represented (30 
males and 20 females). In concern to OFA hip grading, 35 animals were classified as mild (70%), 10 
as moderate (20%) and 5 as severe (10%). Mean values of overall weight, age and weight-bear ing 
distribution of each limb by breed, sex and OFA hip grades at the moment of initial evaluation are 
presented in table 1. No significant differences were observed when comparing values for different 
breeds and sex, nor with different cut-offs for weight at the time of initial evaluation. Correlations for 
weight-bearing distribution for each limb at the moment of the initial evaluation is presented in table 
2. Regarding SI and deviation, no significant differences were found comparing animals with the 
different weight cut off points, by breed, sex or OFA hip grade. A strong correlation was found 
between SI and deviation scores (r=1.0, p<0.01). 
Considering the evolution of weight-bearing distribution during the follow-up period, a 
significant decrease in weight-bearing was observed in the combined thoracic limbs comparing with 
initial evaluation (p<0.01) and increase in the combined pelvic limbs (p=0.05). Correlations for 
weight-bearing distribution for each limb during follow-up evaluations are presented in table 3. 
During this period, significant differences were observed in the weight-bearing distribution of 
individual thoracic limbs considering a weight cut-off point of 20kg, but not on the combined value 
of both. No significant differences were found with the remaining cut-offs. LR showed significantly 
higher weight-bearing on the right thoracic limb than GSD (p<0.01) and BM (p<0.01). They also had 
significantly lower weight-bearing on the right pelvic limb and the combined value of both pelvic 
limbs than GSD (p=0.02 for both), BM (p<0.01 for both) and DSD (p=0.02 and p=0.04, respective ly). 
Female dogs showed significantly lower weight-bearing on the left pelvic limb (p<0.01) and 
combined pelvic limbs (p=0.01), and higher right thoracic limb (p<0.01). Animals with a severe hip 
grade, showed significantly lower weight-bearing on the combination of both pelvic limbs when 
compared with mild and moderate hip grades (p=0.02 and p<0.01, respectively), and higher on the 






Table 1 – Mean values (±standard deviation) of overall weight, age and weight-bearing distribution of each limb by breed, sex and Orthopedic 
Foundation for Animals hip grades on initial evaluation. 
 
Weight Age Stance Analysis left 
thoracic limb  
Stance Analysis right 
thoracic limb  
Stance Analysis left 
pelvic limb  
Stance Analysis right 
pelvic limb  
 (kg, mean±SD) (yrs, mean±SD) (%, mean±SD) (%, mean±SD) (°, mean±SD) (°, mean±SD) 
Overall 26.7±5.3 6.5±2.2 31.6±6.2 30.7±6.7 19.0±4.4 18.7±4.2 
German Shepherd Dog 29.9±6.3 5.7±1.8 31.7±5.4 29.9±5.6 20.0±3.9 18.4±3.6 
Belgian Malinois Shepherd Dog 24.3±4.1 6.5±2.5 30.3±8.4 32.1±7.9 17.8±5.5 19.8±5.9 
Labrador Retriever 24.3±2.5 8.7±2.4 31.9±4.9 30.5±5.7 19.9±4.4 18.6±3.2 
Dutch Shepherd Dog 27.5±3.9 5.3±1.3 33.8±4.6 30.3±8.1 19.0±4.4 17.4±2.9 
Male 29.0±5.4 6.2±2.3 31.3±7.1 30.7±7.4 19.0±5.5 19.3±4.8 
Female 23.5±2.8 6.9±2.8 32.1±4.7 30.6±5.5 19.4±3.5 17.9±3.1 
Mild 26.7±5.2 6.5±2.4 31.7±6.9 30.2±6.6 19.5±4.4 18.9±4.3 
Moderate 26.5±5.4 6.4±2.4 30.5±5.3 32.7±8.3 17.7±6.9 19.1±4.8 











Table 2 – Correlations for weight-bearing distribution for each limb on initial evaluation. LPL – left pelvic limb; LTL – left thoracic limb; RPL – 
right pelvic limb; RTL – right thoracic limb. * indicates significant correlation. 
.Limb 
 
LTL RTL LPL RPL 
LTL rs 1 -0.83 -0.08 -0.20  
Sig.  <0.01* 0.14 <0.01* 
RTL rs -0.83 1 -0.29 -0.14  
Sig. <0.01*  <0.01* <0.01* 
LPL rs -0.08 -0.29 1 -0.14  
Sig. 0.14 <0.01*  0.02* 
RPL rs -0.20 -0.14 -0.14 1  
Sig. <0.01* <0.01* 0.02*  
 
Table 3 – Correlations for weight-bearing distribution for each limb during follow-up evaluations. LPL – left pelvic limb; LTL – left thoracic 




LTL RTL LPL RPL 
LTL rs 1 -0.87 -0.09 -0.16  
Sig.  <0.01* 0.186 0.01* 
RTL rs -0.87 1 -0.23 -0.15  
Sig. <0.01*  <0.01* <0.01* 
LPL rs -0.09 -0.23 1 -0.14  
Sig. 0.19 <0.01*  0.03* 
RPL rs -0.16 -0.15 -0.14 1  






During the follow-up period, and regarding SI, heavier animals (analysed with a 30 and 35kg 
cut-off points) had higher asymmetries on thoracic limbs (p=0.02 and p=0.03, respectively) and also 
on pelvic limbs (p<0.01 for both). The same animals showed significantly higher deviations for 
thoracic limbs (p=0.02 and 0.03, respectively). Comparing animals by breed, LR showed significant 
lower SI and deviation on both thoracic than GSD (p=0.03 and 0.04, respectively) and BM (p<0.01 
for both). Concerning pelvic limbs, LR had higher SI than DSD (p=0.02) and deviation than GSD 
(p=0.03). Male dogs had significantly higher SI and deviation than females (p<0.01). SI showed a 
weak, significant correlation with weight (r=-0.16, p<0.01). 
 
Discussion 
This report characterises weight distribution variations in dogs with bilateral hip OA. Subtle 
changes in posture or weight-bearing may occur in the early stages of the disease process, which can 
be easily missed with the visual assessment[26–28]. Additionally, OA animals may not be overtly 
lame at a walk or a trot but exhibit subtle shifts in body weight distribution at a stance due to pain or 
instability associated with orthopaedic or neural disease[19, 29]. Weight distribution platform, as a 
pressure-sensitive walkway, can provide accurate and consistent measures of weight distribution with 
no significant difference between devices[18]. At the moment of the initial evaluation, a weight shift 
was observed from the pelvic to the thoracic limbs. For dogs presenting with pelvic limb-lameness, 
a load redistribution more by side-to-side compensation rather than pelvic-to-thoracic has been 
described[30, 31]. Our results contrast with this finding, which may be related to the fact that all 
animals exhibited bilateral disease, and therefore may try to relieve the pelvic limbs by transferr ing 
weight to the thoracic limbs. Also, a weak significant correlation was found between pelvic limbs 
with the opposing contralateral thoracic limb.  
Interestingly, no significant differences were observed were comparing the various breeds 
represented in the sample. This is in contrast with what has been described for gait analysis, where 
significant breed differences have been reported, both at a walk and trot, a probable reflection of 
different conformations[32]. Besides, no significant differences were observed when comparing 
animals by sex or with the different weight cut off values. This may increase interest in weight 
distribution analysis as a diagnosis and response to treatment evaluation tool since it did not show 
significant variability for different sets of animals. Additionally, it does not require data normalisat ion 
to compare different animals, a requirement with gait analysis[33, 34].  
Bodyweight distribution at a stance may has been proposed to be an equivalent or superior 
measurement of pain associated with hip OA than both VI and PVF, with highest sensitivity and 




value. This may be since all animals had bilateral disease, and a weight-bearing mean value above 
18% is usually paired with a value below. Also, since these animals are active Police working dogs, 
it is possible that complaints and signs are detected in an earlier stage of the disease (the majority of 
animals were classified with a mild hip grade), and therefore still not exhibit compensation 
mechanisms to a large extent. Similar to what is observed with clinical signs of OA and vertical 
GRF[8], no correlation has been found between hip grade and weight-bearing, SI or deviation. 
During the follow-up period, and in response to treatment, a significant decrease in weight-
bearing in the thoracic limbs was observed, counteracted by an increase in the pelvic limbs, 
approaching the described normal 30/30/20/20 (left thoracic limb/right thoracic limb/ left pelvic 
limb/right pelvic limb)[18, 36]. During this stage, weight-bearing of all limbs correlated with the 
remaining limbs, which may reflect a more even, balanced, weight distribution.  There may exist a 
tendency to see fewer improvements in male dogs concerning bodyweight distribution with pelvic 
limb pain relief, as they naturally tend to carry more weight on the thoracic limbs[29]. We have 
observed a different tendency, with female dogs exhibiting significantly lower pelvic limb weight 
distribution at this stage. In contrast, male dogs had higher SI and deviation values. This may be a 
reflection of the higher body weight of male dogs since body weight showed a significant correlation 
with SI. When comparing animals by breed, with LR showed lower pelvic limb weight distribution 
and higher SI and deviation that remaining breeds. On the other hand, SI and deviation values in the 
thoracic limb were significantly lower in LR, which may reflect breed-specific conformation.  
This study presents some limitations, namely the lack of a disease-free group, with non- lame 
dogs. Also, since the sample was comprised exclusively by police working dogs, there is a need to 
evaluate animals of different breeds, conformations and activity levels. These limitations are due to 
the nature of the sample, comprised of dogs specifically presenting for treatment. Also, there is a need 
to compare different, well-established treatments, such as non-steroidal anti-inflammatory drugs. 
These commonly used therapies were not included in this study, as it aimed to evaluate only intra -
articular treatment modalities. 
 
Conclusions 
This study describes weight-bearing redistribution in dogs presenting with bilateral hip OA, 
and in response to treatment. It provides important information for the evaluation of this prevalent 
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Catarina Falcã o Trigoso Vieira Branco Lavrador,
z DVM, PhD, 
and Luis Miguel Alves Carreira,
§| |{ DVM, PhD 
Investigation performed at the Clı́ nica Veterina  ́ ria de Cã es of the Guarda Nacional Republicana 
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Management of Osteoarthritis Using 1 Intra-articular PlateletConcentrate Administration in a Canine Osteoarthritis Model   
Background: Osteoarthritis (OA) represents a significant burden to societies, as it affects quality of life and performance and 
implies a large cost in terms of health care. Autologous platelets are a regenerative treatment modality for OA that are thought to 
be a potential stimulation of the natural healing cascade. 
Purpose: To describe the effect of the platelet concentra te V-PET in the management of OA in a naturally occurring canine mode l, 
using several outcome assessment modalities. 
Study Design: Controlled laboratory study. 
Methods: A total of 40 joints of active working police dogs with hip OA were randomly assigned to a control group (CG) and a 
platelet concentrate group (PCG; treatment) and evaluated. At treatment day (T0) and 8, 15, 30, 90, and 180 days after treat- ment , 
weight distribut ion, joint range of motion at flexion and extension, thigh girth, digital thermography, radiographic signs, 4 clinica l  
metrology instruments, and synovial fluid interleukin 1 and C-reactive protein levels were recorded. Results were com- pared using 
repeated-measures analysis of variance with a Huynh-Feldt correction, paired-sam ples t test, or Wilcoxon signed rank test, w ith 
P \ .05. 
Results: Dogs were 6.5 6 2.4 years old (mean 6 SD) and had a body weight of 26.7 6 5.2 kg. At T0, 32 (80%) joints were graded as 
having mild OA, 6 (15%) as moderate, and 2 (5%) as severe. No differences were found between groups at T0. Between the PCG and 
CG, the symmetry index showed significant improvements in the PCG from 8 days (P = .01) to 180 days (P = .01). Joint flexion also 
improved in the PCG up to 90 days (P \ .05) and extension improved up to 180 days (P \ .01). Several clinical metrology instru- ment  
scores also improved up to 90 to 180 days after treatment. In the CG, radiograp hic signs progressed, while the PCG showed som e  
improved signs. In both groups, increasing body weight and age corresponded with worse clinical and laboratory findings. 
Conclus ion: A single injection of platelet concentrate had a positive effect, lasting up to 6 months, on several clinical, imaging, and 
laboratory signs in a naturally occurring canine OA model. 
Clinical Relevance: We characterized the effects of this platelet concentrate in dogs, considered the gold standard of the study of 
OA, w ith a group of working animals w ith similar high demands as athletes. 
Keywords: animal model; dog; osteoarthritis; pain; autologous platelet concentrate ; stance analysis; digital thermography; digita l  
radiography; clinical metrology instruments; C-reactive protein; interleukin 1 
 
 
Osteoarthritis (OA) affects all mammals, and it is an important 
disease in humans and dogs and a source of chronic pain, with 
the prevalence expected to rise due to   a simultaneous increase 
in life expectancy and obesity.2,31 
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OA represents a significant burden to societies, as it affects 
quality of life (QOL) and performance and implies a large cost 
in terms of health care.13 The dog is a frequent animal model 
for the study of OA because the pathologic process, clinical 
presentation, and response to treatment are very similar to 
those observed in humans.28 In addition, the nat- urally 
occurring canine model provides the advantage of presenting 
faster disease progression, with equivalent life stages to those 
in humans, while sharing many of the 








environmental variations that also influence human OA, thus 
making it easier to study. For these reasons, the   dog is the 
closest to a gold standard model.23,26,35,37 There- fore, the study 
of canine OA can provide important infor- mation in translation 
medicine under the One Medicine Initiative, which will help 
improve the health and well- being of humans and dogs.8,37 
Despite being a focus of extensive research, OA is a con- dition 
with limited treatment options presently available, and its 
management centers mainly on the alleviation of pain, 
improvement of function, and possible slowing of dis- ease  
progression.37,38  For  that  reason,  there  has  been a growing 
interest in the development of treatments that preserve or 
restore cartilage by promoting its synthesis  or inhibiting its  
breakdown.21  Autologous  platelets  are a potential 
regenerative treatment modality for OA, used with the aim to 
stimulate the natural healing cascade  and regeneration of 
tissues. Platelet-released growth fac- tors include insulin-like 
growth factor 1, transforming growth factor b, platelet-derived 
growth factor, vascular endothelial growth factor, and basic 
fibroblast growth fac- tor, which, by a supraphysiologic release 
directly at the treatment site, signal cells to proliferate and 
influence their maturation, differentiation, and tissue repair. 
Being an autologous product, it does not hold the risk of 
immune rejection or disease transmission.11,39,46 
Pain and functional ability are the most relevant parameters 
in the evaluation of OA as an assessment of treatment 
efficacy.56 For these assessments of the multiple dimensions of 
OA, several clinical metrology instruments (CMIs) have been 
developed. The most commonly used are the Canine Brief Pain 
Inventory (CBPI) and the Liver- pool Osteoarthritis in Dogs 
(LOAD).54,55 The CBPI is divided into 2 sections: a pain severity 
score (PSS) and      a pain interference score (PIS).50 Other 
validated CMIs include the Canine Orthopedic Index (COI; 
divided into 4 scores: stiffness, gait, function, and QOL), and 
the Hudson Visual Analog Scale (HVAS), developed to assess 
the degree of lameness in dogs.6,25 The ventrodorsal hip 
extended view is the most common pelvic radiographic pro- 
jection used for the clinical assessment of OA and determi- 
nation of treatment outcome.43 The circumferential femoral 
head osteophyte (CFHO) and caudolateral curvi- linear 
osteophyte (CCO) are early radiographic signs related to the 
development of the clinical signs of hip OA.33,42 Stance analysis 
has been reported as a sensitive evaluation for detecting 
lameness in dogs.9 It evaluates 
weight distribution, and off-loading or limb favoring at the 
stance is a common assessment during orthopaedic 
examination since  dogs  commonly  bear  less  weight  on a 
painful limb.22 Digital thermal imaging has been shown to be 
a reliable technique to assess inflammatory arthritis pain.17 
This evaluation method relies on heat generated during 
physiologic functions and its relation with skin tem- perature 
control.24,44 Activity levels and mobility impair- ments are 
associated with musculoskeletal pain in humans. For that 
reason, mobility changes have been rec- ommended as 
measures of outcome.29 A simple and inex- pensive method to 
assess mobility levels is through the use of pedometers since 
they are capable of measuring ambulatory activity with 
acceptable accuracy.49 Since muscular atrophy is a consistent 
finding in  dogs  with OA, examination of muscle masses and 
restrictions in joint range of motion (ROM; at flexion and 
extension) is also usually performed.32,57 Interleukin 1 (IL-1) 
has been iden- tified as the most important proinflammatory 
cytokine responsible for the catabolism in OA, with a relation 
to lameness duration.20,36 C-reactive protein (CRP) is an acute-
phase protein produced during inflammatory reac- tions or 
tissue injury, which may also be produced at the level of the 
inflamed tissues, with the advantage of its shifts being noted 
from a very early stage.5,14 
The goal of this study was to describe the effect of the platelet 
concentrate V-PET (Pall Corporation) in the man- agement of 
OA in a naturally occurring canine model using several outcome 
assessment modalities. We hypothesized that it would  be able 
to reduce  the clinical signs of OA,  as compared with a control 
group (CG), where no therapeu- tic options were used. 





The study protocol was approved by the ethical review 
committee of the University of É vora (Ó rgão Responsáv el 
pelo  Bem-estar  dos  Animais  da  Universida de  de  É vora,  
approval GD/32055/2018/P1, September 25, 2018). Informed   
consent   was   obtained   from   the  institution 
responsible for the animals (Guarda Nacional Republi- cana, 
Portugal). The sample comprised 40 joints of active working 
police dogs with bilateral hip OA diagnosed on the basis of 
history and physical, orthopaedic, neurologic, and  
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Evaluation Modalities Used on Each Evaluation 
Momenta 
Abbreviation Definition    
Evaluation Moment 
CBPI Canine Brief Pain Inventory 
CCO caudolateral curvilinear osteophyte 
CFHO circumferential femoral head osteophyte 
CG control group 
CMI clinical metrology instrument 
COI Canine Orthopedic Index 
CRP C-reactive protein 
DV dorsoventral 
HVAS Hudson Visual Analog Scale 
IL-1 interleukin 1 
LOAD Liverpool Osteoarthritis in Dogs 
Lt lateral 
OA osteoarthritis 
PCG platelet concentrate group (treatment) 
PIS pain interference score 
PSS pain severity score 
QOL quality of life 
ROM range of motion 





study, dogs had to have a body weight    20 kg and age .2 
years, and they should have not received any previous  
treatment for hip OA and not received any medication or 
nutritiona l  supplemen ts  for  .6  weeks.  Dogs  with  other  
suspected or documented orthopaedic, neurologic, or con- 
comitant disease or dogs that were not tolerant of data col- 
lection were excluded. 
In a double-blinded study, after selection, dogs were randomly 
assigned to a CG (n = 20) or a treatment group (platelet 
concentrate group [PCG]; n = 20). The CG received an intra-
articular administration of 3 mL  of  0.9% NaCl, while the PCG 
received a single administration of 3 mL of a platelet 
concentrate produced using the com- mercially available V-
PET kit according to the manufac- turer’s instructions. Whole 
blood (55 mL) was collected from the jugular vein using a 60-
mL syringe filled with    5 mL of anticoagulant citrate dextrose 
solution and intro- duced into the provided closed system. The 
blood flowed by action of gravity through the filter where 
platelets were concentrated. The final liquid product was 
collected using the provided syringe and administered within 
10 minutes without activation. These procedures were con- 
ducted at room temperature without direct light exposure and 
took around 25 minutes from blood collection to 
administration. Intra-articular administrations were con- 
ducted under light sedation using a combination of medeto- 
midine (0.01 mg/kg) and butorphanol (0.1 mg/kg) given  
intravenously. The dogs were positioned in lateral recum- 
bency with the affected joint uppermost, and a small win- dow 
of 4 3 4–cm area surrounding the  greater  trochanter was 
clipped and aseptically prepared.  With the help of an assistant, 
the limb was set in a neutral posi- tion, parallel to the table. A 
21-gauge, 2.5-inch needle was introduced just dorsal to the 
greater trochanter and per- pendicular to the long axis of the 




0 db 8 d 15 d 30 d 90 d 180 d 
Treatment 3 
     
Goniometry 3 3 3 3 3 3 
Thigh girth measurement 3 3 3 3 3 3 
HVAS 3 3 3 3 3 3 
CBPI 3 3 3 3 3 3 
COI 3 3 3 3 3 3 
LOAD 3 3 3 3 3 3 
Digital thermography 3 3 3 3 3 3 
Pedometer 3 3 3 3 3 3 
Stance analysis 3 3 3 3 3 3 
Digital radiography 
Synovial fluid 
3   3 3 3 
CRP 3 3  3 3 3 
IL-1 3 3  3 3 3 
Routine blood testing 3   3 3 3 
aCBPI, Canine Brief Pain Inventory; COI, Canine Orthopedic Index; 
CRP, C-reactive protein; HVAS, Hudson Visual Analog Scale; IL-1, 
interleukin 1; LOAD, Liverpool Osteoarthritis in Dogs. 
bTreatment day (days are counted from treatment day). 
 
 
was obtained through the collection of synovial fluid, and the 
treatment or saline was administered. After treatment, 
animals rested for 3 consecutive days and resumed their 
normal activity over a period of 5 days. An outline of eval- 
uations performed and evaluation moments is presented in 
Table 2. All evaluations were performed by the same 
researcher throughout the study (J.C.A.). No additional 
treatments were administered, and no rehabilitation pro- 
tocols were conducted. 
Weight distribution  evaluation  was  conducted  using a weight 
distribution platform (Companion Stance Ana- lyzer; LiteCure 
LLC) following the manufacturer’s guide- lines. For the 
evaluation, animals were encouraged by their trainers to stand 
on the platform with  1  foot on each quadrant of the platform. 
For all animals, at least 
20 measurements were performed, and the mean value was 
determined. A left-right symmetry index (SI) was cal- culated 
using the following formula: SI = [(WBR – WBL) / (WBR 1 WBL) 
3  0.5)]  3  100,53,55 where WBR is the value of weightbearing 
for the right pelvic limb and WBL for the left pelvic limb. 
Negative values were made positive. Devi- ation from the 
normal value of 20% weightbearing for a pel- vic limb was also 
considered10 and was calculated by subtracting weightbearing 
from 20. 
Before digital thermography images were collected, dogs were 
allowed to walk calmly in a room with controlled temperature 
(21°C) for 30 minutes. Then, with the animal positioned in a  
symmetrical  upright  standing  position, a dorsoventral (DV) 
thermographic image, including the area from the last lumbar 
vertebra to the first coccygeal vertebra, was obtained.51 A 
lateral (Lt) view was also obtained with the greater trochanter 
in the center. All 







images were taken at a distance of 60 cm (ThermaCAM E25; 
FLIR Systems). To analyze the images, the free soft- ware Tools 
(FLIR Systems) was used with a rainbow color palette. 
Temperature boxes of equal size were placed on the anatomic 
area of the hip joint on both views, and mean and maximal 
temperatures were determined. Thigh girth and joint ROM were 
determined with the dogs in lateral recum- bency with the 
affected limb uppermost. With use of a Gullick II measuring tape, 
thigh girth was determined at a distance of 70% thigh length, 
measured from the tip of the greater tro- chanter with an extended 
leg.34 Hip joint ROM was obtained using a goniometer at 
extension and flexion with a flexed sti- fle.30 These measurements 
were made in triplicate, and the mean value was calculated. 
Activity levels were measured using the pedometer worn around 
the dogs’ neck and attached to an adjustable lightweight collar.7 
They were placed 1 week before the first evaluation moment to 
deter- mine a baseline value and maintained up to the 30th day 
after treatment. For evaluation at the 90th and 180th post- 
treatment days, animals wore the pedometer for a week before 
the evaluation moment. Mean daily counts were con- sidered and 
were calculated by dividing the registered num- ber of steps by 
the number of days considered. Each trainer completed the 
HVAS, CBPI, COI, and LOAD on evaluation days after receiving 
instructions. The CMIs were completed in sequence by the same 
handler in a quiet room with as much time as needed to answer 
all items. 
For radiographic examination, which was conducted under the 
same light sedation induced for treatment admin- istration of 
synovial fluid collection, a VD extended-legs view was obtained. 
The presence of 7 radiographic OA signs was assessed: irregular 
wear on the femoral head, making it misshapen and have a loss 
of its rounded appearance; a flat- tened or shallow acetabulum, 
with irregular outline; CCO; new bone formation on the 
acetabulum and on the femoral head and neck; a worn-away 
angle formed at the cranial effective acetabular rim; 
subchondral bone sclerosis along the cranial acetabular edge; 
and CFHO.4,18,43,48 Joints were also graded according to the 
Orthopedic Foundation for Animals scheme. A mild score 
corresponded to a partially subluxated femoral head, causing 
an incongruent and wid- ened joint space with a shallow 
acetabulum only partially covering the femoral head. In young 
dogs (24-36 months old), OA lesions may not be present. 
Moderate grades were attributed when significant subluxation 
was present and the femoral head was barely seated in a shallow 
acetab- ulum. Secondary remodeling along the femoral neck 
and head, acetabular osteophytes, and subchondral sclerosis 
were present. In severe cases, the femoral head was partly or 
completely out of a shallow acetabulum, with extensive 
secondary arthritic bone changes along the femoral head and 
neck head, acetabular rim changes, and large amounts of 
abnormal bone pattern changes. A full description of the 
Orthopedic Foundation for Animals hip grading scheme is 
available online (https://www.ofa.org/diseases/hip-dyspla- 
sia/grades). The same researcher, blinded to the group and 
identity of the dog, scored all joints (J.C.A.). A sample of 
synovial fluid was obtained for the determination of IL-1b, and 
CRP concentrations were made using the DuoSet Ancil- lary 
Canine IL-1b Reagent kit (R&D Systems) and read 
using FLUOstar OPTIMA (BMG Labtech), Fuji Dri-Chem 
Slides VC-CRP PS (FUJIFILM Europe GmbH), and DRI- 
Chem NX500i (FUJIFILM Europe GmbH). 
Normality was assessed using a Shapiro-Wilk test. Group 
results were compared in each evaluation moment, and each 
measured parameter was compared with the result observed at 
treatment day. To assess the effect of different parameters on 
the dogs’ clinical evolution, results were compared by sex, age, 
body weight, and presence of CCO and CFHO using a paired-
samples t test, repeated- measures analysis of variance, 
Huynh-Feldt  correction, or Wilcoxon signed rank test. All 
results were analyzed using IBM SPSS Statistics Version 20 




The sample included 40 pelvic limbs of working police dogs, 
equally distributed between left and right pelvic limbs,  with a 
mean 6 SD age of 6.5 6 2.4 years and body weight of 26.7 6 5.2 
kg. Based on the Orthopedic Foundation for Animals hip 
grading at T0, 32 joints were classified as mild (80%), 6 as 
moderate (15%), and 2 as severe (5%). Both sexes were 
represented (26 limbs from males and 14 from females). No 
differences were found between groups at the initial 
evaluation. The composition of the platelet concentrate and 
whole blood is presented in Table 3. 
After treatment, increased lameness was observed in 8 dogs, 
which resolved spontaneously within 48 hours. 
 
Clinical and Laboratory Findings 
When results between groups were compared using repeated-
measures analysis of variance with a Huynh-Feldt correction, 
significant differences were found concerning body weight 
(F[3.29, 92.3] = 5.9; P = .001), maximal temper- ature on the DV 
view (F[3.6, 87.2] = 5.5; P = .001), mean temperature on the Lt 
view (F[4.8, 129] = 44.3; P = .001), maximal temperature on the 
Lt view (F[4.57, 123.4] = 101.6;  P =  .001),  joint  flexion  (F[3.6,  
107.5]  =  11.9 (P = 
.001), IL-1 synovial concentration (F[2.4, 76.9] = 6.4; P = 
.001), and SI (F[3.73, 111.8] = 3.3; P = .016). Evolution of 
SI is presented in Figure 1. 
Significant differences were also observed with different CMIs: 
PSS (F[3.1,81.2] = 3.3; P = .015), PIS (F[3.4, 87.5]  = 
4.3; P = .006), LOAD (F[2.16, 56.2] = 1.5; P = .022), stiffness 
(F[2.7, 71] = 1.3; P = .028), function (F[5, 130] = 2.4; P = 
.040),  gait  (F[2.5,  65.7]  =  1.8;  P =  .016),  and  COI (F[5, 
130] = 2.0; P = .007). Values recorded for the initial evalu- ation 
and its variations throughout the study are pre- sented in 
Tables 4 and 5. 
 
Radiographic Findings 
Table 6 presents the frequency of different radiographic 
findings at the initial and final evaluations. 
In the CG, animals that presented CCO on the radio- graphic 
VD view did not show significant differences ver- sus those that 
did not. At the 30-day evaluation, animals 








Composition of Whole Blood and Platelet Producta 
 
 
Whole Blood Platelet Concentrate 
 
Parameter Mean SD 
 
Mean SD 
Platelets 293.35 65.71 1144.06 256.26 
Red blood cells, 3 106/mm3 6.65 0.92 4.19 0.58 
Hematocrit, % 45.01 6.87 22.05 3.37 
White blood cells 10.47 3.93 19.90 8.25 
Lymphocytes 2.20 1.01 5.50 2.52 
Monocytes 0.74 0.41 0.82 0.46 
Neutrophils 6.97 0.78 11.08 1.24 
Eosinophils 0.54 0.78 0.82 1.20 
Basophils 0.02 0.02 0.00 0.00 
aValues are presented as 3 103/mm3 unless noted otherwise. 
 
 
with CCO had lower mean thermographic evaluation on the Lt 
view (P = .04), worse joint flexion (P = .03), and higher IL-1 and 
lower CRP concentration levels (P = .04 for both). Animals with 
CCO had higher maximal thermo- graphic evaluation on the Lt 
view at the 90-day evaluation (P = .05) and higher CRP at the 
final evaluation (P = .02). In the PCG, dogs with CCO at the 
initial evaluation had worse PSS (P = .01), PIS (P =  .02),  
stiffness  (P \ .01), and gait (P = .02). At the first treatment 
assessment, at 8 days, they had lower mean thermographic 
values on the DV view  (P = .04)  and maximal  values on the 
Lt  view  (P = .05), with worse PIS (P \ .01), LOAD (P = .01), 
func- tion (P = .01), gait (P \ .01), and COI (P = .05). At 15 days, 
the same dogs had worse PSS (P \ .01), PIS (P \ .01), and gait 
(P \ .01). At the 30-day evaluation, those with CCO at the 
initial evaluation had lower pedometer counts (P = .02) and 
worse HVAS (P = .04), PSS (P = .01), PIS (P \ .01), 
LOAD (P = .05), stiffness (P \ .01), function (P =  .03),  gait (P 
= .04), and COI (P = .03). At 90 days, they had higher SI (P = 
.03), higher mean and maximal thermo- graphic values on the 
Lt view (P = .03 and P \ .01, respec- tively), and worse HVAS 
(P = .04) and PSS (P = .01). At the final evaluation, higher 
maximal thermographic values on the DV view (P = .02) were 
observed. 
Dogs in the CG with CFHO on a VD view at the initial 
evaluation had worse joint extension at the 8-day evalua- tion 
(P \ .01) and worse HVAS (P = .02), PSS (P = .01), and PIS (P 
= .03). At 15 days, they had a lower mean ther- mographic 
evaluation on the Lt view (P = .02) and worse PSS (P = .02) and 
PIS (P = .05). The lower mean thermo- graphic  evaluation  on 
the  Lt  view  was also  observed at 
30 days (P = .01). At 90 days, these dogs had  worse  HVAS 
scores (P = .02). At the final evaluation, they had    a lower 
maximal thermographic evaluation on the  Lt view (P = .04) 
and worse PSS (P = .05) and PIS (P = .03). In the PCG, dogs 
with CFHO had better PSS (P = .02)  and PIS (P = .02). At 8 
days, the same dogs had lower thigh girth (P = .05) but better 
PSS (P = .05), PIS (P \ .01), LOAD (P = .02), function (P = .01), 
gait  (P =  .01),  and COI (P = .01). Again at 15 days, they had 
better PSS (P 
= .05), PIS (P = .01), and function (P = .04). At 30 days, these 




Figure 1. Evolution of the symmetry index in the control 
group (CG) and platelet concentra te group (PCG; treatment). Box 
plots represent the median and 25th and 75th percen- tiles, 
and whiskers represent the 10th and 90th percentiles. Circles 
denote outliers; x represents the mean. 
 
and better HVAS (P = .04), PSS (P \ .01), function (P \ 
.01), and gait (P \ .01). This trend with CMI scores was 
again observed at 90 days, with better HVAS (P = .03), PSS 
(P \ .01), PIS (P \ .01), LOAD (P \  .01), stiffness 
(P = .05), function (P \ .01), gait (P \  .01), QOL (P = 
.01), and COI (P \ .01). At the final evaluation moment, only a 
lower mean thermographic value on the DV view  (P = .05) and 
a better PSS score (P = .01) were observed. 
 
 
Comparisons by Sex 
In the CG, when animals were grouped by different find- ings, 
male dogs had significantly higher body weight for all 
evaluation moments (P = .01). At the initial evaluation, males 
had lower values for all thermographic evaluations (P \ .01) 
and higher PIS (P = .04). At 8 days, the same was true 
regarding thermographic evaluation (P \ .01), except for a 
maximal value on the Lt view and lower joint extension values 
(P \ .01). At 15 days, males still showed lower joint extension 
(P = .04) and higher PIS (P = .03).   At the 30-day evaluation, 
females showed higher thermo- graphic maximal values on the 
Lt view (P \ .01). At 90 days, male dogs had higher thigh girth 
(P = .03) and worse PSS and PIS (P = .01). In the final 
evaluation moment, male dogs had lower extension values (P = 
.02) and worse HVAS (P = .02), PSS (P \ .01), PIS (P \ .01), 
stiffness (P = 
.02), function (P = .02), gait (P \ .01), QOL (P = .02), and COI 
(P = .01). In the PCG at the initial evaluation, male dogs had 
higher thigh girth (P \ .01) than did females. Males had lower 
mean thermographic values on the Lt view at the 8-day 
evaluation moment (P = .02) and higher thigh girth at 15 days 
(P = .02). At 30 days, males had lower mean and maximal 
thermographic values on the DV view (P \ .01 for both) and 
Lt view (P \ .01 and P = 
.02, respectively) in addition to higher thigh girth (P \ 
.01). At 90 days, males had a higher mean temperature value 
on the Lt view again (P = .03) and a lower IL-1 con- centration 
(P = .03). At the final evaluation moment, males 











Parameters Evaluated at the Initial Evaluation and at 8 and 15 Days a 
Treatment Day 8 d 15 d 
   
CG PCG CG PCG CG PCG 
Modality Mean      SD      Mean    SD     Mean SD P Value   Mean SD P Value   P Value   Mean SD P Value Mean SD P Value P Value 
Goniometry 
Flexion, deg 55.0 4.4 54.3 6.4    55.3 3.7 \.01b 55.7 5.9 .24 .04b 57.2 5.2 .14 57.1 8.6 .83 ≤.99 
Extension, deg 151.2 3.9     149.4    18.6  149.9 4.6 .95 152.1 7.6 \.01b ≤.99 151.1 3.5 .07 154.2 9.9     \.01b .71 
Thigh girth, cm 31.2 2.6 31.4 4.2    31.1 3.3 .94 31.8 2.7 \.01b ≤.99 31.1 2.9 .86 31.3 2.3 .07 ≤.99 
Pedometer, daily steps      1445.7   755.7   1432.8   468.7 829.5    931.266 .58 1086.9  1639.4 .47 ≤.99 606.0    309.46 .15 937.7    885.5 .04 ≤.99 
CMI 
HVAS, 0-10 6.8 1.2 6.7 1.4 6.7 1.5 .48 7.0 1.2 \.01b ≤.99 6.8 1.2 .6 7.1 1.4     \.01b .26 
CBPI, 0-10 
PSS 3.1 1.9 3.3 2.6 3.4 2.3 .69 2.9 1.8 .38 .53 3.7 2.8 .2 3.2 1.9 .09 .04b 
PIS 3.2 2.2 3.3 2.8 3.4 2.1 .01b 3.2 1.9 .78 .02b 3.6 2.1 .01b 3.3 2.7 .64 .02b 
COI 
Stiffness, 0-16 3.4 3.4 3.9 3.9 4.1 3.3 .31 3.5 3.8 .11 .02b 4.1 3.2 .31 3.2 3.2 .09 .02b 
Function, 0-16 3.6 4.1 4.2 4.7 4.1 4.0 .64 4.0 5.1 .91 ≤.99 4.4 5.5 .72 3.8 3.8 .92 .35 
Gait, 0-20 4.7 5.2 5.1 5.4 5.4 6.1 .29 5.4 4.1 .75 ≤.99 5.8 4.3 .02 5.4 5.1 .38 .02 
QOL, 0-12 4.5 2.6 4.5 3.6 4.6 2.7 .62 3.8 4.2 .23 .49 4.7 2.9 .06 3.9 3.9 .19 .18 
Overall, 0-64 16.4    14.7 17.7    16.9    18.2 13.8 .22 16.8 18.9 .47 .02b 18.6 13.8 .14 17.0 17.5 .06 .02b 
LOAD, 0-52 13.6    10.5 13.3    11.3    14.4 12.7 ≤.99 14.3 10.3 .64 ≤.99 14.3 10.7 .83 13.3 11.7 .11 .02b 
Digital thermography, deg 
DV 24.7 1.9 26.7    20.2    25.2 1.3 .01b 24.3 1.2 .75 .99 24.4 1.6 .61 23.9 1.6 .32 .99 
DV max 26.3 1.9 26.1 1.7    25.8 1.0 .06 25.2 1.6 .76 .01b 26.7 1.6 .97 26.2 1.5 .21 .03b 
Lt 28.7 2.7 29.3 2.8    31.6 2.1 \.01b 31.1 1.6 \.01b \.01b 29.7 2.9 \.01b 30.00 2.2    \.01b \.01b 
Lt max 31.9 3.1 31.2 3.1    34.9 1.0 \.01b 34.7 1.0 \.01b \.01b 34.9 0.8 \.01b 34.3 1.5    \.01b \.01b 
Synovial fluid 
IL-1, pg/mL 170.9   120.4     174.9  134.6    72.3 42.4 \.01b 98.5 85.9 .04b \.01b — — — — — — — 
CRP, mg/mL 0.4 1.0 0.5 1.6 0.3 1.2 \.01b 0.2 1.0 .02b ≤.99 — — — — — — — 
Weightbearing 
Symmetry index 24.7 20.3 22.6 12.4 18.7 17.1 .06 13.0 13.3 .01b .01b 23.9 16.3 .18 10.2 5.4 \.01b .03b 
Deviation 2.8 3.6 2.1 2.2 2.78 1.987 .3 2.0 1.881 \.05b .36 2.94 2.127 .47 1.21 975.0 \.01b .11 
aDashes indicate parameters not measured. CBPI, Canine Brief Pain Inventory; CG, control group; CMI, clinical  metrology instrument; COI, Canine Ortho- pedic 
Index; CRP, C-reactive protein; DV, dorsoventral view; HVAS, Hudson Visual Analog Scale; IL-1, interleukin 1; LOAD, Liverpool Osteoarthritis in Dogs; Lt, lateral 
view; max, maximal; PCG, platelet concentrate group (treatment); PIS, pain interference score; PSS, pain severity score; QOL, quality of life.  
bP \ .05 (evaluation moment vs treatment day and between groups at each follow-up moment). 
 
had lower mean and maximal thermographic values on the Lt 
view (P \ .01 for both). They also had higher body weight 
throughout the study (P \ .01). 
 
Comparisons by Body Weight 
When animals were compared with a weight cutoff set at the 
mean value of the sample, heavier dogs in  the CG  had higher 
PIS (P = .04) at the initial evaluation. At 8 days, heavier dogs 
had lower thermographic mean and maximal values on the DV 
view (P = .03 and P = .02, respectively) and lower thigh girth (P 
= .01), as well as bet- ter stiffness (P = .03), function (P \ .01), 
gait (P = .03), and COI (P \ .01). At 15 days, heavier dogs 
showed higher thigh girth (P = .04) and better HVAS (P = .04), 
stiffness, function, gait, QOL, and COI (P \ .01). Heavier 
animals had higher CRP concentrations at 30 days (P = .04) 
and worse HVAS scores (P = .02). The same animals had higher 
thigh girth (P \ .01) and IL-1 levels (P = .02) at 90 days. In the 
final evaluation point, heavier animals showed lower mean 
thermographic values on the DV view  (P  \ .01) and lower joint 
flexion (P = .02) and extension (P \ .01). In the PCG, animals 
with a weight above the cutoff had higher thigh girth (P = .02) 
at the initial evaluation. At 8 days, they had higher mean and 
maximal temperature val- ues on the DV view (P = .02, for both), 
higher thigh girth (P 
\ .01), and better joint extension (P = .01). After 15 days, 
heavier dogs had lower maximal temperature values on the 
Lt view (P = .01), higher thigh girth (P \ .01), and bet- ter joint 
extension (P = .02). At 30 days, these dogs had lower mean 
and maximal temperature values on the DV view (P \ .01 
for both) and Lt view (P \ .01 for both), in addition to higher 
thigh girth (P \ .01). At the final evalu- ation moment, 
heavier dogs had lower maximal tempera- ture values on the 
Lt view (P = .01), higher thigh girth (P \ .01), and lower IL-
1 concentration (P \ .01). 
 
Comparisons by Age 
When dogs above or below the mean age of the sample were 
considered, older dogs in the CG had lower maximal values on 
the thermographic Lt view (P = .04) and worse LOAD (P 
= .02), stiffness (P \ .01), function (P \ .01), gait (P \ .01), and 
COI (P \ .01). At 8 days, they showed higher SI (P \ 
.01) and lower maximal values on the thermographic Lt 
view (P = .02), as well as worse LOAD (P = .04), stiffness (P 
\ .01),  function  (P \ .01),  gait  (P \ .01), QOL  (P \ 
.01), and COI (P \ .01). The same was also true at the 
15-day evaluation, with these dogs presenting worse LOAD 
(P \ .01), stiffness (P \ .01), function (P \ .01), gait (P \ 
.01), QOL (P \ .01), and COI (P \ .01). At the 30-day 
evaluation, older dogs had higher mean and maxi- mal values  
on the thermographic DV view (P \ .01 and P 
= .02, respectively); higher mean values on the Lt view 
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P Value P Value 
 
Goniometry 
                       
Flexion, deg 53.6 2.9 .11  53.0 4.1 .03b \.05b  52.7 2.9 .02b  48.4 9.5 .01b \.05b  51.6 2.2 \.001b  50.1 1.7 \.01b .01b 
Extension, deg 150. 8 3.4 .06  151.7 5.9 \.01b ≤.99  150.8 2.9 .07  152. 1 3.3 \.01b ≤.99  151.3 2.9 .17  152.7 3.2 \.01b ≤.99 
Thigh girth, cm 30.6 2.7 .39  29.7 2.1 .09 ≤.99  31.6 2.7 .54  30.3 9.1 .81 ≤.99  31.5 2.2 .2  30.7 3.4 .66 ≤.99 
Pedometer, daily steps     594.5    663.375 .48      1086.9    1639.4 .01b .15      451.9    463.0 .4 1238.0    994.685 .18 .06      434.9    455.8 .2 615.5    331.976 .26 .63 
CMI 
HVAS, 0210 6.4 1.4 .14 6.9 1.6       \.01b       ≤.99 6.6 1.7 .22 6.8 1.2 .21 ≤.99 6.5 1.4 .04b 7.1 1.8 \.01b ≤.99 
CBPI, 0-10 
PSS 3.7 2.6 .03b 3.3 2.7       \.05b .04b 4.1 2.9 .02b 3.5 2.2 \.01b .04b 3.6 3.1 .02b 3.4 2.2 .03b ≤.99 
PIS 3.8        2.6 .01b          3.2 2.7         .06 .04b         3.9         2.8          .01b          3.9         3.1         \.01b        ≤.99         3.5         2.4 .01b         3.5         3.4 .04b ≤.99 COI 
Stiffness, 0-16 4.6 4.1 .87 3.7 3.8 .77 .04b 4.6 3.9 .33 4.3 3.7 .13 ≤.99 4.0 5.7 .82 3.3 3.7 .21 ≤.99 
Function, 0-16 5.7 5.3 .2 3.7 4.4 .46 .02b 5.0 5.2 .21 3.3 2.8 .03b .02b 4.0 5.4 ≤.99 3.2 3.8 .24 .04b 
Gait, 0-20 6.9 5.1 .19 3.3 2.7 .55 .02b 5.7 5.5 .11 5.4 5.6 .43 .04b 4.4 5.4 .87 4.6 6.2 .5 ≤.99 
QOL, 0-12 5.3 3.3 .39 4.4 4.1 .74 .18 5.1 2.8 .02b 4.3 3.8 .23 .19 4.7 2.6 .09 3.6 4.6 .87 .23 
Overall, 0-64 22.4      19.1 .04b 16.7 18.3 .43 .04b      20.1       15.7 .29 19.0      18.4 .04b .04b      15.7      14.9 .1 16.1      21.8 .47 ≤.99 
LOAD, 0-52 16.4      13.1 .22 13.4 12.2 .72 \.01b       13.1       12.4 .72 11.8      12.9 .33 .04b      13.1      12.4 .88 11.8      12.9 .983      ≤.99 
Digital thermography, deg 
DV 25.3 1.5 .36 24.2 1.4 .6 ≤.99 26.1 1.2 .04b 25.7 1.2 .09 .16 25.6 1.4 .89 25.8 1.1 .06 .47 
DV max 25.2 2.1 .88 26.8 1.7 .98 ≤.99 27.4 1.4 .14 27.1 1.0 \.05 \.05 26.9 1.4 .74 27.2 1.0 .02 .06 
Lt 29.8 2.2 \.01b 29.5 2.2       \.01b      \.01b       28.4 1.8       \.01b 27.9 1.3 .03b      \.01b       27.3 1.8 .21 28.1 1.6 \.01b         \.01b 
Lt max 33.9 1.2 \.01b 32.9 2.4       \.01b      \.01b       30.5 1.9       \.01b 30.1 1.5 .06 \.01b       29.7 1.9 .13 30.9 1.8 \.01b         \.01b 
Synovial fluid 
IL-1, pg/mL 122.9    108.9 .05 147.9      129.5 .24 .53      159.6      59.1 .13 206.0    139.7 .7 ≤.99      184.2      68.5 .25 167.9      76.2 .34 ≤.99 
CRP, mg/mL 0.48      0.9 .18 0.27 0.7 .37 ≤.99 0.4 0.8 .36 0.23      0.6 .36 ≤.99 0.0 0.0 .5 0.0 0.0 .4 ≤.99 
Weightbearing 
Symmetry index 18.9 12.2 .04b 10.4 10.5 \.01b .01b 27.4 12.1 .29 8.9 7.9 \.01b \.05b 27.0 27.9 .51 11.8 18.6 .02b .01b 
Deviation 2.5 1.917 .2 1.71 1.59 .08 .14 2.72 2.27 .29 2.14 1.748 \.05b ≤.99 2.61 2.973 .55 2.36 3.954 .45 ≤ .99 
 
aCBPI, Canine Brief Pain Inventory; CG, control group; CMI, clinical metrology instrument; COI, Canine Orthopedic Index; CRP, C-reactive protein; 
DV, dorsoventral view; HVAS, Hudson Visual Analog Scale; IL-1, interleukin 1; LOAD, Liverpool Osteoarthritis in Dogs; Lt, lateral view; max, 
maximal; PCG, platelet concentrate group (treatment); PIS, pain interference score; PSS, pain severity score; QOL, quality of life. 
bP \ .05 (evaluation moment vs treatment day [Table 4] and between groups at each follow -up moment). 
 
TABLE 6 
Frequency of Radiographic Findings in the Control and Treatment Groups at the Initial and Final Evaluations a 
Initial Final 
  
CG PCG CG PCG 
 
 
Irregular wear on the femoral head, making it misshapen and 
with a loss of its rounded appearance 
No. % No. % No. % P Value   No. % P Value 
17 85    20    100    20    100  .08 20    100  ≤.99 
Flattened or shallow acetabulum with irregular outline 11 55    14 70    20    100 \.01b 18 90 \.01b b 
CCO 5 25    12 60    20    100 .99 10 50 \.01 
New bone formation on the acetabulum and on the femoral head and neck    20    100    17 85    20    100 .99 18 90 .08 
Angle formed at the cranial effective acetabular rim is worn away 18 90    14 70    20    100 .16 16 80 .10 
Subchondral bone sclerosis along the cranial acetabular edge 19 95    19 95    20    100 .32 18 90 .32 
CFHO 3 15 5 25    20    100 .18 18 90 .23 
Frog leg view 
CCO 2 10 9 45 20 100 \.01b 8 40 .71 
CFHO 18 90 18 90 20 100 .16 18 90 ≤.99 
aCCO, caudolateral curvilinear osteophyte; CFHO, circumferential femoral head osteophyte; CG, control group; PCG, platelet concentrate group 
(treatment). 
bP \ .05. 
 
(P = .02); and worse joint flexion (P = .01), LOAD (P \ .01), 
stiffness (P \ .01), function (P \ .01), gait (P \ .01), QOL (P 
\ .01), and COI (P \ .01). At 90 days, the same dogs had worse 
LOAD (P = .04), stiffness (P \ .01), function (P \ 
.01), gait (P \ .01), QOL (P \ .01), and COI (P \ .01). At 
the final evaluation, older dogs had worse deviation (P = 
.03), SI (P \ .01), stiffness (P \ .01), function (P \ .01), 
gait (P \ .01), QOL (P \ .01), and COI (P \ .01). In the 







PCG, older dogs had worse PSS (P \ .01), PIS (P \ .01), 
stiffness (P = .04), function (P \ .01), and COI (P \ .01) at 
the initial evaluation point. At 8 days, they had lower mean 
and maximal thermography values on the DV view (P \ .01 
for both) and worse joint extension (P \ .01), PIS (P = .01), 
LOAD (P \ .01), function (P = .01), gait (P 
\ .01), and COI (P = .01). At 15 days, they had higher max- 
imal temperature values on the Lt view (P = .04) and worse 
PSS (P \ .01) and PIS (P \ .01). At the 30-day evaluation, 
older dogs had worse PSS (P = .01), PIS (P \ .01), LOAD (P 
= .04), and function (P \ .01). At 90 days, they had worse PSS 
(P = .04), PIS (P = .03), and gait (P = .05). At the final 
evaluation, these dogs had lower serum CRP levels (P \ 
.01) and worse PSS, PIS, LOAD, stiffness, function, gait, 
QOL, and COI (P \ .01 for all). 
 
DISCUSSION 
OA is the most commonly diagnosed joint disease in human and 
veterinary medicine.2 To our knowledge, this is the first study 
to describe the effect of a single injection of platelet concentrate 
on several clinical, imaging, and labo- ratory signs in a 
naturally occurring canine model with    a long follow-up 
period. 
Previous reports in dogs have pointed out that a single intra-
articular injection of platelet products has resulted in clinical 
improvements for 12 weeks.1,15 Multiple-injec- tion protocols 
that provide improvements in ROM, pain, lameness, and 
kinetics have also been described.12 We observed significant 
functional improvements  in  the PCG, reflected in better limb 
weightbearing as measured through the SI and deviation from 
the normal value. These improvements were present up to the 
last evaluation moment, at 180 days, in line with previous 
reports that have pointed out the ability of platelet 
concentrates to improve weightbearing in dogs with OA.15,19 
It is well-established that OA is a complex low-grade 
inflammatory process that affects the progression of the 
disease, with IL-1 considered the most important proin- 
flammatory cytokine responsible for the catabolism in 
OA.20,31,36 Although a decrease in IL-1 levels was recorded at 8 
days in both groups, concentration in the PCG was still 
significantly lower than that in the CG. The platelet con- 
centrate was able to significantly reduce the levels of this 
pivotal cytokine, and the decrease observed in the  CG was 
probably due to the removal of synovial fluid at treat- ment 
day, followed by the injection of 0.9% NaCl, similar to the effect 
of a joint lavage. The anti-inflammatory activity of platelet 
concentrate has been associated with a positive response to 
treatment rather than any effect on tissue anabolism or 
catabolism.12 This reduction of IL-1 may pro- duce a reduction 
in inflammatory levels, which in turn are reflected in the 
temperature values recorded during the thermographic 
evaluations. Measurements made on the Lt view, in particular, 
recorded variations throughout the entire follow-up period, 
similar to what was observed  with other evaluation 
modalities. 
Pain is the most relevant clinical sign of OA and a hall- mark 
of the disease.41 Pain and functional ability are the 
 
most important parameters in the evaluation of OA treat- ment 
efficacy, with canine studies offering valuable data that may 
translate to humans.16,45,56 We used several CMIs to try to 
capture multiple dimensions of OA, and   we observed 
significant improvements with several of them—in some cases, 
up to the last evaluation moment.  A previous report has 
described similar long-lasting effects of a single administration 
of platelet concentrate,1 but fur- ther studies should be done to 
evaluate if different treat- ment frequencies can lead to better 
results. As expected, some improvements were also observed 
in the CG in the initial evaluations when compared with 
treatment day probably because of the reduction of 
inflammatory cyto- kines within the joint. Still, these effects 
were not as marked or as long lasting as in PCG. 
Radiographic evaluation is a staple of OA monitoring, and 
CCO and CFHO represent early radiographic signs that 
predict the development of the clinical signs of hip OA.33,42 
Previous reports have described that a platelet concentrate 
was able to halt the progression of radio- graphic signs in 
treated dogs.3,15,47 In this study, we observed similar results, 
with increased frequency of radio- graphic findings observed in 
the CG in contrast to what was observed in the PCG, where the 
frequency of CCO decreased. It was interesting to note that, 
even though dogs in the PCG showed significant 
improvements, those that presented CCO in either group had 
worse CMI scores and measures of limb function and higher 
thermographic evaluations. 
Risk factors for OA include higher body weight and age 
. 8 years.2 We applied different cutoff values for weight to 
assess its effect on clinical presentation and in response to 
treatment. For both groups, increasing body weight gener- 
ally corresponded to worse clinical and laboratory findings. 
The exception was SI evaluation above the highest cutoff 
considered. This may reflect a weight shift from the pelvic 
to thoracic limbs rather than a real improvement, which 
should be addressed in further studies. Similar effects were 
observed for animals above the mean age of the group, with 
these dogs scoring worse on almost all CMI scores. Since 
OA is a chronic progressive disease, it was not unexpected 
to observe that older dogs had worse eval- uations, which 
may be linked with the progression of the disease at its 
clinical signs. 
In humans, platelet concentrates can produce local and 
transient side effects, such as injection pain and local 
inflammation, that take 2 to 10 days to resolve.27,39,40 Sim- 
ilarly, we observed increased lameness in 8 dogs that spon- 
taneously resolved within 48 hours, and this had no effect at 
the 8-day evaluation. No other side effects were observed. No 
additional medication was administered to the animals during 




To our knowledge, this is the first study to describe the effect 
of a single injection of platelet concentrate on several clinical, 
imaging, and laboratory signs in a naturally occur- ring canine 
model with a long follow-up period. It provides 







important information for the characterization of the effects of 
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To describe the effect of the intra-articular administration of stanozolol in a naturally 
occurring canine OA model. 
Forty canine (N=40) hip joints were randomly assigned to receive stanozolol or saline 
(control). On treatment day and at 8, 15, 30, 90, and 180 days post-treatment, weight distribution, 
joint range of motion, thigh girth, digital thermography, radiographic signs, synovial fluid interleuk in-
1, and C-reactive protein levels were evaluated. Data from four Clinical Metrology Instruments was 
also gathered.  Results were compared with Repeated Measures ANOVA, with a Huynh-Feld t 
correction, paired-samples t-test, or Wilcoxon signed-rank test, with p<0.05. 
OA was graded as mild (90%), moderate (5%), and severe (5%). Patients of both sexes, with 
a mean age of 6.5±2.4 years and a bodyweight of 26.7±5.2kg, were included. No differences were 
found between groups at treatment day in all considered evaluations. Weight distribution showed 
significant improvements with stanozolol from 15 days (p<0.05) up to 180 days (p<0.01). Lower 
values during thermographic evaluation in both views taken and improved joint extension at 90 
(p=0.02) and 180 days (p<0.01) were observed. Pain and function scores improved up to 180 days. 
In the control group, radiographic signs progressed, in contrast with stanozolol. 
The use of stanozolol was safe and produced significant improvements in weight-bear ing, 
pain score, and clinical evaluations in a naturally occurring canine OA model.  
Keywords: Animal model; Canine; Osteoarthritis; Pain; Stanozolol. 
 
Introduction 
Osteoarthritis (OA) is a disease spanning all species of mammals. It is particularly important 
in humans and dogs, being a source of chronic pain and posing a significant burden to societies. Since 
it has such a significant toll on the quality of life, it implies a considerable cost in healthcare. Its 
prevalence is expected to rise due to a simultaneous increase in life expectancy and obesity1–4.  The 
pathologic process, clinical presentation, and response to treatment in dogs are very similar to those 
in humans, where degenerative, trauma, and overuse aetiologies occur, making dogs a frequent animal 
model for the study of OA5. The naturally occurring canine model, in particular, provides substantia l 
benefits in comparison to other models. It presents a foreshortened lifespan while maintaining the 
same life stages of human disease. Also, dogs share many environmental conditions with humans, 
specifically those that influence human OA. For those reasons, the naturally occurring canine model 
is easier to study and considered the closest to a gold standard5–12. The study of canine OA can provide 
important insight into the disease in a translational approach under the One Medicine initiative and 




OA is still an incurable condition, and the medical approach to its treatment aims at slowing 
disease progression while relieving symptoms, particularly pain, but treatment options are still 
limited11,14–16. Stanozolol is a synthetic derivative of testosterone, and its properties include 
anabolic/androgenic activity, probably associated with its affinity for androgenic and, at lower doses, 
glucocorticoid receptors17. It has a high androgenic potential, but its long-term use has not induced 
activity and aggressivity changes in mice18. An anti-catabolic effect potentiates stanozolol's anabolic 
effect at the glucocorticoide receptor level, where it behaves as a competitive antagonist of the 
catabolic corticosteroids19. In vitro human studies and ovine and equine models have described that 
stanozolol was able to induce fibroblasts, to increase collagen production in a dose-dependent 
pathway through transforming growth factor-1β synthesis while decreasing nitric oxide production 
and stimulating the autocrine secretion of insulin-like growth factor-1, which induces osteoblast 
proliferation and collagen synthesis20–23. In humans, an increase of transforming growth factor-1β 
synthesis is related to a decrease in articular pain24. It also demonstrated chondroprotective effects 
through the downregulation of genes for pro-inflammatory/catabolic cytokines and enzymes 
associated with OA in equine in vitro chondrocytes25. In an ovine surgical model of OA, intra-
articular stanozolol was able to preserve the stifle joint's gross anatomy, reducing osteophyte 
formation, subchondral bone reaction, and promoting articular cartilage regeneration, at 3 and 9 
months post-surgery21. In dogs, a 0.3mg/kg dose has been described for intra-articular administrat ion, 
in the management of knee OA, and oral use to treat tracheal collapse26,27. Before evaluating mult ip le 
administrations, as described in other animal models21,23, the assessment of a single administration of 
stanozolol is required to determine treatment safety its effect following intra-articular administrat ion. 
This study aims to compare the effect of stanozolol to a control group in the management of 
OA in a naturally occurring canine model, using several outcome assessment modalities. We 
hypothesize that stanozolol is able to reduce pain levels improve function in OA joints compared to 
a control group. 
 
Materials and Methods 
This project was approved by the ethical review committee of the University of Évora (Órgão 
Responsável pelo Bem-estar dos Animais da Universidade de Évora, approval nº GD/32055/2018/P1, 
September 25th, 2018), and complies with the ARRIVE reporting guidelines. Written, informed 
consent was obtained from the Institution responsible for the animals (Guarda Nacional Republicana, 
Portuguese Gendarmerie). The sample comprised forty (N=40) joints of twenty active Police working 
dogs with bilateral hip OA. It constituted a convenience sample, similar in size to other reports 




jumping, and maintaining obedience positions, stiffness, and decreased overall performance), 
physical examination (pain during joint mobilization, stiffness, and reduced range of motion), and 
radiographic findings (Orthopedic Foundation for Animals hip scores of mild, moderate or severe). 
Additional inclusion criteria comprised bodyweight ≥20kg, age >2 years, and a period >6 weeks 
without receiving any medication or nutritional supplements. All inclusion criteria had to be met for 
the animal to be included in the study. All animals were submitted to a physical, orthopedic, 
neurological examination, complete blood count, and serum biochemistry. Cases of suspected or 
documented orthopaedic, neurological, or concomitant disease were excluded. For this prospective, 
longitudinal, double-blinded, randomly-controlled study, patients were randomly assigned with the 
statistical analysis software to a control group (CG, n=20) or a treatment group (SG, n=20). In SG, 
an intra-articular (IA) administration of stanozolol (Estrombol, Laboratório Fundacion) at a 0.3mg/kg 
dose was administered, while CG received 2ml of 0.9%NaCl, given IA. Both joints received the same 
substance, according to the assigned group. 
Weight-bearing evaluation 
The weight distribution evaluation was performed with a weight distribution platform 
(Companion Stance Analyzer; LiteCure LLC®, Newark, Delaware, United States). Conducted 
procedures followed the manufacturer's guidelines and included placing the equipment in the centre 
of a room, at least 1 meter from the walls, calibrating it at the beginning of each day, and zeroing it 
before each data collection. The evaluation itself was conducted with the animal placing one foot on 
each quadrant of the platform. The patient's head was kept facing forward. The left-right symmetry 
index (SI) was calculated with the following formula: SI=[(WBR-
WBL)/((WBR+WBL)x0.5)]x10031,32, where WBR is the value of weight-bearing for the right pelvic 
limb, and WBL is the value of weight-bearing for the left pelvic limb. Negative values were made 
positive. Since normal weight-bearing for the pelvic limb is 20%33, we also considered the deviation 
from this value, calculated by subtracting weight-bearing to 20.  
Digital thermography evaluation 
For collecting digital thermography images, animals were kept for 30 minutes in a controlled 
temperature room, with the temperature set at 21ºC. Patients were then placed in an upright standing 
position, as symmetrical as possible. A dorsoventral image was obtained, including the last lumbar 
to the first coccygeal vertebrae area, at a distance of 60 cm34. From the same position, a lateral view 
was also obtained, with the greater trochanter at the centre, at the same distance. All images were 
taken with FLIR ThermaCAM E25® model (FLIR Systems, Wilsonville, Oregon, United States). 




pallet. Mean and maximal temperatures were determined by placing boxes of equal size on the hip 
joint's anatomical area on both views.  
Clinical evaluation 
With the patient in lateral recumbency, with the affected limb uppermost, thigh girth was 
determined with a Gullick II measuring tape, at a distance of 70% thigh length, measured from the 
tip of the greater trochanter, with an extended leg35. Hip joint range of motion was then determined 
with a goniometer at extension and flexion with a flexed stifle36. Pedometers (Xiaomi wrist 
pedometer) were used to measure the patient's activity levels. They were worn around the patient's 
neck, attached to an adjustable lightweight collar37, for a week before the first evaluation moment to 
determine a baseline value and then maintained up to the 30th-day post-treatment. For the 90th and 
180th post-treatment days evaluation, the pedometer was placed a week before the evaluat ion 
moment. Mean daily counts were considered, calculated by dividing the register number of steps by 
the number of days considered. 
Radiographic evaluation 
For the IA administrations and radiographic examination, patients were placed under light 
sedation through the intravenous administration of a combination of medetomidine (0.01mg/kg) and 
buthorphanol (0.1mg/kg). A ventrodorsal extended legs and frog-leg views were obtained during 
radiographic examination. In the ventrodorsal view, the presence of several radiographic findings was 
considered: misshapen femoral head with a loss of its rounded appearance; a flattened or shallow 
acetabulum, with an irregular outline; CCO; new bone formation on the acetabulum and femoral head 
and neck; a worn away angle formed at the cranial effective acetabular rim; subchondral bone 
sclerosis along the cranial acetabular edge and CFHO38–41. In the frog-leg view, the presence of CCO 
and CFHO was also recorded.  
Treatment administration, synovial fluid collection, and evaluation 
Patients were positioned in lateral recumbency, with the affected joint uppermost. A small 
window of 4x4cm area surrounding the greater trochanter was clipped and aseptically prepared. An 
assistant placed the limb in a neutral, parallel to the table position. A 21-gauge 2.5" length needle was 
introduced just dorsal to the greater trochanter and perpendicular to the limb's long axis until the joint 
was reached42. Confirmation of correct needle placement was obtained by collecting synovial fluid, 
and the treatment or saline was administered. The syringes containing the substance to be 
administrated were prepared by a different researcher and covered to hyde the substance's 
characteristics and keep the treatment administrator blinded to the treatment. A sample of synovia l 
fluid was saved for the determination of interleukin-1β (IL 1β). C-reactive protein (CRP) 




United Kingdom), read with a FLUOstar OPTIMA (BMG Labtech). Fuji Dri-Chem Slides VC-CRP 
PS (FUJIFILM Europe GmbH), read with a DRIChem NX500i (FUJIFILM Europe GmbH). 
Additionally, dogs' trainers completed a copy of HVAS, CBPI, COI, and LOAD after receiving the 
published instructions for each of them. They were completed in sequence by the same trainer in a 
quiet room with as much time as needed to answer all items. 
After treatment, animals were rested for three consecutive days and resumed their regular 
activity over five days. Signs of exacerbated pain, persistent stiffness of gait, and changes in posture 
exhibited by the dogs, were evaluated by the veterinarian on days 1 and 3 after the IA administrat ion. 
If no complaints were registered, the animal could resume its normal activity43,44. Evaluations were 
conducted on days 0 (treatment day), 8, 15, 30, 90, and 180. An outline of all procedures at each 
moment is presented in table 1. The same researcher, blinded to the animal's assigned group and 
identification and moment of evaluation, performed all assessments. For the radiographic and digita l 
thermography evaluation, all personal information was removed before the evaluation. After the 
study, all patients remained in active Police work. 
Statistical analysis 
Normality was assessed with a Shapiro-Wilk test. Groups' results were compared in each 
evaluation moment, and each measured parameter was compared with the result observed on 
treatment day. Results were compared with a Paired samples t-test, Repeated Measures ANOVA, 
with a Huynh-Feldt correction, or Wilcoxon signed-ranks test to assess the effect of different 
parameters on the patients' clinical evolution. A Kaplan-Meier test was performed to evaluate the 
time to return to baseline values of SI and CMI scores, compared with the Breslow test. With the 
CBPI, a specific measure of success has been defined and set as a reduction of ≥1 in PSS and ≥2 in 
PIS45. For that reason, the Kaplan-Meier test was used to evaluate the time for the score to drop below 
this reduction level in these scores. All results were analysed with IBM SPSS Statistics version 20 












Table 1 – Procedures conducted at each moment. Days are counted from treatment day. 
Legend: CBPI – Canine Brief Pain Inventory; COI – Canine Orthopedic Index; CRP – C-Reactive 
Protein; HVAS – Hudson Visual Analogue Scale; IL-1 – Interleukin 1; LOAD – Liverpool 
Osteoarthritis in Dogs; SF – Synovial fluid. 
Modality Evaluation moment 
0            
treatment day 
8  15  30  90  180 
Stance analysis X X X X X X 
Digital Thermography X X X X X X 
Pedometer X X X X X X 
Goniometry X X X X X X 
Thigh girth 
measurement 
X X X X X X 
Digital radiography X   X X X 
Treatment X         
SF CRP X X  X X X 
SF IL-1 X X  X X X 
HVAS X X X X X X 
CBPI X X X X X X 
COI X X X X X X 
LOAD X X X X X X 
 
Normality was assessed with a Shapiro-Wilk test. Groups' results were compared in each 
evaluation moment, and each measured parameter was compared with the result observed at treatment 
day. Results were compared with a Paired samples t-test, Repeated Measures ANOVA, with a Huynh-
Feldt correction, or Wilcoxon signed-ranks test to assess the effect of different parameters on the 
patients' clinical evolution. A Kaplan-Meier test was performed to evaluate the time to return to 
baseline values of SI and CMI scores, compared with the Breslow test. With the CBPI, a specific 
measure of success has been defined and set as a reduction of ≥1 in PSS and ≥2 in PIS44. For that 
reason, the Kaplan-Meier test was used to evaluate the time for the score to drop below this reduction 
level in these scores. All results were analysed with IBM SPSS Statistics version 20 (IBM 
Corporation, New York, USA), and a significance level of p<0.05 was set. 
 
Results 
The sample included 40 joints of both intact males (n=22, in 12 CG and 10 in SG) and females 
(n=18, in 8 CG and 10 in SG) Police working dogs with a mean age of 6.5±2.4 years and bodyweight 
of 26.7±5.2kg. Dogs were of breeds commonly employed in police forces, similarly distributed 
between CG and SG: German Shepherd Dogs (n=12, 6 in CG and 6 in SG), Labrador Retriever (n=12, 
6 in CG and 6 in SG), Belgian Malinois Shepherd Dogs (n=10, 6 in CG and 4 in SG), and Dutch 




joints (90%, in 18 CG and 18 in SG), moderate as 2 (5%, all in CG), and severe as 2 (5%, all in SG), 
according to the Orthopedic Foundation for Animals hip grading scheme46. Levene's test for 
homogeneity was used to control baseline values, and no differences were found between groups at 
the initial evaluation. All patients were evaluated in all assessment moments. Increased lameness was 
observed in four cases of the stanozolol group following administration, which spontaneous ly 
resolved within a few days. 
Values recorded in stanozolol and control groups for different evaluations made throughout 
the study, are presented in table 2. Comparing results between groups with repeated measures 
ANOVA with a Huynh-Feldt correction, significant differences between groups were found 
concerning deviation (F(4.4,140.1)=11.2, p<0.01), SI (F(3.8,121.5)=6.2, p<0.01) , mean temperature 
on a DV view (F(3.8,107.8)=4.6, p=0.002), maximal temperature on a DV view (F(3.4,95.1)=3.7, 
p=0.011), mean temperature on a Lt view (F(5,150)=37.1, p<0.001), maximal temperature on a Lt 
view (F(3.9,118.2)=123.7, p<0.001), thigh girth (F(5,170)=6.7, p<0.001) joint extension 
(F(3.6,107.5)=171.3, p<0.001), joint flexion (F(5,170)=15.9, p<0.001) and IL-1 synovia l 
concentration (F(1.8,64.5)=7.4, p=0.002).  Evolution of SI is presented in figure 1 and Kaplan Meier 
curves are presented in figure 2.  
Significant differences were also observed with different CMI, specifically PSS 
(F(3.8,124.1)=2.6, p=0.044), PIS (F(3.7,117.6)=3.9, p=0.007), LOAD (F(2.5,81.3)=3.3, p=0.03), 
Function (F(2.9,93.9)=2.8, p=0.048) and Gait (F(5,160)=2.6, p=0.026). Kaplan Meier curves for 
LOAD are presented in figure 3.  
The frequency of different radiographic findings at the initial and final evaluations is presented 
in table 3. The time to return to baseline values for SI and CMIs, calculated with Kaplan-Meier 





Table 2 – Mean values (±standard deviation) of different parameters evaluated throughout the study. CBPI – Canine Brief Pain Inventory; 
CRP – C-reactive protein; COI – Canine Orthopedic Index; DV – dorsoventral view; HVAS – Hudson Visual Analogue Scale; IL-1 – Interleuk in 
1; LOAD – Liverpool Osteoarthritis in Dogs; LT – lateral view; PIS – Pain Interference Score; PSS – Pain Severity Score; QOL – Quality of Life. 
* indicates significance when comparing both groups at each follow-up moment. 
Parameters 













mean SD   mean SD mean SD   mean SD   mean SD   mean SD   
Goniometry 
Flexion (°, mean±SD) 55,0 4.4  56.6 3.7 55.3 3.7  55.9 4.5  1,00 57.2 5.2  56.2 3.2  1,00 
Extension (°, mean±SD) 151.2 3.9  156.9 6,0 149.9 4.6  156.9 6,0  <0.01 151.1 3.5  115.1 6.4  1,00 
 Thigh girth (cm, mean±SD) 31.2 2.6 
 29.1 1.9 31.1 3.3  29.1 2.1  1,00 31.1 2.9  29.8 2,0  1,00 
 Pedometer (daily steps±SD) 1445.7 755.7 
 910.9 811.2 829.5 931.3  1165.2 684.5  1,00 606,0 309.5  1043.2 733.1  0.43 
CMI 
HVAS (0-10) 6.8 1.2   6.7 1.3 6.7 1.5   6.6 1.4   1,00 6.8 1.2   7.1 0.8   1,00 
CBPI - PSS (0-10) 3.1 1.9  2.9 1.5 3.4 2.3  3.1 2.3  0.53 3.7 2.8  1.9 2.1  0.04* 
CBPI - PIS (0-10)  3.2 2.2  2.3 1.7 3.4 2.1  2.9 1.9  0.02* 3.6 2.1  1.9 1.2  0.01* 
COI - Stiffness  (0-16) 3.4 3.4  4,0 2.8 4.1 3.3  2.3 2.3  0.56 4.1 3.2  1.5 1.9  0.02* 
COI - Function (0-16) 3.6 4.1  4,0 3.6 4.1 4,0  1.8 2.1  <0.01* 4.4 5.5  0.9 1.4  <0.01* 
COI - Gait (0-20) 4.7 5.2  5.2 3.9 5.4 6.1  3.1 3.4  1,00 5.8 4.3  1.8 2.9  0.02* 
COI - QOL (0-12) 4.5 2.6  4.3 2.5 4.6 2.7  4,0 2.2  1,00 4.7 2.9  3.3 2.3  1,00 
COI - Overall score (0-64) 16.4 14.7  17.5 12.4 18.2 13.8  11.2 9,0  0.7 18.6 13.8  7.5 7.4  0.29 
LOAD (0-52) 13.6 10.5   8.2 5.2 14.4 12.7   11.1 7.2   0.17 14.3 10.7   11.1 7.2   0.02* 
Digital 
Thermography 
DV (°, mean±SD) 24.7 1.9  25.1 1.9 25.2 1.3  23.7 1.9  0.04* 24.4 1.6  24.2 1.4  1,00 
DV max (°, mean±SD) 26.3 1.9  25.9 1.9 25.8 1,0  25.5 1.9  1,00 26.7 1.6  26.1 2.6  1,00 
Lt (°, mean±SD) 28.7 2.7  25.8 2.2 31.6 2.1  30.1 2,0  <0.01* 29.7 2.9  29.4 2.4  <0.01* 
Lt max (°, mean±SD) 31.9 3.1  27.6 2.1 34.9 1,0  34.7 1.2  <0.01* 34.9 0.8  34.8 1.1  <0.01* 
Synovial fluid 
IL-1 (pg/mL, mean±SD) 170.9 120.4   155,0 145.5 72.3 42.4   92.8 81.9   <0.01* - -   - -   - 
CRP (mg/mL, mean±SD) 0.4 1,0   0.3 0.3 0.3 1.2   0.2 0.3   0.35 - -   - -   - 
Weight-bearing 
Symmetry Index (mean±SD) 24.7 20.3  24.1 13.9 18.7 17.1  21.6 16.4  1,00 23.9 16.3  24.7 18.3  1,00 







Table 2 (cont.) – Mean values (±standard deviation) of different parameters evaluated throughout the study. CBPI – Canine Brief Pain 
Inventory; CRP – C-reactive protein; COI – Canine Orthopedic Index; DV – dorsoventral view; HVAS – Hudson Visual Analogue Scale; IL-1 – 
Interleukin 1; LOAD – Liverpool Osteoarthritis in Dogs; LT – lateral view; PIS – Pain Interference Score; PSS – Pain Severity Score; QOL – 
Quality of Life. * indicates significance when comparing both groups at each follow-up moment. 
Parameters 
















mean SD   mean SD   mean SD   mean SD   mean SD   mean SD   
Goniometry 
Flexion (°, mean±SD) 53.6 2.9  55.4 5.3  1,00 52.7 2.9  55.8 5.5  0.02* 51.6 2.2  50.9 1.8  <0.01* 
Extension (°, mean±SD) 150.8 3.4  153.2 4.6  0.07 150.8 2.9  154.8 2.9  0.59 151.3 2.9  155,0 3,0  0.04* 
 Thigh girth (cm, mean±SD) 30.6 2.7 
 28.9 1.4  1,00 31.6 2.7  32.5 2.7  1,00 31.5 2.2  29.8 1.9  1,00 
 
Pedometer (daily steps±SD) 594.5 663.4  869.2 1091.5  0.58 451.9 463.0  440,0 455.3  0.36 434.9 455.8  588.33 788.3  0.14 
CMI 
HVAS (0-10) 6.4 1.4   7.1 1.3   1,00 6.6 1.7   6.6 1.3   1,00 6.5 1.4   6.9 1.2   1,00 
CBPI - PSS (0-10) 3.7 2.6  2.4 1.9  <0.05* 4.1 2.9  2.9 1.9  0.04* 3.6 3.1  2.6 1.8  0.02* 
CBPI - PIS (0-10)  3.8 2.6  2.4 1.8  <0.01* 3.9 2.8  2.4 1.8  0.02* 3.5 2.4  2.5 1.7  1,00 
COI - Stiffness  (0-16) 4.6 4.1  1.8 2.2  0.03* 4.6 3.9  2.1 2.2  0.58 4,0 5.7  1.5 2.5  0.41 
COI - Function (0-16) 5.7 5.3  0.9 1.6  <0.01* 5,0 5.2  1.6 1.8  <0.01* 4,0 5.4  1.2 2.1  <0.01* 
COI - Gait (0-20) 6.9 5.1  2.2 3,0  <0.02* 5.7 5.5  3.2 4.4  <0.05* 4.4 5.4  2.5 3.7  <0.05* 
COI - QOL (0-12) 5.3 3.3  2.8 2,0  1,00 5.1 2.8  2.7 2.1  1,00 4.7 2.6  2.4 1.2  1,00 
COI - Overall score (0-64) 22.4 19.1  7.6 8.2  0.13 20.1 15.7  9.6 9.2  0.16 15.7 14.9  7.6 9.2  0.14 
LOAD (0-52) 16.4 13.1   6.4 6.5   <0.01* 13.1 12.4   7.1 6.9   <0.01* 13.1 12.4   7.6 7.1   <0.01* 
Digital 
Thermography 
DV (°, mean±SD) 25.3 1.5  25.2 2.9  1,00 26.1 1.2  25.6 1.1  1,00 25.6 1.4  25.8 1.5  1,00 
DV max (°, mean±SD) 25.2 2.1  26.7 2.8  1,00 27.4 1.4  26.9 1.3  0.04* 26.9 1.4  25.9 1.5  0.02* 
Lt (°, mean±SD) 29.8 2.2  29.9 2.2  <0.01* 28.4 1.8  28.7 1.9  <0.01* 27.3 1.8  28.3 2.1  <0.01* 
Lt max (°, mean±SD) 33.9 1.2  34.5 0.9  <0.01* 30.5 1.9  31.1 2.2  <0.01* 29.7 1.9  30.1 2.3  <0.01* 
Synovial fluid 
IL-1 (pg/mL, mean±SD) 122.9 108.9   122.6 96.4   0.58 159.6 59.1   139.8 57.2   1,00 184.2 68.5   165.5 64.2   1,00 
CRP (mg/mL, mean±SD) 0.48 0.9   0.7 2,0   1,00 0.4 0.8   0.3 0.7   1,00 0,0 0,0   0.1 0.4   1,00 
Weight-bearing 
Symmetry Index (mean±SD) 18.9 12.2  5.6 7.2  <0.01* 27.4 12.1  11,0 6.9  <0.01* 27.0 27.9  6.9 7.3  0.01* 






Table 3 – Frequency of radiographic findings in the Control and Treatment Groups, at the 
initial and final evaluations 
 T0 180d 
Radiographic finding 
Control Stanozolol Control Stanozolol 
Absolut %  Absolut %  Absolut %  Absolut %  p 
Irregular wear on the femoral head. making it misshapen 
and with a loss of its rounded appearance 
17 85% 20 100% 20 100% 18 90% 1,00 
Flattened or shallow acetabulum. with irregular outline 11 55% 10 50% 20 100% 16 80% <0.05* 
Caudolateral curvilinear osteophyte (CCO) 5 25% 5 25% 20 100% 15 75% <0.05* 
New bone formation on the acetabulum and on femoral head 
and neck 
20 100% 16 80% 20 100% 18 90% 0.16 
The angle formed at the cranial effective acetabular rim is 
worn away 
18 90% 15 75% 20 100% 18 90% 0.32 
Subchondral bone sclerosis along the cranial acetabular 
edge 
19 95% 20 100% 20 100% 18 90% 1,00 
Circumferential femoral head osteophyte (CFHO) 3 15% 9 45% 20 100% 10 50% 0.71 
 
 
Table 4 – Time to return to baseline values for SI and CMIs, calculated with Kaplan-Meier 
estimators and compared with the Breslow test. * indicates significance. 










47.0±11.8 23.8±70.2 94.2±15.9 62.9±125.4 
HVAS 0.000* 48.7±12.4 25.4±73.9 129.8±13.4 103.5±156.1 
PSS 0.089 63.2±17.2 29.6±96.8 94.6±16.4 62.5±126.7 
PIS 0.000* 8.4±0.4 7.7±9.0 109.6±17.3 75.8±143.2 
LOAD 0.000* 40.7±10.6 19.9±61.4 123.8±14.2 95.9±151.6 
Stiffness 0.019* 64.7±16.9 31.4±97.9 111.2±15.9 80.6±142.9 
Function 0.003* 65.4±13.4 39.2±91.6 124.5±15.4 94.2±154.8 
Gait 0.028* 52.7±14.6 23.9±81.4 103.6±15.7 72.8±134.4 
QOL 0.656 60.9±15.0 31.4±90.4 66.2±17.5 31.8±100.6 






Figure 1 - Overall evolution of Symmetry Index in the control group and treatment group. 
Box plots represent the median, 25th and 75th percentiles, and whiskers represent 10th and 90th 
percentiles. 
 
Figure 2 - Kaplan-Meier curve demonstrating a significant difference between stanozolo l 





Figure 3 - Kaplan-Meier curve demonstrating a significant difference between stanozolo l 




This study describes the effect of a single injection of stanozolol, showing that stanozolol had 
a significant impact on OA joints, improving weight distribution, pain, and function scores compared 
to the control group. Different animal models have been used to study its effects. In horses with 
naturally occurring OA, a positive response to treatment has been described in 82.5% of cases22.  The 
positive effect of stanozolol in this naturally occurring canine model was observed from 15-30 days 
up to the last evaluation moment, at 180 days after treatment, when considering the functiona l 
assessment based on weight distribution. Interestingly, this effect was observed even with a single 
administration, while in the remaining animal models, multiple administrations were carried out21–
23. This effect is observable in the Kaplan Maier test results for SI, with results of the stanozolo l 
group taking significantly longer to return to baseline values. SI is commonly used to assess lameness, 
but their calculation with pressure-sensitive walkways has some limitations in OA patients47. While 
it is still unknown if the same limitations apply to the static evaluation of weight-bearing, we looked 
at different weight-distribution compensation mechanisms by calculating SI and deviation values. It 
was reasonable to expected improvements in SG only after a relatively large period after the intra -
articular administration since stanozolol acts by inducing transforming growth factor 1β synthesis. A 




expression48. It has been demonstrated that the human articular cartilage expresses aromatase and 
that reduced expression of aromatase could facilitate the development of OA49,50. Aromatase 
inhibitor therapy in humans to address other medical conditions might be associated with common 
musculoskeletal symptoms and with substantial functional disability51. 
Pain is a hallmark of OA, and canine studies offer valuable data that may translate to 
humans52–54. Results show that a single intra-articular stanozolol administration significantly 
improved pain and function scores compared with the control group, raging until the 90-day 
evaluation moment and, in some cases, until the last evaluation moment. A significant difference was 
also observed with the Kaplan Meier test for the majority of the considered scores. Through the same 
period, control group scores worsened, as would be expected as the disease progresses. It is interest ing 
to note that some patients in the control group still recorded better scores in follow-up evaluations. 
This may be due to OA's natural course, with patients sometimes showing spontaneous improvements 
through time, only to see symptoms reappear in the future. An additional possibility is based on the 
fact that placebo saline injections can produce an effect in functional improvements that can last up 
to 6-month 55. Even though this is possible and may be reflected in some patients' scores, the control 
group as a whole showed the expected progression of the disease. Additional clinical improvements 
were observed in the stanozolol group, with improved range of motion during joint extension. A 
consistent finding with the thermographic evaluation was that higher values were registered in the 
control group throughout the study, particularly in the last evaluation moments. Digital thermography 
can assess inflammatory pain and identify osteoarthritic patients56,57. Our results seem to support 
this finding, with higher temperature values determined with this technique corresponding to patients 
with worse functional evaluation and clinical signs. During digital thermography of dogs, the coat's 
type and color must be taken into account58,59.  All of the breeds included in this study had short 
hair, some had a double coat, and breeds had similar distribution between groups.   
IL-1 is commonly pointed out as a major proinflammatory cytokine responsible for the 
catabolism in OA in several species, dogs, horses, and humans included1,60,61. Therapeutic 
approaches targeting IL-1 have been developed and shown a positive effect in animal models62. The 
evaluation of synovial fluid can add important information regarding disease burden and 
progression63,64. A previous report has described an improvement in synovial fluid characterist ics 
of animals treated with intra-articular stanozolol22. We only observed significant changes at eight 
days, with both groups showing a reduction from the values recorded at the initial evaluation, but the 
stanozolol group had higher values. Visual inspection of patients' synovial fluid in the control group 
at the 8-day evaluation point showed an easily noticeable increased turbidity. The amount of turbidity 




increase in joint inflammation, which may also account for functional improvements, measured with 
weight distribution, were only observed after this period. Also, since stanozolol acts by inducing 
transforming growth factor 1β synthesis and reducing nitric oxide, it may not significantly impact IL-
1 levels. It is also important to keep in mind that exercise influences inflammatory arthropathies 
parameters, and increase joint loading adds to secondary inflammation in OA joints66,67. As these 
animals were working dogs, physical activity may also play a role in this finding.  The injection of 
0.9% NaCl, used in as the control, added to the removal of  synovial fluid for analysis, thus removing 
pro-inflammatory cytokines, may have had a similar effect to that of a joint lavage, and therefore 
account for the lower IL-1 levels observed in the control group at 8 days.  
Radiographic evaluation is a staple of OA monitoring, and CCO and CFHO represent early 
radiographic signs that predict the development of the clinical signs of hip OA38,68–70. There is a 
low relationship between radiographic changes, clinical signs, and limb function71. As expected, 
radiographic signs in the control group progress throughout the follow-up period, representing the 
natural evolution of OA. In the stanozolol group, the majority of considered radiographic signs did 
not progress, and some improved. This effect has been described in an ovine surgical induce model, 
with stanozolol reducing subchondral bone reaction and promoting articular cartilage regeneration21. 
Although the effect has been previously described, future studies have confirmed these changes as no 
histological samples were collected in this study. 
Studies regarding the use of stanozolol in human OA are not performed due to its potential 
anabolic effects72,73.  The dose demonstrated to produce anabolic effects is 10mg twice a week, 
given through intramuscular administration74. In this model, we used the described 0.3mg/kg dose 
for intra-articular use in dogs26,27. Even if the administered dose may have approached the 10mg 
level in some patients, a single administration was used, thus not exceeding the dose needed to 
produce the anabolic effect. In a study aimed to determine the best intra-articular dose of stanozolo l 
in horses, multiple administrations at the highest dose tested (5mg) also did not produce any side 
effects23. It is known that after intra-articular administration of stanozolol, it passes rapidly from the 
joint space to systemic circulation, with maximal plasma concentration registered at 6 hours post-
administration. It is then eliminated rapidly and detected in plasm for no more than 36h post local 
administration75. In an ovine model, no weight gain was attributed to the anabolic effect of 
stanozolol21. We also did not recorded significant increases in body weight, which could be attributed 
to stanozolol. In mice treated with a long-term, high-dose stanozolol regime did not produce 
significant changes in activity patterns and aggressiveness18. No event of aggressiveness or 




Side-effects of intra-articular stanozolol have been previously reported in horses. They include 
a transient post-injection swelling in the treated joint, which disappeared after a few days without 
intervention22. Similarly, we observed increased lameness in four cases, which spontaneous ly 
resolved within a few days. No additional medication was administered to the animals during the 
follow-up period. The study presents some limitations, namely the fact that the majority of animals 
had mild OA. It would be of interest to include a larger proportion of animals representing the 
remaining hip grades. Including a larger number of patients also is of interest. It is also important to 
determine the biological significance of the changes observed.  This assessment was made with the 
Kaplan-Meier test, but the determination of what constitutes a meaningful improvement has not been 
yet made for some of the evaluations performed. For that reason, we evaluated how long did it take 
for the assessment to return or drop below the value of the initial presentation, as it was the point 
which motivated the need for medical assistance. As this study was a clinical treatment experiment, 
no joint histological samples were collected and analyzed. For that reason, the effect of stanozolol on 
actual disease progression could not be determined on this animal model, and only radiographic 
progression was evaluated. Further studies should also consider this drug's intra-articular effects, 
including cytotoxicity, different dose evaluations, and administration frequencies, similar to what is 
described in other animal models. 
 
Conclusions 
This study describes the effect of a single injection of stanozolol in a naturally occurring 
canine model, with a long follow-up period. The use of stanozolol was safe and produced significant 
improvements in weight-bearing, pain score, and clinical evaluations. 
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concept can improve both humans and dogs’ health and well-being. 
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Osteoarthritis (OA) is a highly prevalent disease world- wide, 
which affects all mammals and a leading cause of disability.  
It  can  negatively  impact  both  the  population’s physical and 
mental well-being, with substantial health- care resources 
and costs associated with managing the dis - ease [1, 2]. The 
dog is an ideal species to study human OA, with the 
advantages of being anatomically, biochem- ically, 
genomically, and molecularly similar to humans, with 
clinical progression and treatment similarities [3]. At the 
same time, they have a foreshortened lifespan but with human 
equivalent life and disease stages while sharing many 
environmental variations that influence human OA. The 
study of spontaneous canine OA and its treatment can add 
to the knowledge of the treatment of the human disease as 
well, under the One Medicine initiative [4, 5]. 
OA is an incurable condition, and its management fo- cuses 
on alleviating symptoms, particularly pain. An add- itional 
goal is to improve overall joint function while slowing down 
disease progression [5, 6]. Hyaluronan, the high molecular 
glycosaminoglycan, is synthesized by chondrocytes and 
synovial fibroblasts [7]. It forms the backbone of 
proteoglycans aggregates interwoven with collagen to create 
hyaline cartilage’s unique structure [8]. Information from 
animal models shows that endogenous hyaluronan is cleaved 
by free radicals in OA. Its quantity and quality are affected 
in OA joints, more severely in clinically affected patients, 
supporting its exogenous ad- ministration [9]. Even though 
its mechanism of action is  not entirely understood and 
clinical trials have provided contradictory results, hyaluronan 
treatment aims to re- duce pain and improve function by 
supplementing syn- ovial fluid viscosity and elasticity [10]. 
Additional anti- inflammatory, anti-nociceptive, and 
chondroprotective properties have been suggested, through 
the enhancement of cartilage synthesis, blunting response to 
IL-1, protec- tion from the damage of oxygen free radicals, 
and protec- tion of chondrocytes from apoptosis [7, 11]. 
Human reports show that intra-articular hyaluronan, given  
once weekly for 3 weeks, increased mobility and reduces 
pain and the need for nonsteroidal anti- inflammatory  
drugs to control pain [12]. A systematic review concluded  
that there is a lack of standardization regarding intra -
articular hyaluronan administrations for hip OA, with no 
consensus on its efficacy [13]. Although it is not clear if any 
formulation has a superior disease- modifying effect [14], 
high molecular weight products  seem to produce better 
results, particularly in patients  with mild radiograph ic 
disease [15]. A recent report showed that both single or 1–
3 weekly injections of Hylan G-F 20 at 1 year following  
the first injection for knee OA are efficacious and 
generally well tolerated for long-term use [16]. Many 
studies performed in canine experimental OA models  
have failed  to demonstrate 
clear benefits of hyaluronan supplementation [17]. In a 
canine surgical model, IA hyaluronan provided clinically  
significant improvement in pain, function, lameness, and  
kinetics compared to pre-treatment and saline control, 
without preventing OA’s progression [18]. In a rabbit model, 
hyaluronan administration produced a more nor- mal 
cartilage after immobilizat ion [19]. In dogs with nat- urally  
occurring OA, treatment groups have significantly  better 
results than a control group by the 6th week post- treatment 
[20]. 
Multiple agents influence OA catabolism, but interleu- kin 1 
(IL-1) is commonly pointed out as the major pro- 
inflammatory cytokine [21]. C-reactive protein (CRP) is an 
acute-phase protein produced during inflammatory reactions 
or tissue injury from an early stage [22]. 
Radiographic examination is a staple in OA’s assess- ment, 
and the ventrodorsal (VD)  hip  extended view  is  the most 
commonly used projection.  An additional use- ful projection 
is the ventrodorsal flexed view, also called frog-legged view 
(FL), specifically in the evaluation of the circumferential  
femoral  head  osteophyte  (CFHO) and caudolateral 
curvilinear osteophyte (CCO), early radiographic signs 
related to the development of the clinical symptoms [23]. 
Digital thermal imaging relies on the between physiologic 
functions generated heat and its  relation with skin 
temperature control, being reliable in assessing inflammatory  
arthritis pain and osteoarthritic subjects [24]. Functional 
evaluation is also paramount in determining response to 
treatment in OA, and stance analysis has been reported as a 
sensitive evaluation for detecting lameness in dogs [25]. It 
evaluates weight dis- tribution since patients commonly bear 
less weight on a painful limb [26]. An additional functional 
evaluation in- cludes determining activity levels and mobility  
impair- ments since they are  associated  with   
musculoskeletal pain [27]. Pedometers are capable of 
measuring ambula- tory activity with acceptable accuracy 
[28]. Clinical examination of patients commonly includes 
evaluating muscle masses, muscular atrophy being a 
consistent finding in OA patients,  and determining  the  joint 
range of motion (ROM, flexion, and extension), which can 
present restrictions [29]. 
Pain is a hallmark of OA, and canine studies offer valuable 
data that may translate to humans [30, 31]. For pain 
evaluation and its impact on patients ’ lives, several clinical 
metrology instruments (CMI) have been devel- oped. The 
Liverpool Osteoarthritis in Dogs (LOAD) and the Canine 
Brief Pain Inventory (CBPI) are the most commonly used 
[27], with the CBPI being divided into a pain severity score 
(PSS) and a pain interference score (PIS) [32]. The Canine 
Orthopedic Index (COI, divided into four scores: stiffness, 
gait, function, and quality of life (QOL) and the Hudson 
Visual Analogue Scale (HVAS), developed to assess the 
degree of lameness in 









dogs, are additional validated evaluation tools [33, 34]. 
Digital thermal imaging is a technique that has recently 
gained attention. It relies on heat generated during 
physiologic functions and its relation with skin temperature 
control [35]. It has been used to assess in- flammatory 
arthritis pain and differentiate normal from osteoarthritis 
subjects [24]. 
This study aimed to describe the effect of a high mo- lecular 
weight hyaluronan product  (Hylan  G-F  20)  in OA 
management in a naturally occurring canine model. We 
hypothesize that a single administration will reduce clinical 
signs of OA compared with a control group. 
 
Methods 
The study protocol was approved by the ethical review 
committee of the Universidade de Évora (ORBEA, ap- 
proval n° GD/32055/2018/P1, September 25, 2018) and 
complies with the ARRIVE guidelines. Written informed  
consent was obtained  from  the  Institution  responsible for 
the animals. Twenty patients with naturally occurring 
bilateral hip OA, constituting  a  convenience  sample, were 
signaled from a population of active police working dogs, 
comprising forty (N=40) hips joints. The diagnosis  was made 
based on history, physical, orthopedic, neuro- logical, and 
radiographic examinations. Additional inclu- sion criteria 
included a bodyweight of ≥ 20kg, age ≥2 years, and they 
should not have received any medication or nutritional 
supplements for at least 6 weeks. Patients  with other 
suspected or documented orthopedic or con- comitant disease 
and not tolerant of data collection were excluded. 
 
Treatment administration 
In a double-blinded study, patients were randomly  
assigned using the statistical analysis software to two 
groups, 10 dogs per group, and treated bilaterally: a con- 
trol group (CG, n=20), which received an intra-articu lar 
(IA) administration of 2ml of 0.9%NaCl, and a treatment  
group (HG, n=20), which received a single IA adminis - 
tration of 2ml of Hylan G-F 20 (Synvisc®, Sanofi, 
Portugal). Radiographic examinat ions and IA adminis - 
trations were conducted under light sedation, using a 
combination of medetomidine (0.01mg/kg) and buthor- 
phanol (0.1mg/kg), both given intravenously simultan - 
eously. The procedure for intra-articular administrations to 
the hip joint has been described before [36]. The patient  
was positioned in lateral recumbency, with the affected  
joint uppermost, to access the joint of interest. A window 
of 4 × 4cm surrounding the greater trochan- ter was 
clipped and aseptically prepared. An assistant then 
positioned the limb in a neutral and parallel to the table 
position. The joint space was accessed using a 21- gauge 
with 2.5″ length needle, introduced just dorsal to the 
greater trochanter and perpendicular to the limb’s 
 
long axis. Correct needle placement was confirmed by 
collecting synovial fluid (immediately collected and 
processed for future analysis), and the treatment or sa- 
line were administered. Patients were rested for three 
consecutive days following treatment, after which  nor- mal 
activity was resumed over 5 days. One and 3 days  after the 
IA procedure, animals were examined by the assisting 
veterinarian for signs of exacerbated pain, per- sistent 
stiffness of gait, and changes in posture exhibited. 
Evaluations were conducted on days 0 (treatment day), 8, 
15, 30, 90, and 180 by the same researcher. An outline of 
procedures and evaluations conducted in each evalu- ation 
moment is presented in Table 1. 
 
Evaluation of weight-bearing distribution 
The weight distribution evaluation was performed with a weight 
distribution platform (Companion Stance Ana- lyser; LiteCure 
LLC®, Newark, DE, USA). According to the manufacturer’s 
guidelines, the equipment was placed in the center of a room, 
at least 1 m from the walls. It was calibrated at the beginning 
of each day and zeroed before each data collection. After this 
procedure, animals were placed with one foot in each quadrant 
of the plat- form, using gentle restraint when required. A left-
right symmetry index (SI) was calculated with the following 
formula: SI=[(WBR-WBL)/((WBR+WBL) × 0.5)]×100 
(WBR is the weight-bearing of the right limb, and WBL is 
the weight-bearing of the left limb). Negative values were 
made positive [37]. We additionally considered a deviation 
from normal 20% weight-bearing for a pelvic limb, 
calculated by subtracting WB to 20. 
 
Digital thermography imaging 
Digital thermography evaluation was conducted in a room 
with a controlled temperature, set at 21°C. Previous to col- 
lecting the images, animals were allowed to walk around the 
room for 30 min. They were then placed in an upright  
standing position, and a dorsoventral thermographic image 
was obtained, including the area from the last lum- bar 
vertebra to the first coccygeal vertebra, at a distance of 60cm 
[38], FLIR ThermaCAM E25® model (FLIR Systems, 
Wilsonville, OR, USA). Images were analyzed using the free 
software Tools (FLIR Systems, Inc), with a rainbow color 
pallet. Boxes of equal size were placed on the hip joint’s 




In the VD radiographic projection [23], seven radio- graphic 
signs were assessed: irregular wear on the fem- oral head, 
making it misshapen and with a loss of its rounded 
appearance; a flattened or shallow acetabulum, with irregular 
outline; CCO; new bone formation on the acetabulum and 
femoral head and neck; a worn away 









Table 1 Outline of procedures and evaluat ions conducte d in 
each evaluation moment. Days are counted from treatment day 
 
 
Modality Evaluation moment 
 
 





Functional assessment  
Stance analysis X X X X X X 
Pedometer X X X X X X 
Goniometry X X X X X X 
Thigh girth measurement X X X X X X 
Imaging       
Digital Thermography X X X X X X 
Digital radiography X   X X X 
Clinical Metrology Instruments 
HVAS X X X X X X 
CBPI X X X X X X 
COI X X X X X X 
LOAD X X X X X X 
Laboratorial evaluation       
SF CRP X X X X X 
SF IL-1 X X X X X 
CBPI, Canine Brief Pain Inventory; COI, Canine Orthope di c Index; CRP, C- reactive 
protein; HVAS, Hudson Visual Analogue Scale; IL-1, interleukin 1; LOAD, 
Liverp o ol Oste o a rt h ri ti s in Dogs; SF, syno vi al fluid 
 
angle formed at the cranial effective acetabular rim; sub- 
chondral bone sclerosis along  the  cranial  acetabular edge; 
and CFHO. 
 
Clinical and laboratorial findings 
Thigh girth was determined with a Gullick II measuring  
tape, at a distance of 70% thigh length, measured from the  
greater  trochanter’s  tip,  with  an  extended  leg  [39]. Hip  
joint ROM was obtained with a goniometer at ex- tension 
and flexion with a flexed stifle [40]. Pedometers were worn 
around the patient’s neck, attached to an ad- justable 
lightweight collar [41]. Pedometers were worn for 1 week 
before the first evaluation moment to set a baseline value. 
For each of the following evaluations, ani- mals worn the 
pedometer for a week before that evalu- ation moment. A 
mean daily count was calculated by dividing the registered  
number of steps by the number of considered days. In each 
evaluation moment, trainers  completed a copy of HVAS, 
CBPI, COI, and LOAD after receiving the published  
instructions for each of them. They were completed  
sequentially by the same handler, in a quiet room, with as 
much time as needed to answer all items. From the synovial 
sample collected, IL 1β and CRP concentrations were 
determined with the DuoSet Ancillary Canine IL-1β 
Reagent kit (R&D Systems, UK), read with a FLUOs tar 
OPTIMA (BMG Labtech), and Fuji Dri-Chem  Slides VC-
CRP PS  (FUJIFILM Europe 
 




Normality was assessed with a Shapiro-Wilk test. Results 
were compared between groups in each of the evaluation  
moments. To evaluate the effect of different parameters on 
patients’ clinical evolution, results were compared by sex, 
body weight, age, and different radiographic findings  with  
repeated measures ANOVA, with a Huynh-Feldt correction, 
paired samples T-test, or Wilcoxon signed- ranks test. A 
Kaplan-Meier test was performed to evalu- ate the time to 
return to baseline values of SI and CMI scores, compared  
with the Breslow test. All results were analyzed with IBM 
SPSS Statistics version 20, and a sig- nificance level of 
p<0.05 was set. 
 
Results 
This study sample comprised 40 joints of active police  
working dogs, with a mean age of 6.5±2.4 years, a mean  
bodyweight of 26.6±5.2kg, and of both sexes (13 males and 
7 females). Dogs were of breeds commonly employed in  
police forces, similarly distributed between CG and TH: 
German Shepherd Dogs  (n=6,  3 in CG  and 3 in TH), 
Labrador Retriever (n=6,  3 in CG  and  3 in TH), Belgian  
Malinois Shepherd Dogs (n=5, 3 in CG and 2 in TH), and 
Dutch Shepherd Dog (n=3, 2 in CG and 1 in TH). At the 
initial evaluation, joints were graded with the OFA hip 
grading scheme as mild (n=28, 70%), mod- erate (n=6, 15%), 
and severe (n=6, 15%). No differences were found between 
groups at the initial evaluation. In- creased lameness was 
observed in 6 joints HG, which spontaneously resolved 
within 48–72h. 
 
Clinical and CMI results 
Values recorded for different evaluations in each group at  T0 
are presented in Table 2. Comparing results between groups 
with repeated measures ANOVA with a Huynh- Feldt  
correction, significant differences between groups  were 
found concerning deviation (F(5, 160)=3.7, p=0.004), SI 
(F(3.6, 114.4)=3.6, p=0.011), mean temperature on a DV 
view (F(3.9, 103.1)=4.8, p=0.001), maximal temperature on 
a DV view (F(3.9, 101.7)=4.4, p=0.003), mean temperature  
on a Lt view (F(5, 140)=36.3, p<0.001), maximal temperature  
on a Lt view (F(4.8, 133.3)=86.7, p< 0.001), joint flexion  
(F(4.2, 130.5)=18.4, p<0.001), and IL-1 
synovial concentration (F(2.4, 85.8)=5.3, p=0.004). Signifi- 
cant differences were also observed with different CMI, 
specifically PSS (F(5, 140)=2.8, p=0.021), PIS (F(2.7, 75.1)= 
3.4, p=0.026), Function (F(5, 140)=2.6, p=0.026), Gait (F(5, 
140)=2.3, p=0.044), and COI (F(5, 140=2.2, p<0.05). The 
evolution of SI in CG and HG is presented in Fig. 1. Re- sults 
of the Kaplan-Meier test are presented in Table 3. 









Kaplan-Meier curves for stiffness score and PIS are pre- 
sented in Figs. 2 and 3, respectively. 
 
Radiographic evaluations 
The frequency of different radiographic findings at the initial 
and final evaluations is presented  in  Table  4. Cases without 
CFHO on a VD view in the CG, on the first assessment, 
had a better joint extension at the 8-day evaluation (p<0.01) 
and better HVAS (p=0.02), PSS (p= 0.01), and PIS scores 
(p=0.03). At 15 days, they had a higher mean thermographic 
evaluation on a Lt view (p= 0.02), better PSS (p=0.02), and 
PIS scores (p<0.05). The higher mean thermographic 
evaluation on a Lt view was  also observed at 30 days 
(p=0.01). At 90  days,  these joints had better HVAS scores 
(p=0.02). At the final evaluation, they had higher maximal 
thermographic evaluation on a Lt view (p=0.04) and better 
PSS (p=0.05) and PIS scores (p<0.03). In the HG, cases 
without CFHO had higher thigh girth (p=0.03). At 8 days, 
they  had higher body weight (p<0.01), lower deviation 
(p<0.01), lower mean and maximal thermographic 
evaluation on a DV (p=0.02 and p=0.04, respectively) and 
mean on a Lt view (p<0.02), and higher thigh girth (p=0.01). 
At  15 days, these joints had lower deviation (p=0.03), lower 
mean, and maximal thermographic evaluation on a DV 
(p=0.03 for both) and maximal on a Lt view (p<0.05). At 30 
days, they had a higher thigh girth (p<0.01). At the 90-day  
evaluation moment, they had better deviation (p=0.02), a 
finding again observed at 180 days (p<0.05). 
 
Evaluations by sex 
In the CG, female dogs had significantly lower body weight 
in all evaluation moments (p=0.01). At the initial evaluation, 
females had higher values in all thermo- graphic evaluations 
(p<0.01) and lower PIS scores (p= 0.04). At 8 days, the same 
was true regarding thermo- graphic evaluation (p<0.01), 
except  maximal value on a Lt view and higher joint 
extension values (p<0.01). At 15 days, females still showed 
higher joint  extension  (p= 0.04) and lower PIS scores 
(p=0.03). At the 30 days’ evaluation, females showed higher 
thermographic max- imal values on an LT view max 
(p<0.01). At 90 days, fe- male dogs had lower thigh girth 
(p=0.03) and better PSS and PIS scores (p=0.01). In the final 
evaluation moment, female dogs had higher extension values 
(p=0.02) and better HVAS (p=0.02), PSS (p<0.01), PIS 
(p<0.01), stiff- 
ness (p=0.02), function (p=0.02), gait (p<0.01), QOL (p= 
0.02), and COI (p=0.01) scores. In the HG, at the initial 
evaluation, females had lower pedometer counts  (p= 0.02), 
better deviation (p=0.02) and SI (p<0.05), higher mean and 
maximal values on a Lt view (p=0.02 and p< 0.01, 
respectively), and lower thigh girth (p<0.01). At the 8-day 
evaluation moment, females had higher mean and maximal  
thermographic  values  on  the  DV  view  and 
 
mean value on a Lt view (p<0.01 for all) and lower thigh  
girth (p<0.01). At 15 days, females had lower pedometer 
counts (p=0.04), still had mean and maximal thermo - 
graphic values on the DV, and mean value on a Lt view 
(p<0.01 for all), lower thigh girth (p<0.01), and wors e  
joint extension (p=0.02). At 30 days, females still had 
mean and maximal thermographic values on the DV and 
mean value on a Lt view (p<0.01, p=0.01, and p<0.05, re- 
spectively), in addition to lower thigh girth (p<0.01). At 
the 90 days’ evaluation moment, females had worse SI  
(p=0.03), higher maximal thermography evaluation on a 
lateral (p<0.05), and synovial fluid CRP (p=0.02). At the 
final evaluation moment, females had better joint flexion  
(p=0.04) and serum higher CRP (p=0.02). They also had 
lower body weight throughout the study (p<0,01). 
 
 
Evaluations by bodyweight 
Comparing animals with a weight cut-off set at the sample’s 
mean value at 8 days, lighter  subjects  had higher 
thermographic mean and  maximal  values  on  a DV (p=0.03 
and p=0.02, respectively), higher thigh girth (p=0.01), and 
worse stiffness (p=0.03),  function  (p< 0.01), gait (p=0.03), 
and COI scores (p<0.01).  At  15 days, lighter cases showed 
lower  thigh  girth  (p=0.04) and worse HVAS (p<0.05), 
stiffness, function, gait QOL, and COI scores (p<0.01). 
Lighter  animals  had lower PCR concentrations at 30 days 
(p=0.04) and bet- ter HVAS scores (p=0.02). The same 
animals had lower thigh girth (p<0.01) and IL-1 levels 
(p=0.02) at 90 days. In the final evaluation point, lighter 
animals  showed higher mean thermographic values on a DV 
view  (p< 0.01) and higher joint flexion (p=0.02) and 
extension (p<0.01). In HG, animals below the threshold  had  
a higher mean value on a Lt view (p=0.03), lower thigh 
girth (p<0.01), and worse  joint  extension  (p<0.05)  on the 
initial evaluation. At 8 days, they had lower pedom- eter 
counts (p<0.01), worse deviation (p=0.03), higher mean  
temperature values on a Lt view (p<0.01), lower thigh girth 
(p<0.01), and worse function score (p=0.02). After 15 days, 
lighter subjects had lower  pedometer counts (p=0.04), higher 
mean and maximal temperature values on the DV view 
(p=0.01 for both), as mean value on a Lt view (p=0.02), lower 
thigh girth (p<0.01), worse joint extension (p=0.02),  and  
function  score  (p<0.01). At 30 days, these cases had lower 
thigh girth (p<0.01), worse joint extension (p<0.01), 
function, and QOL scores (p=0.03). At the 90-day  
evaluation, animals below the cut-off had worse flexion  
(p=0.03), higher synovial CRP concentration (p=0.04), and 
worse  func- tion score (p=0.03). At the final evaluation 
moment, lighter subjects had worse deviation (p<0.01),  
higher mean and maximal temperature values on the Lt view 




Table 2 Mean values (±standard deviation) of different parameters evaluated at the initial evaluation and throughout the study 
Modality Treatment day 8 days 15 days 
 CG   HG  CG   HG  p CG   HG  p 
Mean SD  Mean SD Mean SD  Mean SD  Mean SD  Mean SD  
Goniometry Flexion (°, mean±SD)   55.0 4.4  54.9 4.1 55.3 3.7  55.9 3.8 0.1 57.2 5.2  58.6 4.7 0.3 
Extension (°, mean±SD)   151.2 3.9  149.8 8.6 149.9 4.6  149.8 8.6 1.00 151.1 3.5  150.2 5.5  
Thigh girth (cm, mean±SD)   31.2 2.6  30.4 3.3 31.1 3.3  29.3 2.8 1.0 31.1 2.9  31.3 3.2 1.0 
Pedometer (daily steps±SD)   1445.7 755.7  1107.0 998.8 829.5 931.3  782.0 842.9 1.0 606.0 309.5  845.0 472.0 1.0 
CMI HVAS (0–10)   6.8 1.2  6.6 1.4 6.7 1.5  6.7 1.3 1.0 6.8 1.2  6.8 1.4 1.0 
CBPI—PSS (0–10)   3.1 1.9  3.3 2.6 3.4 2.3  2.8 1.5 0.04* 3.7 2.8  2.6 1.6 0.04* 
CBPI—PIS (0–10)   3.2 2.2  3.4 2.3 3.4 2.1  3.2 1.9 0.02* 3.6 2.1  3.3 2.7 0.02* 
COI—Stiffness (0–16)   3.4 3.4  17.0 10.5 4.1 3.3  4.2 3.2 0.88 4.1 3.2  3.8 2.6 0.38 
COI—Function (0–16)   3.6 4.1  3.4 2.9 4.1 4.0  4.4 3.2 0.06 4.4 5.5  4.3 3.2 0.37 
COI—Gait (0–20)   4.7 5.2  4.6 3.5 5.4 6.1  6.6 4.2 0.46 5.8 4.3  7.0 4.3 0.86 
COI—QOL (0–12)   4.5 2.6  7.4 4.7 4.6 2.7  4.4 2.5 0.40 4.7 2.9  4.4 2.2 0.22 
COI—Overall score (0–64)   16.4 14.7  4.5 3.1 18.2 13.8  19.7 12.0 0.75 18.6 13.8  19.6 11.1 0.19 
LOAD (0–52)   13.6 10.5  19.9 12.7 14.4 12.7  16.2 9.4 0.73 14.3 10.7  16.6 9.4 0.18 
Digital thermography DV (°, mean±SD)   24.7 1.9  25.8 1.4 25.2 1.3  24.9 1.3 0.02* 24.4 1.6  24.4 1.5 1.0 
DV max (°, mean±SD)   26.3 1.9  26.6 1.6 25.8 1.0  26.2 1.2 1.0 26.7 1.6  25.8 1.4 1.0 
Lt (°, mean±SD)   28.7 2.7  26.9 2.1 31.6 2.1  31.6 2.6 <0.01* 29.7 2.9  30.8 2.5 <0.01* 
Lt max (°, mean±SD)   31.9 3.1  30.4 3.3 34.9 1.0  33.8 2.8 <0.01* 34.9 0.8  34.3 0.7 <0.01* 
Synovial fluid IL-1 (pg/mL, mean±SD)   170.9 120.4  182.4 157.4 72.3 42.4  141.2 138.1 0.01* - -  - - - 
CRP (mg/mL, mean±SD)   0.4 1.0  0.2 0.3 0.3 1.2  0.2 0.0 0.2 - -  - - - 
Weight bearing Symmetry index (mean±SD)   24.7 20.3  21.7 24.9 18.7 17.1  36.4 37.5 <0.01* 23.9 16.3  23.9 23.7 0.4 
Deviation (mean±SD)   2.8 3.6  3.8 3.5 2.78 1.987  4.1 3.6 1.0 2.94 2.127  2.5 2.7 1.0 
Modality 30 days      90 days      180 days       
 CG  HG   p CG  HG   p CG  HG   p  
 mean SD mean SD   mean SD mean  SD  mean SD mean  SD   
Goniometry Flexion (°, mean±SD) 53.6 2.9 56.3 4.5  1.0 52.7 2.9 51.7  2.6 0.03* 51.6 2.2 49.1  5.0 <0.01*  
Extension (°, mean±SD) 150.8 3.4 152.0 6.0   150.8 2.9 152.0  4.7  151.3 2.9 150.7  11.5   
Thigh girth (cm, mean±SD) 30.6 2.7 29.3 2.2  0.4 31.6 2.7 31.1  5.5 1.0 31.5 2.2 31.6  4.2 1.0  
Pedometer (daily steps±SD) 594.5 663.4 760.0 292.0  1.0 451.9 463.0 635.0  43.0 1.0 434.9 455.8 652.0  90.9 1.0  
CMI HVAS (0–10) 6.4 1.4 6.9 1.5  0.56 6.6 1.7 6.5  1.2 0.85 6.5 1.4 6.5  1.6 0.61  
CBPI—PSS (0-10) 3.7 2.6 3.0 2.6  <0.05* 4.1 2.9 2.9  2.1 0.04* 3.6 3.1 2.9  2.4 0.04*  
CBPI—PIS (0-10) 3.8 2.6 3.2 2.7  0.02* 3.9 2.8 3.2  2.7 0.03* 3.5 2.4 3.2  2.7 <0.05*  
A












Table 2 Mean values (±standard deviation) of different parameters evaluated at the initial evaluation and throughout the study (Continued) 
Modality Treatment day 8 days 15 days 
 CG   HG   CG   HG  p  CG   HG  p 
Mean SD  Mean SD  Mean SD  Mean SD   Mean SD  Mean SD  
 COI—Stiffness (0–16) 4.6 4.1 3.5 3.8  0.11 4.6  3.9 4.0  4.0 0.49 4.0  5.7 4.3  4.3 0.81  
 COI—Function (0–16) 5.7 5.3 4.3 3.9  0.02* 5.0  5.2 4.1  4.1 0.02* 4.0  5.4 3.3  3.8 <0.05*  
 COI—Gait (0–20) 6.9 5.1 5.2 5.1  0.03* 5.7  5.5 5.0  4.9 <0.05* 4.4  5.4 6.1  5.8 0.36  
 COI—QOL (0–12) 5.3 3.3 4.0 2.4  0.11 5.1  2.8 4.4  2.7 0.84 4.7  2.6 4.2  2.9 0.79  
 COI—Overall score (0–64) 22.4 19.1 5.2 5.1  <0.01* 20.1  15.7 5.0  4.9 0.01* 15.7  14.9 19.7  17.3 0.59  
 LOAD (0–52) 16.4 13.1 15.0 9.7  0.09 13.1  12.4 15.3  10.8 0.56 13.1  12.4 16.4  11.8 0.99  
Digital termography DV (°, mean±SD) 25.3 1.5 26.3 2.2  1.0 26.1  1.2 26.5  0.9 0.7 25.6  1.4 25.6  26.0 1.0  
 DV max (°, mean±SD) 25.2 2.1 27.6 2.0  <0.05* 27.4  1.4 27.5  1.2 0.2 26.9  1.4 27.4  0.9 0.3  
 Lt (°, mean±SD) 29.8 2.2 31.6 1.8  <0.01* 28.4  1.8 29.9  1.7 <0.01* 27.3  1.8 29.9  1.7 <0.01*  
 Lt max (°, mean±SD) 33.9 1.2 34.6 0.7  <0.01* 30.5  1.9 31.8  1.7 <0.01* 29.7  1.9 30.9  2.0 <0.01*  
Synovial fluid IL-1 (pg/mL, mean±SD) 122.9 108.9 124.2 86.9  0.2 159.6  59.1 159.6  59.1 0.6 184.2  68.5 152.3  83.7 1.0  
 CRP (mg/mL, mean±SD) 0.48 0.9 0.3 0.1  0.2 0.4  0.8 0.4  0.2 0.1 0.0  0.0 0.3  0.2 1.0  
Weight bearing Symmetry index (mean±SD) 18.9 12.2 14.5 15.0  <0.01* 27.4  12.1 7.6  7.5 <0.05* 27.0  27.9 5.2  3.9 0.01*  
 Deviation (mean±SD) 2.5 1.9 1.9 1.8  <0.01* 2.72  2.27 1.3  1.3 <0.05* 2.61  2.973 2.6  2.9 0.01*  
CBPI, Canine Brief Pain Invento ry; CRP, C-reacti ve protein; COI, Canine Orthop edi c Index; DV, dorso ve nt ral view; HVAS, Hudson Visual Analogue Scale; IL-1, interleukin 1; LOAD, Liverpool Osteoa rt h riti s in Dogs; LT, lateral v iew; 
PIS, Pain Interf erence Score; PSS, Pain Sev erity  Score; QOL, quality  of  lif e 
*Significa n ce when compa ri n g the value regist e re d by a group at an evalu ati o n mome nt with T0, and compa ri n g both group at each follow-u p mome nt 
A
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Evaluations by age 
Considering cases above or below the mean age of the 
sample, in the CG, younger subjects had higher maxima l  
values on the thermographic Lt view (p=0.04) and better 
LOAD (p=0.02), stiffness (p<0.01), function (p<0.01), gait 
(p<0.01), and COI (p<0.01) scores. At 8 days, they showed 
lower SI (p<0.01), higher maximal values on the 
thermographic Lt view (p=0.02), and better LOAD (p= 
0.04), stiffness (p<0.01), function (p<0.01), gait (p<0.01), 
QOL (p<0.01), and COI (p<0.01) scores. The same was also 
true at the 15-day evaluation, with these cases pre- senting 
better LOAD (p<0.01), stiffness (p<0.01), 
function (p<0.01), gait (p<0.01), QOL (p<0.01), and COI 
(p<0.01) scores. At the 30-day evaluation, younger sub- jects 
had lower mean and maximal values on the thermographic 
DV (p<0.01 and p=0.02, respectively) and Lt view (p=0.02, 
for the mean value), better joint flexion (p=0.01), and better 
LOAD (p<0.01), stiffness (p<0.01), function (p<0.01), gait 
(p<0.01), QOL (p<0.01), and COI (p<0.01) scores. At 90 
days, the same cases had better LOAD (p=0.04), stiffness 
(p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01), 
and COI (p<0.01) scores. At the final evaluation, younger 
subjects had  better  deviation and SI (p=0.03 and p<0.01, 
respectively), and stiffness 
Table 3 Time to return to baseline values for weight bearing distribut ions (symmetry index and deviation) and CMIs, calculated with 
Kaplan-Meier estimators and compared with the Breslow test 
Variable Breslow  Group  
 test CG   HG  
  mean±SD 95% CI  mean±SD 95% CI 
Simmetry Index <0.01* 47.0±11.8 23.8±70.2  104.1±15.1 15.1±74.5 
Deviation <0.01* 44.8±12.1 21.1±68.5  96.2±16.3 64.2±128.1 
HVAS <0.01* 48.7±12.4 25.4±73.9  117.0±13.2 91.1±142.9 
PSS <0.01* 63.2±17.2 29.6±96.8  142.6±11.9 119.1±166.0 
PIS <0.01* 8.4±0.4 7.7±9.0  114.0±16.0 82.6±145.4 
LOAD <0.01* 40.7±10.6 19.9±61.4  141.8±11.6 119.2±164.4 
Stiffness 0.03* 64.7±16.9 31.4±97.9  129.8±13.9 102.6±157.0 
Function <0.01* 65.4±13.4 39.2±91.6  168.0±6.6 155.1±180.8 
Gait <0.01* 52.7±14.6 23.9±81.4  115.5±13.1 89.9±141.1 
QOL <0.01* 60.9±15.0 31.4±90.4  125.6±12.2 101.6±149.6 
COI 0.06 52.7±13.4 26.5±78.9  93.1±16.7 60.3±125.9 
COI, Canine Orthop edi c Index; HVAS, Hudson Visual Analogue Scale; LOAD, Liverpool Osteoar th riti s in Dogs; PIS, Pain Interfere n ce Score; PSS, Pain Severity Score; 
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Table 4 Frequency of radiographic findings in the control and treatment groups, at the initial and final evaluat ions 
Radiographic f inding T0      180d  
 CG   HG   CG    HG   
 Absolut %  Absolut %  Absolut % p  Absolut % p 
Irregular wear on the femoral head, making it misshapen and with 
a loss of its rounded appearance 
18 90%  17 85%  20 100% 0.08  20 100% 0.16 
Flattened or shallow acetabulum, with irregular outline 9 45%  11 55%  20 100% < 
0.01* 
 20 100% < 
0.01* 
Caudolateral curvilinear osteophyte (CCO) 5 25%  5 25%  20 100% 1.00  20 100% 0.48 
New bone formation on the acetabulum and on femoral head 
and neck 
16 80%  20 100%  20 100% 1.00  20 100% < 
0.05* 
The angle formed at the cranial effective acetabular rim is worn 
aw ay 
12 60%  18 90%  20 100% 0.16  20 100% < 
0.05* 
Subchondral bone sclerosis along the cranial acetabular edge 20 100%  19 95%  20 100% 0.32  20 100% 1.0 
Circumferential femoral head osteophyte (CFHO) 3 15%  3 15%  20 100% 0.18  20 100% < 
0.01* 
 
(p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01), 
and COI (p<0.01) scores. In the HG,  younger  subjects  had 
higher pedometer counts (p<0.01), lower mean and maxima l 
values on the thermographic DV (p<0.01 for both) and Lt  
view (p<0.02, for the mean value), higher thigh girth 
(p=0.04), and worse HVAS (p=0.02),  PSS, PIS, LOAD, 
stiffness, and function scores (p<0.01 for all) at the initial 
evaluation. The same was  observed  at  8 days for mean and 
maximal values on the thermographic DV (p<0.01 for both), 
lower joint flexion (p<0.05), and worse HVAS, PSS, PIS, 
LOAD, stiffness, function, and QOL scores (p<0.01 for all). 
At 15 days, they had thigh girth (p=0.03) and worse HVAS, 
PSS, PIS, LOAD, stiff- ness, and gait scores (p<0.01 for all). 
After 30 days, these joints had lower mean and maxima l 
values on the thermographic DV  (p<0.01  for both) and 
Lt  view  (p< 
0.01 for both), better joint flexion (p=0.01), and better 
HVAS, PSS, PIS, stiffness, function, and QOL scores (p< 
0.01 for all). At the 90-day evaluation, again, they had lower 
mean and maximal values on the thermographic on the Lt  
view (p<0.01 for both), and better HVAS, PSS, PIS, LOAD, 
stiffness, function, QOL, and COI scores (p<0.01 for all). At 
the final evaluation, they had devi- ation and SI (p<0.05 and 
p=0.03, respectively), and better HVAS, PSS, PIS, stiffness, 
gait, and QOL scores (p<0.01 for all). 
 
Discussion 
Osteoarthritis is the most commonly diagnosed joint dis- 
ease in human and veterinary medicine, with limited  
treatment options. In addition to the anatomical and 
biochemical similarities between dogs and humans, they 
also share an environment and lifestyle. For those rea - 
sons, the study of animal OA could be beneficial for both 
species [2, 5]. To our knowledge, this is the first study to 
describe the effect of a single injection of high- 
density hyaluronan (G-F 20) on several clinical, imaging ,  
and laboratorial signs in a naturally occurring canine model, 
with a long follow-up period. Dog OA, particu- larly  
naturally occurring OA, resembles closely  human OA 
regarding anatomy, disease heterogeneity, and pro- gression 
[42]. 
Many studies performed in canine experimental OA  
models have failed to demonstrate clear benefits of hya- 
luronan supplementation [17]. IA hyaluronan provided  
clinically significant improvement in animals with stifle OA 
in pain, function, lameness, and kinetics compared to pre-
treatment and saline control in a canine surgical model. 
Maximum benefits were noted at 4–8 weeks and gradually  
tapered down by a 6-month evaluation time point [18]. In  
dogs with naturally occurring OA, treat- ment groups have 
significantly better results than a con- trol group by the 6th  
week post-treatment but accompanied by exercis e  
restrictions, leading to im- provements in the control group 
[20]. In this study, we have observed significan t  
improvements in the HG with several evaluation  
modalities, which, in some cases, lasted up to the last 
evaluation moment, at 180 days  post-treatment. These 
include functional improvements  measured by the 
evaluation of weight-bearing, to im- provements in other 
dimensions of OA, as measured with the CMIs, but 
particularly with the two scores of the CBPI. In addition  
to group improvements in HG, in- dividual CMI scores also 
improved in most animals from the first evaluation post-
treatment, but particularly after 
15 days. This improvement is observable with the Kaplan-
Meier test results for SI, with results in HG tak- ing 
significantly longer to return to baseline  values.  It was also 
noticeable with different CMI scores and di- mensions. 
Although clear anatomical similarities exist, some care must 
be taken when extrapolating dogs to humans. The dog, 
being a quadruped, supports 60% of 




body weight in the thoracic limbs and 40% in the pelvic  
limbs, which differs from the biped posture of humans, 
which can affect OA’s progression [43, 44]. 
A proposed direct analgesic effect for hyaluronan has  been 
suggested in animal models by action over the opi- oid 
receptor [45]. An additional proposed mechanism of action 
for hyaluronan is producing endogenous hyaluro- nan 
production by the exogenous administration, based on in 
vitro and in vivo studies [46]. This last mechanism may be 
supported because the product is rapidly cleared from the 
joint, and maximal clinical improvement does not occur for 
several weeks, between 60 and 90 days, while persisting for 
much longer [47]. Our results partly support these findings, 
with  the difference that signifi- cant improvements were 
reached sooner and lasted lon- ger. Although we did not 
measure the amount and the persistence of the  exogenous  
hyaluronan  within  the joint, the visual examination of SF in  
HG at the 8-day evaluation showed a clear SF, with  
increased viscosity that of Hylan G-F 20. 
OA is a low-grade inflammatory disease, and IL-1 is the most 
important pro-inflammatory cytokine responsible for the 
catabolism in OA, affecting the disease’s progression [48], 
and the histopathology and pathogenesis of dog OA closely 
resembles that of human OA [5]. IA hyaluronan in- hibits 
degenerative cartilage changes in animal models due mainly 
to its pro-inflammatory cytokines and degradative en- zymes 
[49]. Low molecular weight hyaluronan seems to be most 
effective in reducing the release of cytokines [50]. Al- though 
a decrease in IL-1 levels was recorded in both groups, at 8 days, 
its concentration in CG was significantly lower. At this 
moment, this is probably due to the removal of synovial fluid  
at treatment day, followed by the injection of 0.9% NaCl, 
similar to the effect of a joint lavage, which may be more 
effective than the administration of hyaluronan in re- ducing 
IL-1 levels. Still, IL-1 concentration levels remained lower 
than those at the initial evaluation in both groups. As this study 
was a clinical treatment experiment, no joint histo- logical 
samples were collected, which would help evaluate 
differences between Hylan G-F 20 and 0.9% NaCl injection. 
The reduction of IL-1 may reduce inflammatory levels,  
which are reflected in the temperature values re- corded 
during the thermographic evaluations. Mea- surements 
made on the Lt view, in   particular, recorded variations 
throughout the entire follow-up period, with lower levels 
being recorded in CG. 
Pain is the most relevant clinical sign of OA, and its  
evaluation is paramount to determine OA treatment effi- 
cacy so that data may be translated to human medicine [30]. 
There is strong evidence that humans and animals ’ type of 
pain is analogous, as they share neurophysiologic 
similarities [51]. However, painful experiences in OA are 
complex, involving several dimensions [52]. While ex- 
tremely useful in a clinical setting, CMIs can be 
susceptible to the caregiver placebo  effect,  associated with 
the variability in emotional and cognitive compo- nents of 
pain perception. On the other hand, the animal itself will not 
show a significant placebo effect, and the ability to perform 
daily activities will likely reflect  a lower level of  pain [53, 
54]. We used  several CMIs,  to try to capture multiple 
dimensions of OA. As a whole, individual CMI scores in CG 
tended to worsen through time, while HG scores tended to 
improve. Still, some an- imals in CG showed improvements.  
While some patients  with OA may spontaneously improve, 
a more plausible explanation is related to removing cytokine-
loaded SF at treatment day, followed by the injection of 0.9% 
NaCl, similar to the effect of a joint lavage. Placebo saline 
in- jections have shown functional improvements  that  can 
last up to a 6-month follow-up [55]. 
Radiographic evaluation is a staple of OA monitoring. CCO 
and CFHO represent early radiographic signs that predict the 
development of hip OA clinical signs [23]. Previous reports 
have described that  hyaluronan  could not prevent OA 
progression based on radiographic as- sessment [18]. 
However, it decreased signs of pain and improved joint 
function after the onset of OA [56]. Our results support these 
findings. In CG, several radio- graphic findings progressed 
throughout the follow-up period, as expected in the disease’s  
natural  evolution. This was also observed in HG, even 
though some radio- graphic findings did only change at 180 
days. Still, des- pite the evolution of radiographic findings,  
patients  in HG showed better clinical, functional, and pain 
findings than CG. Also, in the 8–30 days’ evaluation period, 
no significant differences were observed in HG between ani- 
mals with and without CCO and CFHO at the initial 
evaluation. 
OA risk factors are well characterized and include hav- ing 
a higher bodyweight or being of older age [2]. To as- sess 
these factors’ influence in response to treatment, we applied 
different cut-off values for weight.  In  both groups, 
increasing body  weight  generally  corresponded to worse 
CMI. In HG, heavier patients had SI evaluation and 
deviation, even though the group still had better re- sults than 
CG throughout the study. Previous reports in- dicated that 
larger dogs achieved improvements of 30% or more at 12 
weeks [47]. We described improvements earlier, even in 
heavier patients. Male dogs also scored worse in considered 
CMI, but this may be related to the fact that male dogs were 
significantly heavier than fe- males in all considered 
moments. 
Regarding age, similar results were observed. Consid- ering 
animals above the sample’s mean age, these pa- tients 
scoring worse on almost all CMI scores had lower pedometer 
counts and higher thermography values. Since OA is a 
chronic, progressive disease, it was not unexpected to see 
older patients record worse 




evaluations, which may be linked with the disease’s pro- 
gression at its clinical signs. While expected, the differ- ence 
in  treatment  results  is  quite  pronounced,  more than the 
effect of increased body weight. 
IA hyaluronan administration has been described as  
producing mild heat, swelling, and/or erythema post- 
injection, which resolved spontaneously within a week  
[18]. These adverse effects are well tolerated and usually 
restricted to the injected joint [57, 58]. Similarly , we ob- 
served increased lameness in six cases, reflecting on the 8-
day SI and deviation evaluations, when significan t ly  
worse scores were kept at HG. This spontaneously re - 
solved by the 15-day evaluation. No additional medica - 
tion was administered to the animals during the follow- up 
period. Considering the obtained results, Hylan G-F 20 
may be a good therapeutic option for managing ca- nine 
hip OA. Its administration was able to reduce pain levels  
and improve joint function compared to a control group. 
Due to the close resemblance of canine and hu- man OA, 
it is possible that the same recommendat ion can be made 
for human hip OA. Still, as some differ- ences in weigh t  
bearing exist between the two species, futures studies 
should enroll a greater number of ani- mals and assess if 
similar results are observed in humans. 
 
Conclusions 
This study describes the effect of a single injection high  
molecular weight hyaluronan product in a naturally oc- 
curring canine model, with a long follow-up period. It 
provides important information  for  the  characterization of 
the response to treatment, showing that Hylan G-F 20 can 
produce significant functional and pain level im- provements 
in patients with OA, even those with factors  related to worse 
response to treatment. For that reason, Hylan G-F 20 can be 
considered as a good therapeutic option for OA 
management, even in  more  advanced cases. 
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To evaluate the effect of an intra-articular (IA) administration of triamcinolone hexacetonide, 
compared with saline. 
 
Patients and methods 
Forty (N = 40) hip joints were randomly assigned to a treatment group (THG, n = 20, receiv- 
ing IA triamcinolone hexacetonide) and a control group (CG, n = 20, receiving IA saline). On 
treatment day (T0), and at 8, 15, 30, 90 and 180 days post-treatment, weight distribution, 
joint range of motion, thigh girth, digital thermography, radiographic signs, synovial fluid 
interleukin-1 and C-reactive protein levels were evaluated. Data from four Clinical Metrology 
Instruments was also gathered. Results were compared Repeated Measures ANOVA, with a 
Huynh-Feldt correction, Paired Samples T-Test or Wilcoxon Signed Ranks Test. A Kaplan-
Meier test was performed to compare both groups, with p<0.05. 
 
Results 
Joints were graded as mild (65%), moderate (20%) and severe (15%). Patients of both 
sexes, with a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg, were included. No 
differences were found between groups at T0. Comparing THG to CG, weight distribution 
showed significant improvements in THG from 8 (p = 0.05) up to 90 days (p = 0.01). THG 
showed lower values during thermographic evaluation in the Lt view (p<0.01). Pain and 
function scores also improved from 30 to 180 days. Increasing body weight, age, and pres- 
ence of caudolateral curvilinear osteophyte corresponded to worse response to treatment. 
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Results of the Kaplan Meier test showed significant differences between groups, with THG 
performing better considering several evaluations and scores. 
 
Conclusion 
THG recorded significant improvements in weight-bearing and in with the considered CMIs, 
particularly pain scores. Lower thermographic values were registered in THG up to the last 








Osteoarthritis (OA) is a disease transversal to all mammals and a source of chronic pain. For 
that reason, it represents a considerable burden to societies, representing a large investment in 
healthcare, while reducing productivity and quality of life [1–3]. Since OA is symptomatic only 
in the affected joint while, at the same time, lacking obvious extra-articular manifesta- tions, it 
is well suited to administer local therapy by intra-articular (IA) injection [4, 5]. The changes 
that occur in slowly progressive spontaneous dog OA closely match those of human OA, while 
maintaining the same life stages that go by at a faster progression rate, and sharing many of the 
same environmental conditions. For those reasons, the naturally occurring canine model is 
considered the closest to a gold standard [6–11]. 
The medical approach to OA aims at slowing disease progression while relieving symptoms, 
particularly pain [9, 12]. IA corticosteroids have been used for several decades to palliate pain 
and inflammation associated with OA and of joint’s  surrounding tissues [13, 14]. Its use should 
be especially considered in patients with moderate to severe pain, nonresponding to oral anal- 
gesic/non-steroidal anti-inflammatory drugs. A human systematic review has deemed triam- 
cinolone more effective than betamethasone and methylprednisolone [15]. Triamcinolone 
hexacetonide (TH), in particular, is described as able to provide pain relief and improved 
mobility for prolonged periods [16, 17]. In a canine model of OA, animals treated with IA TH 
showed a significant reduction of osteophyte size compared with a control group. At the histo- 
logical level, TH significantly reduced the severity of OA structural changes of cartilage and 
had no deleterious effects on normal cartilage [18]. By effect is obtained through a dose-depen- 
dent reduction in the cartilage proteolytic enzyme stromelysin, interleukin 1β, and the onco- 
genes c-fos and c-myc, which are involved in the metalloproteinases synthesis [19]. In human 
patients, the mean duration of effect of TH in patients with OA is around seven months [20]. 
Since pain and functional limitations are the most relevant clinical signs of OA, clinical tri- als 
and studies need to assess these parameters in order to evaluate patients and assessment of 
response to treatment [21–23]. Clinical metrology instruments (CMI) represent a patient-cen- 
tred approach, and the most commonly used are the Canine Brief Pain Inventory (CBPI, 
divided in a pain severity score—PSS, and a pain interference score—PIS) and the Liverpool 
Osteoarthritis in Dogs (LOAD). Further validated CMIs include the Hudson Visual Analogue 
Scale (HVAS), and the Canine Orthopaedic Index (COI, divided into four scores: stiffness, gait, 
function and quality of life—QOL). As a whole, CMIs complement the evaluation of the multi-
dimensional experience that is OA related pain [9, 23–31]. Typically, OA pain is local- ized 
and related to movement or weight-bearing of the affected joints, and affected patients 
commonly bear less weight on a painful limb. Evaluating weight distribution through stance 
analysis is a sensitive evaluation canine lameness [22, 23, 32]. Additional functional 
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evaluations aim at assessing activity levels and mobility impairments [26]. Pedometry is a sim- 
ple and inexpensive method to assess mobility levels, which can measure ambulatory activity 
with an acceptable level of accuracy [33]. Additional clinical measurements include the exami- 
nation of muscle masses and evaluation of the joint range of motion, which are consistently 
reduced and restricted in OA patients [34–37]. 
Imaging plays a key role in the assessment of patients with joint disease and, in cases of hip 
OA, the ventrodorsal (VD) hip extended view is the most common pelvic radiographic projec- 
tion. The ventrodorsal flexed view, also called frog-legged view (FL), useful for further evalua- 
tion of the presence of the circumferential femoral head osteophyte (CFHO) and caudolateral 
curvilinear osteophyte (CCO), radiographic findings related with the development of clinical 
signs [38–43]. By correlating changes in temperature patterns with various disease, degenera- 
tive or injury processes, digital thermography can provide a reproducible diagnostic tool [44– 
46]. This diagnosis modality can differentiate normal from osteoarthritis subjects [47, 48]. 
Since OA is a low-grade inflammatory disease, the analysis of synovial fluid (SF) can add 
additional information regarding the disease’s characterization [1]. Interleukin 1 (IL-1) is the 
most important proinflammatory catabolic cytokine in OA, with a highly potent capability of 
inducting cartilage degradation and relation with lameness duration [49–51]. C-reactive pro- 
tein (CRP) can be produced at the level of the inflamed tissues, and its shifts occur from a very 
early stage [52, 53]. It has been highly associated with knee OA in humans [54]. 
The goal of this study is to compare the effect of triamcinolone hexacetonide to a control group 
in the management of OA in a naturally occurring canine model, using several outcome 
assessment modalities. We hypothesize the intra-articular administration of triamcinolone 
hexacetonide will be able to reduce the clinical signs of OA, compared to a control group. 
 
Materials and methods 
The study protocol was approved by the ethical review committee of the Universidade de  
Évora (ORBEA , approval n˚ GD/32 05 5/20 1 8/P1, September 25th, 2018), and complie s with the 
ARRIVE guidelines. Written, informed consent was obtained from the Institution responsible 
for the animals. Twenty dogs were selected based on medical history records, physical, ortho - 
paedic, neurological and radiographic examinations compatible with hip OA, and the sample 
comprised forty (N = 40) joints of twenty active police working dogs with bilateral hip OA. To 
be included in the study, patients should be over two years, have a bodyweight over 20kg and 
should not have received any medication or nutritional supplement for over six weeks before 
enrolment in the study. Patients with any other documented or suspected orthopaedic or neu - 
rological disease, or additional concomitant disease (ruled out through physical examination, 
complete blood count, and serum chemistry profile), were excluded. 
In a double-blinded study, dogs with affect joints were randomly assigned to a control 
group (CG, n = 20 joints) or a treatment group (THG, n = 20 joints). Evaluations were con- 
ducted on days 0 (treatment day), 8, 15, 30, 90 and 180. Days were counted from treatment 
day (day 0). An outline of all procedures on each evaluation day is presented in Table 1. The 
same researcher performed all evaluations. 
On treatment day, patients  in CG received an IA administration of 2ml of 0.9%NaCl. On the 
same day, patients in THG received an IA administration of 20mg in a volume of 1 ml of 
triamcinolone hexacetonide (Bluxam, Riemser Pharma). IA administrations and radiographic 
examination were conducted under light sedation, induced with a combination of medetomi- 
dine (0.01mg/kg) and buthorphanol (0.1mg/kg), given intravenously. After all procedures 
were conducted, sedation was reversed with atipamezole (100–150μg/kg), administered intra- 
muscularly. Both a VD extended legs and FL views were obtained. On the VD view, the  
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Table 1. Procedures conducted in each day. Days are counted from treatment day. 
 
Procedure Day 
0 8 15 30 90 180 
Treatment X      
Digital Thermography X X X X X X 
Digital radiography X   X X X 
Stance analysis X X X X X X 
Pedometer X X X X X X 
Goniometry X X X X X X 
Thigh girth measurement X X X X X X 
Clinical Metrology Instruments X X X X X X 
Synovial fluid CRP X X  X X X 
Synovial fluid IL-1 X X  X X X 
 




presence of the following findings was assessed; an irregular wear on the femoral head, making 
it misshapen and with a loss of its rounded appearance; a flattened or shallow acetabulum, 
with irregular outline; CCO; new bone formation on the acetabulum and femoral head and  
neck; a worn away angle formed at the cranial effective acetabular rim; subchondral bone scle- 
rosis along the cranial acetabular edge; and CFHO [43, 55, 56]. For the IA administration, 
patients were positioned in lateral recumbency, with the joint of interest uppermost. A window 
of 4x4cm in the area surrounding the greater trochanter was clipped and aseptically prepared. 
The limb was then placed in a neutral, parallel to the table position and a 21-gauge with 2.5” 
length needle was introduced just dorsal to the greater trochanter, perpendicular to the long 
axis of the limb until the joint was reached [57]. Confirmation of correct needle placement was 
obtained through the collection of SF. As much SF as possible was aspirated and kept for the 
posterior determination of IL-1β and CRP concentrations, and the treatment or saline was 
administered. 
Evaluation of weight distribution was carried out with a weight distribution platform 
(Companion Stanc e Analy ze r; LiteC ure LLC1, Newa rk , Dela w a re , United States) , follow ing 
manufacturer’s  guidelines. The equipment was placed in the centre of a room, at least 1 meter 
from the walls. It was also calibrated at the beginning of each day and zeroed before each data 
collection. For the evaluation, patients were led to stand on the platform, with one foot on 
each quadrant, with their heads facing forward. The left-right symmetry index was calculated 
with the following formula: symmetry index = [(WBR-WBL)/((WBR+WBL)x0.5)]x100 [28, 58], 
where WBR is the value of weight-bearing for the right pelvic limb, and WBL is the value of 
weight-bearing for the left pelvic limb. Negative values were made positive. Additionally, we 
considered a deviation from the normal 20% weight-bearing for a pelvic limb [59], calculated 
by subtracting WB to 20. 
Pedometers were worn around the patient’s  neck, attached to an adjustable lightweight col- lar, 
to measure ambulatory activity and mobility levels [60]. They were worn for a week before the 
first evaluation time, to order to establish a baseline value, and before each evaluation time. 
Mean daily counts were considered, calculated by dividing the register number of steps by the 
number of considered days. In a quiet room, with as much time as needed to answer all items, 
trainers completed a copy of HVAS, CBPI, COI and LOAD, in sequence by the same handler 
at all evaluation days. 
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Fig 1. A lateral view of a dog with moderate osteoarthritis, with the greater trochanter in the centre, at a distance 
of 60 cm. The range of temperature was set at 15–40˚C and emissivity at 0.98. Thermographic images were analyzed 




For the digital thermography evaluation, animals were kept for 30 minutes in a room with 
controlled temperature, at 21˚C. During this period, they were allowed to walk around the 
room calmly. A dorsoventral image was obtained with patients in a symmetrical upright stand - 
ing, including the area from the last lumbar to the first coccygeal vertebrae, at a distance of 60 
cm [61]. A lateral view was also obtained, with the greater trochanter in the centre, at the same 
distance. All imag es were taken with a FLIR ThermaCAM E251 model (FLIR System s, Wil- 
sonville, Oregon, United States). The posterior analysis was conducted with free software 
(Tools, FLIR Systems, Inc), using a rainbow colour pallet. Temperature boxes were placed on 
the anatomical area of the hip joint, to determine mean and maximal temperatures (Fig 1). 
Both thigh girth and joint range of motion were determined with the patient in lateral 
recumbency. A Gullick II measuring tape was used to evaluate thigh girth, at a distance of 70% 
thigh length, measured from the tip of the greater trochanter, with an extended leg [62]. Hip 
joint ROM was then determined with a goniometer at extension and flexion with a flexed stifle 
[63]. 
Determination of IL-1β and CRP concentrations were made using Fuji Dri-Chem Slides 
VC-CRP PS (FUJIFILM Europe GmbH), read with a DRIChem NX500i (FUJIFILM Europe 
GmbH), and a DuoSet Ancillary Canine IL-1β Reagent kit (R&D Systems, United Kingdom), 
read with a FLUOstar OPTIMA (BMG Labtech). 
After treatment, animals were rested for three consecutive days and resumed their regular 
activity over five days. On days 1 and 3 after the procedure, the veterinarian examined all 
patients in order to determine existing signs of exacerbated pain, persistent stiffness of gait 
and changes in posture. If no complaints were registered, the animal could resume its normal 
activity [64, 65]. 
Normality was assessed with a Shapiro-Wilk test. Different group’s  results were compared in 
each evaluation day, and each measured parameter was compared with the result observed at  
treatment day. To assess the effect of different parameters on the patients’ clinical evolution, 
results were compared by sex, age and different cut off values for body weight with Repeated 
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Measures ANOVA, with a Huynh-Feldt correction, Paired Samples T-Test, or Wilcoxon 
Signed Ranks Test. A Kaplan-Meier test was performed to evaluate the time to return to base- 
line values of symmetry index and CMI scores, compared with the Breslow test. All results 
were analyzed with IBM SPSS Statistics version 20, and a significance level of p<0.05 was set. 
 
Results 
The sample included 40 hip joints (n = 20 left and n = 20 right) of active police working dogs 
with a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg. Both sexes (male n = 28, 
female n = 12) and four breeds were represented: German Shepherd Dogs (n = 8), Belgian 
Malinois Shepherd Dogs (n = 6), and Dutch Shepherd Dog (n = 6). At T0, 26 joints were classi- 
fied as mild (65%), 8 as moderate (20%) and 6 as severe (15%), according to the Orthopedic 
Foundation for Animals hip grading scheme. No differences were found between groups at 
the initial evaluation. After the initial rest period, all animals resumed normal activity, with 
similar workload and movement compared to that before treatment. 
 
Clinical and laboratorial findings 
Values recorded for different assessments at the initial evaluation, and its variations through- 
out the study, for THG and CG, are presented in Table 2. Comparing results between groups 
with repeated measures ANOVA with a Huynh-Feldt correction, significant differences 
between groups were found concerning body weight (F(2.8,140) = 4.2, p<0.01), deviation (F 
(4.8,109) = 2.8, p = 0.02), symmetry index (F(2.8,77.8) = 7.5, p<0.01), mean temperature on a 
DV view (F(3.9,93.9) = 6.6, p<0.01), maximal temperature on a DV view (F(3.6,86.2) = 6.9, 
p<0.01), mean temperature on a Lt view (F(4.5,113.2) = 26.7, p<0.01), maximal temperature 
on a Lt view (F(4.1,101.6) = 96.2, p<0.01), joint flexion (F(4.9,146.7) = 19.5, p<0.01), IL-1 
synovial concentration (F(1.9,58.3) = 4.9, p = 0.02). Significant differences were observed 
between groups regarding CMI scores, specifically PSS (F(5,120) = 2.4, p<0.05), PIS (F(5,120) 
= 2.6, p = 0.03) and function (F(2.8,69.2) = 2.4, p = 0.04). Evolution of the symmetry index in  
CG and THG is presented in Fig 2. Results of the Kaplan Meier test are presented in Table 3. 
Kaplan Meier curves for symmetry index and function score are presented in Figs 3 and 4, 
respectively. A dorsoventral digital thermography view is presented in Fig 5. 
 
Radiographic findings 
Frequency of different radiographic findings observed in CG and THG, at the initial evalua- 
tion, are presented in Table 4. In THG, an increase in the frequency of flattened or shallow ace- 
tabulum, with irregular outline was observed at 90 and 180 day (p<0.05). Increased new bone 
formation on the acetabulum and femoral head and neck was also observed at 90 day 
(p<0.05), as the frequency of CCO at 180 day (p<0.05). 
In CG, an increase in the frequency of flattened or shallow acetabulum, with irregular out- line, 
an increase was observed at 90 (p<0.01) and 180 day (p<0.01), compared with the initial 
evaluation day. In the THG, patients without CCO had higher LOAD (p<0.05), PSS 
(p = 0.02), PIS (p = 0.01), stiffness (p = 0.01), function (p<0.05), gait (p<0.01), QOL (p<0.01) 
and COI scores (p<0.01), and lower HVAS scores (p<0.01). At 15 day, they had lower mean 
and maximal thermographic evaluations on a DV (p = 0.01 for both) and mean on a Lt view 
(p = 0.04), and higher LOAD (p<0.01), stiffness (p = 0.04), function (p<0.01), gait (p<0.01), 
QOL (p<0.01) and COI scores (p<0.01). Again at the 30 and 90 day evaluations, those without 
CCO at the initial evaluation had higher HVAS (p<0.05 and p<0.01, respectively), and lower 
PSS (p<0.01 for both), PIS (p<0.01 and p = 0.02, respectively), LOAD (p<0.01 for both), stiff- 
ness (p = 0.04 and p = 0.02, respectively), function (p<0.01 and p = 0.04, respectively), gait 




Modality Treatment day 8 days 15 days    
CG THG CG THG P CG THG P 
mean SD mean SD mean SD p mean SD p mean SD p mean SD p 
Goniometry  Flexion (˚. mean±SD) 55.0 4.4 57.0 4.1 55.3 3.7 <0.01 55.3 4.7 0.09 1.0 57.2 5.2 0.14 58.0 5.3 0.53 1.0    
Extension (˚. mean±SD) 151.2 3.9 148.0 8.8 149.9 4.6 0.95 149.4 4.5 0.41  151.1 3.5 0.07 151.3 5.1 <0.05 1.0    
Thigh girth (cm. mean 
±SD) 
31.2 2.6 30.4 3.4 31.1 3.3 0.94 30.8 3.1 1.0 0.49 31.1 2.9 0.86 32.6 3.5 <0.01 0.58    
Pedometer (daily  steps 
±SD) 
1445.7 755.7 1539.6 397.3 829.5 931.3 0.58 989.8 1554.6 0.85  606.0 309.5 0.15 1215.1 793.8 0.03 1.0    
CMI HVAS (0–10) 6.8 1.2 5.7 1.9 6.7 1.5 0.48 6.4 1.7 0.19 0.16 6.8 1.2 0.6 6.3 1.6 0.72 0.16    
CBPI—PSS (0–10) 3.1 1.9 4.2 2.8 3.4 2.3 0.69 2.9 1.8 0.03 <0.05 3.7 2.8 0.2 3.2 1.9 0.04 0.04    
CBPI—PIS (0–10) 3.2 2.2 4.8 3.3 3.4 2.1 0.01 3.3 2.1 0.04 0.02 3.6 2.1 0.01 3.5 2.1 0.03 0.01    
COI—Stiffness (0–16) 3.4 3.4 6.8 4.2 4.1 3.3 0.31 5.5 3.6 0.38 0.51 4.1 3.2 0.31 5.1 4.0 0.46 10.19    
COI—Function (0–16) 3.6 4.1 6.3 5.7 4.1 4.0 0.64 4.1 4.0 0.21 <0.05 4.4 5.5 0.72 3.8 3.9 0.75 0.03    
COI—Gait (0–20) 4.7 5.2 10.5 5.9 5.4 6.1 0.29 7.3 4.7 0.18 0.21 5.8 4.3 0.02 6.8 5.6 <0.05 0.19    
COI—QOL (0–12) 4.5 2.6 6.2 3.9 4.6 2.7 0.62 5.5 3.0 0.28 0.85 4.7 2.9 0.06 4.4 3.6 0.56 0.09    
COI—Overall score (0–64) 16.4 14.7 29.8 19.1 18.2 13.8 0.22 23.8 14.6 0.19 0.48 18.6 13.8 0.14 21.0 16.7 0.83 0.19    
LOAD (0–52) 13.6 10.5 23.2 14.1 14.4 12.7 1.0 18.3 12.0 0.98 0.33 14.3 10.7 0.83 18.0 12.3 0.88 0.14    
Digital 
Thermography  
DV (˚. mean±SD) 24.7 1.9 25.3 0.6 25.2 1.3 0.01 25.3 0.6 0.08 <0.01 24.4 1.6 0.61 23.4 2.5 0.03 1.0    
DV max (˚. mean±SD) 26.3 1.9 26.4 1.6 25.8 1.0 0.06 24.9 1.6 0.24 <0.01 26.7 1.6 0.97 24.6 2.5 0.03 1.0    
Lt (˚. mean±SD) 28.7 2.7 26.5 1.9 31.6 2.1 <0.01 30.5 2.8 <0.01 <0.01 29.7 2.9 <0.01 28.5 4.0 0.02 <0.01    
Lt max (˚. mean±SD) 31.9 3.1 30.4 4.1 34.9 1.0 <0.01
 34.6 1.1 <0.01
 <0.01 34.9 0.8 <0.01
 34.0 1.9 <0.01
 <0.01    
Synovial fluid IL-1 (pg/mL. mean±SD) 170.9 120.4 208.5 95.2 72.3 42.4 <0.01 98.4 80.8 0.04 0.04 - - - - - - -    
CRP (mg/mL. mean±SD) 0.4 1.0 2.5 3.5 0.3 1.2 <0.01 0.0 0.0 0.18 1.0 - - - - - - -    
Weight-bearing Symmetry Index (mean 
±SD) 
24.7 20.3 53.9 50.4 18.7 17.1 0.06 19.2 18.1 <0.05
 <0.05 23.9 16.3 0.18 18.9 10.9 0.01 0.03    
Deviation (mean±SD) 2.8 3.6 4.7 4.4 2.78 1.987 0.3 2.1 1.9 0.08 0.43 2.94 2.127 0.47 2.2 1.6 <0.05 0.02    
Modality 30 days 90 days 180 days 
CG THG P CG THG P CG THG P 
mean SD P mean SD P mean SD p mean SD p mean SD P mean SD P 
Goniometry  Flexion (˚. mean±SD) 53.6 2.9 0.11 51.8 3.9 <0.01 <0.01 52.7 2.9 0.02 52.0 3.8 <0.01 <0.01 51.6 2.2 0.00 49.3 4.3 <0.01 <0.01 
Extension (˚. mean±SD) 150.8 3.4 0.06 152.3 3.7 0.09 1.0 150.8 2.9 0.07 151.9 3.0 <0.01 0.23 151.3 2.9 0.17 150.2 3.7 0.26 1.0 
Thigh girth (cm. mean 
±SD) 
30.6 2.7 0.39 29.5 3.1 0.25 0.44 31.6 2.7 0.54 31.5 3.7 0.09 0.43 31.5 2.2 0.2 30.2 3.7 0.96 0.32 
Pedometer (daily  steps 
±SD) 
594.5 663.4 0.48 747.9 548.2 0.65 0.15 451.9 463.0 0.4 410.8 497.4 0.15 0.08 434.9 455.8 0.2 376.0 263.3 <0.01
 0.63 
CMI HVAS (0–10) 6.4 1.4 0.14 6.3 1.9 0.64 0.17 6.6 1.7 0.22 6.5 1.3 0.84 0.21 6.5 1.4 0.04 6.4 1.6 0.13 0.12 
CBPI—PSS (0–10) 3.7 2.6 0.03 3.8 2.6 0.02 0.01 4.1 2.9 0.02 3.2 2.1 0.57 0.32 3.6 3.1 0.02 3.6 2.5 0.98 0.23 
CBPI—PIS (0–10) 3.8 2.6 0.01 5.7 5.3 0.04 <0.05 3.9 2.8 0.01 3.1 2.4 0.07 0.33 3.5 2.4 0.01 4.0 3.0 0.63 0.22 
COI—Stiffness (0–16) 4.6 4.1 0.87 5.3 4.0 0.78 0.48 4.6 3.9 0.33 4.9 3.6 0.50 0.39 4.0 5.7 0.82 4.8 4.4 0.10 0.48 
COI—Function (0–16) 5.7 5.3 0.2 5.7 5.3 0.79 <0.05 5.0 5.2 0.21 4.9 4.4 0.75 <0.01 4.0 5.4 1.0 3.3 3.8 0.39 0.01 
COI—Gait (0–20) 6.9 5.1 0.19 7.8 6.8 0.69 0.19 5.7 5.5 0.11 6.7 4.6 0.18 0.16 4.4 5.4 0.87 6.5 5.8 0.01 0.46 
COI—QOL (0–12) 5.3 3.3 0.39 5.0 3.7 <0.01 0.57 5.1 2.8 0.02 4.3 2.7 0.49 0.59 4.7 2.6 0.09 4.4 3.2 0.03 0.25 
COI—Overall score (0–64) 22.4 19.1 0.04 22.9 19.7 0.75 0.26 20.1 15.7 0.29 20.3 14.5 0.53 0.14 15.7 14.9 0.1 20.9 18.9 0.09 0.21 
LOAD (0–52) 16.4 13.1 0.22 18.1 13.5 0.47 0.88 13.1 12.4 0.72 15.1 9.4 0.07 0.17 13.1 12.4 0.88 16.0 12.0 0.03 0.07 
Digital 
Thermography  
DV (˚. mean±SD) 25.3 1.5 0.36 24.4 0.8 0.36 1.0 26.1 1.2 0.04 26.3 1.6 0.02 0.68 25.6 1.4 0.89 25.1 0.9 0.57 1.0 
DV max (˚. mean±SD) 25.2 2.1 0.88 25.9 0.7 0.31 1.0 27.4 1.4 0.14 27.6 1.1 <0.01 0.02 26.9 1.4 0.74 26.5 0.9 0.78 1.0 
Lt (˚. mean±SD) 29.8 2.2 <0.01 29.5 2.3 <0.01 <0.01 28.4 1.8 <0.01 29.0 2.6 <0.01 <0.01 27.3 1.8 0.21 28.7 2.3 <0.01 <0.01 
Lt max (˚. mean±SD) 33.9 1.2 <0.01 33.7 1.6 <0.01 <0.01 30.5 1.9 <0.01 31.4 2.6 <0.01 <0.01 29.7 1.9 0.13 31.2 2.3 <0.01 <0.01 



































































































Synovial fluid IL-1 (pg/mL. mean±SD) 122.9 108.9 0.05 186.6 104.5 0.24 1.0 159.6 59.1 0.13 169.1 55.3 0.36 1.0 184.2 68.5 0.25 145.1 33.5 0.07 1.0 
CRP (mg/mL. mean±SD) 0.48 0.9 0.18 0.1 0.2 0.43 1.0 0.4 0.8 0.36 0.0 0.0 0.42 1.0 0.0 0.0 0.5 0.0 0.0 0.18 1.0 
Weight-bearing Symmetry Index (mean 
±SD) 
18.9 12.2 0.04 13.3 8.6 <0.01 <0.01 27.4 12.1 0.29 14.0 13.5 0.02 0.02 27.0 27.9 0.51 20.7 22.7 0.01 0.22 
Deviation (mean±SD) 2.5 1.917 0.2 1.8 2.3 0.02 <0.01 2.72 2.27 0.29 2.3 2.1 0.04
 <0.01 2.61 2.973 0.55 2.0 2.8 0.04
 0.75 
 
CBPI—Canine Brief Pain Inventory; CRP—C-reactive protein; COI—Canine Orthopedic Index; DV—dorsoventral view; HVAS—Hudson Visual Analogue Scale; IL-1 –Interleukin 1; LOAD— Liverpool 
Osteoarthritis in Dogs; LT—lateral view; PIS—Pain Interference Score; PSS—Pain Severity Score; QOL—Quality of Life. 
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Fig 2. Overall evolution of symmetry index in the control group (CG) and treatment group (THG). Box plots 




(p<0.01 and p = 0.04, respectively), QOL (p<0.01 for both) and COI scores  p<0.01 and 
p = 0.02, respectively). At the final evaluation, they had only higher HVAS score  (p = 0.03). In 
CG, animals without CCO at the initial evaluation did now show significant  differences with 
those that did. However, at the 30-day evaluation, they had higher mean thermographic evalu- 
ation on a Lt view (p = 0.04), better joint flexion (p = 0.03), lower IL-1 and higher CRP concen- 
tration levels (p = 0.04 for both). On the 90 day evaluation, animals without CCO had lower 
maximal thermographic evaluation on a Lt view (p<0.05) and lower CRP values  t 180 days (p = 
0.02). 
Table  3. Time to return to baseline values for weight-bearing distributions (symmetry index and deviation) and 
CMIs, calculated with Kaplan-Meier estimators and compared with the Breslow test. 
  Treatment 
Variable Breslow test CG THG 
mean±SD 95% CI mean±SD 95% CI 
Symmetry Index 0.003
 47.0±11.8 23.8±70.2 96.0±12.8 70.9±121.1 
Deviation 0.022
 44.8±12.1 21.1±68.5 81.8±14.7 52.9±110.6 
HVAS 0.269 48.7±12.4 25.4±73.9 66.1±14.2 38.3±93.9 
PSS 0.065 63.2±17.2 29.6±96.8 90.2±17.6 55.7±124.7 
PIS 0.000 8.4±0.4 7.7±9.0 118.6±16.3 86.7±150.5 
LOAD 0.000
 40.7±10.6 19.9±61.4 124.3±15.9 93.1±155.5 
Stiffness 0.004
 64.7±16.9 31.4±97.9 130.8±11.6 108.1±153.5 
Function 0.046
 65.4±13.4 39.2±91.6 112.6±15.6 81.9±143.2 
Gait  0.001
 52.7±14.6 23.9±81.4 117.0±15.1 87.5±146.5 
QOL 0.044
 60.9±15.0 31.4±90.4 119.3±17.5 85.0±153.6 
COI 0.146 52.7±13.4 26.5±78.9 85.6±15.9 54.4±116.9 
 
COI—Canine Orthopedic Index; HVAS—Hudson Visual Analogue Scale; LOAD—Liverpool Osteoarthritis in Dogs; 
PIS—Pain Interference Score; PSS—Pain Severity Score; QOL—Quality of Life. 
 indicates significance. 
https://doi.org/10.1371/journal.pone.0245553.t003 
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Fig 3. Kaplan-Meier curve demonstrating a significant difference between the control group (CG) and 






Fig 4. Kaplan-Meier curve demonstrating a significant difference between the control group (CG) and 
triamcinolone hexacetonide group (THG) in time for function score to return to ba  seline values (p = 0.046). 
 
https://doi.org/10.1371/journal.pone.0245553.g004 
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Fig 5. A dorsoventral view of a dog with moderate osteoarthritis, including the area from the last lumbar vertebra to the first coccygeal vertebra 
at a minimum, at a distance of 60 cm. Arrow indicates cranial direction. The range of temperature was set at 15–40˚C and emissivity at 0.98. 




In the THG, patients without CFHO at the initial evaluation had lower pedometer counts (p<0.01) and 
lower HVAS (p = 0.04) and higher PIS scores (p = 0.03) on that day. At 8 day, they had higher body 
weight (p = 0.02) and higher deviation (p = 0.01) and symmetry index (p<0.05). At 15 day, they had higher 
body weight (p = 0.04), lower pedometer count (p<0.01) 
and higher LOAD score (p<0.05). Again at 30 day, these patients showed higher deviation 
(p = 0.04) and symmetry index (p<0.01). At 90 day, they had higher deviation (p = 0.03), sym- metry index 
(p<0.01) and higher synovial IL-1 concentration (p = 0.01). At the final 
 
Table  4. Frequency of radiographic findings in the Control (CG) and Treatment Groups (THG) in a ventrodorsal and frog-leg 
views, at the initial evaluation. 
Radiographic finding THG CG 
Present Absent Present Absent 
Irregular wear on the femoral head, making it  misshapen and with a 
loss of its rounded appearance 
20 100% 0 0% 17 85% 3 15% 
Flattened or shallow acetabulum, with irregular outline 16 80% 4 20% 11 55% 9 45% 
Caudolateral curvilinear osteophyte (CCO) 8 40% 12 60% 5 25% 15 75% 
New bone formation on the acetabulum and on femoral head and neck 17 85% 3 15% 20 100% 0 0% 
The angle formed at the cranial effective acetabular rim is worn away 18 90% 2 10% 18 90% 2 10% 
Subchondral bone sclerosis along the cranial acetabular edge 20 100% 0 0% 19 95% 1 5% 
Circumferential femoral head osteophyte (CFHO) 8 40% 12 60% 3 15% 17 85% 
https://doi.org/10.1371/journal.pone.0245553.t004 
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evaluation day, they had lower pedometer counts (p = 0.02). In CG, joints without CFHO at 
the initial evaluation had higher joint extension (p<0.01) and HVAS (p = 0.02), lower PSS 
(p = 0.01) and PIS scores (p = 0.03) at the 8 day evaluation. At 15 day, they had higher mean 
thermographic values on a Lt view (p = 0.02), lower PSS (p = 0.02) and PIS scores (p<0.05). 
This higher mean thermographic values on a Lt view was again observed at 30 day (p = 0.01) 
and higher HVAS scores (p = 0.02) at 90 day. At the final evaluation, they had higher maximal 
thermographic values on a Lt view (p = 0.04), and lower PSS (p = 0.05) and PIS scores 
(p<0.03). 
 
Comparisons by sex 
In the THG, females had lower symmetry index (p<0.01) and lower synovial CRP concentra- 
tion (p<0.01). At the 8 day evaluation day, females were lighter than males (p = 0.04) and had 
higher synovial IL-1 levels (p = 0.04). Additional differences were observed at 15 days, with 
female dogs having lower mean and maximal temperatures on a DV (p<0.01 for both) and Lt 
views (p = 0.04 and p<0.01, respectively). At 30 days, females had higher pedometer counts 
(p<0.01) and, at 90 days, lower mean and maximal temperatures on a DV view (p<0.05 and 
p<0.01, respectively). At the final evaluation day, no differences were observed between sexes. 
Female dogs of CG had significantly lower body weight throughout the study (p = 0.01). In the 
first evaluation, they also showed higher values in all thermographic evaluations (p<0.01) and 
lower PIS scores (p = 0.04). Again at 8 days, higher thermographic evaluations were recorded 
(p<0.01), except maximal value on a Lt view, as higher joint extension values (p<0.01). A 
higher joint extension was again observed in female dogs at 15 days (p = 0.04), with lower PIS 
scores (p = 0.03). At the 30 days evaluation females again showed higher thermographic maxi- 
mal values on an LT view max (p<0.01). Female dogs at 90 days had lower thigh girth 
(p = 0.03) and lower PSS and PIS scores (p = 0.01). At the final evaluation day, they had higher 
extension values (p = 0.02), higher HVAS (p = 0.02), and lower PSS (p<0.01) e PIS (p<0.01), 
stiffness (p = 0.02), function (p = 0.02), gait (p<0.01), QOL (p = 0.02) and COI (p = 0.01) 
scores. 
 
Comparisons by bodyweight 
Comparing animals in THG with a weight below the mean value of the sample, had higher 
deviation (p = 0.03), symmetry index (p = 0.04), mean and maximal values on thermography 
DV view (p<0.01 and p = 0.02, respectively), lower thigh girth (p<0.01) and lower synovial 
IL-1 levels (p = 0.02). At 8 days, they had lower thigh girth (p<0.01) and lower PSS (p = 0.01), 
PIS (p<0.01) and stiffness scores (p = 0.01). After 15 days, lighter patients had higher symme- 
try index (p = 0.03) and lower thigh girth (p<0.01). At 30 days, these patients had higher 
pedometer counts (p = 0.01) and lower thigh girth (p<0.01). At the 90-day evaluation, they 
had higher mean and maximal values on thermography Lt view (p = 0.02 and p<0.01, respec- 
tively), lower thigh girth (p<0.01) and higher joint flexion (p = 0.03). 30 At the final evaluation 
day, lighter animals had lower mean and maximal values on thermography a DV (p<0.01 for 
both) but higher on a Lt view (p<0.01 for both), lower thigh girth (p<0.01) and higher joint 
flexion (p = 0.03). In CG, lighter patients registered had lower PIS scores (p = 0.04) at the ini- 
tial evaluation. These patients, at the 8 day evaluation, had higher thermographic mean and 
maximal values on a DV (p = 0.03 and p = 0.02, respectively), lower thigh girth (p = 0.01), and 
higher stiffness (p = 0.03), function (p<0.01), gait (p = 0.03) and COI scores (p<0.01). Signifi- 
cant differences were again observed at 15 days, with lighter patients showing lower thigh  
girth (p = 0.04) and HVAS (p<0.05), and higher stiffness, function, gait QOL e COI scores 
(p<0.01). They also had lower CRP concentrations at 30 days (p = 0.04) and higher HVAS 
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scores (p = 0.02). At 90 days, they had lower thigh girth (p<0.01) and IL-1 levels (p = 0.02) at 
90 days. At the final day of evaluation, lighter animals showed higher mean thermographic val- 
ues on a DV view (p<0.01), and higher joint flexion (p = 0.02) and extension (p<0.01). 
 
Comparisons by age  
Considering patients above or below the mean age in the THG, at the initial evaluation youn- 
ger patients had higher mean and maximal temperature on a Lt view (p<0.01 for both), and 
lower PSS (p = 0.01), stiffness (p = 0.04), function (p = 0.02), gait (p = 0.02), QOL (p = 0.04), 
and COI scores (0.01). After treatment, at 8 days, they had lower deviation (p = 0.03) and sym- 
metry index (p = 0.04), higher mean temperature on a Lt view (p<0.01), lower synovial IL-1 
concentration (p = 0.04), and lower PIS (p<0.02) and function scores (p = 0.03). At 15 days, 
they had higher mean and maximal temperature on a DV view (p<0.01 for both) and Lt view 
(p<0.01 for both), and lower PIS (p<0.01), stiffness (p = 0.03), gait (p<0.01) and COI score 
(p = 0.04). After 30 days, younger animals had higher mean and maximal temperature on a Lt 
view (p = 0.01 for both), higher HVAS (p<0.01), and lower PSS (p<0.01), PIS (p<0.01), 
LOAD (p<0.01), stiffness (p<0.01) and QOL scores (p<0.01). Differences regarding CMI 
scores were observed again at 90 days, with the same patients having higher HVAS (p<0.01), 
and lower PSS (p = 0.01), PIS (p<0.01) and QOL scores (p = 0.01). At the final evaluation, 
patients bellow the mean age value had higher pedometer counts (p<0.01), lower deviation 
(p = 0.02) and SI (p<0.01), higher HVAS (p<0.01), and lower PSS (p<0.01), PIS (p<0.01), 
LOAD (p<0.01), stiffness (p<0.01), function (p = 0.04), gait (p<0.01), QOL (p<0.01) and 
COI scores (p<0.01). In the CG at the initial evaluation, younger patients had higher maximal 
values on the thermographic Lt view (p = 0.04), lower LOAD (p = 0.02), stiffness (p<0.01), 
function (p<0.01), gait (p<0.01) and COI (p<0.01) scores. After 8 days, they showed lower SI 
(p<0.01), higher maximal values on the thermographic Lt view (p = 0.02) and lower LOAD 
(p = 0.04), stiffness (p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01) and COI 
(p<0.01) scores. Again at 15 days, younger patients presented lower LOAD (p<0.01), stiffness 
(p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01) and COI (p<0.01) scores. At the 
30 day evaluation, they again presented improved evaluations in several parameters, with 
lower mean and maximal values on the thermographic DV (p<0.01 and p = 0.02, respectively) 
Lt view (p = 0.02, for the mean value), higher joint flexion (p = 0.01) and lower LOAD 
(p<0.01), stiffness (p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01) and COI 
(p<0.01) scores. Better CMI scores was again observed at 90 days, specifically lower LOAD 
(p = 0.04), stiffness (p<0.01), function (p<0.01), gait (p<0.01), QOL (p<0.01) and COI 
(p<0.01) scores. At the final evaluation, patients bellow the sample mean age had lower devia- 
tion and SI (p = 0.03 and p<0.01, respectively), and stiffness (p<0.01), function (p<0.01), gait 
(p<0.01), QOL (p<0.01) and COI (p<0.01) scores. 
 
Discussion 
OA is a leading cause of disability around the world, impacting the physical and mental well- 
being of populations, posing a substantial toll on healthcare and financial resources [66]. To 
our knowledge, this is the first study to describe the effect of a single injection of triamcinolone 
hexacetonide on several clinical, imaging and laboratorial signs in a naturally occurring canine 
osteoarthritis model, with a long follow up period. 
There are some reports evaluating the effect of IA TH in humans. A 2-year follow-up study 
showed that TH has long-term safety, with no deleterious effects being observed deriving from 
IA administration [67–69]. Also, patients treated had significant increases in ROM and 
improvements in pain [67]. These improvements are noticeable with the results of the Kaplan 
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Maier test for symmetry index, with results in SG taking significantly longer to return to base- 
line values. It was also observable with different scores, as function or stiffness. Comparing TH 
to a saline injection, TH (40mg) had higher effectiveness than the placebo group in the four 
weeks in terms of pain in movement, pain scale, and ultra-sound measurement of synovial 
hypertrophy [70]. Treatment with 20mg or 40mg of TH produced equal relapse after six 
months in patients with chronic polyarthritis and when treating medium-sized joints. With 
that in mind, since no difference in outcome was found between the compared doses, the 
authors advised that lower dose should be preferred, reducing pharmaceutical costs and meta - 
bolic side effects [71, 72]. As a whole, these reports present the overall safety and effectiveness 
of IA TH in the management of OA, measured with multiple validated CMI and other clinical 
evaluations. With this animal model, a single IA TH administration was able to significantly 
reduce weight-bearing changes in affected joints up to the 90-day evaluation compared with a 
control group. Besides changes in different CMI scores, particularly pain scores calculated 
with the CBPI, were observed. This is of particular interest, since pain is a hallmark of OA, and 
its characterization produces valuable data that may translate to humans [21, 73, 74]. Individ- 
ual CMI scores in THG improved for a majority of animals were observed with several of the 
considered questionnaires, in many cases up to the last evaluation. A significant difference was 
also observed with the Kaplan Meier test for the majority of the considered scores. In contrast, 
patients in the CG had worse scores (meaning lower HVAS scores and higher values in the 
remaining considered CMIs scores) throughout the follow-up period, particularly with as time 
progressed. Our results are in line with previously described effects for TH, but since in dogs 
OA progresses faster while maintaining the same stages [9], it is possible that in humans results 
may be observed for a more extended period. Additionally, since patients who composed this 
sample are active working dogs, their musculoskeletal structures are under increased stress 
and effort [75], leading to an earlier decline in initially observed improvements. It would also 
be of interest to have intermediary follow-ups between the 90 and 180-day evaluations, in 
order to further precise the duration of treatment efficacy. Some patients in the CG also 
showed some improvements, particularly at the 8 and 15-day evaluations. It may be due to the 
natural evolution of osteoarthritis, with the possibility for spontaneous improvements in some 
stages of the disease. An additional possibility is related to the removal of cytokine loaded 
synovial fluid at the time of the evaluation and the posterior administration of saline, which 
can lead to an effect similar to a joint lavage. In fact, placebo saline injections have shown an 
effect in functional improvements that can last up to a 6-month follow-up [76]. 
IL-1 is commonly pointed out as the most important proinflammatory cytokine responsible 
for the catabolic events in OA [1, 49, 50]. Corticosteroids are, of the medications available for 
the treatment of OA, the ones with most potent anti-inflammatory activity, specifically 
through the downregulation of the synthesis of inflammatory mediators such as IL-1β, TNF-α 
and COX-2 in the synovial fluid [64, 77–79]. In this study, significant differences between CG 
and THG were only observed at the 8-day evaluation and, even though IL-1 levels were lower 
in both groups compared to the initial evaluation, levels in CG were lower. This shows that TH 
can reduce IL-1 levels, which can be partly responsible for its ability to improve OA clinical 
signs, but the removal of synovial fluid and the administration of saline is also able to do so. 
Despite this effect, IL-1 levels cannot be the sole responsible for OA clinical signs, since, 
despite lower IL-1 levels of CG, this group still had worse clinical signs. 
Radiographic evaluation is a staple of OA monitoring. Previous OA animal studies have 
demonstrated a decrease in disease progression or a protective role of corticosteroids injec - 
tions, based on histological and biochemical findings [18, 80–84]. A recent systematic review 
of canine models of OA induction concludes that the reports regarding its IA use appear to be 
unanimously positive, with lower doses with sustained joint concentrations having a pro tective 
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effect [85]. In CG, the natural progression of the disease was observed as expected, and radio- 
graphic signs progressed throughout the follow-up period. In the THG, radiographic signs  
also progressed, particularly in the more advanced follow-up days. Although radiographic 
signs progressed, they seemed to be less severe in THG. We only characterized radiographic 
sings as present or absent, so this eventual protective role of IA TH may not be entirely 
recorded. The evaluation of CCO and CFHO is of particular clinical interest, as they represent 
early radiographic signs that predict the development of the clinical [42, 43, 86, 87]. Our results 
support this finding since animals with CCO or CFHO in both views showed worse clinical 
signs at the initial evaluations. Also, animals with these radiographic findings showed a worse 
response to treatment, despite THG having a positive evolution compared with CG. Digital 
thermography can assess inflammatory pain in osteoarthritic patients [47, 48]. Our findings 
showed mixed results regarding the thermographic evaluation. While, in some evaluation 
days, animals with higher temperatures recorded in different thermography evaluations corre - 
sponded to those patients with worse clinical signs, in other days, it did not. This may indicate 
that other characteristics may play an important role, e.g. the amount of muscle masses sur- 
rounding the joint, in this case, represented by thigh girth, or variations in body weight. 
Documented risk factors for OA include higher bodyweight and increasing age [2]. To eval- 
uate the effect of these factors, we considered results with a cut-off for weight and compared 
younger to older patients. Considering bodyweight at different cut -off points, heavier patients 
in both groups generally showed worse clinical signs, particularly with different CMI scores. 
This effect of body weight may also be responsible for the fact that females also had better CMI 
scores than males since they were also lighter. Similarly, patients with age above the mean sam- 
ple age showed worse evaluations during the follow-up period and worse response to treat- 
ment in THG. This may reflect that older patients may have a more degenerate joint with 
more advanced OA-induced changes, and therefore worse clinical signs, with a reduced ability 
to show improvements in response to therapy. 
Side effects of IA procedures are mainly related to discomfort from the procedure itself, 
localized pain post-injection and flushing. IA corticosteroids can also cause synovitis, in a reac- 
tive reaction called a steroid flare, with a described prevalence of 2–6% [4, 78, 88, 89]. More 
rare reported side effects include crystal-induced synovitis, calcification and steroid arthropa- 
thy [90]. We observed increased lameness in four patients, which spontaneously resolved 
within 48 hours. No additional medication was administered to the animals during the follow- 
up period. When compared to other therapeutic options, IA TH may be a more cost -effective 
option due to its lower cost [91]. 
 
Conclusions 
To our knowledge, this is the first study to describe the effect of a single injection of triamcino- 
lone hexacetonide in a naturally occurring canine model, with a long follow up period. THG 
recorded significant improvements in weight-bearing up to the 90-day follow-up. Improve- 
ments were also observed with the considered CMIs, particularly pain scores. Lower thermo - 
graphic values were registered in THG up to the last evaluation day. Age, sex, and 
radiographic findings did significantly influenced response to treatment. 
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61. Vainionp ä ä M, Raekallio M, Tuhkalainen E, Hä nninen H, Alhopuro N, Savolainen M, et al. Comparison 
of three thermal cameras with canine hip area thermographic images. J Vet Med Sci. 2012; 74: 1539– 
44. Available: http://www.ncbi.nlm.nih.gov/pubmed/22785576 
62. McCarthy DA, Millis DL, Levine D, Weigel JP. Variables Affecting Thigh Girth Measurement and Observer 
Reliability in Dogs. Front Vet Sci. 2018; 5. https://doi.org/10.3389/fvets.2018.00203 PMID: 30214905 
63. Levine, D., Millis DL. Canine Rehabilitation and Physical Therapy. 2014. 
64. Caron JP. Intra-Articular Injections for Joint Disease in Horses. Vet Clin North Am Equine Pract. 2005; 
21: 559–573. https://doi.org/10.1016/j.cveq.2005.07.003 PMID: 16297721 
65. Chakravarty K, Pharoah PDP, Scott DGI. A randomized controlled study of post-injection rest following 
intra-articular steroid therapy for knee synovitis. Rheumatology. 1994; 33: 464–468. https://doi.org/10. 
1093/rheumatology/33.5.464 PMID: 8173852 
66. Vina ER, Kw oh CK. Epidemiology of osteoarthritis. Curr Opin Rheumatol. 2018; 30: 160–167. https:// 
doi.org/10.1097/BOR.0000000000000479 PMID: 29227353 
67. Raynauld J-P, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al. Safety and 
eff icacy of long-term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double- 
blind, placebo-controlled trial. Arthritis Rheum. 2003; 48: 370–377. https://doi.org/10.1002/art.10777 
PMID: 12571845 
68. Spolidoro Paschoal N d. O, Natour J, Machado FS, de Oliveira HA V., Furtado. Effectiveness of Triam- 
cinolone Hexacetonide Intraarticular Injection in Interphalangeal Joints: A 12-week Randomized Con- 
trolled Trial in Patients w ith Hand Osteoarthritis. J Rheumatol. 2015; 42: 1869–1877. https://doi.org/10. 
3899/jrheum.140736 PMID: 26233501 
69. Meenagh GK. A randomized controlled trial of intra-articular corticosteroid injection of the carpometa- 
carpal joint of the thumb in osteoarthritis. Ann Rheum Dis. 2004; 63: 1260–1263. https://doi.org/10. 
1136/ard.2003.015438 PMID: 15361383 
70. Mendes JG, Natour J, Nunes-Tamashiro JC, Toffolo SR, Rosenfeld A, Furtado RNV. Comparison 
betw een intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: a ran- 
domized controlled trial. Clin Rehabil. 2019; 33: 1015–1026. https://doi.org/10.1177/ 
0269215519827996 PMID: 30782000 
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6. A THERAPEUTIC PROTOCOL FOR THE INTRA-ARTICULAR TREATMENT OF 
PATIENTS WITH HIP OA USING THE DOG AS AN ANIMAL MODEL 
 
Intra-articular triamcinolone hexacetonide, stanozolol, hylan G-F 20 and a platelet concentrate 
for the control and treatment of osteoarthritis in a naturally occurring canine osteoarthritis model: a 
randomized controlled study – Published in Scientific Reports – Impact factor 3.998, Quartile 1. 
Comparison of efficacy if the intra-articular injection of triamcinolone hexacetonide, 
stanozolol, hylan G-F 20 and a platelet concentrate in police working dogs with bilateral hip 














hexacetonide, stanozolol, Hylan 
G‑F 20 and platelet concentrate in a 
naturally occurring canine 
osteoarthritis model 
J. C. Alves1,2, A. Santos1, P. Jorge1, C. Lavrador2 & L. Miguel Carreira3,4,5 
Osteoarthritis (OA) is a disease transversal to all mammals, a source of chronic pain and disability, a huge 
burden to societies, with a significant toll in healthcare cost, while reducing productivity and quality of 
life. The dog is considered a useful model for the translational study of the disease, closely matching 
human OA, with the advantage of a faster disease progression while maintaining the same life stages. In a 
prospective, longitudinal, double‑blinded, negative controlled study, one hundred (N = 100) hip joints 
were selected and randomly assigned to five groups: control group (CG, n  = 20, receiving a saline 
injection), triamcinolone hexacetonide group (THG, n = 20), platelet concentrate group (PCG, n = 20), 
stanozolol group (SG, n = 20) and hylan G‑F 20 group (HG). Evaluations were conducted on days 0 (T0, 
treatment day), 8, 15, 30, 60, 90, 120, 150 and 180 days post‑treatment, consisting of weight distribution 
analysis and data from four Clinical Metrology Instruments (CMI). Kaplan–Meier estimators were 
generated and compared with the Breslow test. Cox proportional hazard regression analysis was used to 
investigate the influence of variables of interest on treatment survival. All results were analyzed with IBM 
SPSS Statistics version 20 and a significance level of p < 0.05 was set. Sample included joints of 100 pelvic 
limbs (of patients with a mean age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg. Joints were graded 
as mild (n = 70), moderate (n = 20) and severe (n = 10) OA. No differences were found between groups at 
T0. Kaplan–Meier analysis showed that all treatments produced longer periods with better results in the 
various evaluations compared to CG. Patients in HG and PCG took longer to return to baseline values and 
scores. A higher impact on pain interference was observed in THG, with a 95% improvement over CG. PCG 
and HG experienced 57–81% improvements in functional evaluation and impairments due to OA, and may 
be a better options for these cases. This study documented the efficacy of several approaches to relieve 
OA clinical signs. These approaches varied in intensity and duration. HG and PCG where the groups were 
more significant improvements were observed throughout the follow‑up periods, with lower variation in 
results. 
Osteoarthritis (OA) is a disease transversal to all mammals1. Being a source of chronic pain and disability, it 
represents a huge burden to societies, with a significant toll in healthcare cost, while reducing productivity and 
quality of life2,3. Its prevalence is expected to rise, due to a simultaneous increase in life expectancy and obesity 4. 
The pathologic process, clinical presentation and response to treatment are very similar in humans and dogs, 
making the dog a frequent animal model for the study of osteoarthritis5. In fact, the changes that occur in slowly 
progressive spontaneous dog OA closely match those of human OA, with the added advantage of a faster disease 
progression while maintaining a juvenile, adolescent, adult and geriatric life stages. In addition, companion 
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animals share many of the same environmental conditions that their human counterparts. For those reasons the 
natural occurring canine model is considered an useful model of human OA, and exploring spontaneous canine 
OA can help improve human and dog health6–11. 
The medical approach to OA aims at slowing disease progression while relieving symptoms, particularly pain, and 
improving overall function9,12. Imaging plays a key role in the assessment of patients with joint disease. In the 
case of hip OA, the ventrodorsal (VD) hip extended view is the most commonly performed radiographic view 13,14. 
This view is a valuable tool for evaluating the presence of hip OA15. Affected patients commonly bear less weight 
on an affected limb, since OA pain is related to movement or weight-bearing impairments of the affected joints. 
Evaluating weight distribution through stance analysis is a sensitive evaluation of lameness in dogs 16–19. Weight 
distribution and off-loading or limb favouring at the stance are commonly used subjective assessments during the 
orthopaedic examination20. Dogs with OA may not be overtly lame at a walk or a trot but exhibit subtle shifts in 
body weight distribution at a stance due to pain18,21. Stance analysis has been reported as sensitive for detecting 
lameness in dogs, proposed to be an equivalent or superior measurement of pain associ- ated with hip OA than 
vertical impulse and peak vertical force VI and PVF18. OA pain is a multi-dimensional experience, which 
encompasses more than just a functional aspect, and treatment interventions must address this reality 17,22,23. 
Clinical metrology instruments (CM I) represent a patient-centred approach, and the most commonly used ones to 
evaluate dogs are the Canine Brief Pain Inventory (CBPI, divided in a pain severity score—PSS, and a pain 
interference score—PIS) and the Liverpool Osteoarthritis in Dogs (LOAD). In addition, the Hudson Visual 
Analogue Scale (HVAS), developed to assess the degree of lameness in dogs, and the Canine Orthopaedic Index 
(COI, divided in four scores: stiffness, gait, function and quality of life—QOL) are further validated CMIs which 
can complement the evaluation of the multi-dimensional, not directly measured experi- ence that is OA related 
pain9,17,19,24–30. 
IA therapies several advantages over systemic medications, as safety, especially when certain comorbidities  
are present, and bioavailability 31. IA corticosteroids have been used for several decades to palliate pain and 
inflammation associated with OA and surrounding tissues32,33. Triamcinolone hexacetonide (TH), in particular, is 
described as able to provide pain relief and improved mobility for prolonged periods34,35. Autologous platelets are 
a regenerative treatment modality for OA, used with the aim to stimulate the natural healing cascade and 
regeneration of tissues, through a supraphysiologic release of growth factors directly at the treatment site36–39. 
Stanozolol is a synthetic derivative of testosterone, and its properties include anabolic/androgenic activity 40. When 
administered IA, it is able to induce fibroblasts to increase collagen production, decrease nitric oxide production 
and induce osteoblast proliferation and collagen synthesis41–44. It also has a chondroprotective and cartilage 
regeneration effect, while reducing osteophyte formation and subchondral bone reaction42,45. Even though 
hyaluronan’s mechanism of action is not completely known and clinical trials have provided contradic- tory 
results, the aim of its use in the treatment of patients with OA is to reduce pain and improve function by 
supplementing the viscosity and elasticity of synovial fluid46,47. Additional anti-inflammatory, anti-nociceptive 
and chondroprotective properties have been suggested48,49. High molecular weight products seem to produce better 
results, particularly in patients with mild radiographic disease50,51. 
In order to assess long-term outcomes and to identify factors associated with poorer outcome, we compared the 
effect of the intraarticular administration triamcinolone hexacetonide, hylan G-F 20, stanozolol and a platelet 
concentrate in the management of OA in a natural occurring canine model. We hypothesize that the different 
treatments will be able to reduce the clinical signs of OA, compared to a control group. 
Results 
The sample included 100 pelvic limbs (n = 50 left and n = 50 right) of fifty active Police working dogs, with a mean 
age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg, representing both sexes (male n = 60, female n = 40). They 
were housed in kennels of the Portuguese Gendarmerie Canine Unit, similar in size. All dogs remained in active 
work during and after the study, and engaged in search and rescue, product detection and use of force mission. 
Active work and training were conducted on a daily basis, with their individual handlers. At T0, 70 joints were 
classified as mild, 20 as moderate and 10 as severe, according to the Orthopedic Foundation for Animals hip 
grading scheme. Values and scores of each evaluation in all groups at T0 are presented in Table 1. No differences  
were found between groups at the initial evaluation (p = 0.22 for SI, p = 0.075 for deviation, p = 0.12 for HVAS, p 
= 0.23 for PSS, p = 0.22 for PIS, p = 0.07 for LOAD, p = 0.48 for stiffness, p = 0.10 for function, p = 0.46 for gait, p = 
0.25 for QOL and p = 0.21 for COI). 
All patients were followed up to the last evaluation moment (180 days) and, during this period, no additional 
treatment or medications was administered. Results of the Kaplan–Meier estimators with each evaluation method are 
presented in Table 2. All treatments showed longer periods with better results in the various evaluations compared 
to CG. Patients in HG and PCG, in particular, took longer to return to baseline values and scores. Results  of the 
Cox proportional hazard regression are presented in Table 3. Increased lameness was observed in 16 patients in 
PCG, 8 in SG, 6 in HG and 4 in THG, which spontaneously resolved within 48–72 h. 
 
Discussion 
Osteoarthritis is a leading cause of disability around the world, which affects both the physical and mental well- 
being of populations. It poses a huge toll on healthcare resources and productivity52. Despite extensive research, 
still has limited treatment options available9,12. To our knowledge, this is the first prospective, negative 
controlled, double-blinded study to compare the effect of commonly used and novel IA treatments for the 
management of OA, in a naturally occurring canine model, with a long follow up period. Human reports on the 
effect of IA TH describe its long term safety, with improvements in joint range of motion and pain compared with 






 CG THG HG SG PCG 
Weight (kg. mean ± SD) 28.2 ± 6.2 26.5 ± 6.5 26.7 ± 3.5 27.1 ± 3.2 25.1 ± 9.6 
Deviation (mean ± SD) 3.6 ± 2.7 4.7 ± 4.4 3.8 ± 3.5 4.3 ± 3.5 4.1 ± 2.2 
Symmetry Index (mean ± SD) 24.8 ± 26.5 23.9 ± 50.4 21.7 ± 24.9 24.1 ± 13.9 22.6 ± 12.4 
HVAS (0–10) 6.8 ± 1.2 5.7 ± 1.9 6.6 ± 1.4 6.7 ± 1.3 6.7 ± 1.4 
PSS (0–10) 3.1 ± 1.9 4.2 ± 2.8 3.3 ± 2.6 2.9 ± 1.5 3.3 ± 2.6 
PIS (0–10) 2.8 ± 1.7 4.8 ± 3.3 3.4 ± 2.3 2.3 ± 1.7 3.3 ± 2.8 
LOAD (0–52) 13.6 ± 10.5 23.2 ± 14.1 17.0 ± 10.5 8.2 ± 5.2 13.3 ± 11.3 
Stiffness (0–16) 3.4 ± 3.4 6.8 ± 4.2 3.4 ± 2.9 4.0 ± 2.8 3.9 ± 3.9 
Function (0–16) 3.6 ± 4.1 6.3 ± 5.7 4.6 ± 3.5 4.0 ± 3.6 4.2 ± 4.7 
Gait (0–20) 5.3 ± 3.9 10.5 ± 5.9 7.4 ± 4.7 5.2 ± 3.9 5.1 ± 5.4 
QOL (0–12) 4.3 ± 2.5 6.2 ± 3.9 4.5 ± 3.1 4.3 ± 2.5 4.5 ± 3.6 
COI (0–64) 17.6 ± 12.4 19.8 ± 19.1 19.9 ± 127 17.5 ± 12.4 17.7 ± 16.9 
Table 1. Mean values (± standard deviation) at initial evaluation of evaluation conducted for control and 
treatment groups. CG Control group, THG Triamcinolone hexacetonide group, HG Hylan G-F 20 group, SG 
Stanozolol group, PCG Platelet concentrate group, HVAS Hudson Visual Analogue Scale, PSS Pain Severity 













CG THG SG HG PCG 
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI 
Symmetry Index 0.000* 47.0 ± 11.8 23.8–70.2 96.0 ± 12.8 70.9–121.1 94.2 ± 15.9 62.9–125.4 104.1 ± 15.1 15.1–74.5 159.0 ± 10.3 138.9–179.1 
Deviation 0.000* 44.8 ± 12.1 21.1–68.5 81.8 ± 14.7 52.9–110.6 55.6 ± 11.8 32.3–78.8 96.2 ± 16.3 64.2–128.1 138.0 ± 12.5 113.4–162.6 
HVAS 0.000* 48.7 ± 12.4 25.4–73.9 66.1 ± 14.2 38.3–93.9 129.8 ± 13.4 103.5–156.1 117.0 ± 13.2 91.1–142.9 144.0 ± 11.6 121.2–166.8 
PSS 0.015* 63.2 ± 17.2 29.6–96.8 90.2 ± 17.6 55.7–124.7 94.6 ± 16.4 62.5–126.7 142.6 ± 11.9 119.1–166.0 150.5 ± 9.7 130.9–169.1 
PIS 0.000* 8.4 ± 0.4 7.7–9.0 118.6 ± 16.3 86.7–150.5 109.6 ± 17.3 75.8–143.2 114.0 ± 16.0 82.6–145.4 135.0 ± 10.6 114.2–155.8 
LOAD 0.000* 40.7 ± 10.6 19.9–61.4 124.3 ± 15.9 93.1–155.5 123.8 ± 14.2 95.9–151.6 141.8 ± 11.6 119.2–164.4 120.0 ± 12.8 94.9–145.0 
Stiffness 0.009* 64.7 ± 16.9 31.4–97.9 130.8 ± 11.6 108.1–153.5 111.2 ± 15.9 80.6–142.9 129.8 ± 13.9 102.6–157.0 141.0 ± 16.9 119.9–162.1 
Function 0.000* 65.4 ± 13.4 39.2–91.6 112.6 ± 15.6 81.9–143.2 124.5 ± 15.4 94.2–154.8 168.0 ± 6.6 155.1–180.8 135.0 ± 9.4 116.5–153.5 
Gait 0.001* 52.7 ± 14.6 23.9–81.4 117.0 ± 15.1 87.5–146.5 103.6 ± 15.7 72.8–134.4 115.5 ± 13.1 89.9–141.1 123.0 ± 12.5 98.5–147.5 
QOL 0.004* 60.9 ± 15.0 31.4–90.4 119.3 ± 17.5 85.0–153.6 66.2 ± 17.5 31.8–100.6 125.6 ± 12.2 101.6–149.6 120.8 ± 13.1 95.1–146.5 
COI 0.011* 52.7 ± 13.4 26.5–78.9 85.6 ± 15.9 54.4–116.9 78.1 ± 14.0 50.6–105.6 93.1 ± 16.7 60.3–125.9 138.0 ± 10.8 116.9–159.1 
Table 2. Survival probability calculated with Kaplan–Meier estimators and compared with the Breslow test. 
See Table 1 for legend. *Indicates significance. 
 
 
of TH53–55. Previous reports on the effect of a single administration of a platelet concentrate showed improve- 
ments in pain, kinetics and joint range of motion, up to the last evaluation point considered, which ranged from 
12 weeks to 6 months56,57. Different reports on the use of stanozolol in animals described it as being able to resolve 
signs of lameness, while reducing osteophyte formation, subchondral bone reaction, and promoting articular 
cartilage regeneration42,43. A previous study on a canine model has provided information on the efficacy of IA 
hyaluronan in animals with OA of pain, function, lameness and kinetics when compared to pre-treatment and 
saline control, with maximum benefits noted at 4–8 weeks and gradually tampered down by a 6-month evaluation 
time point58. OA is characterized by variable degrees of clinical and functional impairments, with the severity 
of pain correlating with the functional status rather than radiographic grading of osteoarthritis, which does not 
correlate with functional status. Treatment, therefore, could be planned according to the clinical features and 
functional status instead of radiological findings59,60. For that reason, we compared well established to novel 
therapeutic approaches, while evaluating the impact of documented predisposing and clinical factors of OA. All 
treatments were able to improve clinical signs of OA compared with the treatment groups, in all of the evaluated 
dimensions, from pain, function and quality of life. As a whole, patients in PCG and HG took longer to return to 
baseline values, which may indicate that these approaches are better therapeutic approaches for the management  
of OA. It was interesting to see that patients in the CG did not remained or returned to initial values and scores 
at the first follow-up evaluations, in some cases taking 60 days to do so. It has been documented that placebo 
saline injections may have an effect in functional improvements that can last up to a 6-month follow-up61, and 
a similar phenomenon may have occurred in this study. 
We also investigated variables which could influence patient’s response to treatment, regarding different 











Wheight distribution  
 
HVAS (p = 0.000) 
CBPI  
 
LOAD (p = 0.000) 
Symmetry Index (p 
= 0.008) 
 
Deviation (p = 0.024) 
 
PSS (p = 0.412) 
 
PIS (p = 0.000) 
HR (95% CI)  
p 






































































Treatment  0.002*  0.005*  0.003*  0.154  0.000*  0.000* 
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Table 3. Results Cox proportional hazard regression with the different outcome evaluations. See Table 1 for 
legend. *Indicates significance. 
 
 
of OA, with patients with severe OA showing an impact on HVAS and function score. These findings could be 
explained with the fact that OA is a progressive, degenerative disease, which ultimately has a toll on joint func- 
tion, without, however, a corresponding increase in pain levels. It is also well established that individuals with 









0 8 15 30 60 90 120 150 180 
Treatment X         
Stance analysis X X X X  X   X 
Digital radiography X   X  X   X 
HVAS X X X X X X X X X 
CBPI X X X X X X X X X 
COI X X X X X X X X X 
LOAD X X X X X X X X X 
Table 4. Procedures conducted in each evaluation moment. Days are counted from treatment day. CBPI 
Canine Brief Pain Inventory, COI Canine Orthopedic Index, HVAS Hudson Visual Analogue Scale, LOAD 
Liverpool Osteoarthritis in Dogs. 
 
body weight in the evolution of OA, which is not the same as body mass index, but since patients in this sample 
were working dogs, with an ideal body condition score, we chose to evaluate body weight instead which did not 
influenced any of the evaluation made. 
Comparing the effect of different treatments, as a whole they had an effect on all dimensions evaluated, except PSS. 
Reasons for that may be related with the nature of these animals are working dogs and, for that reason, tend to 
show few signs of overt pain. In fact, pain is more easily and commonly detected through its impact  on 
measurable parameters, such as weigh bearing, or on active exercises57. This may be reflected on an effect of 
different treatments on the PIS score, but not on the PSS score. PCG and HG registered effects for longer 
periods, and better improvements according to the Cox hazard regression with the different evaluations made. 
Considering measurable parameters, patients in PCH showed an 81% and 69% improvement in SI and devia- 
tion, respectively, while HG showed 61% and 57% improvements. These seem to be the preferred treatments 
for functional impairments due to OA. In addition to these evaluations, PCG and HG also registered greater 
improvements in several scores as HVAS, stiffness, function, gait and COI. Better impact on pain interference 
was observed in THG, which could be attributed to the high anti-inflammatory effect of corticosteroids, and the 
relation between pain and inflammation. 
Side effects related after IA treatment are documented, and usually include injection pain and local inflamma- tion, 
that take 2–10 days to resolve43,58,63,64. We observed increased lameness in all groups, which spontaneously 
resolved within 48–72 h. 
This study presents some limitations, namely the inclusion of two joints from each dogs, as an association may 
occur between limbs. This effect has been described in humans65,66. Still, the inclusion of contralateral limbs 
from the same patient is common in animal models, even for the calculation of a symmetry index27,42,58. A reason 
for this is that quadrupeds show more complex compensation mechanism than just side-to-side. Results from 
the weight bearing evaluation of the patients of this study show that the major compensation occurs in the 
contralateral thoracic limb, rather than side-to-side. In addition, a majority of joints considered in this study had 
mild OA. Further studies should include a larger number of the remaining hip grades to determine if similar 
results are obtained. The safety and efficacy of repeated IA injections should also be investigated. 
 
Conclusions 
To our knowledge, this is the first prospective, negative controlled, double-blinded study to compare the effect 
of commonly used and novel IA treatments for the management of OA, in a naturally occurring canine model, 
with a long follow up period. It provides important information for the characterization of the effects of these 
treatment modalities, duration of observed improvements function and pain, in addition to information regard - 
ing candidates for each one. 
 
Methods 
The study protocol was approved by the ethical review committee of the University of Évora (Órgão Responsável 
pelo Bem-estar dos Animais da Universidade de Évora, approval nº GD/32055/2018/P1, September 25th, 2018), 
and complies with ARRIVE guidelines. All experiments were performed in accordance with relevant guidelines  
and regulations. Written, informed consent was obtained from the Institution responsible for the animals. In a 
prospective, longitudinal, double-blinded, negative controlled study, patients were selected after screening of the 
Portuguese Gendarmerie Canine Unit, based on history, physical, orthopedic, neurological and radiographic 
examinations compatible with bilateral hip OA. The sample comprised one hundred (N = 100) hip joints of fifty 
active Police working dogs. It constituted a convenience sample, similar in size to previously published reports 
on this topic58,67,68. Inclusion criteria comprised age over two years, bodyweight over 20 kg, symptomatic in both 
limbs, with the same OA grade on both hips, and patients should not have received any medication or nutritional 
supplement for over six weeks. Cases with any other documented or suspected orthopaedic or neurological 
disease, or any other concomitant disease, were ruled out through physical and radiographic, examination, 
complete blood count and serum chemistry profile. 
After selection, patients were randomly assigned to one of five groups, 10 dogs per group, and treated bilat- 
erally: control group (CG, n = 20 joints), triamcinolone hexacetonide group (THG, n = 20 joints), platelet con- 





joints). Evaluations were conducted on days 0 (treatment day), 8, 15, 30, 60, 90, 120, 150 and 180 days post 
treatment. An outline of all procedures on each moment is presented in Table 4. All evaluations and procedures 
were performed by the same researcher. 
On treatment day, patients in CG received an IA administration of 2 ml of 0.9%NaCl, given IA. On the same day, 
patients in THG received an IA administration of 20 mg/1 ml of triamcinolone hexacetonide (Bluxam, Riemser 
Pharma, Portugal). In SG, IA administration of stanozolol (Estrombol, Laboratório Fundacion), at a 
0 .3  mg/kg dose was performed69,70. Patients in HG received 2 ml of hylan G-F 20 (Synvisc, Sanofi, Portugal). For 
patients in PCG, 3 ml of platelet concentrate, prepared with the commercially available V-PET kit, according to 
the manufacturer’s instructions, was applied. For the preparation of the platelet concentrate, fifty-five milliliters 
of whole blood were collected from the jugular vein of the patient and then introduced into the provided closed 
system. There, the blood flowed by action of gravity through a filter, where the platelets where concentrated. The 
final platelet concentrate was then collected and was used in the following 5 min of its preparation. 
IA administrations and radiographic examination were conducted under light sedation, induced with a 
combination of medetomidine (0.01 mg/kg) and buthorphanol (0.1 mg/kg), given intravenously. A VD extended 
legs projection was used, and joints classified according to the Orthopedic Foundation for Animals hip grading 
scheme14. A full description of the OFA hip grading scheme is available online. For the IA administration, patients 
were placed in lateral recumbency, with the affected limb uppermost. A window of 4 × 4 cm in the area surround- 
ing the greater trochanter was clipped and aseptically prepared. The limb was then placed in a neutral position, 
parallel to the table. A 21-gauge with 2.5″ length needle was then introduced just dorsal to the greater trochanter, 
perpendicular to the long axis of the limb, until the joint was reached71. Confirmation of correct needle placement 
was obtained through the collection of synovial fluid, and the treatment or saline were administered. Stance 
analysis was conducted with a weight distribution platform (Companion Stance Analyzer; LiteCure LLC, Newark, 
Delaware, United States). The equipment was placed in the centre of an observation room, at least 1-m from the 
walls. Complying with manufacturer’s guidelines, the platform was calibrated at the beginning of each testing 
day and zeroed before each data collection. After an acclimatization period, animals were encouraged to stand 
on the weight distribution platform. To secure a correct position, the patient’s trainer helped to ensure it placed 
one foot on each quadrant of the platform, while maintaining a natural stance with its their centre of gravity and 
stability (measured by the platform) near the middle of the platform. When required, gentle restraint was used 
to maintain the patient’s head in a natural, forward-facing position. For all animals, at least 20 measure- ments 
were performed, and the mean value was determined. The left–right symmetry index (SI) was calculated 
according to the following formula: SI = [(WBR − WBL)/((WBR + WBL) × 0.5)] × 10027,72, where WBR is the value 
of weight-bearing for the right pelvic limb and WBL is the value of weight-bearing for the left pelvic limb. Nega- 
tive values were made positive. We also considered deviation from the normal 20% weight-bearing for a pelvic 
limb18, calculated by subtracting WB to 20. Before completion of an online copy of the HVAS, CBPI, COI and 
LOAD, handlers received the published instructions for each of them. The CMIs were completed sequentially by 
the same handler in each of the follow-up assessments, without knowledge of their previous answers, in a calm 
room with as much time as needed to answer all items. As CBPI has two section (PSS and PIS), and COI has four 
dimensions (stiffness, function, gait and QOL), were considered all sections and dimensions in the analysis. After 
treatment, animals were rested for three consecutive days and resumed their normal activity over a period of   5 
days. On days 1 and 3 after the procedure, the veterinarian examined all patients in order to determine possible 
signs of exacerbated pain, persistent stiffness of gait and changes in posture. If no complaints were registered, 
the animal could resume its normal activity 73,74. If a deterioration of the animal’s condition was detected, rescue 
analgesia would be provided and based on the administration of a combination of opioids (tramadol, 2–5 mg/ 
kg BID or TID) and gabapentin (10–20 mg/kg TID), as needed. 
The outcome considered was as return to or drop below baseline values of SI or deviation and scores of the 
considered CMIs at the 180-day post treatment. Demographic data consisting of age, sex and body weight, was 
noted. Results are expressed as mean ± SD. Kaplan–Meier estimators were conducted to generate survival 
curves, survival probability and compared with the Breslow test. Cox proportional hazard regression analysis 
was carried out to investigate the influence of the variables of interest (age, sex, body weight and OFA score) on 
treatment survival. Treatments were compared to control at initial evaluation with a Wilcoxon signed-rank test. 
Patients with values or scores above baseline values at 180 days post treatment were censored. All results were 
analyzed with IBM SPSS Statistics for Windows, Version 20.0. (Armonk, NY: IBM Corp., released 2011) and a 
significance level of p < 0.05 was set. 
Data availability 
All data generated or analysed during this study are included in this published article. 
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Objectives: To compare the effect of intra-articular treatment with triamcinolone 
hexacetonide (TH), stanozolol, hyaluronan, and a platelet concentrate in police working 
dogs with bilateral hip osteoarthritis (OA). 
Study Design: Prospective, longitudinal, double-blinded, negative controlled study. 
Sample Population: Fifty police working dogs with naturally occurring hip OA.  
Methods: Animals were randomly assigned to a control group (CG, n = 10), TH group 
(THG, n = 10), platelet concentrate group (PCG, n = 10), stanozolol group (SG, n = 10),  
and Hylan G-F 20 group (HG). On days 0 (T0), 8, 15, 30, 90, and 180 days post -
treatment, weight-bearing distribution was evaluated. In those days, and on days 60, 
120, and 150, four clinical metrology instruments were completed. Kaplan–Meier 
estimators were conducted and compared with the log-rank test. Cox proportional 
hazard regression analysis was performed to determine treatment survival. Significance 
was set at p < 0.05. 
Results: Patients had a mean age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg. 
At T0, hips were classified as mild (n = 35), moderate (n = 10), and severe (n = 5), 
according to the Orthopedic Foundation for Animals grading scheme. No differences 
were found between groups at that moment considering age, body weight, OFA hip 
score, and all assessments performed. All treatments improved clinical signs in various 
OA dimensions in some groups, with a broad effect interval. PCG showed a lower range of 
variation while maintaining a positive result for more extended periods (p < 0.01 for 
symmetry index and 0.01 < p < 0.04 in the majority of scores). Breed, age, sex, and 
OFA grade did not significantly influence response to treatment.  





Conclusions and Clinical Relevance: This is the first prospective, negative controlled,  
double-blinded study to compare the effect of a single administration of these IA 
treatments in dogs with hip OA. HG and PCG recorded more significant improvements  
throughout the 180-day follow-up. In particular, PCG also registered a lower variation 
in results, seemingly the best therapeutic option. Nevertheless, improvements were 
still observed in THG and SG, and these treatment options can be considered, mainly 
when the first two treatments are not available. 
Key words: animal model, osteoarthritis, pain, intra-articular, platelet, triamcinolone, hy lan G-F 20 
 
INTRODUCTION 
Osteoarthritis (OA) is the most commonly diagnosed joint disease 
in veterinary medicine, with  at  least  80%  of  the  cases of 
lameness and joint diseases in companion animals broadly 
classified as OA  (1–3).  Risk  factors  for  developing  OA are well 
documented and include breed, neutering, higher body weight, 
and age > 8 years  (4).  For  the  evaluation  of hip OA, pelvic 
radiographs are frequently performed (5–7). 
Weight distribution, off-loading,  or  l imb  favoring  at  stance  is a 
commonly used subjective assessment during orthopedic 
examination (8). Animals with OA may not  be  overtly  lame but 
exhibit subtle shifts in body weight distribution at a stance due to 
pain or instability, which are detectable with force plate gait 
analysis and weight distribution platforms (9, 10). Body weight 
distribution at a stance may even be an equivalent or superior 
measurement of pain associated with hip OA than vertical 
impulse or peak vertical force (10, 11). Pain is a hallmark of OA, 
affecting more than just the functional aspect of the disease, and 
the evaluation of treatment success should encompass the 
assessment of these multiple  dimensions  of OA (12, 13). Clinical 
metrology instruments (CMIs) aim to evaluate multiple 
dimensions of OA, and the commonly used instruments in dogs 
are the Canine Brief Pain Inventory (CBPI, divided into a pain 
severity score—PSS, and a pain interference score—PIS) and the 
Liverpool Osteoarthritis in Dogs (LOAD) (12, 14–20). Additional 
validated CMIs include the Hudson Visual Analog Scale (HVAS),  a 
valid tool to assess the degree    of lameness in dogs, with force 
plate analysis as a criterion- referenced standard, and the Canine 
Orthopedic Index (COI, divided into four scores: stiffness, gait, 
function, and quality of l ife—QOL) (21–23). 
The medical approach to OA aims at slowing disease progression, 
relieving pain, and improving  overall  function (14,  24),  and  it  is  
well  suited  to  be  addressed  through    the  use  of  local  therapy  
by  intra-articular   (IA)   injection (25, 26). IA corticosteroids have 
been used for  several  decades. Currently, different guidelines for 
the management  of human OA provide varying strength  of  
recommendation  for the use of IA corti costeroids, from weak to 
strong recommendation (27–31). Some reports present 
deleterious effects of IA corticosteroids, namely, the induction of 
a low- quantity and high-viscosity synovial fluid. These results are 
often based on multiple injections, particularly of 
methylprednisolone, while a single dose does not seem to cause 
long-term 
 
detrimental effects (32, 33). Triamcinolone hexacetonide (TH), in 
particular, can provide pain relief, improve mobility for prolonged 
periods, and reduce the severity of structural changes (28, 34–36). 
Hyaluronan is also a commonly used treatment modality in OA 
management, although its action mechanism is not entirely 
known (37, 38). It has  been proposed to have anti -inflammatory, 
anti-nociceptive, and chondroprotective properties (39–42). 
High-molecular-weight products seem to produce better results 
(43–46). Autologous platelets are a regenerative treatment 
modality for OA, acting through a supraphysiologic release of 
growth factors directly   at the treatment site, promoting tissue 
regeneration and attraction of mesenchymal stem cells (47–50). 
In dogs,  a  single  IA  PRP  (platelet-rich  plasma)  injection  has  
resulted  in clinical improvements for 12 weeks in some reports, 
and    up to 6 months according to others. In some cases, these 
improvements occur without the progression of radiographic 
signs (51–54). 
Multiple injection protocols have also been described, producing 
a positive effect on joint range of motion, pain, lameness, and 
kinetics (55). More recently, the use of stanozolol, a synthetic 
derivative of testosterone, has been described in animal models. 
When administered IA, it induced fibroblasts to increase collagen 
production, decrease nitric oxide production, and induce 
osteoblast proliferation and collagen synthesis. It also has a 
chondroprotective and cartilage regeneration effect while 
reducing osteophyte formation and subchondral bone reaction 
(56–61). 
To compare long-term outcomes and to identify factors 
associated with response to treatment, we compared the effect of 
the IA administration  of  TH,  Hylan  G-F  20,  stanozolol,  and a 
platelet concentrate in the treatment of police working dogs with 
bilateral hip OA. We hypothesize that the different treatments 
will  be able to improve CMIs scores and weight- bearing 
distribution in dogs with OA, compared to a control group (CG). 
 
METHODS 
The study protocol was approved by the ethical review committee 
of the University of Évora (Órgão  Responsável  pelo  Bem-  estar 
dos Animais da Universidade de Évora, approval no 
GD/32055/2018/P1, September 25, 2018). Written informed 
consent was obtained from the institution responsible for the 




animals. Fifty active police working dogs with bilateral hip OA 
were selected to participate in this prospective, longitudinal, 
double-blinded, negative controlled study. They were included 
based on history, physical, orthopedic, neurological, and 
radiographic examinations compatible with bilateral hip OA. Hips  
were classified according to the Orthopedic Foundation for 
Animals hip grading scheme at the initial evaluation, on day 0 (62, 
63). Animals suspected or with any other orthopedic, or 
concomitant disease (ruled out through physical examination, 
complete  blood  count,  and  serum  chemistry  profile)  were 
excluded.  Additionally,  animals  were  >2  years  old, weighed 
>20 kg and had no other medications or nutritional supplements 
administered for the previous 6 weeks and during the study 
period. Patients were randomly assigned to five different 
groups, using the statistical analysis software, according to the 
treatment being administered: a CG (n = 10), receiving an IA 
administration of 2 ml of NaCl 0.9% per hip joint; a 
triamcinolone hexacetonide group (THG, n = 10), receiving 20 
mg/ml of TH (Bluxam, Riemser Pharma, Portugal) per hip joint; a 
platelet concentrate group (PCG, n = 10), which received 3 ml 
of platelet concentrate per hip joint; a stanozolol group (SG, n 
= 10), to which 0.3 mg/kg of stanozolol (Estrombol, 
Laboratório Fundacion) per hip joint (64, 65) was administered; 
and a hyaluronan group (HG, n = 10), which received 2 ml of 
Hylan  G-F  20  (SynviscⓍR ,  Sanofi,  Portugal)  per  hip  joint.  All 
treatments were administered only on day 0 (treatment day) 
through IA administration. According to the manufacturer’s 
instructions, this specific platelet concentrate was prepared with 
the  commercially  available  kit  (V-PETⓍR ,  PALL  Corporation). 
Briefly, 55 ml of whole blood was collected from the jugular 
vein and introduced into the provided closed system for its 
preparation. The blood was then allowed to flow by gravity 
through a filter, where the platelets were concentrated. The 
platelet concentrate was then recovered and administered within 5 
min of preparation. 
All IA administrations and radiographic examinations were 
conducted under l ight sedation, obtained with the simultaneous 
intravenous administration of medetomidine (0.01 mg/kg) and 
butorphanol (0.1 mg/kg). For IA administrations, patients were 
placed in lateral recumbency with the treatment joint dorsal. 
The anatomical reference for access was the greater trochanter, 
around which a 4 × 4 cm window was clipped and aseptically 
prepared. After preparation, an assistant placed the limb in a 
neutral  position, parallel  to the table. A 21-gauge with 2.5 length 
needle was then introduced just dorsal to the greater trochanter, 
perpendicular to the limb’s long axis until the joint was reached 
(66). Confirmation of correct needle placement was obtained 
by collecting synovial fluid, withdrawing as much synovial fluid 
as possible, and the respective substance was administered. 
Ultrasound guidance was available if required to confirm the 
correct needle placement. After treatment, animals were rested 
for three consecutive days and examined by a veterinarian on 
days 1 and 3 post procedure to determine signs of exacerbated 
pain, persistent stiffness of gait, and posture changes. If no 
complaints were registered, the animal was allowed to resume its 
normal activity (54, 67). On days 0, 8, 15, 30, 90, and 180 post-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analysis platform (Companion Stance Analyzer; LiteCure LLC, 
Newark, Delaware, United States), placed in the center of a 
room, at least 1 m from the walls. It was calibrated at the 
beginning of each testing day and zeroed before each data 
collection. Animals stood on the platform, with one foot on 
each quadrant of the platform, while maintaining a natural 
stance with their center of gravity near the platform’s middle. 
When required, gentle restraint was used to maintain the 
patient’s head in a natural forward-facing position. The left–
right symmetry index (SI) was calculated according to the 
following formula: SI = [(WBR – WBL)/((WBR + WBL) × 0.5)]  × 
100,  where  WBR  is  the  value of weight-bearing for the right 
pelvic limb and WBL is the value of weight-bearing for the left 
pelvic l imb. Negative values were made positive (19, 68). 
Since all animals included in the study had bilateral disease, 
we also considered a deviation from the normal 40% weight-
bearing for the combined pelvic l imbs (10), calculated by 
subtracting WB to the normal 40%. On days 0, 8, 15, 
30, 60, 90, 120, 150, and 180 post-treatment after treatment, an 
online copy of the HVAS, CBPI, COI, and LOAD was completed 
by the dogs’ trainers after receiving the published instructions 
for each of them. Dogs’ trainers were unaware of which 
treatment the animal received. The CMIs were completed in 
sequence by the same handler in all follow-up moments, 
without knowing their previous answer. The two sections of 
the CBPI (PSS and PIS) and COI’s four dimensions (stiffness, 
function, gait, and QOL) were considered separately in the 
analysis. All evaluations were performed at the same moment 
by the same researcher blinded to the group and identity of 
the patient. 
For the considered IA treatments, some side effects are 
documented and include local pain and local inflammation. 
These are usually self-limiting and take 2–10 days to resolve 
(69). The occurrence of these side effects was monitored 
during treatment follow-up assessments and recorded. 
Demographic data as age, sex, body weight, and breed were 
recorded. Kaplan–Meier estimators were conducted to 
generate survival curves and survival probability and 
compared with the log-rank test. Cox proportional hazard 
regression analysis was carried out to investigate interest 
variables’ influence (age, sex, body weight, breed, and OFA 
score) on survival. All  results were analyzed with IBM SPSS 
Statistics version 20, and a significance level of p <  0.05 was 
set. With the CBPI, a specific measure of 
success was defined and set as a reduction of ≥1 in PSS and ≥2 
in PIS (70). The time for PIS and PSS scores to drop below the 
defined level of reduction was evaluated. For the remaining 
CMIs scores and weight-bearing evaluation, the outcome 
considered was a return to or drop below values recorded at 
the initial evaluation. Patients with values or scores above 
baseline values at the evaluation moment the event was 
recorded were censored. 
 
RESULTS 
The sample included 50 police working dogs, of both genders 
(30 males and 20 females), with a mean age of  6.5  ±  2.4 
years and body weight of 26.7 ± 5.2 kg. Four dog breeds were 
represented: German Shepherd Dogs (GSD, n = 17), Belgian 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 3 | Results Cox proportional hazard regression with the dif f erent outcome ev aluations.  
Weight distribution CBPI 
 
Variable Sy mmetry  Index (p = 0.014) Dev iation (p = 0.251) HVAS (p = 0.036) PSS (p = 0.881) PIS (p = 0.025) LOAD (p = 0.006) 
 
HR (95% CI) p 
 
HR (95% CI) p 
 
HR (95% CI) p 
 
HR (95% CI) p 
 
HR (95% CI) p 
 



























HG 0.23 (0.08–0.65) 0.006*  0.25 (0.07– 0. 8 4 ) 0.026*  0.19 (0.06–0.64) 0.007*  0.29 (0.08–1.16) 0.081  0.06 (0.15–0.26) 0.000*  0.06 (0.02– 0. 2 5 ) 0.000* 
PCG 0.24 (0.21–0.26) 0.000*  0.29 (0.09– 0. 9 6 ) 0.042*  0.26 (0.09–0.82) 0.021*  0.57 (0.19–1.73) 0.322  0.12 (0.03–0.43) 0.001*  0.19 (0.06– 0. 6 2 ) 0.005* 
SG 0.21 (0.07–0.60) 0.004*  0.42 (0.12– 1. 4 7 ) 0.176  0.31 (0.09–1.08) 0.066  0.65 (0.19–2.18) 0.487  0.09 (0.02–0.36) 0.001*  0.08 (0.02– 0. 2 8 ) 0.000* 





0.582   
1.00 
0.608   
1.00 
0.195   
1.00 
0.998   
1.00 
0.621   
1.00 
0.211 
Moderate 0.70 (0.29–1.69) 0.430  0.75 (0.30– 1. 8 5 ) 0.528  1.49 (0.63–3.52) 0.358  1.024 (0.41-2.57) 0.960  1.53 (0.65–3.61) 0.330  2.18 (0.89– 5. 3 4 ) 0.088 
Sev ere 0.58 (0.17–1.94) 0.378  1.44 (0.37– 5. 5 8 ) 0.597  3.00 (0.88–10.29) 0.079  0.99 (0.22–4.41) 0.990  1.25 (0.31–5.00) 0.749  1.03 (0.23– 4. 6 1 ) 0.972 
Breed  0.861   0.293   0.752   0.856   0.631   0.073 
LR 1.00   1.00   1.00   1.00   1.00   1.00  
GSD 0.74 (0.24–2.28) 0.589  0.44 (0.13– 1. 5 4 ) 0.202  0.52 (0.13–2.14) 0.368  1.42 (0.36–5.61) 0.619  0.52 (0.14–1.92) 0.327  0.76 (0.21– 2. 7 6 ) 0.672 
BM 0.63 (0.21–1.91) 0.411  0.31 (0.09– 1. 1 3 ) 0.076  0.47 (0.12–1.85) 0.283  0.92 (0.27–3.15) 0.888  0.46 (0.14–1.58) 0.217  0.35 (0.09– 1. 3 3 ) 0.121 
DSD 0.79 (0.22–2.86) 0.724  0.58 (0.12– 2. 7 4 ) 0.493  0.58 (0.13–2.72) 0.493  1.39 (0.54–2.92) 0.684  0.43 (0.10–1.82) 0.249  0.17 (0.03– 0. 8 3 ) 0.028* 
Sex                  
Male 1.00   1.00   1.00   1.00   1.00   1.00  
Female 1.51 (0.76–2.99) 0.238  0.77 (0.34– 1. 7 5 ) 0.536  0.33 (0.12–0.87) 0.025*  1.25 (0.54–2.92) 0.607  0.85 (0.37–1.97) 0.704  1.17 (0.49– 2. 7 9 ) 0.721 
Age 0.90 (0.77–1.06) 0.216  0.9 (0.75– 1. 0 9 ) 0.274  1.09 (0.91–1.29) 0.363  1.13 (0.93–1.37) 0.222  0.912 (0.77–1.08) 0.299  0.9 (0.76– 1. 0 7 ) 0.229 
COI 
Variable Stif f ness (p = 0.034) Function (p = 0.023) Gait (p = 0.069) QOL (p = 0.325) Total (p = 0.053) 
 
HR (95% CI) p 
 
HR (95% CI) p 
 
HR (95% CI) p 
 
HR (95% CI) p 
 












Control 1.00   1.00   1.00   1.00   1.00  
HG 0.19 (0.05–0.74) 0.016*  0.09 (0.02–0.43) 0.002*  0.20 (0.06–0.71) 0.012*  0.64 (0.19–2.09) 0.463  0.29 (0.09–0.92) 0.036* 
PCG 0.23 (0.07–0.77) 0.018*  0.33 (0.11–1.02) 0.054  0.21 (0.07–0.67) 0.009*  0.57 (0.21–1.58) 0.282  0.29 (0.09–0.87) 0.030* 
SG 0.31 (0.09–1.09) 0.069  0.28 (0.08–1.01) 0.051  0.36 (0.11–1.15) 0.083  0.87 (0.28–0.67) 0.807  0.54 (0.17–1.66) 0.279 
THG 0.31 (0.09–1.09) 0.069  0.33 (0.11–1.02) 0.054  0.29 (0.09–0.92) 0.036*  0.65 (0.22–1.96) 0.444  0.49 (0.17–1.41) 0.188 
OFA score  0.223   0.068   0.439   0.303   0.041* 
Mild 1.00   1.00   1.00   1.00   1.00  
Moderate 1.05 (0.39–2.84) 0.918  0.89 (0.34–2.36) 0.823  0.63 (0.24–1.64) 0.344  0.48 (0.19–1.22) 0.123  0.69 (0.28–1.73) 0.431 
Sev ere 3.11 (0.79–12.13) 0.102  5.09 (1.18–21.98) 0.029*  1.34 (0.39–4.629 0.641  0.78 (0.22–2.77) 0.696  4.19 (1.08–16.24) 0.038* 
Breed  0.069   0.559   0.255   0.320   0.997 
LR 1.00   1.00   1.00   1.00   1.00  
GSD 0.46 (0.10–2.00) 0.298  2.54 (0.56–11.47) 0.226  0.71 (0.18–2.78) 0.622  2.31 (0.65–8.25) 0.199  0.92 (0.26–3.28) 0.898 
BM 1.39 (0.40–4.81) 0.606  2.04 (0.52–7.99) 0.309  1.15 (0.33−3.96) 0.824  0.87 (0.33–7.49) 0.814  0.92 (0.29–2.93) 0.893 
DSD 0.22 (0.03–1.51) 0.124  1.18 (0.22–6.22) 0.845  0.29 (0.05–1.58) 0.153  1.57 (0.33–7.49) 0.572  1.00 (0.24–4.15) 0.995 
Sex               
Male 1.00   1.00   1.00   1.00   1.00  
Female 1.49 (0.60–3.69) 0.386  1.58 (0.62–4.01) 0.337  1.19 (0.52–2.74) 0.685  3.16 (1.35–7.39) 0.008*  2.02 (0.89–4.55) 0.089 
Age 1.08 (0.91–1.29) 0.378  1.16 (0.96–1.41) 0.119  1.19 (0.99–1.43) 0.071  1.06 (0.87–1.29) 0.572  1.14 (0.94–1.37) 0.180 
BM, Belgian Malinois Shepherd Dog; CBPI, Canine Brief Pain Inventory; COI, Canine Orthopedic Index; DSD, Dutch Shepherd Dog; GSD, German Shepherd Dog; HG, Hylan G-F 20 group; HVAS, Hudson Visual Analog Scale; LOAD, 
Liverpool Osteoarthritis in Dogs; LR, Labrador Retriever; OFA, Orthopedic Foundation for Animals; PCG, Platelet Concentrate group; PIS, Pain Interference Score; PSS, Pain Severity Score; QOL, Quality of Life, SG, Stanozolol group; 
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n = 10), and Dutch Shepherd Dogs (DSD, n = 8). Considering OFA 
hip grading, 35 animals were classified as mild (70%), 10 were 
classified as moderate (20%), and 5 were classified as severe (10%). 
The platelet concentrate obtained had a four-fold platelet 
concentration, a two-fold leukocyte concentration, and a 50% 
reduction in platelet concentrate hematocrit than whole blood 
values. These values are in line with those previously described 
kinetics, and joint range of motion, lasting from 12 weeks to 6 
months (52, 54). The use of IA stanozolol has been published in 
horses and an ovine model and presented as able to resolve 
signs of lameness, reduce osteophyte formation and subchondral 
bone reaction, and promote articular cartilage regeneration 
(58, 59). In the study presented here, all treatments improved 
clinical signs in various dimensions of OA in police working 
for  V-PETⓍR (71). The results of the evaluation performed at dogs with bilateral disease. While being able to do so, the 
day 0, by group, are presented in Table 1, where no significant 
differences were found between groups. Results of the Kaplan– 
Meier estimators are presented in Table 2. All treatments were 
able to produce better results than CG, with variable periods  of 
duration. Better results were observed in the PCG and HG   in all 
considered outcome measures, with a lower range with a 95% 
confidence interval. Results of the Cox proportional hazard 
regression are presented in Table 3. Treatment was the covariable 
that contributed more frequently to the outcomes observed. In 
fact, in some cases (as SI, HVAS, PIS, and others), it was the  only 
one. Only overall COI also influenced the OFA score, with dogs 
with a severe hip grade having a 4.1-fold probability of returning 
to baseline values, compared with dogs with a mild grade. LOAD 
was the only outcome measure influenced by breed, with DSD 
showing a lower risk baseline values. All patients were followed up 
to the 180-day evaluation moment. Post-injection increased 
lameness was observed in eight patients in PCG, four in SG, three 
in HG, and two in THG, which spontaneously resolved within 48–
72 h. No additional treatment or medications was administered to 
the animals during this period. 
 
DISCUSSION 
OA is a chronic disease with no cure. Therefore, the main focus of 
OA management is to control clinical signs, mainly pain levels (72, 
73). Hip OA, in particular, is very common in large breed dogs such 
as German Shepherd Dogs and Labradors. It has a toll  on the 
quality of l ife, particularly in working dogs, to whom it also affects 
performance (74, 75). To our knowledge, this is the first 
prospective, negative controlled, double-blinded study to 
compare the long-term effects of these different IA approaches for 
the management of dogs with bilateral hip OA. 
Clinical presentation of patients with OA  is  characterized by 
variable degrees of clinical and functional impairments. It    is well 
established that clinical signs and the severity of pain,   in 
particular, correlate with the functional status rather than 
radiographic grading of OA. For that reason, treatment should be 
planned according to clinical features and functional status 
instead of radiological findings (62, 76–78). With that in mind, we 
evaluated the impact of predisposing and clinical factors    of OA 
as demographic characteristics of interest. The IA TH 
administration has been described as having long-term safety 
while improving the joint range of motion and pain compared 
with saline injection (79–82). 
Similarly, IA hyaluronan improves pain, function, lameness, and 
kinetics compared to pre-treatment and saline control in 
patients with OA (69). Reports of canine OA treatment with 
this same platelet concentrate present improvements in pain, 
95% confidence interval was wide for those treatments in some 
groups. Values and scores in PCG showed a lower range of 
variation while maintaining a positive result for more extended 
periods. Except for pain scores, mean values in CG did not return to 
baseline values immediately at the first follow-up periods, as 
would possibly be expected. A functional improvement following 
NaCl IA injections has been described, and, in some instances, 
effects were noted up until  6-month post-administration (83). 
This fact can be associated with the removal of inflammatory 
mediators presented in the synovial fluid, and an effect similar to 
a joint lavage produced by the administration of saline (83), and 
may be the reason for the recorded evaluation in CG. Also 
noteworthy, while any treatment did not significantly influence 
PSS scores, PIS scores were. It is not uncommon that police 
working dogs do not show overt signs of pain, which is easily 
detected through its effect on daily activities and performance 
(84). Probably for that reason, all  treatments were able to 
produce an 88–94% improvement compared to CG, as evaluated 
with the PSS. The weight-bearing evaluation platform has been 
deemed a repeatable and accessible device to measure static 
weight distribution, compared to a pressure-sensitive walkway 
(10, 85, 86). A significant improvement was observed only with SI 
considering the two weight-bearing evaluations evaluated. Dogs 
presenting with pelvic l imb lameness tend to distribute weight 
more by side-to-side compensation than pelvic-to-thoracic (87, 
88). This compensation mechanism may be the reason for this 
result, and the same compensation mechanism may be present in 
animals with bilateral disease, such as hip OA. This may be the 
reason for the wide ranges observed in standard deviations of the SI 
at the initial evaluation. Despite being a bilateral disease, it is not 
to say that both joints are affected equally, causing the animal to 
off-load one limb while supporting more weight on the 
contralateral l imb. The degree of this compensation mechanism 
can vary between individual dogs. The same can be considered for 
the wide ranges in COI scores, since this CMI focuses on the ability 
of the dog to perform daily activities, and the clinical signs of OA 
patients can vary quite significantly (21). 
Also, dogs included were active police working dogs, known 
to be stoic and not to show overt pain signs (75, 84). The fact that 
they were signaled to undergo treatment for hip may indicate that 
these animals were, at the time, in pain (86). With HVAS, HG and 
PCG registered more significant improvements throughout the 
180-day follow-up, also with a lower variation with the 95% 
confidence interval. When using LOAD, all treatments produced 
improvements that ranged from 81 to 94%. When using the 
various dimensions of COI, PCG and HG were the treatments 
consistently leading to improvements. With this information in 
mind, and considering the variety of evaluations performed, the 
platelet concentrate and Hylan G-F 20 seem to be the best IA 
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therapeutic choices for treating bilateral hip OA. Nevertheless, TH 
and stanozolol were also able to improve patients’ condition and 
are valid therapeutic options that should be considered, mainly 
when the first two treatments are not available. 
Heavier dogs are more prone to develop OA earlier in life (89, 90), 
and being overweight is a risk factor for OA. While being related, 
these two concepts are not the same. Since the animals that 
comprised the sample were active working dogs, with a body 
condition score of 4 or 5/9, none was overweight. Also, since 
represented dog breeds were all large, we chose  not to include 
body weight as a possible influencing factor in our models. Age 
did not have a significant role in any of the evaluations performed, 
but increasing age, particularly over 8 years, is a predisposing 
factor for OA (4). This lack of effect  may be attributed to the fact 
that the sample animals’ mean age was below 8 years. It is also 
possible that age is not a factor    by itself, and instead reflects the 
progression of the disease, which, in turn, may affect response to 
treatment. OFA grading only influenced function evaluation, with 
animals with a severe classification showing a significantly worse 
evolution than those graded as mild. Hylan G-F 20 seems to be the 
better therapeutic option for these patients since HG was the only 
group to show significant improvements compared to control. 
The reason for this may be related to the mechanism of action of 
hyaluronan, which supplements the viscosity and elasticity of 
synovial fluid (37). The remaining treatments act by interacting 
with joint cells and tissues, which may not be as responsive or 
even present in enough number to show a better response. Certain 
dog breeds are also at increased risk of developing hip OA since it 
is a common consequence of hip dysplasia and influenced by a 
wide range  of breed-specific genes (polygenetic trait) (4, 62). Dog 
breeds included in this sample are known breeds at risk to 
develop   OA and similar size and conformation. With the 
considered evaluation, no significant differences were observed 
regarding response to treatment. 
There  are  recommendations  for  different  administration 
frequency in human, canine, and horse reports. For 
corticosteroids, a period of at least 6–12 weeks should be 
respected between administrations, without  exceeding  two  to 
four injections of the same joint within a year (91, 92). In horses, 
a study considering triamcinolone acetonide showed no 
difference between single or multiple administrations (93). For 
hyaluronan, some reports indicate that three injections weekly 
are more effective in reducing pain in humans when compared to a 
single administration, although both protocols improved joint 
function (94). For canine platelet products, two administrations 
2–3 weeks apart have been recommended (52). We chose to 
administer a single IA inject to compare all treatments before 
evaluating multiple-administration protocols. Also, available 
canine recommendations are usually based on recommendations 
for other species or on data from canine surgical models, raising 
the need for information from dogs with naturally occurring OA. 
The fact that the animals enrolled in this study are working dogs 
means that their musculoskeletal structures are under greater 
demand than in a companion animal (95). While results may 
remain significant for a more extended time in companion 
animals, due to lower physical demand, most of the animals 
included in this study were being treated at an early age and with 
less radiographic changes than what is described in companion 
animals (4). 
With all used IA treatments, some side effects are documented and 
include local pain and local inflammation. These are usually self-
limiting and take 2–10 days to resolve, being attributed to a 
joint capsule expansion following the IA administration (59, 69, 
96, 97). Similarly, we observed increased lameness in eight 
patients in  PCG,  four  in  SG,  three  in  HG,  and  two in THG, 
which spontaneously resolved within 48–72 h. PCG was the 
group where the higher treatment volume was administer, 
which may account for higher number of increased lameness 
observed. 
This study presents some limitations, namely, the inclusion of a 
majority  of  dogs  with  mild  OA.  For  that  reason,  further studies 
should include a larger number of dogs with moderate and severe 
OA to determine if similar results are obtained. Still, a significant 
difference between mild and severe OA was  observable  in  the  
COI  score.  Different  volumes were administered  in  different  
groups,  ranging  from  1 ml  (in  THG)  to  3 ml  (in  PCG).  This  
difference   in   volumes   may  impact  clinical  signs  following  the  
administration,  as    a higher volume can produce joint capsule 
dilation and, consequently, pain. In our study, this did not 
significantly impacted the overall results, as this increased 
lameness resolved within 72 h in all groups, but is a variation to  
consider  in  future studies. Different numbers of administration 
should also be tested. 
 
CONCLUSIONS AND CLINICAL RELEVANCE 
To our knowledge, this is the first prospective, negative 
controlled, double-blinded study to compare the effect of  these 
different IA treatment modalities  in  police  working  dogs with 
bilateral hip OA. It describes each treatment modality’s effect on 
pain level  and  functional  evaluation,  their duration, and relevant 
information regarding patient selection  for  each  treatment.  HG  
and   PCG   recorded greater  improvements  throughout  the   180-
day   follow-up. In particular, PCG also registered a lower variation 
in results, seemingly the best therapeutic option. Improvements  
were stil l observed in THG and SG, and  these  treatment  options 
can be considered, mainly when the first two treatments are not 
available. 
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51.  Arican M, Simşek  A, Parlak K, Atli K, Sönmez G. Matrix metalloproteinases   
2 and 9 activity after intra-articular injection of autologous platelet-rich 
plasma for the treatment of osteoarthritis in dogs. Acta Vet Brno. (2018) 
87:127–35. doi: 10.2754/avb201887020127 
52.  Fahie MA, Ortolano GA, Guercio V,  Schaffer JA, Johnston G, Au J,  et al.         
A randomized controlled trial of the efficacy of autologous platelet therapy 
for the treatment of osteoarthritis in dogs. J Am Vet Med Assoc. (2013) 
243:1291–7. doi: 10.2460/javma.243.9.1291 
53.  Silva RF, Carmona JU, Rezende CMF.  Intra-articular  injections  of 
autologous platelet concentrates in dogs with surgical  reparation  of  
cranial cruciate ligament rupture. Vet Comp Orthop Traumatol. (2013) 
26:285–90. doi: 10.3415/VCOT-12-06-0075 
54.  Alves JC, Santos A, Jorge P, Lavrador  C, Carreira  LM. A report on  the  use  
of a single intra-articular administration of autologous platelet therapy in a 
naturally occurring canine osteoarthritis model - a preliminary study. BMC 
Musculoskelet Disord. (2020) 21:127. doi: 10.1186/s12891-020-3140-9 
55.  Cook JL, Smith PA, Bozynski CC, Kuroki K, Cook CR, Stoker AM, et al.  
Multiple injections of leukoreduced platelet rich plasma reduce pain and 
functional impairment in a canine model of ACL and meniscal deficiency. J 
Orthop Res. (2016) 34:607–15. doi: 10.1002/jor.23054 
56.  Fernández  L,  Chirino  R,  Boada  LD,  Navarro   D,   Cabrera   N,  del  Rio  I,  
et al. Stanozolol and danazol, unlike natural androgens, interact with the 
low affinity glucocorticoid-binding sites from male rat liver microsomes. 
Endocrinology. (1994) 134:1401–8. doi: 10.1210/endo.134.3.8119180 
57.  Wright JK, Smith AJ, Cawston TE, Hazleman BL.  The  effects  of  the  
anabolic steroid, stanozolol, on the production of procollagenase  by  
human synovial and skin fibroblasts in vitro. Agents Act. (1989) 28:279–  
82. doi: 10.1007/BF01967415 
58.  Spadari A, Romagnoli N, Predieri PG, Borghetti P, Cantoni AM, Corradi 
A. Effects of intraarticular treatment with stanozolol on synovial membrane and 
cartilage in an ovine model of osteoarthritis. Res Vet Sci. (2013) 94:379– 87. doi: 
10.1016/j.rvsc.2012.11.020 
59.  Spadari A, Rinnovati R, Babbini S, Romagnoli N. Clinical evaluation of intra- 
articular administration of stanozolol to manage lameness associated with 
acute andchronic osteoarthritis in horses. J Eq uine Vet Sci. (2015) 35:105– 
10. doi: 10.1016/j.jevs.2014.12.003 
60.  Rinnovati R, Romagnoli N, Spadari A. Dose-finding study for intraarticular 
treatment with stanozolol  in  horses.  J  Eq uine  Vet  Sci.  (2015)  35:860– 
4. doi: 10.1016/j.jevs.2015.08.009 
61.  Martins MC, Peffers MJ, Lee K, Rubio-Martinez  LM. Effects  of  stanozolol 
on normal and IL-1β-stimulated equine chondrocytes in vitro. BMC Vet Res. 
(2018) 14:1–7. doi: 10.1186/s12917-018-1426-z 
62.  Puckler K, Tellhelm B, Kirberger R. The hip joint and pelvis. In: Kirberger      
R, McEvoy F, editors. BSAVA Manual of Canine and Feline Musculoskeletal 
Imaging. Gloucester: Wiley (2016). p. 212–31. 
63.  Smith G, Karbe G, Agnello K, McDonald-Lynch M. Pathogenesis, diagnosis, 
and control of canine hip dysplasia. In: Tobias K. Johnston S, editors. 
Veterinary  Surgery: Small Animal. 1st ed. Saunders (St. Louis, MS). (2011). 
p. 824–48. 
64.  Cotta J, Aires JM, Cotta R, António D, De J, Ferreira A, et al. Estudo preliminar 
para a avaliação da eficácia clínica das infiltrações intra-articulares com 
estanozolol em canídeos com doença degenerativa articular e a sua relaçõa 
Alv es et al. Intra-articular Treatments in Hip Osteoarthritis  
320  
com a interleucina-1β sérica. University of Lisbon (2016). Available online 
at: http://hdl.handle.net/10400.5/11299 (accessed June 17, 2018). 
65.  Adamama-Moraitou KK, Pardali D, Athanasiou L V., Prassinos NN, 
Kritsepi M, Rallis TS. Conservative management of canine tracheal 
collapse with stanozolol: a double blinded, placebo control clinical 
trial. Int J Immunopathol Pharmacol. (2011) 24:111–8. doi: 
10.1177/039463201102400113 
66.  Van Vynckt D, Samoy Y, Mosselmans L, Verhoeven G, Verschooten 
F, Van Ryssen B. The use of intra-articular anesthesia as a 
diagnostic tool in canine lameness. Vlaams Diergeneeskd Tijdschr. 
(2012) 81:290–7. 
67.  Caron JP. Intra-articular injections for joint disease in horses. Vet 
Clin North Am  Equine Pract. (2005) 21:559–73. doi: 
10.1016/j.cveq.2005.07.003 
68.  Volstad N, Sandberg G, Robb S, Budsberg S. The evaluation of 
limb symmetry indices using ground reaction forces collected 
with one or two force plates in healthy  dogs. Vet Comp Orthop 
Traumatol. (2017) 30:54–  8. doi: 10.3415/VCOT-16-04-0054 
69.  Pashuck TD, Kuroki K, Cook CR, Stoker AM, Cook JL. Hyaluronic 
acid versus saline intra-articular injections for amelioration of 
chronic knee osteoarthritis: a canine model. J Orthop Res. (2016) 
34:1772–9. doi: 10.1002/jor.23191 
70.  Brown DC, Bell M, Rhodes L. Power of treatment success 
definitions when the canine brief pain inventory is used to evaluate 
carprofen treatment for the control of pain and inflammation in 
dogs with osteoarthritis. Am J Vet Res. (2013) 74:1467–73. doi: 
10.2460/ajvr.74.12.1467 
71.  Carr  BJ,  Canapp  SO,  Mason  DR,   Cox   C,   Hess   T.   Canine   
platelet-   rich  plasma  systems:  a  prospective  analysis.  Front  
Vet  Sci.   (2016) 2:73. doi: 10.3389/fvets.2015.00073 
72.  Mobasheri A, Henrotin Y. Identification, validation and 
qualification of biomarkers for osteoarthritis in humans and 
companion animals: mission for the next decade. Vet J. (2010) 
185:95–7. doi: 10.1016/j.tvjl.2010.05.026 
73.  Kuroki K, Cook JL, Kreeger JM. Mechanisms of action and 
potential uses     of hyaluronan in dogs with osteoarthritis. J Am 
Vet Med Assoc. (2002) 221:944–50. doi: 
10.2460/javma.2002.221.944 
74.  Comhaire  FH,  Snaps  F.  Comparison  of  two  canine  registry  
databases  on the prevalence of hip dysplasia by breed and the 
relationship of dysplasia with body weight  and  height.  Am  J  
Vet  Res.  (2008)  69:330– 3. doi: 10.2460/ajvr.69.3.330 
75.  Alves  JC,  Santos  AM,  Jorge  PI.  Effect  of  an  oral  joint   
supplement when  compared  to  carprofen  in  the  management   
of   hip   osteoarthritis in working dogs. Top Companion Anim 
Med. (2017) 32:126–9. doi: 10.1053/j.tcam.2017.10.003 
76.  Psychogios    N,    Hau    DD,    Peng    J,    Guo    AC,    Mandal    R,    
Bouatra  S,  et  al.  The  human  serum  metabolome.  PLoS   
ONE.   (2011)  6:e16957. doi: 10.1371/journal.pone.0016957 
77.  Cubukcu D, Sarsan A, Alkan H. Relationships between pain, 
function and radiographic findings in osteoarthritis of the knee: a 
cross-sectional study. Arthritis. (2012) 2012:1–5. doi: 
10.1155/2012/984060 
78.  Khairina AD, Moeliono MA, Rahmadi AR.  Correlation  between  
radiographic grading  of  osteoarthritis,  pain  severity  and  
functional  status   in   knee   osteoarthritis   patients.   Althea   
Med   J.    (2018) 5:43–6. doi: 10.15850/amj.v5n1.1335 
79.  Raynauld J-P, Buckland-Wright C, Ward R, Choquette D, Haraoui B, 
Martel- Pelletier J, et al. Safety and efficacy of long-term 
intraarticular steroid injections in osteoarthritis of the knee: a 
randomized, double-blind, placebo- controlled trial. Arthritis 
Rheum. (2003) 48:370–7. doi: 10.1002/art.10777 
80.  Mendes JG, Natour J, Nunes-Tamashiro JC, Toffolo SR, Rosenfeld  
A,  Furtado RNV. Comparison between intra-articular Botulinum 
toxin type A, corticosteroid, and saline in knee osteoarthritis: a 
randomized controlled trial. Clin Rehabil. (2019) 33:1015–26. doi: 
10.1177/0269215519827996 
81.  Weitoft T,  Öberg K. Dosing of intra-articular triamcinolone 
hexacetonide  for knee synovitis  in  chronic  polyarthritis:  a  
randomized  controlled study. Scand J Rheumatol. (2019) 48:279–
83. doi: 10.1080/03009742.2019. 1571222 
82.  Cushman  DM,  Ofek  E,  Syed  RH,  Clements  N,  Gardner  JE,  
Sams  JM,     et al. Comparison of varying corticosteroid  type,  
dose,  and  volume  for the  treatment  of  pain  in  small-  and  
intermediate-size  joint  injections:  a narrative review. PMR. 
(2019) 11:758–70. doi: 10.1016/j.pmrj.2018. 09.040 
83.  Previtali D, Merli G, Di Laura Frattura G, Candrian C, Zaffagnini S, 
Filardo G. The long-lasting effects of “placebo injections” in knee 
osteoarthritis: a meta- analysis . Cartil ag e. (2020) 
194760 35 2 0 9 0 65 9 . doi: 10.117 7/1 9 47 6 0 3 5 20 9 0 6 59 7 
84.  Alves JC, Santos A, Fernandes Â. Evaluation of the effect of 
mesotherapy in the management of back pain in police working 
dogs. Vet Anaesth  Analg. (2018) 45:123–8. doi: 
10.1016/j.vaa.2017.07.006 
85.  Bosscher G, Tomas A, Roe S, Marcellin-Little D, Lascelles BD. 
Repeatability and accuracy testing of a weight distribution 
platform and comparison to    a pressure sensitive walkway to 
assess static weight distribution. Vet Comp Orthop Traumatol. 
(2017) 30:160–4. doi: 10.3415/VCOT-16-09-0128 
86.  Mölsä SH, Hyytiäinen HK, Morelius KM, Palmu MK, Pesonen TS,  
Lappalainen AK. Radiographic findings have an association with 
weight bearing and locomotion in English  bulldogs.  Acta  Vet  
Scand.  (2020) 62:19. doi: 10.1186/s13028-020-00517-3 
87.  Kennedy  S,  Lee  DV,   Bertram  JEA,  Lust  G,  Williams  AJ,   
Soderholm  LV,    et al. Gait evaluation in  hip  osteoarthritic  and  
normal  dogs  using  a  serial force plate system.  Vet  Comp  
Orthop  Traumatol.  (2003)  16:170– 7. doi: 10.1055/s-0038-
1632773 
88.  Vassalo  FG,  Rahal  SC,   Agostinho   FS,   Mamprim   MJ,   
Melchert   A,   Kano WT, et al. Gait analysis in dogs with pelvic 
fractures treated conservatively using a pressure-sensing 
walkway. Acta Vet Scand. (2015) 57:68. doi: 10.1186/s13028-
015-0158-3 
89.  Riser WH, Cohen D, Lindqvist S, Mansson J, Chen S. Influence of 
early rapid growth and weight gain on hip dysplasia in the 
German Shepherd Dog. J Am Vet Med Assoc. (1964) 145:661–8. 
90.  Kealy RD, Lawler DF, Ballam JM, Mantz SL, Biery DN, Greeley EH, 
et al. Effects of diet restriction on life span and age-related 
changes in dogs. J Am Vet Med Assoc. (2002) 220:1315–20. doi: 
10.2460/javma.2002.220.1315 
91.  Innes JF. Arthritis. In: Tobias KM, Johnson SA, editors. Veterinary 
Surgery: Small Animal. St. Louis: Elsevier Saunders (2012). p. 
1078–111. 
92.  Douglas RJ. Corticosteroid injection into the osteoarthritic knee: 
drug selection, dose, and injection frequency. Int J Clin Pract. 
(2012) 66:699– 704. doi: 10.1111/j.1742-1241.2012.02963.x 
93.  Labens R, Mellor DJ, Voûte LC. Retrospective study of the effect 
of intra- articular treatment of osteoarthritis of the distal tarsal 
joints in 51 horses. Vet Rec. (2007) 161:611–6. doi: 
10.1136/vr.161.18.611 
94.  Zóboli AAC, de Rezende MU, de Campos GC, Pasqualin T, Frucchi 
R,  Camargo OP de. Ensaio clínico prospectivo e randomizado: 
regime único      e semanal de viscossuplementação. Acta 
Ortopédica Bras. (2013) 21:271– 5. doi: 10.1590/S1413-
78522013000500006 
95.  Baltzer WI, Owen R, Bridges J. Survey of handlers of 158 police 
dogs in New Zealand: functional assessment and canine 
orthopedic index. Front Vet Sci. (2019) 6:1–6. doi: 
10.3389/fvets.2019.00085 
96.  Ornetti P, Nourissat G, Berenbaum F, Sellam J, Richette P, 
Chevalier X. Does platelet-rich plasma have a role in the 
treatment of osteoarthritis? Jt Bone Spine. (2016) 83:31–6. doi: 
10.1016/j.jbspin.2015.05.002 
97.  Popma JW, Snel FW, Haagsma CJ, Brummelhuis-Visser P, 
Oldenhof HGJ, van der Palen J, et al. Comparison of 2 dosages of 
intraarticular triamcinolone for the treatment of knee arthritis: 
results of a 12-week randomized controlled clinical trial. J 
Rheumatol. (2015) 42:1865–8. doi: 10.3899/jrheum.141630 
Conflict of Interest: The V-PET kits used in this study were provided 
by the  Pall Corporation and the Stance Analyser used in this study was 
provided by Companion, LiteCure LLCⓍR  . 
The authors declare that the research was conducted in the absence of 
any commercial or financial relationships that could be construed as a 
potential conflict of interest. 
 
Copyright © 2021 Alves, Santos, Jorge, Lavrador and Carreira. This is an 
open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) and the 
copyright owner(s) are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, 




IV. CONCLUSIONS AND RESEARCH PERSPECTIVES  
 
Osteoarthritis is a disease as old as joints themselves, and its presence and prevalence 
continued to accompany all species, particularly with an increase in the population's life expectancy. 
With a significant impact on the quality of life and function of individuals, OA is difficult to manage, 
with treatment often offering an unsatisfactory level of control. The complexity of treatment is 
reflected by the vast number of treatment modalities and different approaches that are used to manage 
it. In most cases, satisfactory control of symptoms is only achieved through a multi-modal approach. 
As a chronic progressive disease, in tissues with limited regeneration ability, early diagnos is, 
associated with precise monitoring, are crucial for long-term success. The use of intra-articular 
therapies is an attractive option for the management of the disease. This is particularly interesting for 
regenerative therapies, which aim to have a direct action on the tissues most directly affected by the 
disease. Being a common approach in humans and horses, it is not yet a frequent option in canine 
medicine. This was one of the starting points for this study. The lack of data to guide the action of 
clinicians in monitoring their patients, associated with the particular characteristics of the dog, which 
make it an optimal model for the study of human OA, were the major determinants for the project 
developed. 
One of the most significant difficulties felt in designing the experimental protocol of the study 
was the selection of treatments and evaluation modalities to include and those to exclude. In the last 
decades, several new treatments have appeared or become more accessible, as well as objective 
measures of patient assessment and response to treatment. As a principle for that choice, we selected 
what, in our view, would be the options of interest to the clinician who daily treats these patients, and 
is not necessarily an investigator. For the evaluation of results, objective quantification methods were 
selected, which can be developed in laboratory facilities but also in the daily in-house Veterinary 
Medical Centers. 
The evaluation of animals over an extended follow-up period, and the use of several evaluat ion 
modalities, allowed us to obtain an accurate characterization of each treatment effects at different 
levels, namely, molecular, imagiological, and clinical. A large amount of data gathered made it 
possible to exceed significantly the scientific production initial proposed. This production is reflected 
in the several manuscripts produced, from the preliminary evaluations to the characterization of 
patients, to the evaluation and validation of the different monitoring modalities, the characterizat ion 
of each of the treatments used, and, in the end, the comparison between them. This whole process 
required the acquisition of many skills, from the execution of the procedures themselves to working 
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with the stance analysis platform and the thermographic camera, the realization of the laboratory 
component for the analysis of the synovial fluid, to the realization of various statistical analys is 
methods. 
In practical terms, with the results obtained it was possible to present important data to work 
as a guideline for clinicians in the early diagnosis of the OA disease. Also, to reassess and validate 
different clinical metrology instruments, to compare projections and to validate digital thermography 
as a method of monitoring osteoarthritis, and to list the strengths of each treatment depending on the 
patient's clinical presentation. The study results also point out new lines for future studies. For 
instance, it would be very interesting to evaluate different platelet products, considering that different 
compositions will lead to different results. Or the use of accelerometers, centering the study on the 
patient's functional capability and quality of life, and not only on the results of exams. Also, the 
interaction and relation with several companies allowed an approach of the academic and business 
worlds.  
This dissertation presents a contribution to several aspects of veterinary and human medicine, 
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APPENDIX I – The Canine Brief Pain Inventory 
 
Description of Pain:  
Rate your dog’s pain. (0-10, 0 = no pain, 10 = extreme pain) 
1. Which one number best describes the pain at its worst in the last 7 days.  
2. Which one number best describes the pain at its least in the last 7 days.  
3. Which one number best describes the pain at its average in the last 7 days.  
4. Which one number best describes the pain as it is right now.  
 
 Description of Function:  
Which one number best describes how during the past 7 days pain has interfered with your 
dog’s (0-10, 0 = does not interfere, 10 = completely interferes):  
5. General Activity  
6. Enjoyment of Life  
7. Ability to Rise to Standing From Lying Down  
8. Ability to Walk  
9. Ability to Run  
10. Ability to Climb Up (for example Stairs or Curbs)  
 
Overall Impression:  
11. Which response best describes your dog’s overall quality of life over the last 7 days? 




APPENDIX II – The Canine Orthopedic Index 
 
Description of Stiffness:  
The following questions concern the amount of joint stiffness your dog has experienced in the 
past 7 days. 
Stiffness is the restriction or slowness in the ease with which your dog moves his/her joints. 
Please select one answer for each question below. 
 













3. How much of a problem does your dog have rising to standing after lying down for at least 
15 minutes? 
- No problems; 
- Mild problems; 
- Moderate problems; 
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- Severe problems; 
- Extreme problems. 








Description of Function:  
Please indicate how much of a problem each of the following activities has been for your dog 
over the past 7 days. 
Please select one answer for each question below. 
5. Jumping up (as in getting into the car or onto the bed)? 
- No problems; 
- Mild problems; 
- Moderate problems; 
- Severe problems; 
- Extreme problems. 
 
6. Jumping down (as in getting out of the car or off of the bed)? 
- No problems; 
- Mild problems; 
- Moderate problems; 
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- Severe problems; 
- Extreme problems. 
7. Climbing up (as in stairs, ramps or curbs)? 
- No problems; 
- Mild problems; 
- Moderate problems; 
- Severe problems; 
- Extreme problems. 
8. Climbing down (as in stairs, ramps or curbs)? 
- No problems; 
- Mild problems; 
- Moderate problems; 
- Severe problems; 
- Extreme problems. 
Description of Gait:  
The following questions concern your dog’s gait over past 7 days. 
Gait refrs to the manner in which your dog uses its legs as it moves 
Please select one answer for each question below. 









10. On average, how severe was your dog’s limp during mild activities (such as long walks, 




























Description of Quality of Life:  
Please select one answer for each question below. 
14. In the past 7 days, what has been your level of concern that your dog’s joint problems will 













16. Overall, how would you rate your dog’s quality of life over the past 7 day? 
- Excellent; 











1. How is your dog’s mobility in general? 




- Very poor. 
 
2. How disabled is your dog by his/her lameness?  
- Not at all disabled; 
- Slightly disabled; 
- Moderately disabled; 
- Severely disabled; 
- Extremely disabled; 
 
3. How active is your dog?  
- Extremely active; 
- Very active; 
- Moderately active; 
- Slightly active; 





4. What is the effect of cold, damp weather on your dog’s lameness?  
- No effect; 
- Mild effect; 
- Moderate effect; 
- Severe effect; 
- Extreme effect; 
 
5. To what degree does your dog show stiffness in the affected leg after a ‘lie down’?   
- No stiffness; 
- Mild stiffness; 
- Moderate stiffness; 
- Severe stiffness; 
- Extreme stiffness; 
 
At exercise 
6. At exercise, how active is your dog? 
- Extremely active; 
- Very active; 
- Fairly active; 
- Not very active; 
- Not at all active; 
 
7. How keen to exercise is your dog? 
- Extremely keen; 
- Very keen; 
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- Fairly keen; 
- Not very keen; 
- Not at all keen. 
 
8. How would you rate your dog’s ability to exercise? 




- Very poor; 
 
9. What overall effect does exercise have on your dog’s lameness? 
- No effect; 
- Mild effect; 
- Moderate effect; 
- Severe effect; 
- Extreme effect. 
 
10. How often does your dog rest (stop/sit down) during exercise? 
- Never; 
- Hardly ever; 
- Occasionally; 
- Frequently; 




11. What is the effect of cold, damp weather on your pet’s ability to exercise? 
- No effect; 
- Mild effect; 
- Moderate effect; 
- Severe effect; 
- Extreme effect. 
 
12. To what degree does your dog show stiffness in the affected leg after a ‘lie down’ following 
exercise? 
- No stiffness; 
- Mild stiffness; 
- Moderate stiffness; 
- Severe stiffness; 
- Extreme stiffness; 
 
13. What is the effect of your dog’s lameness on his/her ability to exercise? 
- No effect; 
- Mild effect; 
- Moderate effect; 
- Severe effect; 







APPENDIX IV – Hudson visual analogue scale 
 
Hudson Visual Analogue Scale 
 
1. How would you describe your overall assessment of your dog in the last month? 
(0-10, 0 = bad, 10 = good) 
2. What kind of mood has your dog been in the last month? (0-10, 0 = bad, 10 = good) 
3. How has your dog’s attitude been in the last month? (0-10, 0 = bad, 10 = good) 
4. How frequently does your dog display comfort or “happy dog” postures (e.g., lying 
on back with toy in mouth? (0-10, 0 = bad, 10 = good) 
 
Tell us what type of daily activities your dog engages in (e.g., fetching newspapers, playing 
frisbee) and then answer question 5. 
 
5. Has your dog changed the amount of these activities? (0-10, 0 = not at all, 10 = a 
lot) 
6. How willing is your dog to play voluntarily? (0-10, 0 = not at all, 10 = a lot) 
7. How often does your dog get exercise? (0-10, 0 = not at all, 10 = a lot) 
8. How stiff is your dog when arising for the day (0-10, 0 = not at all, 10 = a lot) 
9. How stiff is your dog at the end of the day (post-activities)? (0-10, 0 = not at all, 10 
= a lot) 
10. Does your dog indicate any lameness at a walk? (0-10, 0 = not at all, 10 = a lot) 
11. Does your dog indicate any pain when turning suddenly at a walk? (0-10, 0 = not 
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METHYLPREDNISOLONE ACETATE AND TRIAMCINOLONE ACETONIDE IN A NATURAL 
OCCURRING OSTEOARTHRITIS CANINE MODEL 
 
João Carlos Alves1,2 , Ana Santos1 , Patrícia Jorge1 , Catarina Lavrador2 , L. Miguel Carreira3,4,5 
1 Divisão de Medicina Veterinária, Guarda Nacional Republicana 2 ICAAM – Instituto de Ciências 
Agrárias e Ambientais Mediterrâneas – Universidade de Évora 3 Faculty of Veterinary Medicine, 
University of Lisbon (FMV/ULisboa) 4 Interdisciplinary Centre for Research in Animal Health (CIISA) – 





The goal of this study was to describe the use and effectiveness of intra-articular MPA and TA in the 
management of naturally occurring hip osteoarthritis (OA) in an animal model. Twenty police working 
dogs were divided in two groups according to the drug administered through intra-articular (IA) 
injection: GT (20mg of triamcinolone acetonide – TA, per hip joint) and GMPA (40mg of 
methylprednisolone acetate – MPA, per hip joint). Seven different time points were considered during 
the study for data collection purposes: T0 (before treatment), T1 (15 days after treatment), T2, T3, 
T4, T5, T6, and T7 (1, 2, 3, 4, 5 and 6 months after treatment respectively). Response to treatment 
was measured using the Canine Brief Pain Inventory (CBPI) and Hudson Visual Analogue Scale 
(HVAS). Significant results were considered when p<0.05. 
 
Treatment successfully reduced pain interference scores (PSS) in two animals of GT at T1 (20%), 
three at T2-T3 (37.5%) and two at T4-T7 (28.6%). For GMPA, treatment was successful in two 
animals at T1 (20%), four at T2 (40%), three at T3 (30%) and two at T4-T5 (20%). Considering pain 
interference score (PIS), treatment was a success in two animals in both GTA and GMPA from T1-
T7. However, no significant differences were registered when comparing each time point with T0 at 
T1 nor between groups. No significant differences were registered with HVAS. 
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RESUMEN CORTO/RESUME 
To describe the use and effectiveness of intra-articular triamcinolone acetonide (TA), hyaluronan 
(HA) and a combination of both (TA+HA), thirty police working dogs with naturally occurring hip 
osteoarthritis (OA) were selected. Sample comprised 6 females and 24 males, with a mean age of 
6 years old and weight of 33.3 kg. Animals were randomly divided in three groups and treated with 
either a single administration of 20mg of TA (GT), 20mg of HA (GH) or a combination of 20mg of 
TA and 20mg of HA (GTH) per hip joint.. 
 
Response to treatment, measured by the Canine Brief Pain Inventory (CBPI) and the Hudson 
Visual Analogue Scale (HVAS), was evaluated at T0 (before treatment), T1 (after 15 days), T2, T3, 
T4, T5 and T6 (after 1, 2, 3, 4 and 5 months respectively). Results were compared using a Kruskal-
Wallis test or a Wilcoxon signed ranks test. 
. 
Comparing results of the different time points considered with T0, significant differences were 
observed in GH at T1 for HVAS (p=0.03) and PIS (p=0.04); and in GTH at T1 (p=0.05 for HVAS 
and p<0.05 for PIS), T2 (p<0.04 for PIS), T3 (p<0.03 for HVAS and p=0.05 for PIS), T4 (p<0.03 for 
HVAS and p<0.05) and T5 (p<0.05 for HVAS). No significant differences were found between 
groups when comparing results by time point. Intra-articular TA and HA may be a treatment option 
for dogs with naturally occurring OA, but their simultaneously use seems to improve the results. 
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RESUMEN CORTO/RESUME 
The goal of this study was to describe the use and effectiveness of intra-articular a platelet 
concentrate (V-PET) in the management of naturally occurring hip osteoarthritis (OA) in an animal 
model. Twelve working dogs were treated with 3ml of platelet concentrate per hip, prepared with V-
PET. Evaluations were conducted at T0 (before treatment), T1 (15 days after treatment), T2, T3, 
T4 and T5 (1, 2, 3, and 4 months after treatment). Response to treatment was evaluated with the 
Canine Brief Pain Inventory (divided in Pain Severity Score (PSS) and Interference Score (PIS)), 
Liverpool Osteoarthritis in Dogs (LOAD), Canine Orthopedic Index (divided in stiffness (Stiff), 
function, gait and quality of life (QOL)) and Hudson Visual Analogue Scale (HVAS). 
When comparing each moment with T0, significant differences where found at T1 (p=0.03 for 
HVAS and PIS, p=0.00 for PSS and Gait, p=0.05 for Function, p=0.01 for QOL), T2 (p=0.00 for 
PSS, PIS and Gait, p=0.03 for Function and LOAD), T3 (p=0.01 for HVAS, PSS and Gait, p=0.05 
for PIS and QOL, p=0.03 for Function), T4 (p=0.02 for PSS) and T5 (p=0.01 for PSS and Function, 
p=0.03 for Gait).  
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Digital thermal imaging is a non-invasive, nonradiating, contact-free, physiologic diagnostic tool, 
that depends on heat resulting from physiological functions related to skin temperature control 
(Hildebrandt, Zeilberger, John Ring, & Raschner, 2012). It can be used to assess soft tissue injur ies 
including muscle stains, sprains and tendinopathies but also OA and has been described as being 
useful in several species, from humans to horses and cats, but it’s clinical utility has rarely been 
studied in small animals (Hildebrandt et al., 2012; M. H. Vainionpää et al., 2013). This study aimed 
to compare the ventro-dorsal view and lateral view thermographic images in dogs with bilateral hip 
osteoarthritis (OA).  
Two hundred and eighty-two (n=282) sets of images were considered. Each comprised a dorso-
ventral (DV), left lateral (LL) and right lateral (RL) images. Before imaging, dogs were mainta ined 
in a room at 21°C for 30 min. For the DV, they were positioned standing in a symmetrical upright 
position, as symmetrically as possible, without the trainer or veterinarian touching the dog’s torso, 
and each image included the area from the last lumbar to the first coccygeal vertebra (M. Vainionpää 
et al., 2012). Each lateral view was set with the greater trochanter in the centre. All mages were taken 
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with a FLIR ThermaCAM E25 from a distance of 60 cm. Mean and maximal temperatures were 
recorded, and analyzed with a Wilcoxon Signed Ranks Test and Spearman correlation. 
For the right hip, mean temperature recorded on a DV was 25.7ºC (±0.84) and 29.1ºC (±0.18) on the 
RL. Maximal values were 25.7ºC (±0.13) on the DV and 32.2ºC (±0.19) on the RL. In both cases, 
values were significantly different (p<0.01) and a showed week correlation (0.33 and 0.13, 
respectively). For the left hip, mean temperature on a DV was 24.97ºC (±0.12) and 28.7ºC (±0.18) 
on the LL view. Maximal values were 25.9ºC (±0.13) on the DV and 32.0ºC (±0.20) on the LL. 
Values varied significantly in both cases (p<0.01) and a showed low correlation (0.38 and 0.12, 
respectively). 
Results obtained with a dorso-ventral and a lateral image are significantly different. Further studies 
are required, to determine which approach best reflects evaluation and treatment results. 
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In dogs, hip OA is commonly a consequence of HD. This is the most common orthopaedic condition 
in dogs, often bilateral, with a prevalence of up to 71% in affected breeds, and causes joint 
inflammation with variable degrees of clinical discomfort (King, 2017). Physical examination is an 
essential part of the diagnosis process, and several parameters should be determined. Coxofemora l 
range of motion (ROM) can be diminished, particularly during extension (Smith, Karbe, Agnello, & 
McDonald-Lynch, 2011). Thigh girth is a useful measurement, not only in the initial assessment but 
also as an outcome measure, since the quadriceps muscle group is particularly prone to atrophy 
secondary to decreased limb function (McCarthy, Millis, Levine, & Weigel, 2018). Stance analyser 
has been reported as a sensitive for detecting lameness in dogs, being more sensitive in large breed 
dogs) (Clough, Canapp, Taboada, Dycus, & Leasure, 2018). . It has been proposed that body weight  
distribution at a stance may, in fact, be an equivalent or superior measurement of pain associated with 
hip OA than both VI and PVF. This study aimed to describe individual limb disease severity in dogs 
with bilateral hip osteoarthritis (OA). 
Fifty police working dogs (N=50) with bilateral hip osteoarthritis were evaluated. Four breeds were 
represented: German Shepherd dog (n=17), Belgian Malinois (n=15), Labrador Retriever (n=10) and 
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Dutch Shepherd Dog (n=8). Weight bearing (WB) of each limb was collected with a Stance Analyzer. 
Thigh girth (TG) was measured with a Gullick II measuring tape at a distance of 70% thigh length, 
measured from the tip of the greater trochanter, with the leg in an extended position while in lateral 
recumbency. Hip joints range of motion were obtained at extension (Ext) and flexion (Flex) with a 
flexed stifle. Results were compared with an independent samples T-Test, with p<0.05. 
Animals included had a mean age of 6.4 (±2.4) years old and body-weight of 26.7kg (±5.3). For the 
left pelvic limb, mean WB was 19.2% (±4.8), TG was 30.6cm (±2.9), Flex was 55.6° (±4.1) and Ext 
was 149.2° (±9.5).  For the right pelvic limb, mean WB was 18.7% (±4.2), TG was 30.4cm (±2.6), 
Flex was 55.2° (±4.5) and Ext was 150.6° (±7.1). No significant differences were observed when 
comparing measurements from left and right limbs. 
No significant variations between limbs were observed in WB, TG, Ext and Flex. Further studies are 
required, to determine if the same is true in animals of different sizes, breeds and ages.    
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RESUMEN CORTO/RESUME 
To compare the effect of a single intra-articular administration of different treatments in a natural 
occurring canine osteoarthritis (OA) model, one hundred (N=100) hip joints with naturally occurring 
osteoarthritis (OA) and randomly assigned to five groups: control group (CG, n=20), triamcinolone 
hexacetonide group (THG, n=20), platelet concentrate group (PCG, n=20), stanozolol group (SG, 
n=20) and hylan G-F 20 group (HG). Evaluations were conducted on days 0 (treatment day), 8, 15, 
30, 60, 90, 120, 150 and 180 days post treatment, and consisted of weight distribution analysis and 
data from four Clinical Metrology Instruments. Cox proportional hazard regression analysis was 
carried out to investigate the influence of the variables of interest on treatment survival. All results 
were analyzed with IBM SPSS Statistics version 20 and a significance level of p< 0.05 was set. 
The sample included joints of 100 pelvic limbs (n=50 left and n=50 right), with a mean age of 
6.5±2.4 years and body weight of 26.7±5.2kg, classified as mild (n=70), moderate (20) and severe 
(10). Patients in HG and PCG took longer to return to baseline values and scores. PCH and HG 
experienced 57%-81% improvements in functional evaluation and impairments due to OA, and 
may be a better options for these cases. Better impact on pain interference was observed in THG, 
with a 95% improvement over CG. 
This study provides important information for the characterization of the effects of these treatment 
modalities, duration of observed improvements function and pain, in addition to information 
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RESUMEN CORTO/RESUME 
In this study, we aimed describe the effect of the intra-articular administration of stanozolol in a 
natural occurring canine osteoarthritis model. Forty (N=40) hip joints of active police working dogs 
were randomly assigned to a control (CG) and treatment (SG) group. Weight distribution, joint 
range of motion, thigh girth, digital thermography, radiographic signs, synovial fluid interleukin-1 
levels were recorded at treatment day (day 0),  and at 8, 15, 30, 90 and 180 days post-treatment. 
The Hudson Visual Analogue Scale, the Liverpool Osteoarthritis in Dogs, the Canine Brief Pain 
Inventory and the Canine Orthopedic Index.  Results were compared using Repeated Measures 
ANOVA, with a Huynh-Feldt correction, Wilcoxon Signed Ranks Test, with p<0.05. 
Sample included joints from 40 pelvic limbs, graded as mild (n=36, 90%), moderate (n=2, 5%) and 
severe (n=2, 5%), with a mean age of 6.5±2.4 years and body weight of 26.7±5.2kg. No 
differences were found between groups at day 0. Comparing CG to SG, symmetry index showed 
significant improvements in SG from 15 days (p=0.05) up to 180 days (p=0.01). SG also showed 
lower values during thermographic evaluation in both views taken, and improved joint extension at 
90 (p=0.02) and 180 days (p<0.01). Pain and function scores, improved up to 90.180 days. In SG, 
improvements in some radiographic findings was observed.  
To our knowledge, this is the first study to describe the effect of a single injection of stanozolol in a 
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RESUMEN CORTO/RESUME 
Osteoarthritis (OA) affects all mammals, being an important and costly disease. We aimed to 
evaluate IL-1 and C-reactive protein (CRP) levels in the synovial fluid in dogs with naturally 
occurring hip osteoarthritis (OA), and its relation with patients’ clinical, radiographic and 
thermographic disease signs. 
One hundred (N=100) joints of active police working dogs with hip OA were evaluated. SF IL-1 and 
CRP levels, weight distribution, joint range of motion at flexion and extension, thigh girth, digital 
thermography and hip grade were recorded. Data from four Clinical Metrology Instruments, the 
Hudson Visual Analogue Scale, Liverpool Osteoarthritis in Dogs, Canine Brief Pain Inventory and 
Canine Orthopedic Index, were collected.  Results were compared by different IL-1 and CRP 
concentration levels and OFA scores with the Independent Samples T-Test, ANOVA and Pearson 
correlation coefficient, with p<0.05. 
Sample included 100 pelvic limbs, equally distributed between left and right pelvic limbs 30 males 
and 20 females, with a mean age of 6.5±2.4 years and body weight of 26.7±5.2kg.  IL-1 levels, 
particularly above 200pg/mL, may be related with the development of radiographic signs, which 
then reflects on worse CMI scores. It was unclear if CRP level was a consequence of inflammatory 
activity within the joint or a reflection of better prognosis. Increasing body weight was related with 
worse CMI scores. 
This is the first study to describe the relation of IL-1 and CRP synovial concentrations levels with 
several clinical signs, diagnostic imaging, laboratorial findings and clinical metrology instruments 
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RESUMEN CORTO/RESUME 
This study aimed to describe weight bearing redistribution present in police working diagnosed with 
bilateral hip osteoarthritis (OA), and in response to treatment. Fifty Police working dogs with 
bilateral hip OA was performed at the time of initial evaluation and after treatment, on days 0 
(treatment day) and on 8, 15, 30, 90 and 180 post-treatment. Results were compared by breed, 
age, sex, weight and OFA scores with the Independent Samples T-Test, one-way ANOVA and 
Pearson correlation coefficient, with p< 0.05. 
Patients had a mean age of 6.5±2.4 years and body weight of 26.7±5.2kg, of both sexes (30 males 
and 20 females). Four breeds were represented: German Shepherd Dogs (n=17), Belgian Malinois 
Shepherd Dogs (n=15), Labrador Retriever (n=10), and Dutch Shepherd Dog (n=8). Thirty-five 
animals were classified as mild (70%), 10 as moderate (20%) and 5 as severe (10%). No 
significant differences were observed when comparing weight bearing for different breeds, sex, hip 
grades or different cut-offs for weight at the initial evaluation. A weight shift from pelvic to thoracic 
limbs was observed, with a weak significant correlation found between a pelvic limb and the 
opposing contralateral thoracic limb. Labrador Retrievers showed higher symmetry index and 
deviation from normal values than other breeds. During the follow-up period, after treatment, 
weight bearing of all limbs correlated with the remaining limbs, reflecting a more balanced weight 
distribution. 
This study first describes weight-bearing redistribution in dogs with bilateral hip OA and also in 
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APPENDIX XVII - Use of an autologous platelet therapy in police working dogs with 
hip osteoarthritis 
 
Objectives: To describe the effect of the platelet concentrate V-PET in dogs with hip osteoarthrit is 
(OA). 
Methods: In a prospective, randomly controlled, double-blind study, forty (N=40) joints of active 
police working dogs with hip OA were randomly assigned to control and V-PET groups. Weight 
distribution, joint range of motion, thigh girth, radiographic signs, and four clinical metrology 
instruments (CMI) were recorded at treatment day, 8, 15, 30, 90, and 180-days post-treatment. Results 
were compared with repeated measures ANOVA, with a Huynh-Feldt correction, or Wilcoxon Signed 
Ranks Test, with p<0.05. Kaplan-Meier estimators were conducted and compared with the log-rank 
test.    
Results: Patients had a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg. At T0, 32 (80%) 
joints were graded as mild, 6 (15%) as moderate, and 2 (5%) as severe OA. No differences were 
found between groups on treatment day. Comparing control to V-PET groups, weight-bearing showed 
significant improvements with V-PET from 8 days (p<0.01) up to 180 days (p=0.01), alongside joint 
flexion up to 90 days (p=0.05), and extension up to 180 days (p=0.01). Several CMI scores also 
improved up to 90 to 180 days post-treatment. In radiographic signs in the control group progressed, 
while in the V-PET group showed some improved signs. Kaplan-Meier estimators showed 
significantly better CMI and weight-bearing results in the V-PET group.  
Impact: A single injection of V-PET had a positive effect on several clinical and imaging signs, 





APPENDIX XVIII - Comparison of the intra-articular treatment with a platelet 
concentrate, high-density hyaluronan, triamcinolone hexacetonide, and stanozolol in 
dogs with hip osteoarthritis 
 
Objectives: To compare the effect of the intra-articular treatment with triamcinolone hexacetonide 
(TH), stanozolol, hyaluronan, and platelet concentrate (PC) in Police working dogs with bilateral hip 
osteoarthritis (OA).  
Methods: In a prospective, longitudinal, double-blinded, negative controlled study, fifty (N=50) 
police working dogs with hip OA were randomly assigned to a control group (CG, n=10), TH group 
(THG, n=10), PC group (PCG, n=10), stanozolol group (SG, n=10) and Hylan G-F 20 group (HG). 
On days 0, 8, 15, 30, 90, and 180 days post-treatment, weight-bearing distribution was evaluated. 
Three clinical metrology instruments (CMI - Canine Brief Pain Inventory, Liverpool Osteoarthrit is 
in Dogs, and Canine Orthopedic Index) were also completed.  Kaplan-Meier estimators were 
conducted and compared with the log-rank test. Cox proportional hazard regression analysis was 
performed to determine treatment survival. Significance was set at p<0.05. 
Results: Patients had a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg. At initia l 
evaluation, hips were graded as mild (n=35), moderate (n=10), and severe (N=5). No differences were 
found between groups at that moment. All treatments were able to improve CMI scores and weight -
bearing, but in some groups with a wide interval of efficacy. PCG showed a lower range of variation 
while maintaining a positive result for more extended periods. Breed, age, sex, and OFA grade did 
not significantly influence response to treatment.  
Impact: This is the first study to compare the effect of IA treatments in dogs with hip osteoarthrit is. 
PC and hyaluronan showed better results in the management of OA. 
 
